<SEC-DOCUMENT>0000320017-23-000063.txt : 20231102
<SEC-HEADER>0000320017-23-000063.hdr.sgml : 20231102
<ACCEPTANCE-DATETIME>20231102161138
ACCESSION NUMBER:		0000320017-23-000063
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231102
DATE AS OF CHANGE:		20231102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LISATA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		231372421

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-229-2590

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALADRIUS BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20170808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lsta-20230930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:b3932c72-a861-4a02-8e8c-886f49fbe91d,g:dd0049eb-adfc-4bb4-a64a-f5d2d3c1c00a,d:35e3411510dd4ffe8f0b873f3f439282--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:lsta="http://www.caladrius.com/20230930" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lsta-20230930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000320017</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-78" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-376">.067</ix:nonFraction><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-566">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-567">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-572">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-573">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-576">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-577">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-660">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-113" decimals="2" name="lsta:SaleOfStockAvailableForSalePercentage" scale="0" id="f-670">.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lsta-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CaladriusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-04</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-05</xbrli:startDate><xbrli:endDate>2023-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-04</xbrli:startDate><xbrli:endDate>2023-09-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i35e3411510dd4ffe8f0b873f3f439282_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2023</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Transition Period from __________________&#160;&#160;&#160;to _________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33650</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">LISATA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">22-2343568</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">110 Allen Road, 2nd Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Basking Ridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">07920</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(zip code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">908</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">842-0100</ix:nonNumeric></span></div><div style="text-align:center"><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:34.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">LSTA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:20.16pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:331.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of November 2, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">8,139,449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares</span></td></tr></table></div><div style="padding-right:2.25pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:3.3pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report (this &#8220;Quarterly Report&#8221;) contains &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;outlook,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including collecting amounts owed to us under various licensing and other strategic arrangements, meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build and maintain the management and human resources infrastructure necessary to support the operation and/or growth of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether a market is established for our products and our ability to capture a meaningful share of this market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientific, regulatory and medical developments beyond our control;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business,&#160;and our ability to commercialize products without infringing upon the claims of third-party patents;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any potential strategic or financial benefits of various licensing agreements will be realized;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to diversify our pipeline of development product candidates, which could include an acquisition, merger, business combination, in-license or other strategic transaction, and whether any of such efforts will result in us entering into or completing any transaction or that any such transaction, if completed, will add to shareholder value;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our development activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population, competition with other clinical trials for similar subjects, patient and/or investigator site availability and accessibility due to external macroenvironmental factors and the need of patients to meet the inclusion criteria of the trial or otherwise; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the COVID-19 pandemic and any future pandemic and/or their long-term effects may impact, directly or indirectly, our business, including our clinical trials and financial condition; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors discussed in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 30, 2023 (our &#8220;2022 Form 10-K&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors discussed herein, including those risks described in &#8220;Item 1A. Risk Factors&#8221; and elsewhere in our 2022 Form 10-K and in our other periodic filings with the SEC, which are available for review at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="margin-bottom:3.3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:3.3pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I- FINANCIAL INFORMATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Page No.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_10">Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_16">Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_16"> 30, 2023 (unaudited) and December 31, 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_19">Consolidated Statements of Operations for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_19">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_19"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_19">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_19"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_19">30, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_22">Consolidated Statements of Comprehensive Loss for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_22">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_22"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_22">30, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_22">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_25">Consolidated Statements of Equity for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_25">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_25">Se</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_25">ptember</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_25"> 30, 2023 and 2022 (unaudited) </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_28">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_28">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_28"> 30, 2023 and 2022 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_28">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Unaudited Consolidated Financial Statements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_31">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_88">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_100">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Controls and Procedures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_103">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II- OTHER INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Proceedings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_109">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_112">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_115">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Defaults Upon Senior Securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_118">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_121">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Information</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_124">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_127">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Signatures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e3411510dd4ffe8f0b873f3f439282_130">37</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_13"></div><div><span><br/></span></div><div><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">32,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">32,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-32">21,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-33">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">2,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">57,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">71,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-38">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-39">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired license - intangible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-40">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-41">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-42">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-43">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-44">58,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-45">73,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">2,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">3,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">5,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">6,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-52">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-53">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-54">5,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">6,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and Contingencies (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-56"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-57"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-58"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-59">0.001</ix:nonFraction></ix:nonFraction> par value, authorized <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-60"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-61">33,333,333</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-62">8,140,187</ix:nonFraction></span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-63">7,866,799</ix:nonFraction> shares at September 30, 2023 and December 31, 2022, respectively; and </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">outstanding, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-64">8,139,449</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-65">7,866,061</ix:nonFraction> shares at September 30, 2023 and December 31, 2022, </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-66">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-67">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-68">576,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-69">574,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="f-71">738</ix:nonFraction></ix:nonFraction> shares at September 30, 2023 and December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="f-72">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="f-73">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-74">522,716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-75">507,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-76">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-77">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Lisata Therapeutics, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-78">52,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-79">66,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="f-80">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="f-81">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-82">52,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-83">66,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities, non-controlling interests and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-84">58,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-85">73,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-86">3,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-87">3,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-88">9,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-89">9,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lsta:InProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lsta:InProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-91">30,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lsta:InProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lsta:InProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-93">30,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-94">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-95">3,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-96">9,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-97">10,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-98">5,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-99">37,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-100">19,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-101">51,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-102">5,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-103">37,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-104">19,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">51,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-106">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-107">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-108">2,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-109">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-110">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-112">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-113">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-114">703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-115">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-117">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net loss before benefit from income taxes and noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-118">5,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-119">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-120">17,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-121">50,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-124">2,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-125">2,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">5,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-128">15,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:25.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="f-130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="f-131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">5,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">15,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic and diluted loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lisata Therapeutics, Inc. common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-138"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-139">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-140"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-141">7.88</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-142"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-143">1.92</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-144"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-145">11.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average common shares outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted shares</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-146"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-147">8,141</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-148"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-149">4,747</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-150"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-151">8,050</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-152"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-153">4,276</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">5,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">37,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-156">15,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-157">48,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale securities - net unrealized gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-159">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-160">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-161">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative translation adjustment arising during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-162">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-163">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-164">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-165">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-166">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-167">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-168">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-169">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Lisata Therapeutics, Inc. common</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">stockholders</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-170">5,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-171">37,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-172">15,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-173">48,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.316%"><tr><td style="width:1.0%"></td><td style="width:27.153%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.409%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-174">4,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-175">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-176">547,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-177">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-178">463,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-179">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-180">82,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-181">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-182">82,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-186">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-187">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-188">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-189">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with Merger</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="lsta:StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" format="ixt:num-dot-decimal" scale="3" id="f-190">3,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" scale="3" id="f-191">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" format="ixt:num-dot-decimal" scale="3" id="f-192">26,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" format="ixt:num-dot-decimal" scale="3" id="f-193">26,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" format="ixt:num-dot-decimal" scale="3" id="f-194">26,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-195">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-196">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-197">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-198">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-199">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-200">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-201">7,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-202">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-203">574,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-204">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-205">501,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-206">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-207">72,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-208">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-209">71,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-210">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-211">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-212">546,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-213">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">453,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-215">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-216">92,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-217">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-218">92,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-219">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-220">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-221">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-222">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-223">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-224">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-225">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuances of common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-226">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-227">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-228">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-229">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with Merger</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="lsta:StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" format="ixt:num-dot-decimal" scale="3" id="f-230">3,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" scale="3" id="f-231">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" format="ixt:num-dot-decimal" scale="3" id="f-232">26,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" format="ixt:num-dot-decimal" scale="3" id="f-233">26,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" format="ixt:num-dot-decimal" scale="3" id="f-234">26,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-235">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-236">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-237">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-238">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-239">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-240">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-241">7,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-242">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-243">574,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-244">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-245">501,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-246">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-247">72,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-248">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-249">71,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.610%"><tr><td style="width:1.0%"></td><td style="width:24.986%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.643%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-250">8,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-251">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-252">576,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-253">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-254">517,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-255">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-256">57,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-257">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-258">57,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-259">5,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-260">5,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-261">5,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-262">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-263">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-264">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-265">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-266">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-267">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-268">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-269">8,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-270">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-271">576,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-272">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-273">522,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-274">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-275">52,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-276">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-277">52,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-278">7,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-279">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-280">574,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-281">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-282">507,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-283">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-284">66,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-285">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-286">66,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-287">15,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-288">15,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-289">15,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-290">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-291">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-292">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-293">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuances of common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-294">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-295">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-296">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-297">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from option exercises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-298">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-299">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-300">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-301">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-302">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-303">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-304">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-305">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-306">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-307">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-308">8,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-309">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-310">576,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-311">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-312">522,716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-313">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-314">52,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-315">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-316">52,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-317">15,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-318">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="f-319">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="f-320">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-321">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-322">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-323">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In process research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="f-326">30,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization/accretion on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-327">709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-328">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-329">314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-330">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-331">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-332">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-333">1,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" scale="3" id="f-334">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-335">15,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-336">14,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-337">77,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-338">68,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-339">93,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-340">93,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset acquisition costs, net of cash acquired related to merger with Cend</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lsta:PaymentsForAssetAcquisitionCostsNet" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="lsta:PaymentsForAssetAcquisitionCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-342">3,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-344">259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-345">15,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-346">21,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-347">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments on net share settlement equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-349">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-350">267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-351">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-352">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-353">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-354">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-355">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-356">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-357">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-358">6,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-359">32,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-360">24,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-361">32,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-362">31,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with merger</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-364">23,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options assumed</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="f-366">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_34"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 1&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="lsta:BusinessTextBlock" id="f-367" continuedAt="f-367-1" escape="true">The Business</ix:nonNumeric></span></div><ix:continuation id="f-367-1" continuedAt="f-367-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. LSTA1 also has the potential to modify the tumor microenvironment (&#8220;TME&#8221;), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, the Company has development programs based on its autologous CD34+ cell therapy technology platform that it is seeking to partner while incurring no additional capital outlay.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs. The Company&#8217;s current development pipeline includes: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including, metastatic pancreatic ductal adenocarcinoma (mPDAC) and other forms of pancreatic cancer, cholangiocarcinoma, esophageal cancer, head and neck cancer, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#8220;Caladrius&#8221;), completed its acquisition of Cend Therapeutics, Inc. (&#8220;Cend&#8221;), a Delaware corporation (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#8220;Merger Sub&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#8220;Effective Time&#8221;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc., and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#8220;Reverse Stock Split&#8221;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#8217;s common stock based on an exchange ratio of <ix:nonFraction unitRef="number" contextRef="c-74" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-368">0.5338</ix:nonFraction>, after taking into account the Reverse Stock Split (the &#8220;Exchange Ratio&#8221;). In connection with the Merger close, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-369">3,772,768</ix:nonFraction> shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#8220;Cend Plan&#8221;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#8217;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-370">1,227,776</ix:nonFraction> shares of the Company's common stock. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately <ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="f-371">52</ix:nonFraction>% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team provided a vast majority of the individuals on the management team and holds the chief executive officer (&#8220;CEO&#8221;), chief medical officer (&#8220;CMO&#8221;) and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#8217;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><ix:continuation id="f-367-2" continuedAt="f-367-3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no alternative future use being expensed as reported in the consolidated statement of operations. Operating results presented in the consolidated statements of operations and comprehensive loss prior to the Merger are solely related to Caladrius Biosciences, Inc. and subsidiaries.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company&#8217;s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company&#8217;s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-372" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-373" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Accordingly, actual results could differ from those estimates and assumptions.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-374" continuedAt="f-374-1" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-374-1">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</ix:continuation>.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><ix:continuation id="f-367-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-375" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_37"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 2 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-377" continuedAt="f-377-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-377-1" continuedAt="f-377-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-378" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-379" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-380" continuedAt="f-380-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-380-1">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-381" continuedAt="f-381-1" escape="true">The estimated useful lives of property and equipment are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><ix:continuation id="f-381-1" continuedAt="f-381-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-79" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-382">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-80" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-383">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-81" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-384">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="f-385" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-377-2" continuedAt="f-377-3"><div style="margin-bottom:8pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-386" continuedAt="f-386-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></ix:nonNumeric></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-386-1">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-387" continuedAt="f-387-1" escape="true">Loss Per Share</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-387-1">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-388" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="f-389" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-390" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, Cend&#8217;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Merger, with a value of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-391">0.4</ix:nonFraction>&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of <ix:nonNumeric contextRef="c-3" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-392">5</ix:nonNumeric> years. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-393">18</ix:nonFraction>&#160;thousand for the three months ended September&#160;30, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-394">53</ix:nonFraction>&#160;thousand for the nine months ended September&#160;30, 2023. <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-395" escape="true">The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.</ix:nonNumeric>  The projected amortization expense is $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-396"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-397"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-398"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-399"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-400">71</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;thousand per year for the next five years. </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><ix:continuation id="f-377-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-401" continuedAt="f-401-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-401-1">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-402"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-403"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-404"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-405">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue recognized for the three and nine months ended September&#160;30, 2023 and 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-406" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September&#160;30, 2023 and September&#160;30, 2022, the Company has <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-407"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-408"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-409"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-410">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <ix:nonFraction unitRef="usd" contextRef="c-82" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-411">not</ix:nonFraction> recognized any royalty revenue from any collaborative arrangement.</span></div></ix:nonNumeric></ix:continuation><div id="i35e3411510dd4ffe8f0b873f3f439282_40"></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 3 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:AssetAcquisitionTextBlock" id="f-412" continuedAt="f-412-1" escape="true">Merger</ix:nonNumeric></span></div><ix:continuation id="f-412-1"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;D. Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D being expensed. The fair value of total consideration was $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-413">36.1</ix:nonFraction>&#160;million. <ix:nonNumeric contextRef="c-1" name="us-gaap:AssetAcquisitionTableTextBlock" id="f-414" continuedAt="f-414-1" escape="true">The following table is a summary of the purchase price calculation (in thousands except per share data).</ix:nonNumeric></span></div><ix:continuation id="f-414-1"><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-415">3,772,768</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="2" name="lsta:AssetAcquisitionSharePrice" scale="0" id="f-416">6.25</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="lsta:AssetAcquisitionConsiderationTransferredEquityValue" format="ixt:num-dot-decimal" scale="3" id="f-417">23,580</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-418">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="f-419">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" scale="3" id="f-420">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="f-421">36,098</ix:nonFraction></span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="lsta:AssetAcquisitionCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-422">7,062</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="lsta:AssetAcquisitionNetWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-423">1,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="lsta:AssetAcquisitionOtherLiabilities" scale="3" id="f-424">22</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="lsta:AssetAcquisitionAcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-425">30,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="lsta:AssetAcquisitionIntangibles" scale="3" id="f-426">355</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="f-427">36,098</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_43"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 4 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-428" continuedAt="f-428-1" escape="true">Available-for-Sale-Securities</ix:nonNumeric></span></div><ix:continuation id="f-428-1" continuedAt="f-428-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-429" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-430">28,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-432">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-433">28,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-434">44,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-436">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-437">44,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-438">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-441">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-442">7,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-445">7,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-446">13,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-449">13,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-450">4,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-453">4,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-454">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-456">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-457">1,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-462">3,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-465">3,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-470">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-473">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-474">7,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-476">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-477">7,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-478">51,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-480">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-481">51,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-482">64,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-484">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-485">64,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-486" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-487">29,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-488">27,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-489">21,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-490">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-491">51,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-492">64,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-428-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-493" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-494">51,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-495">51,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:fixed-zero" scale="3" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-498">51,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-499">51,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_46"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 5 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-500" continuedAt="f-500-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-500-1"><ix:continuation id="f-381-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-502">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-503">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-504">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-505">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-506">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-507">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-508">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-509">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-510">417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-511">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-512">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results included depreciation expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-513">89</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-514">22</ix:nonFraction>&#160;thousand for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_49"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 6 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-515" continuedAt="f-515-1" escape="true">Income (Loss) Per Share</ix:nonNumeric></span></div><ix:continuation id="f-515-1"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2023 and 2022, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-516" continuedAt="f-516-1" escape="true">At September&#160;30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="f-516-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-517">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-518">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-101" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-519">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-520">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-103" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-521">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-104" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-522">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_52"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 7 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-523" continuedAt="f-523-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-523-1" continuedAt="f-523-2"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><ix:continuation id="f-523-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-524" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-525">29,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-528">29,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-529">27,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-532">27,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-534">21,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-536">21,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-538">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-540">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-541">29,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-542">21,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-544">51,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-545">27,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-546">37,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-548">64,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts payable and accrued expenses approximate fair value as of September&#160;30, 2023 and December&#160;31, 2022, due to the short maturity nature of these items.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_55"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 8&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-549" continuedAt="f-549-1" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="f-549-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-550" escape="true"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September&#160;30, 2023 and December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-551">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-552">2,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:ClinicalAndRDRelatedLiabilities" scale="3" id="f-553">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lsta:ClinicalAndRDRelatedLiabilities" scale="3" id="f-554">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AccruedGrantFunding" scale="3" id="f-555">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lsta:AccruedGrantFunding" format="ixt:fixed-zero" scale="3" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-557">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-558">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-559">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-560">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-561">3,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-562">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_58"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 9&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-563" continuedAt="f-563-1" escape="true">Operating Leases</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-563-1" continuedAt="f-563-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-564" escape="true">The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</ix:nonNumeric></ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><ix:continuation id="f-563-2"><ix:nonNumeric contextRef="c-1" name="lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" id="f-565" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-566"><span style="-sec-ix-hidden:f-567">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-568">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-569">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-570">348</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-571">487</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-572"><span style="-sec-ix-hidden:f-573">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-574">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-575">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-576"><span style="-sec-ix-hidden:f-577">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-578">181</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-579">305</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-580">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-581">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the weighted average remaining lease term for our operating lease was <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-582">2.0</ix:nonNumeric> years, and the weighted average discount rate for our operating lease was <ix:nonFraction unitRef="number" contextRef="c-3" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-583">9.625</ix:nonFraction>%. As of December&#160;31, 2022, the weighted average remaining lease term for our operating leases was <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-584">1.5</ix:nonNumeric> years, and the weighted average discount rate for our operating leases was <ix:nonFraction unitRef="number" contextRef="c-4" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-585">9.625</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-586" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of September&#160;30, 2023 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-587">48</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-588">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-589">143</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="f-590">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-591">36</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-592">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_61"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 10 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-593" continuedAt="f-593-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-593-1" continuedAt="f-593-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="lsta:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="f-594">50.0</ix:nonFraction>&#160;million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-595">43.6</ix:nonFraction>&#160;million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="lsta:OutstandingStockThreshold" format="ixt:num-dot-decimal" scale="6" id="f-596">75.0</ix:nonFraction>&#160;million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="lsta:SaleOfStockAvailableForSale" format="ixt:num-dot-decimal" scale="0" id="f-597">17,698,943</ix:nonFraction>, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. During the nine months ended September&#160;30, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-598">64,394</ix:nonFraction> shares of common stock under the ATM Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-599">270,774</ix:nonFraction>. Since inception, the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-600">64,394</ix:nonFraction> shares of common stock under the ATM Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-601">270,774</ix:nonFraction>.  </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><ix:continuation id="f-593-2" continuedAt="f-593-3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger closing on September 15, 2022, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-602">3,772,768</ix:nonFraction> shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-603">1,227,776</ix:nonFraction> options outstanding of Cend. The options granted under the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than <ix:nonNumeric contextRef="c-118" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-604">ten years</ix:nonNumeric> from their original date of grant. The Cend Plan stock options generally vest over a <ix:nonNumeric contextRef="c-119" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-605">four-year</ix:nonNumeric> term. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-606" continuedAt="f-606-1" escape="true">The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2023:</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="f-606-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-607">1,391,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-608">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-120" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-609">7.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-610">187.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="lsta:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="f-611">1,423,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="f-612">42.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-120" name="lsta:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="f-613">3.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-615">180,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-616">3.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsGranted" format="ixt:fixed-zero" scale="0" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsGranted" format="ixt:fixed-zero" scale="0" id="f-618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-619">82,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-620">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-623">144,594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-624">3.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsCanceled" format="ixt:fixed-zero" scale="0" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsCanceled" format="ixt:fixed-zero" scale="0" id="f-626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-627">24,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-628">29.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsExpired" format="ixt:num-dot-decimal" scale="0" id="f-629">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsExpired" scale="0" id="f-630">88.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-631">1,320,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-632">10.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-633">6.30</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-634">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="lsta:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="f-635">1,421,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="f-636">42.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="f-637">2.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-639">1,316,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-640">10.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-641">6.29</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-642">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="lsta:Sharesvestedandexpectedtovest" format="ixt:num-dot-decimal" scale="0" id="f-643">1,421,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" scale="0" id="f-644">42.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" format="ixt-sec:duryear" id="f-645">2.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsvestedandexpectedtovest" format="ixt:fixed-zero" scale="3" id="f-646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-647">1,229,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-648">11.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:OptionsVestedweightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-649">6.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="f-650">78.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="lsta:WarrantsVested" format="ixt:num-dot-decimal" scale="0" id="f-651">1,421,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsExercisable" scale="0" id="f-652">42.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:WeightedAverageRemainingContractualTermwarrantsvested" format="ixt-sec:duryear" id="f-653">2.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsvested" format="ixt:fixed-zero" scale="3" id="f-654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-655" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-656">159,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-657">70,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-658">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-659">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:f-660">one</span> and <ix:nonNumeric contextRef="c-124" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-661">four years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-662" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-663">188,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-664">111,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-665">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="f-666">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-593-3">The weighted average estimated fair value of restricted stock units issued for services in the nine months ended September&#160;30, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-121" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-667">3.00</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-668">12.46</ix:nonFraction> per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally <ix:nonNumeric contextRef="c-125" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-669">one year</ix:nonNumeric>, or upon the achievement of performance-based milestones.</ix:continuation> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 11 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-671" continuedAt="f-671-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-671-1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-672" continuedAt="f-672-1" escape="true">The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2023 and 2022 (in thousands):</ix:nonNumeric></span></div><div style="text-align:center;text-indent:18pt"><ix:continuation id="f-672-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-673">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-674">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-675">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-676">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-677">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-678">769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-679">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-680">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-681">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-682">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-683">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-684">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-685" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-686">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-687">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-688">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-119" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-689">1.85</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-125" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-690">1.10</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-121" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-691">1.69</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-692" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2023 and 2022 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-693">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="f-694">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-119" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-695">2.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-138" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-696">1.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_70"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 12 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-697" continuedAt="f-697-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-697-1" continuedAt="f-697-2"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-698">281.0</ix:nonFraction>&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-699">168.8</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-700">281.0</ix:nonFraction>&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-701">112.3</ix:nonFraction>&#160;million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173&#160;thousand under Internal Revenue Code Section 382. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="lsta:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-702">34.0</ix:nonFraction>&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><ix:continuation id="f-697-2" continuedAt="f-697-3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-703">88.2</ix:nonFraction>&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="lsta:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-704">34.0</ix:nonFraction>&#160;million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Cend Therapeutics had approximately $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-705">10.9</ix:nonFraction>&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-706">10.7</ix:nonFraction>&#160;million of Federal and $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-707">15.0</ix:nonFraction>&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="lsta:FairValueMarketOfTaxNOLs" format="ixt:num-dot-decimal" scale="6" id="f-708">36.1</ix:nonFraction>&#160;million and applying an applicable federal rate of <ix:nonFraction unitRef="number" contextRef="c-145" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-709">2.54</ix:nonFraction>% Cend will have an annual limitation of approximately $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="lsta:NetCarryforwardOperatingLossCarryforwardAnnualLimitation" format="ixt:num-dot-decimal" scale="3" id="f-710">917</ix:nonFraction>&#160;thousand each year. The Federal NOL of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="lsta:OperatingLossCarryforwardsPostAcquisition" format="ixt:num-dot-decimal" scale="3" id="f-711">106</ix:nonFraction>&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. Cend&#8217;s wholly owned Australian subsidiary has $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-712">1.8</ix:nonFraction>&#160;million of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had State NOLs available in New Jersey of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-713">35.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-714">97.0</ix:nonFraction>&#160;million, respectively, California of $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-715">10.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-716">69.5</ix:nonFraction>&#160;million, respectively, and New York City of $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-717">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-718">13.0</ix:nonFraction>&#160;million, respectively, to offset future taxable income expiring from 2032 through 2042. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs is limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company&#8217;s uncertain tax positions were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-719">344</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="f-720">0</ix:nonFraction>, respectively. Due to the acquisition of Cend, the Company&#8217;s uncertain tax positions increased by $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="f-721">344</ix:nonFraction>&#160;thousand related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. As of September&#160;30, 2023, the Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2019, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from the date of filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, the Company received final approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) under the Technology Business Tax Certificate Transfer Program (&#8220;Program&#8221;) to sell a percentage of its New Jersey net operating losses (&#8220;NJ NOLs&#8221;), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="lsta:ProceedsFromSaleOfNOLS" format="ixt:num-dot-decimal" scale="6" id="f-722">2.2</ix:nonFraction>&#160;million. The $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-723">2.3</ix:nonFraction>&#160;million of NJ NOLs related tax benefits has been recorded as a benefit from income taxes and the loss on sale of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="lsta:LossOnSaleOfNOL" format="ixt:num-dot-decimal" scale="6" id="f-724">0.1</ix:nonFraction>&#160;million recorded in other income (expense).</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-697-3">On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company&#8217;s results of operations for the year ended December 31, 2022. The Company will continue to monitor the future impact of changes in tax legislation.</ix:continuation>  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 13 &#8211; <ix:nonNumeric contextRef="c-1" name="lsta:ResearchAndDevelopmentTaxIncentiveTextBlock" id="f-725" continuedAt="f-725-1" escape="true">Australia Research and Development Tax Incentive</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-725-1" continuedAt="f-725-2">The Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between <ix:nonFraction unitRef="number" contextRef="c-155" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-726">43.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-156" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-727">48.5</ix:nonFraction>% (depending upon the income tax rate) for qualified research and development activities. As of the nine months ended September&#160;30, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="lsta:IncomeTaxIncentiveReceivable" format="ixt:num-dot-decimal" scale="6" id="f-728">0.5</ix:nonFraction>&#160;million was recorded as an income tax incentive receivable in  prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed. On </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-725-2">September 4, 2023 the Company's Australian subsidiary received a $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:num-dot-decimal" scale="6" id="f-729">0.6</ix:nonFraction>&#160;million tax refund from the Australian Taxation Office related to the 2022 tax year.</ix:continuation></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_76"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 14 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-730" continuedAt="f-730-1" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-730-1" continuedAt="f-730-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-730-2">In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022. Lingmed filed an answer to Cend&#8217;s response on July 11, 2022. At a Case Management Conference held on August 4, 2023, the Court set a trial date in the matter for August 2, 2024. The Company denies these allegations made by Lingmed and intends to vigorously defend itself.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_1115"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 15 &#8211; <ix:nonNumeric contextRef="c-1" name="lsta:TechnologyTransferAgreementTextBlock" id="f-731" continuedAt="f-731-1" escape="true">Technology Transfer Agreement</ix:nonNumeric></span></div><ix:continuation id="f-731-1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impilo Therapeutics </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (&#8220;Impilo&#8221;) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-732">766,000</ix:nonFraction> shares of its pre-seed preferred stock to the Company. On October 3, 2023 in connection with the Sanford Burnham Prebys license agreement (Note 16) Impilo cancelled the original stock certificate for <ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="lsta:InvestmentOwnedCanceledShares" format="ixt:num-dot-decimal" scale="0" id="f-733">766,000</ix:nonFraction> shares and reissued <ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-734">574,500</ix:nonFraction> shares of its pre-seed preferred stock to the Company.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_79"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 16 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-735" continuedAt="f-735-1" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="f-735-1" continuedAt="f-735-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend&#8217;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="lsta:SharesIssuedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-736">382,030</ix:nonFraction> shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="f-737">10,000</ix:nonFraction> increasing to $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" format="ixt:num-dot-decimal" scale="3" id="f-738">20,000</ix:nonFraction> on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="f-739">10.6</ix:nonFraction>&#160;million. The Company has also agreed to pay SBP royalties of <ix:nonFraction unitRef="number" contextRef="c-160" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="f-740">4</ix:nonFraction>% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP <ix:nonFraction unitRef="number" contextRef="c-160" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="f-741">25</ix:nonFraction>% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-742">191,500</ix:nonFraction> shares of the Company&#8217;s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><ix:continuation id="f-735-2" continuedAt="f-735-3"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="f-743">20,000</ix:nonFraction>, increasing to $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" format="ixt:num-dot-decimal" scale="3" id="f-744">30,000</ix:nonFraction> on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="f-745">23.2</ix:nonFraction>&#160;million. The Company is obligated to pay SBP royalties of <ix:nonFraction unitRef="number" contextRef="c-162" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="f-746">4</ix:nonFraction>% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from <ix:nonFraction unitRef="number" contextRef="c-163" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="f-747">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-164" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="f-748">25</ix:nonFraction>%, dependent on when the related milestones are reached. On September 14, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="lsta:SharesHeldByThirdParty" format="ixt:num-dot-decimal" scale="0" id="f-749">382,030</ix:nonFraction> shares of the Company&#8217;s common stock as of September&#160;30, 2023 and is a related party. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#8220;UCSD&#8221;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="f-750">1.2</ix:nonFraction>&#160;million. The Company has also agreed to pay UCSD royalties of <ix:nonFraction unitRef="number" contextRef="c-166" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="f-751">1.5</ix:nonFraction>% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from <ix:nonFraction unitRef="number" contextRef="c-167" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="f-752">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-168" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="f-753">20</ix:nonFraction>%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#8217; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-754">43,236</ix:nonFraction> shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="f-755">20,000</ix:nonFraction>, increasing to $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" format="ixt:num-dot-decimal" scale="3" id="f-756">25,000</ix:nonFraction> for year two and three of the agreement, increasing to $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" format="ixt:num-dot-decimal" scale="3" id="f-757">50,000</ix:nonFraction> on year four of the agreement and thereafter until the first commercial sale, and increasing to $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" format="ixt:num-dot-decimal" scale="3" id="f-758">150,000</ix:nonFraction> each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="f-759">5.0</ix:nonFraction>&#160;million. The Company has also agreed to pay MIT royalties of <ix:nonFraction unitRef="number" contextRef="c-170" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="f-760">2</ix:nonFraction>% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from <ix:nonFraction unitRef="number" contextRef="c-171" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="f-761">3</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-172" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="f-762">20</ix:nonFraction>%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="lsta:CollaborativeArrangementRightsAndObligationsChangeOfControlFee" format="ixt:num-dot-decimal" scale="6" id="f-763">0.3</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement expires upon the expiration or abandonment of all valid claims. The agreement may be earlier terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may also be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, in accordance with the provisions of the license agreement, the Company provided notice to MIT that the license agreement would terminate effective December 30, 2023. Until such date, the license remains in full force and effect.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIT owned <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="lsta:SharesHeldByThirdParty" format="ixt:num-dot-decimal" scale="0" id="f-764">43,236</ix:nonFraction> shares of the Company&#8217;s common stock as of September&#160;30, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 17 &#8211; <ix:continuation id="f-735-3" continuedAt="f-735-4">Research Collaboration and License Agreement</ix:continuation></span></div><ix:continuation id="f-735-4"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-765">10</ix:nonFraction>&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-766">5</ix:nonFraction>&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-767">95</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-768">125</ix:nonFraction>&#160;million, respectively, tiered royalties on net sales ranging from <ix:nonFraction unitRef="number" contextRef="c-176" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="f-769">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-177" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="f-770">15</ix:nonFraction>%, and tiered sublicensing revenues ranging from <ix:nonFraction unitRef="number" contextRef="c-176" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="f-771">12</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-177" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="f-772">35</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least <ix:nonNumeric contextRef="c-178" name="lsta:ResearchCollaborationAndLicenseAgreementOptionToTerminate" format="ixt-sec:durwordsen" id="f-773">sixty days</ix:nonNumeric> written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; herein and under &#8220;Risk Factors&#8221; in our 2022 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2022 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Our lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. LSTA1 also has the potential to modify the tumor microenvironment (&#8220;TME&#8221;), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability, and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. We are exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, we have development programs based on our autologous CD34+ cell therapy technology platform that we are seeking to partner while incurring no additional capital outlay.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Our goal is to develop and commercialize products that address important unmet medical needs. Our current development pipeline includes our product candidate LSTA1, which is the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including, metastatic pancreatic ductal adenocarcinoma (mPDAC) and other forms of pancreatic cancer, cholangiocarcinoma, esophageal cancer, head and neck cancer, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Targeted Solid Tumor Penetration via CendR Active Transport</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many solid tumor cancers, including pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;), are surrounded by dense fibrotic tissue, or stroma. This limits the efficacy of current chemotherapies for these cancers. Emerging immunotherapy treatments, including checkpoint inhibitors, adoptive cell therapies such as chimeric antigen receptor T (&#8220;CAR-T&#8221;) cells, as well as nucleic acid-based therapies, such as short interfering RNA (&#8220;siRNA&#8221;), antisense oligonucleotides (&#8220;ASO&#8221;), and messenger RNAs (&#8220;mRNAs&#8221;) also face challenges in penetrating solid tumors. Many tumors also exhibit an immunosuppressive tumor microenvironment (&#8220;TME&#8221;), which suppresses patients&#8217; immune systems&#8217; ability to fight their cancer and can limit effectiveness of immunotherapies and/or contribute to metastases. These factors negatively impact the ability of many therapeutic agents to effectively treat these cancers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the tumor stroma&#8217;s role as a primary impediment to effective treatment, our approach is to activate the C-end rule (&#8220;CendR&#8221;), or CendR system, a naturally occurring active transport system. Our lead investigational drug, LSTA1 (a specific internalizing R-G-D or iRGD peptide), activates this transport system in a tumor-specific manner (Sugahara, Science, 2010). LSTA1 enables more selective and efficient uptake of systemically administered anti-cancer drugs resulting in more intratumoral drug accumulation. The overall result is enhanced anticancer activity without an increase in side effects. While it is possible to couple/tether or conjugate some anticancer drugs to LSTA1, we believe that the co-administration approach is an advantage because it does not create a new chemical entity with its attendant development and regulatory hurdles, thereby providing an anticipated faster-to-clinic and faster-to-market product opportunity for a range of co-administration therapies. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LSTA1 has demonstrated favorable safety/tolerability and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for mPDAC. LSTA1&#8217;s cancer-targeted delivery may enable such emerging treatment modalities to treat a range of solid tumors potentially more effectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LSTA1 as a treatment for solid tumor cancers in combination with other anti-cancer agents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LSTA1 is an investigational drug that actuates the CendR active transport mechanism while also having the potential to modify the TME and make it less immunosuppressive, thereby making the tumor more susceptible to attack by the immune system and/or inhibiting the metastasis cascade. It is targeted to tumor vasculature, endothelial cells, tumor cells and some intratumoral immunosuppressive cells by its affinity for alpha-v, beta-3 and beta-5 integrins that are upregulated on these cells. LSTA1 is a nine amino acid cyclic internalizing RGD (&#8220;iRGD&#8221;) peptide that, once bound to these integrins, is cleaved by proteases expressed in tumors to release a peptide fragment, called a CendR fragment. The CendR fragment then binds to an adjacent receptor, called neuropilin-1 receptor, to activate a novel uptake pathway that allows circulating moieties such as anticancer drugs to more selectively and effectively penetrate solid tumors. The ability of LSTA1 to modify the TME to enhance delivery and efficacy of co-administered drugs has been demonstrated in many preclinical models in a range of solid tumors with the results from Lisata, collaborators and research groups around the world having been the subject of over 300 related scientific publications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to clinical development, LSTA1 is the subject of a completed Phase 1b clinical trial of 31 first-line metastatic pancreatic ductal adenocarcinoma patients, of which 29 were evaluable. Results from the trial showed that the safety profile of the LSTA1 combination regimen was similar to standard of care (&#8220;SoC&#8221;) alone with LSTA1 being well-tolerated with no-dose limiting toxicities. An Objective Response Rate (&#8220;ORR&#8221;) of fifty nine percent was observed, including a rare complete response, which compares favorably to the twenty three percent ORR observed in the &#8220;MPACT&#8221; clinical trial that served as the basis for approval of nab-paclitaxel for use in combination with gemcitabine for the treatment of first line, metastatic pancreatic ductal adenocarcinoma (Von Hoff, et al. 2013). A Disease Control Rate (&#8220;DCR&#8221;); (partial and complete responses plus stable disease) of over seventy nine percent was observed in comparison to a DCR of forty eight percent observed in the MPACT trial. Reduction in the level of circulating tumor biomarker CA19-9 was observed in 96% of patients versus 61% in the MPACT trial. Importantly, median progression-free survival and median overall survival of nearly ten months and over thirteen months were observed, respectively, vs. less than six months and less than nine months, respectively, in the MPACT trial. These results have been published in The Lancet Gastroenterology and Hepatology (Dean, et al. 2022).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, LSTA1 is the subject of multiple ongoing and planned clinical trials being conducted globally in a variety of solid tumor types and in combination with several chemotherapy and immunotherapy anti-cancer regimens. The following diagram summarizes these studies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><img src="lsta-20230930_g1.jpg" alt="Slide1.jpg" style="height:371px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><img src="lsta-20230930_g2.jpg" alt="Slide2.jpg" style="height:371px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34+ Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, we seek to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. We believe that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology, including, but not limited to, Buerger's disease, critical limb ischemia (&#8220;CLI&#8221;), coronary microvascular dysfunction (&#8220;CMD&#8221;), refractory angina, and diabetic kidney disease (&#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our randomized, open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study's enrollment, however, was significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that persisted for much of 2020, 2021, and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, we suspended further enrollment in the fourth quarter of 2021. Following study suspension, we completed all protocol-defined patient observations and completed the clinical study report. Data from the follow-up of all patients completed in the registration-eligible clinical trial in Japan have been compiled and are the subject of discussions with the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) in Japan as part of the Japanese regulatory pre-consultation process and in preparation for the formal clinical consultation meetings which precede a Japanese new drug application (&#8220;JNDA&#8221;). To date, the PMDA has provided advice on how to prepare for the formal consultation meeting and has indicated their preference for additional clinical information to accompany the filing of a JNDA. Concomitantly, the Company has reinforced its efforts to secure a Japanese partner to complete the remaining steps of development/registration as well as eventual commercialization in Japan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#8220;Caladrius&#8221;), completed its acquisition of Cend Therapeutics, Inc. (&#8220;Cend&#8221;), a Delaware corporation (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#8220;Merger Sub&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#8220;Effective Time&#8221;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc. in connection with and immediately following to the Effective Time, and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#8220;Reverse Stock Split&#8221;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#8217;s common stock based on an exchange ratio of 0.5338 (the &#8220;Exchange Ratio&#8221;), after taking into account the Reverse Stock Split. In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, we assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#8220;Cend Plan&#8221;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#8217;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, we assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team has more individuals on the management team and will hold the CEO, CMO and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#8217;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no alternative future use being expensed. The prior reported operating results prior to the Merger close are those of Caladrius.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad intellectual property portfolio of assets includes notable programs available for out-licensing in order to augment or continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_91"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended September&#160;30, 2023 Compared to Three Months Ended September&#160;30, 2022 </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September&#160;30, 2023 and September&#160;30, 2022 (in thousands):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"></td><td style="width:50.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,964&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,720&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,756)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,261)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,383)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $5.3 million for the three months ended September&#160;30, 2023, compared to $37.4 million for the three months ended September&#160;30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023, operating expenses totaled $6.0 million, compared to $37.7 million for the three months ended September&#160;30, 2022, representing a decrease of 84.2%. Excluding the in-process research and development expense of $30.4 million relating to the Merger, operating expenses decreased by $1.4 million, or 18.6% compared to the three months ended September&#160;30, 2022. Operating expenses comprised the following:&#160;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and development expenses were approximately $3.4 million for the three months ended September&#160;30, 2023, compared to $3.3 million for the three months ended September&#160;30, 2022, representing an increase of $45.0 thousand or 1.3%. This was primarily due to expenses associated with our study activities in the current year for our LSTA1 Phase 2a proof-of-concept Bolster trial in various solid tumors in combination with the corresponding standards of care, enrollment activities for the LSTA1 Phase 2b ASCEND study, chemistry, manufacturing and control (&#8220;CMC&#8221;) activities for LSTA1 and study start up activities for the LSTA1 Phase 2a study for the treatment of glioblastoma multiforme being offset by expenses associated with our Ischemic Repair programs (XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study, HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and diabetic kidney disease) in the prior year.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $2.6 million for the three months ended September&#160;30, 2023, compared to $4.0 million for the three months ended September&#160;30, 2022, representing a decrease of $1.4 million or 35.3%. This was primarily due to non-recurring merger related costs in the prior year, a decrease in equity expense due to prior year performance stock unit vesting, Merger option assumption expense and departing board member restricted stock unit vesting and timing of our annual stockholder meeting versus the prior year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense) is comprised primarily of investment income from cash, cash equivalents and marketable securities for both three months ended September&#160;30, 2023 and 2022.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine Months Ended September&#160;30, 2023 Compared to Nine Months Ended September&#160;30, 2022 </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September&#160;30, 2023 and September&#160;30, 2022 (in thousands):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:52.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,683&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,378)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,479)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,475)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,235)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $15.5 million for the nine months ended September&#160;30, 2023, compared to $48.2 million for the nine months ended September&#160;30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2023, operating expenses totaled $19.7 million compared to $51.1 million for the nine months ended September&#160;30, 2022, representing a decrease of 61.5%. Excluding the in-process research and development expense of $30.4 million relating to the Merger, operating expenses decreased by $1.0 million, or 4.8% compared to the nine months ended September&#160;30, 2022. Operating expenses comprised the following:&#160;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and development expenses were approximately $9.7&#160;million for the nine months ended September&#160;30, 2023, compared to $9.9&#160;million for the nine months ended September&#160;30, 2022, representing a decrease of $0.1 million or 1.3%. This was primarily due to expenses associated with our study activities in the current year for our LSTA1 Phase 2a proof-of-concept Bolster trial in various solid tumors in combination with the corresponding standards of care, enrollment activities for the LSTA1 Phase 2b ASCEND study, chemistry, manufacturing and control (&#8220;CMC&#8221;) activities for LSTA1 and study start up activities for the LSTA1 Phase 2a study for the treatment of glioblastoma multiforme being offset by expenses associated with our Ischemic Repair programs (XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study, HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and diabetic kidney disease) in the prior year.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $10.0 million for the nine months ended September&#160;30, 2023, compared to $10.8 million for the nine months ended September&#160;30, 2022, representing a decrease of $0.9 million or 7.9%. This was primarily due to non-recurring Merger related costs in the prior year, a decrease in equity expense due to prior year performance stock unit vesting, Merger option assumption expense and departing board member restricted stock unit vesting, lower annual stockholder meeting expenses and a decrease in directors and officers insurance premiums, partially offset by severance costs associated with the elimination of the Chief Business Officer position on May 1, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense) is comprised of investment income from cash, cash equivalents and marketable securities for both nine months ended September&#160;30, 2023 and 2022 and a loss on sale related to the sale of our NJ NOLs in the nine months ended September&#160;30, 2023 and 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 2023, we received final approval from the NJEDA under the Program to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.2&#160;million. The $2.3 million of our NJ NOL Tax Benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we received final approval from the NJEDA under the Program to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3 million. The $2.5 million of our NJ NOL Tax Benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2023, we had cash, cash equivalents and marketable securities of approximately $54.4 million, working capital of approximately $52.1 million, and stockholders&#8217; equity of approximately $53.0 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023, we met our immediate cash requirements through existing cash balances.  Additionally, we used equity and equity-linked instruments to pay for services and compensation. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) or provided by, operating, investing and financing activities were as follows (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,963)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,702)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the nine months ended September&#160;30, 2023 was $16.0 million, which is comprised of (i) our net loss of $15.5 million, adjusted for non-cash expenses totaling $1.0&#160;million (which includes adjustments for equity-based compensation, depreciation and amortization, a loss on disposal of fixed assets, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $1.5 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the nine months ended September&#160;30, 2022 was $14.7 million, which is comprised of (i) our net loss of $48.2 million, adjusted for non-cash expenses totaling $33.5 million (which includes adjustments for equity-based compensation, depreciation and amortization, in process research and development expenses, and amortization/accretion of marketable securities) and (ii) changes in operating assets and liabilities providing approximately $0.1 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the nine months ended September&#160;30, 2023 totaled $15.8 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the nine months ended September&#160;30, 2022 totaled $21.8 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities) partially offset by the asset acquisition costs, net of cash acquired related to the Merger and purchase of property and equipment.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by financing activities during the nine months ended September&#160;30, 2023 totaled $0.4 million and consisted of proceeds from the issuance of shares through our ATM Agreement (as defined below) of $0.3&#160;million, option exercise proceeds of $0.2&#160;million partially offset by tax withholding-related payments of $0.1&#160;million on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in financing activities during the nine months ended September&#160;30, 2022 totaled $0.2 million and consisted primarily of tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Requirements Outlook</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our short and long-term liquidity needs, we expect to use existing cash balances, marketable securities and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of pharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand and marketable securities will enable us to fund operating expenses for at least the next 12 months following the issuance of our financial statements. Our future capital requirements are difficult to forecast and will depend on many factors including the timing and nature of any other strategic transactions that we undertake; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and the financial terms of such agreements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, we entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC as sales agent, in connection with an &#8220;at the market offering&#8221; under which we from time to time may offer and sell shares of our common stock having an aggregate offering price of up to $50.0&#160;million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6 million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0 million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. Since inception we have issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_97"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates during the three and nine months ended September&#160;30, 2023, compared to those reported in our 2022 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_100"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.<br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_103"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer, who serves as our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, we evaluated, with the participation of our management, including our Chief Executive Officer, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_109"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as disclosed in &#8220;Note 14 &#8211; Contingencies&#8221; set forth in the Notes to Unaudited Consolidated Financial Statements, which are included herein, there are no material changes to the disclosures previously reported in our 2022 Form 10-K.<br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_112"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors previously reported in our 2022 Form 10-K.  See the risk factors set forth in our 2022 Annual Report on Form 10-K under the caption &#8220;Item 1A - Risk Factors.&#8221;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_115"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_118"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_121"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_124"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i35e3411510dd4ffe8f0b873f3f439282_127"></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LISATA THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> /s/ David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:   President &amp; Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer, Principal Financial Officer </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37 </span></div></div></div><div id="i35e3411510dd4ffe8f0b873f3f439282_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e3411510dd4ffe8f0b873f3f439282_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:461.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex311_20230930.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex32_20230930.htm">32</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:16.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:502.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">             </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>lsta-ex311_20230930.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iaceed0f54fe8456481936594bc9a3486_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Mazzo, PhD, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;2, 2023 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD&#160;&#160;&#160;&#160;       </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; David J. Mazzo, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; President &#38; Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>lsta-ex32_20230930.htm
<DESCRIPTION>EX-32
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i54d2d86ff49f47ab961c949d3659f7ac_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the &#8220;Company&#8221;) for the quarter ended September&#160;30, 2023 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David J. Mazzo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;November&#160;2, 2023 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD     </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Mazzo, PhD</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President &#38; Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>lsta-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b3932c72-a861-4a02-8e8c-886f49fbe91d,g:dd0049eb-adfc-4bb4-a64a-f5d2d3c1c00a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lsta="http://www.caladrius.com/20230930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.caladrius.com/20230930">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.caladrius.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParentheticals" roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFEQUITY" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusiness" roleURI="http://www.caladrius.com/role/TheBusiness">
        <link:definition>0000008 - Disclosure - The Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Merger" roleURI="http://www.caladrius.com/role/Merger">
        <link:definition>0000010 - Disclosure - Merger</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecurities" roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities">
        <link:definition>0000011 - Disclosure - Available-for-Sale-Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.caladrius.com/role/PropertyandEquipment">
        <link:definition>0000012 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShare" roleURI="http://www.caladrius.com/role/IncomeLossPerShare">
        <link:definition>0000013 - Disclosure - Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.caladrius.com/role/FairValueMeasurements">
        <link:definition>0000014 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.caladrius.com/role/AccruedLiabilities">
        <link:definition>0000015 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.caladrius.com/role/OperatingLeases">
        <link:definition>0000016 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.caladrius.com/role/StockholdersEquity">
        <link:definition>0000017 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.caladrius.com/role/ShareBasedCompensation">
        <link:definition>0000018 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.caladrius.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AustraliaResearchandDevelopmentTaxIncentive" roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive">
        <link:definition>0000020 - Disclosure - Australia Research and Development Tax Incentive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.caladrius.com/role/Contingencies">
        <link:definition>0000021 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TechnologyTransferAgreement" roleURI="http://www.caladrius.com/role/TechnologyTransferAgreement">
        <link:definition>0000022 - Disclosure - Technology Transfer Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.caladrius.com/role/LicenseAgreements">
        <link:definition>0000023 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreement" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement">
        <link:definition>0000024 - Disclosure - Research Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerTables" roleURI="http://www.caladrius.com/role/MergerTables">
        <link:definition>9954473 - Disclosure - Merger (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesTables" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables">
        <link:definition>9954474 - Disclosure - Available-for-Sale-Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables">
        <link:definition>9954475 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareTables" roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables">
        <link:definition>9954476 - Disclosure - Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables">
        <link:definition>9954477 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables">
        <link:definition>9954478 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.caladrius.com/role/OperatingLeasesTables">
        <link:definition>9954479 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.caladrius.com/role/StockholdersEquityTables">
        <link:definition>9954480 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables">
        <link:definition>9954481 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessDetails" roleURI="http://www.caladrius.com/role/TheBusinessDetails">
        <link:definition>9954482 - Disclosure - The Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>9954483 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954484 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerNarrativeDetails" roleURI="http://www.caladrius.com/role/MergerNarrativeDetails">
        <link:definition>9954485 - Disclosure - Merger - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerDetails" roleURI="http://www.caladrius.com/role/MergerDetails">
        <link:definition>9954486 - Disclosure - Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
        <link:definition>9954487 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails">
        <link:definition>9954488 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>9954489 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails">
        <link:definition>9954490 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareDetails" roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails">
        <link:definition>9954491 - Disclosure - Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails">
        <link:definition>9954492 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails">
        <link:definition>9954493 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>9954494 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesBalanceSheetPresentationDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails">
        <link:definition>9954495 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>9954496 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>9954496 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityEquityIssuancesDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails">
        <link:definition>9954497 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandWarrantsNarrativeDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails">
        <link:definition>9954498 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandWarrantsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails">
        <link:definition>9954499 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
        <link:definition>9954500 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>9954501 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostNotYetRecognizedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
        <link:definition>9954502 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
        <link:definition>9954503 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesDetails">
        <link:definition>9954504 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AustraliaResearchandDevelopmentTaxIncentiveDetails" roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails">
        <link:definition>9954505 - Disclosure - Australia Research and Development Tax Incentive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TechnologyTransferAgreementDetails" roleURI="http://www.caladrius.com/role/TechnologyTransferAgreementDetails">
        <link:definition>9954506 - Disclosure - Technology Transfer Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails">
        <link:definition>9954507 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementDetails" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails">
        <link:definition>9954508 - Disclosure - Research Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lsta_LossOnSaleOfNOL" abstract="false" name="LossOnSaleOfNOL" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CENDMember" abstract="true" name="CENDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" abstract="false" name="SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ImpiloMember" abstract="true" name="ImpiloMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" abstract="false" name="CollaborativeArrangementRightsAndObligationsSublicensingFees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_IncomeTaxIncentiveReceivable" abstract="false" name="IncomeTaxIncentiveReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WarrantsExpired" abstract="false" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WarrantsOtherDisclosuresAbstract" abstract="true" name="WarrantsOtherDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_WarrantsVested" abstract="false" name="WarrantsVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WarrantsCanceled" abstract="false" name="WarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_MassachusettsInstituteOfTechnologyMember" abstract="true" name="MassachusettsInstituteOfTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_BusinessTextBlock" abstract="false" name="BusinessTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lsta_FairValueMarketOfTaxNOLs" abstract="false" name="FairValueMarketOfTaxNOLs" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" abstract="false" name="NetCarryforwardOperatingLossCarryforwardAnnualLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" abstract="false" name="AssetAcquisitionAcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ProceedsFromSaleOfNOLS" abstract="false" name="ProceedsFromSaleOfNOLS" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_OutstandingStockThreshold" abstract="false" name="OutstandingStockThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_SanfordBurnhamPrebysMember" abstract="true" name="SanfordBurnhamPrebysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsChangeOfControlFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_Sharesvestedandexpectedtovest" abstract="false" name="Sharesvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_ExclusiveLicenseAndCollaborationAgreementMember" abstract="true" name="ExclusiveLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_AccruedGrantFunding" abstract="false" name="AccruedGrantFunding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ClinicalAndRDRelatedLiabilities" abstract="false" name="ClinicalAndRDRelatedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsCanceled" abstract="false" name="WeightedAverageExercisePriceWarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_PaymentsForAssetAcquisitionCostsNet" abstract="false" name="PaymentsForAssetAcquisitionCostsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" abstract="false" name="CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsGranted" abstract="false" name="WeightedAverageExercisePriceWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_AssetAcquisitionIntangibles" abstract="false" name="AssetAcquisitionIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" abstract="false" name="WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsExercised" abstract="false" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" abstract="false" name="RevenuePerformanceObligationPercentageOfSublicensingRevenues" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" abstract="false" name="WeightedAverageRemainingContractualTermwarrantoutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_SharesIssuedUnderLicenseAgreement" abstract="false" name="SharesIssuedUnderLicenseAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_InvestmentOwnedCanceledShares" abstract="false" name="InvestmentOwnedCanceledShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_CommonStockWarrantsShares" abstract="false" name="CommonStockWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_SharesHeldByThirdParty" abstract="false" name="SharesHeldByThirdParty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_QiluMember" abstract="true" name="QiluMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" abstract="false" name="AggregateIntrinsicValueWarrantsvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AssetAcquisitionSharePrice" abstract="false" name="AssetAcquisitionSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_InProcessResearchAndDevelopment" abstract="false" name="InProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" abstract="false" name="ResearchAndDevelopmentTaxIncentiveTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lsta_WeightedAverageRemainingContractualTermwarrantsvested" abstract="false" name="WeightedAverageRemainingContractualTermwarrantsvested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_EPSAbstract" abstract="true" name="EPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_OptionsVestedweightedAverageRemainingContractualTerm" abstract="false" name="OptionsVestedweightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_RevenuePerformanceObligationPercentageOfNetSale" abstract="false" name="RevenuePerformanceObligationPercentageOfNetSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lsta_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsExpired" abstract="false" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_OperatingLossCarryforwardsPostAcquisition" abstract="false" name="OperatingLossCarryforwardsPostAcquisition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AssetAcquisitionCashAndCashEquivalents" abstract="false" name="AssetAcquisitionCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AssetAcquisitionOtherLiabilities" abstract="false" name="AssetAcquisitionOtherLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_UniversityOfCaliforniaAtSanDiegoMember" abstract="true" name="UniversityOfCaliforniaAtSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_TechnologyTransferAgreementTextBlock" abstract="false" name="TechnologyTransferAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_SaleOfStockAvailableForSalePercentage" abstract="false" name="SaleOfStockAvailableForSalePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_SaleOfStockAvailableForSale" abstract="false" name="SaleOfStockAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" abstract="false" name="ResearchCollaborationAndLicenseAgreementOptionToTerminate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_AssetAcquisitionNetWorkingCapital" abstract="false" name="AssetAcquisitionNetWorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_TechnologyTransferAgreementAbstract" abstract="true" name="TechnologyTransferAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_AssetAcquisitionConsiderationTransferredEquityValue" abstract="false" name="AssetAcquisitionConsiderationTransferredEquityValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" abstract="false" name="LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lsta_CaladriusMember" abstract="true" name="CaladriusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsOutstanding" abstract="false" name="WeightedAverageExercisePriceWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" abstract="false" name="StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_OperatingLossCarryforwardsBeforeWriteDown" abstract="false" name="OperatingLossCarryforwardsBeforeWriteDown" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_AggregateIntrinsicValueWarrantsvested" abstract="false" name="AggregateIntrinsicValueWarrantsvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AggregateIntrinsicValueWarrantsOutstanding" abstract="false" name="AggregateIntrinsicValueWarrantsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" abstract="false" name="WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsExercisable" abstract="false" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_OperatingLeaseRightOfUseAssetAbstract" abstract="true" name="OperatingLeaseRightOfUseAssetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_WarrantsGranted" abstract="false" name="WarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>lsta-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b3932c72-a861-4a02-8e8c-886f49fbe91d,g:dd0049eb-adfc-4bb4-a64a-f5d2d3c1c00a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bff2bf47-49f8-4e12-b98a-c615662c8eda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cb605626-30e6-4e2a-bf21-058757e984b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bff2bf47-49f8-4e12-b98a-c615662c8eda" xlink:to="loc_us-gaap_StockholdersEquity_cb605626-30e6-4e2a-bf21-058757e984b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_afaa6361-b7fe-458f-8746-1cf735bfdd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bff2bf47-49f8-4e12-b98a-c615662c8eda" xlink:to="loc_us-gaap_MinorityInterest_afaa6361-b7fe-458f-8746-1cf735bfdd22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_84ad1f59-8342-40eb-96e9-cd0630a474f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8d5466a9-329f-4f69-93a1-b380369ca9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_84ad1f59-8342-40eb-96e9-cd0630a474f1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8d5466a9-329f-4f69-93a1-b380369ca9f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59fe1776-3bb4-4b99-8431-b08acd2ebcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_84ad1f59-8342-40eb-96e9-cd0630a474f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59fe1776-3bb4-4b99-8431-b08acd2ebcc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f9132369-78d0-4f9c-9b39-cec7f3ba5189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_84ad1f59-8342-40eb-96e9-cd0630a474f1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f9132369-78d0-4f9c-9b39-cec7f3ba5189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_82958bec-5853-424a-ab51-2fa51064d391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_84ad1f59-8342-40eb-96e9-cd0630a474f1" xlink:to="loc_us-gaap_CommonStockValue_82958bec-5853-424a-ab51-2fa51064d391" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_d06fea8b-e898-474b-ae47-9c9a1e7a499d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_84ad1f59-8342-40eb-96e9-cd0630a474f1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_d06fea8b-e898-474b-ae47-9c9a1e7a499d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0090fa1-cb45-4a16-a054-2fa44e0d2cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_149ecea6-48e6-453b-9a84-5da22335d93c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0090fa1-cb45-4a16-a054-2fa44e0d2cf4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_149ecea6-48e6-453b-9a84-5da22335d93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2fd61f38-b649-4725-97e0-284812f35eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0090fa1-cb45-4a16-a054-2fa44e0d2cf4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2fd61f38-b649-4725-97e0-284812f35eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c40c84c9-06d0-4f87-946a-876e0c65c2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0090fa1-cb45-4a16-a054-2fa44e0d2cf4" xlink:to="loc_us-gaap_Liabilities_c40c84c9-06d0-4f87-946a-876e0c65c2a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f9f2e10f-67c2-4d6b-9952-720d0b91161c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b9dd0eca-d1f8-452a-a7ae-0cce3ac5fbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f9f2e10f-67c2-4d6b-9952-720d0b91161c" xlink:to="loc_us-gaap_LiabilitiesCurrent_b9dd0eca-d1f8-452a-a7ae-0cce3ac5fbf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_01c53a1e-ec54-4c68-82ef-c89859962a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f9f2e10f-67c2-4d6b-9952-720d0b91161c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_01c53a1e-ec54-4c68-82ef-c89859962a77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d94526da-3e65-4852-a9e0-e74dcca77900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_32522dc6-25c6-48cc-b252-8becbdc55b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d94526da-3e65-4852-a9e0-e74dcca77900" xlink:to="loc_us-gaap_AccountsPayableCurrent_32522dc6-25c6-48cc-b252-8becbdc55b0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_97d61bb7-0f5e-496a-b274-7f0d9d19c9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d94526da-3e65-4852-a9e0-e74dcca77900" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_97d61bb7-0f5e-496a-b274-7f0d9d19c9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_777ebc6c-3af4-4baa-b334-be7676d11e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3d4b354a-8e92-4991-9c28-e42036087dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_777ebc6c-3af4-4baa-b334-be7676d11e0c" xlink:to="loc_us-gaap_AssetsCurrent_3d4b354a-8e92-4991-9c28-e42036087dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d49b9a32-bebf-48ef-b2a8-c2d035912954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_777ebc6c-3af4-4baa-b334-be7676d11e0c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d49b9a32-bebf-48ef-b2a8-c2d035912954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bf28fa78-deea-499b-97a2-c64c854b468d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_777ebc6c-3af4-4baa-b334-be7676d11e0c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bf28fa78-deea-499b-97a2-c64c854b468d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b89cba57-92f0-4a01-a1a1-45333e03ad65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_777ebc6c-3af4-4baa-b334-be7676d11e0c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b89cba57-92f0-4a01-a1a1-45333e03ad65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7802e226-5014-47b1-bde6-cc04b50599b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b1c205ba-7c1b-4eb5-963a-87ab3d7b48ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7802e226-5014-47b1-bde6-cc04b50599b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b1c205ba-7c1b-4eb5-963a-87ab3d7b48ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_6e238f4e-a520-4485-b764-98b0fd0f1975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7802e226-5014-47b1-bde6-cc04b50599b3" xlink:to="loc_us-gaap_MarketableSecurities_6e238f4e-a520-4485-b764-98b0fd0f1975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3bda39d5-9bc0-427a-82a5-813ffe69d52e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7802e226-5014-47b1-bde6-cc04b50599b3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3bda39d5-9bc0-427a-82a5-813ffe69d52e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4e842d6f-1a07-4492-99b2-8c23559ef70a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_9efa1bfe-a961-4360-a552-25829b5db4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4e842d6f-1a07-4492-99b2-8c23559ef70a" xlink:to="loc_us-gaap_InvestmentIncomeNet_9efa1bfe-a961-4360-a552-25829b5db4a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_383be972-5969-42ac-a8eb-0e81708574d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4e842d6f-1a07-4492-99b2-8c23559ef70a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_383be972-5969-42ac-a8eb-0e81708574d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7b214b5b-fe62-43ae-8054-d2dd0cc5189a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a09bf96b-6db9-4274-b11d-561f75037bad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7b214b5b-fe62-43ae-8054-d2dd0cc5189a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a09bf96b-6db9-4274-b11d-561f75037bad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f80cc6f1-a4a8-4b2a-b320-f315d92f9296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7b214b5b-fe62-43ae-8054-d2dd0cc5189a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f80cc6f1-a4a8-4b2a-b320-f315d92f9296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c4ac49a-2475-427a-a646-7e53c58e7491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3d30ffcf-b3bb-4e7e-98a1-ca92f0435461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7c4ac49a-2475-427a-a646-7e53c58e7491" xlink:to="loc_us-gaap_ProfitLoss_3d30ffcf-b3bb-4e7e-98a1-ca92f0435461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_7a26ad68-fd0a-4902-a398-35ec85c29a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7c4ac49a-2475-427a-a646-7e53c58e7491" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_7a26ad68-fd0a-4902-a398-35ec85c29a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_89578bc8-39af-4099-8fba-211011b9414b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InProcessResearchAndDevelopment_817c76b6-bf75-4167-8c4b-dbf96741b2c5" xlink:href="lsta-20230930.xsd#lsta_InProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_89578bc8-39af-4099-8fba-211011b9414b" xlink:to="loc_lsta_InProcessResearchAndDevelopment_817c76b6-bf75-4167-8c4b-dbf96741b2c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7dbb0bcc-ffb9-4c3d-9976-13caeb835c80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_89578bc8-39af-4099-8fba-211011b9414b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7dbb0bcc-ffb9-4c3d-9976-13caeb835c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75eca1a7-75ed-48d1-817c-74b401766eba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_89578bc8-39af-4099-8fba-211011b9414b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75eca1a7-75ed-48d1-817c-74b401766eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5a4dab3e-0f52-4656-adb1-bd2cf4ea7ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_01345173-d84c-49ae-9d92-1acecdbc4a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5a4dab3e-0f52-4656-adb1-bd2cf4ea7ba7" xlink:to="loc_us-gaap_OperatingExpenses_01345173-d84c-49ae-9d92-1acecdbc4a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b653ac2-f136-4928-baa8-2f2efc9c556f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c29cfb0c-0bfb-4546-9450-0f5bbefe4721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b653ac2-f136-4928-baa8-2f2efc9c556f" xlink:to="loc_us-gaap_OperatingIncomeLoss_c29cfb0c-0bfb-4546-9450-0f5bbefe4721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_85602812-a790-48f2-a221-78ed8146f8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b653ac2-f136-4928-baa8-2f2efc9c556f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_85602812-a790-48f2-a221-78ed8146f8b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_de300e5f-a9e1-48b1-9bf8-b7c11e0da23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_779bf8ae-0012-41a3-861d-97ff37c33b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_de300e5f-a9e1-48b1-9bf8-b7c11e0da23a" xlink:to="loc_us-gaap_ProfitLoss_779bf8ae-0012-41a3-861d-97ff37c33b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_58301c93-eea9-4951-8c94-eba83fd9514e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_de300e5f-a9e1-48b1-9bf8-b7c11e0da23a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_58301c93-eea9-4951-8c94-eba83fd9514e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_80324550-476c-4913-bd4f-04ced9339a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_16c1fbe4-9ee5-452c-9b63-d9e7720ea511" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_80324550-476c-4913-bd4f-04ced9339a8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_16c1fbe4-9ee5-452c-9b63-d9e7720ea511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1c674b58-139c-49f0-a3fe-1b61e9dc345c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_80324550-476c-4913-bd4f-04ced9339a8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1c674b58-139c-49f0-a3fe-1b61e9dc345c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_026dfe73-c6ee-4dee-8225-44a1331096cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_026dfe73-c6ee-4dee-8225-44a1331096cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_c35a7e33-2b06-48f7-8896-9f9ff6ced55f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_c35a7e33-2b06-48f7-8896-9f9ff6ced55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a40ba452-c573-49b8-a204-803f49e6ea3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a40ba452-c573-49b8-a204-803f49e6ea3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_31ceb377-12fc-45c9-9d32-91b0d1ff55d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:to="loc_us-gaap_ProfitLoss_31ceb377-12fc-45c9-9d32-91b0d1ff55d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2abeb595-0f3a-480b-89bb-0c5028971ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2abeb595-0f3a-480b-89bb-0c5028971ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_6963689f-c5f2-465c-8772-2f6a6da128a4" xlink:href="lsta-20230930.xsd#lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:to="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_6963689f-c5f2-465c-8772-2f6a6da128a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_44b4ac41-e16d-479a-aa8a-eb268efc00e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:to="loc_us-gaap_DepreciationAndAmortization_44b4ac41-e16d-479a-aa8a-eb268efc00e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c71df857-706c-43db-9344-6ef6af167da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c71df857-706c-43db-9344-6ef6af167da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5d7900a2-9d48-4e82-9616-48e93aad9e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd07564a-11e3-40b6-ac03-701eb275b5c5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5d7900a2-9d48-4e82-9616-48e93aad9e2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35d1d9aa-6712-41d0-a2ca-6db23215c59a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ead1a2ce-344d-443f-95ea-66d67db0e7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35d1d9aa-6712-41d0-a2ca-6db23215c59a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ead1a2ce-344d-443f-95ea-66d67db0e7a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_PaymentsForAssetAcquisitionCostsNet_a0729ebc-33e6-431b-8f26-7a5a74c82fe0" xlink:href="lsta-20230930.xsd#lsta_PaymentsForAssetAcquisitionCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35d1d9aa-6712-41d0-a2ca-6db23215c59a" xlink:to="loc_lsta_PaymentsForAssetAcquisitionCostsNet_a0729ebc-33e6-431b-8f26-7a5a74c82fe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637be869-8945-4745-9cd3-59c0c036d37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35d1d9aa-6712-41d0-a2ca-6db23215c59a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637be869-8945-4745-9cd3-59c0c036d37b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2266f710-829c-4de2-b6d5-43de7647e7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35d1d9aa-6712-41d0-a2ca-6db23215c59a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2266f710-829c-4de2-b6d5-43de7647e7e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43db5ada-ef7b-438f-a834-423da963ac4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2a888c7-84c5-48cc-9cbd-207f2f83a048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43db5ada-ef7b-438f-a834-423da963ac4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2a888c7-84c5-48cc-9cbd-207f2f83a048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ef7c685-6f73-4745-8c09-e609960d3ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43db5ada-ef7b-438f-a834-423da963ac4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ef7c685-6f73-4745-8c09-e609960d3ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_308bbe60-535f-4014-809d-8e7741773d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43db5ada-ef7b-438f-a834-423da963ac4a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_308bbe60-535f-4014-809d-8e7741773d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81b4cabc-2eee-4d1f-be97-f9e8785daaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43db5ada-ef7b-438f-a834-423da963ac4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81b4cabc-2eee-4d1f-be97-f9e8785daaa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd94cf0d-7f19-4761-a6d2-70f322a336c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5a7f785a-682f-42b5-b8bb-b8abf66950cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd94cf0d-7f19-4761-a6d2-70f322a336c4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5a7f785a-682f-42b5-b8bb-b8abf66950cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bf9b0ee8-66b2-43b7-88a7-0446bbdfbecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd94cf0d-7f19-4761-a6d2-70f322a336c4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bf9b0ee8-66b2-43b7-88a7-0446bbdfbecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_10c3d6db-c1bd-4ccf-bec6-43c1b7f25fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd94cf0d-7f19-4761-a6d2-70f322a336c4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_10c3d6db-c1bd-4ccf-bec6-43c1b7f25fa0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_76827a97-0bd2-4924-9fab-c39a4552ed6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_87d9d6de-1731-4995-8ace-352b07146918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_76827a97-0bd2-4924-9fab-c39a4552ed6c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_87d9d6de-1731-4995-8ace-352b07146918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8f50caf-1066-4682-a948-5f63205bd825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_76827a97-0bd2-4924-9fab-c39a4552ed6c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8f50caf-1066-4682-a948-5f63205bd825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897c35e9-ecb2-4ba9-9126-0536e6091886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_76827a97-0bd2-4924-9fab-c39a4552ed6c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897c35e9-ecb2-4ba9-9126-0536e6091886" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4bb13da6-3e71-4738-b743-486eb3ba031c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_2edd7e3a-d88f-4e20-93a3-97f39f856b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4bb13da6-3e71-4738-b743-486eb3ba031c" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_2edd7e3a-d88f-4e20-93a3-97f39f856b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_c3520cee-fab5-4afc-8ba9-ca122aae1620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4bb13da6-3e71-4738-b743-486eb3ba031c" xlink:to="loc_us-gaap_MarketableSecurities_c3520cee-fab5-4afc-8ba9-ca122aae1620" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2d6ab71d-665d-4d96-96f5-3446d6a43852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_bd4203eb-a51c-4cdd-869d-6cfb77112d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2d6ab71d-665d-4d96-96f5-3446d6a43852" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_bd4203eb-a51c-4cdd-869d-6cfb77112d2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_4452ddd5-b0bb-46e0-afc1-38fee4bf9211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2d6ab71d-665d-4d96-96f5-3446d6a43852" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_4452ddd5-b0bb-46e0-afc1-38fee4bf9211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a0495ba0-2597-4451-92d9-83f046021098" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_9cf2f489-9b4b-4583-82c2-183156d2548c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a0495ba0-2597-4451-92d9-83f046021098" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_9cf2f489-9b4b-4583-82c2-183156d2548c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_86909902-37bc-4be1-9f13-ea6fe02ee33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a0495ba0-2597-4451-92d9-83f046021098" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_86909902-37bc-4be1-9f13-ea6fe02ee33e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_90975544-ae53-4fd3-89dc-c1cbeebd2cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a51008d-c4c0-4bdd-a805-3eab243c45a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_90975544-ae53-4fd3-89dc-c1cbeebd2cbb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a51008d-c4c0-4bdd-a805-3eab243c45a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_85407f2e-2549-4b3c-9171-fae062aada62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_90975544-ae53-4fd3-89dc-c1cbeebd2cbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_85407f2e-2549-4b3c-9171-fae062aada62" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b23f7b85-cfbf-4b62-860b-1130f9602ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fe9e8f09-07e4-4be7-9bcd-9c31ab3a4cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b23f7b85-cfbf-4b62-860b-1130f9602ff4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fe9e8f09-07e4-4be7-9bcd-9c31ab3a4cdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_afb0805f-65ce-4aad-b540-b62d27c3e630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b23f7b85-cfbf-4b62-860b-1130f9602ff4" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_afb0805f-65ce-4aad-b540-b62d27c3e630" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2acb08b5-5d9e-4efb-bac6-a5455adf99d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6807e097-41e6-4ffb-98fd-ffd793d4b80a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2acb08b5-5d9e-4efb-bac6-a5455adf99d5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6807e097-41e6-4ffb-98fd-ffd793d4b80a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_347e72fe-796f-4ea7-9fda-106623bf7ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2acb08b5-5d9e-4efb-bac6-a5455adf99d5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_347e72fe-796f-4ea7-9fda-106623bf7ab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalAndRDRelatedLiabilities_47b3b71f-5c5a-4085-a9f1-6f6d1e699c03" xlink:href="lsta-20230930.xsd#lsta_ClinicalAndRDRelatedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2acb08b5-5d9e-4efb-bac6-a5455adf99d5" xlink:to="loc_lsta_ClinicalAndRDRelatedLiabilities_47b3b71f-5c5a-4085-a9f1-6f6d1e699c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f025ddff-0553-4471-9834-a02d60fae980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2acb08b5-5d9e-4efb-bac6-a5455adf99d5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f025ddff-0553-4471-9834-a02d60fae980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AccruedGrantFunding_c893fb78-532a-465e-b1c8-5ee71d3daed0" xlink:href="lsta-20230930.xsd#lsta_AccruedGrantFunding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2acb08b5-5d9e-4efb-bac6-a5455adf99d5" xlink:to="loc_lsta_AccruedGrantFunding_c893fb78-532a-465e-b1c8-5ee71d3daed0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5fc533f1-236f-4f11-8881-a3ec67c08dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5744072-2893-4eed-b2d4-b7aed1246503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5fc533f1-236f-4f11-8881-a3ec67c08dfc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5744072-2893-4eed-b2d4-b7aed1246503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_218220f2-5f05-40a4-ab17-5c075eb708fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5fc533f1-236f-4f11-8881-a3ec67c08dfc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_218220f2-5f05-40a4-ab17-5c075eb708fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4e328869-9ed4-45b7-8f2e-f11700a063d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9f4dae34-66df-4447-9624-49e4deb7da71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4e328869-9ed4-45b7-8f2e-f11700a063d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9f4dae34-66df-4447-9624-49e4deb7da71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b9732aa-1843-4986-a73a-c8317bd9da67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4e328869-9ed4-45b7-8f2e-f11700a063d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b9732aa-1843-4986-a73a-c8317bd9da67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8bd456e5-6eec-4514-9739-20430ade8f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4e328869-9ed4-45b7-8f2e-f11700a063d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8bd456e5-6eec-4514-9739-20430ade8f9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="lsta-20230930.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8dc3d35f-bc2c-4783-a05f-5c3c888c0c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e54acec8-02b2-4588-97d2-b2f71ca519d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8dc3d35f-bc2c-4783-a05f-5c3c888c0c78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e54acec8-02b2-4588-97d2-b2f71ca519d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2db5b529-1543-405e-a6e8-eb82a4c02269" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8dc3d35f-bc2c-4783-a05f-5c3c888c0c78" xlink:to="loc_us-gaap_OperatingLeaseLiability_2db5b529-1543-405e-a6e8-eb82a4c02269" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>lsta-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b3932c72-a861-4a02-8e8c-886f49fbe91d,g:dd0049eb-adfc-4bb4-a64a-f5d2d3c1c00a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f1c79462-b943-4e3d-96ee-6ddf00a43bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f1c79462-b943-4e3d-96ee-6ddf00a43bf7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2bbf31b3-3791-4422-b2d4-b3bbf08f3fad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2bbf31b3-3791-4422-b2d4-b3bbf08f3fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67546216-1d9b-49dd-b9e3-d7ce942df33c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67546216-1d9b-49dd-b9e3-d7ce942df33c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_afad07cf-c985-4651-bd0d-8b825ec79071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_ProfitLoss_afad07cf-c985-4651-bd0d-8b825ec79071" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7f901d7b-4ae7-42e6-9247-262ba7759348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7f901d7b-4ae7-42e6-9247-262ba7759348" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d7aab36-6b72-49da-b9a9-6f64ede0f116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d7aab36-6b72-49da-b9a9-6f64ede0f116" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76176240-b673-41a9-8c5c-31e15d95a15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76176240-b673-41a9-8c5c-31e15d95a15c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_792237a8-20da-47cb-9e3d-e82ce97b9dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_792237a8-20da-47cb-9e3d-e82ce97b9dec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger_fabc386a-70b7-4251-a45a-c9d0dc6eae26" xlink:href="lsta-20230930.xsd#lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger_fabc386a-70b7-4251-a45a-c9d0dc6eae26" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger_866b7917-4c1f-4b82-8b01-b489f705e40f" xlink:href="lsta-20230930.xsd#lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger_866b7917-4c1f-4b82-8b01-b489f705e40f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2be67fcd-2d25-4775-97b9-be65f8ad61fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2be67fcd-2d25-4775-97b9-be65f8ad61fc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10687956-1a65-491b-b9c2-70b0a89fd855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10687956-1a65-491b-b9c2-70b0a89fd855" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2b2102c0-8513-4f21-b939-3aff70e60477" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2b2102c0-8513-4f21-b939-3aff70e60477" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_96c1a64f-088d-4cb0-85d0-d77d28b5bf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_96c1a64f-088d-4cb0-85d0-d77d28b5bf6e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_406eb2e3-ec82-49c3-aa50-40d18c7365c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bba30778-916d-44e7-a5b8-580d51ee5fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b16fef6d-d2c3-4b86-9809-193a71e09a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f1c79462-b943-4e3d-96ee-6ddf00a43bf7" xlink:to="loc_us-gaap_StatementTable_b16fef6d-d2c3-4b86-9809-193a71e09a4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aa54e3dc-d120-41e3-8304-75fb2069cb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b16fef6d-d2c3-4b86-9809-193a71e09a4c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aa54e3dc-d120-41e3-8304-75fb2069cb85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aa54e3dc-d120-41e3-8304-75fb2069cb85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aa54e3dc-d120-41e3-8304-75fb2069cb85" xlink:to="loc_us-gaap_EquityComponentDomain_aa54e3dc-d120-41e3-8304-75fb2069cb85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21bcab2b-63a7-4e0d-b1e0-e4cdea9f81e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aa54e3dc-d120-41e3-8304-75fb2069cb85" xlink:to="loc_us-gaap_EquityComponentDomain_21bcab2b-63a7-4e0d-b1e0-e4cdea9f81e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21bcab2b-63a7-4e0d-b1e0-e4cdea9f81e0" xlink:to="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_784b1e80-a64c-4e9c-9f77-d2eb7bca764d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_CommonStockMember_784b1e80-a64c-4e9c-9f77-d2eb7bca764d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1a6681d7-865c-4619-bc19-3a4ff1304186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1a6681d7-865c-4619-bc19-3a4ff1304186" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_76292277-4d0e-44ab-a77d-f949c3d03e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_76292277-4d0e-44ab-a77d-f949c3d03e80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a135e16b-1cb7-4818-af81-481f7250844d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_RetainedEarningsMember_a135e16b-1cb7-4818-af81-481f7250844d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_228ca7ba-c9c4-46bb-9d5b-7eb89f50bea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_TreasuryStockCommonMember_228ca7ba-c9c4-46bb-9d5b-7eb89f50bea8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7460d62e-443f-4ae7-bfb5-e6023045aa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21bcab2b-63a7-4e0d-b1e0-e4cdea9f81e0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7460d62e-443f-4ae7-bfb5-e6023045aa3a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#TheBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a2076d30-6226-4c2d-9c66-fe7c20569474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a2076d30-6226-4c2d-9c66-fe7c20569474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c1eb60a8-2f42-4dbf-b755-1b3530bfb292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:to="loc_us-gaap_SharesIssued_c1eb60a8-2f42-4dbf-b755-1b3530bfb292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_c24e75e2-221c-45a3-a348-14aaf74320c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_c24e75e2-221c-45a3-a348-14aaf74320c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c5052d7e-a47d-4096-99ba-885de08069c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c5052d7e-a47d-4096-99ba-885de08069c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_1fbdfae3-3e5e-4e00-96ae-596d847e2893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:to="loc_us-gaap_AssetAcquisitionTable_1fbdfae3-3e5e-4e00-96ae-596d847e2893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_84bc7a01-4e6c-48b0-98a8-10fed08709ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_1fbdfae3-3e5e-4e00-96ae-596d847e2893" xlink:to="loc_us-gaap_AssetAcquisitionAxis_84bc7a01-4e6c-48b0-98a8-10fed08709ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_84bc7a01-4e6c-48b0-98a8-10fed08709ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_84bc7a01-4e6c-48b0-98a8-10fed08709ca" xlink:to="loc_us-gaap_AssetAcquisitionDomain_84bc7a01-4e6c-48b0-98a8-10fed08709ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_89c24d1c-1df5-45ea-815c-c6c4ac731a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_84bc7a01-4e6c-48b0-98a8-10fed08709ca" xlink:to="loc_us-gaap_AssetAcquisitionDomain_89c24d1c-1df5-45ea-815c-c6c4ac731a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_000822ad-c92b-4f62-9342-7cf0b2c0510b" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_89c24d1c-1df5-45ea-815c-c6c4ac731a03" xlink:to="loc_lsta_CENDMember_000822ad-c92b-4f62-9342-7cf0b2c0510b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f0e2700d-d893-4aec-b6dc-bc7bf5f468b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_1fbdfae3-3e5e-4e00-96ae-596d847e2893" xlink:to="loc_dei_LegalEntityAxis_f0e2700d-d893-4aec-b6dc-bc7bf5f468b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f0e2700d-d893-4aec-b6dc-bc7bf5f468b5_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f0e2700d-d893-4aec-b6dc-bc7bf5f468b5" xlink:to="loc_dei_EntityDomain_f0e2700d-d893-4aec-b6dc-bc7bf5f468b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_dfd7a49a-b4b5-4c20-9214-f5be5b89cf55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f0e2700d-d893-4aec-b6dc-bc7bf5f468b5" xlink:to="loc_dei_EntityDomain_dfd7a49a-b4b5-4c20-9214-f5be5b89cf55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CaladriusMember_2d9e86da-c804-4c97-b803-204c37ffce3a" xlink:href="lsta-20230930.xsd#lsta_CaladriusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_dfd7a49a-b4b5-4c20-9214-f5be5b89cf55" xlink:to="loc_lsta_CaladriusMember_2d9e86da-c804-4c97-b803-204c37ffce3a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_009803dd-9945-4ec0-a5a5-0ee37a8ad5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f969aff1-a971-4757-8214-7aea29038f52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_009803dd-9945-4ec0-a5a5-0ee37a8ad5a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f969aff1-a971-4757-8214-7aea29038f52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dd5c975f-349f-40b7-bbd9-77bc7ee4a279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_009803dd-9945-4ec0-a5a5-0ee37a8ad5a6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dd5c975f-349f-40b7-bbd9-77bc7ee4a279" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d960223-1bc3-4dbd-8007-fb70a6704845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dd5c975f-349f-40b7-bbd9-77bc7ee4a279" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d960223-1bc3-4dbd-8007-fb70a6704845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d960223-1bc3-4dbd-8007-fb70a6704845_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d960223-1bc3-4dbd-8007-fb70a6704845" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d960223-1bc3-4dbd-8007-fb70a6704845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d960223-1bc3-4dbd-8007-fb70a6704845" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_929b62bb-cc0d-427a-a6ee-f4dc2f4b41c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_929b62bb-cc0d-427a-a6ee-f4dc2f4b41c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_599b65ff-f6e6-42a6-b906-e2763f5e0a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:to="loc_us-gaap_ComputerEquipmentMember_599b65ff-f6e6-42a6-b906-e2763f5e0a8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_02d47cfc-f535-40ff-86b8-f09d78894571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_02d47cfc-f535-40ff-86b8-f09d78894571" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_eb72edd4-6719-4528-aa79-5b5c10ba5f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_22b2b8e9-d555-415e-9030-a521b491a389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eb72edd4-6719-4528-aa79-5b5c10ba5f3a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_22b2b8e9-d555-415e-9030-a521b491a389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6ef850b7-0b07-4858-a14c-7345d8161cae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eb72edd4-6719-4528-aa79-5b5c10ba5f3a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6ef850b7-0b07-4858-a14c-7345d8161cae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f82ee625-a249-4904-822c-8229813b8643" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ef850b7-0b07-4858-a14c-7345d8161cae" xlink:to="loc_srt_ProductOrServiceAxis_f82ee625-a249-4904-822c-8229813b8643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f82ee625-a249-4904-822c-8229813b8643_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f82ee625-a249-4904-822c-8229813b8643" xlink:to="loc_srt_ProductsAndServicesDomain_f82ee625-a249-4904-822c-8229813b8643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25b2ad62-e1ab-40d6-80ee-b0b13d4eb153" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f82ee625-a249-4904-822c-8229813b8643" xlink:to="loc_srt_ProductsAndServicesDomain_25b2ad62-e1ab-40d6-80ee-b0b13d4eb153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_f812935a-1d79-4744-8fe8-ad00f19314f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_25b2ad62-e1ab-40d6-80ee-b0b13d4eb153" xlink:to="loc_us-gaap_RoyaltyMember_f812935a-1d79-4744-8fe8-ad00f19314f1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerNarrativeDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#MergerNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/MergerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_2ade814b-bcb9-455b-91c2-4f34cfe39b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_010e8ac4-2451-4547-b607-b170ac449b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2ade814b-bcb9-455b-91c2-4f34cfe39b7f" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_010e8ac4-2451-4547-b607-b170ac449b8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_18ce9505-c1b0-4743-8977-bbeda55c8939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2ade814b-bcb9-455b-91c2-4f34cfe39b7f" xlink:to="loc_us-gaap_AssetAcquisitionTable_18ce9505-c1b0-4743-8977-bbeda55c8939" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_fe8042f8-670d-4daa-82cb-682229137aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_18ce9505-c1b0-4743-8977-bbeda55c8939" xlink:to="loc_us-gaap_AssetAcquisitionAxis_fe8042f8-670d-4daa-82cb-682229137aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_fe8042f8-670d-4daa-82cb-682229137aec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_fe8042f8-670d-4daa-82cb-682229137aec" xlink:to="loc_us-gaap_AssetAcquisitionDomain_fe8042f8-670d-4daa-82cb-682229137aec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bc3180c9-955f-42f4-83c5-fbe71f139485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_fe8042f8-670d-4daa-82cb-682229137aec" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bc3180c9-955f-42f4-83c5-fbe71f139485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_136df4ed-5c4e-45dc-97f6-713278714d26" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bc3180c9-955f-42f4-83c5-fbe71f139485" xlink:to="loc_lsta_CENDMember_136df4ed-5c4e-45dc-97f6-713278714d26" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#MergerDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/MergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e33a139f-18ea-4da0-9ce6-abd08688255e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e33a139f-18ea-4da0-9ce6-abd08688255e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionSharePrice_97c634ff-0043-449a-9361-408dfbc0b01e" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionSharePrice_97c634ff-0043-449a-9361-408dfbc0b01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionConsiderationTransferredEquityValue_b190954f-778f-419e-812e-fbf7acaa5279" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionConsiderationTransferredEquityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionConsiderationTransferredEquityValue_b190954f-778f-419e-812e-fbf7acaa5279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_6143f87f-551d-4f6d-9691-55df1ef866f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_6143f87f-551d-4f6d-9691-55df1ef866f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2a987cd8-e64b-4e67-b2c9-60640b071afc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2a987cd8-e64b-4e67-b2c9-60640b071afc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_28e7525d-5ab2-4764-8aa8-16ae8e32c1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_28e7525d-5ab2-4764-8aa8-16ae8e32c1b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1862328c-2cfa-4ca3-9161-7bb688fedcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1862328c-2cfa-4ca3-9161-7bb688fedcf3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionCashAndCashEquivalents_fd2d2d93-aa9d-428c-b132-49e1c766d145" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionCashAndCashEquivalents_fd2d2d93-aa9d-428c-b132-49e1c766d145" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionNetWorkingCapital_59e5ae11-ca82-4a22-934a-d7bcbc4e9326" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionNetWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionNetWorkingCapital_59e5ae11-ca82-4a22-934a-d7bcbc4e9326" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionOtherLiabilities_ef3c0023-5988-44d7-a741-9a00cd481389" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionOtherLiabilities_ef3c0023-5988-44d7-a741-9a00cd481389" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_4e6fc687-c721-415f-a7cb-305f8fbe642e" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_4e6fc687-c721-415f-a7cb-305f8fbe642e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionIntangibles_f64dde64-ba11-4251-b950-9e7fa66a704d" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionIntangibles_f64dde64-ba11-4251-b950-9e7fa66a704d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_589284e8-2404-4110-8c0f-e7492a3127d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_AssetAcquisitionTable_589284e8-2404-4110-8c0f-e7492a3127d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2a48784d-cc4e-4942-a9ea-21791cd0f1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_589284e8-2404-4110-8c0f-e7492a3127d1" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2a48784d-cc4e-4942-a9ea-21791cd0f1f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2a48784d-cc4e-4942-a9ea-21791cd0f1f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2a48784d-cc4e-4942-a9ea-21791cd0f1f3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2a48784d-cc4e-4942-a9ea-21791cd0f1f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_7544388f-3691-43ee-8e8e-325cfbd38acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2a48784d-cc4e-4942-a9ea-21791cd0f1f3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_7544388f-3691-43ee-8e8e-325cfbd38acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_75b6838c-be27-489b-b0d5-bec09a54c02b" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7544388f-3691-43ee-8e8e-325cfbd38acd" xlink:to="loc_lsta_CENDMember_75b6838c-be27-489b-b0d5-bec09a54c02b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4f3021a7-b8bc-4e2f-aea0-75cfeb979834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4f3021a7-b8bc-4e2f-aea0-75cfeb979834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bbad768c-15d7-43cc-b95d-4a144e15bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bbad768c-15d7-43cc-b95d-4a144e15bec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2cbf7cd2-8264-4a76-82fe-fe31afd1b04b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2cbf7cd2-8264-4a76-82fe-fe31afd1b04b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7faab08f-4964-4e5f-b0cd-db90647c471d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7faab08f-4964-4e5f-b0cd-db90647c471d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_177be5e1-e05c-47de-97ee-4510f6d69cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_177be5e1-e05c-47de-97ee-4510f6d69cd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7604201d-dd69-4a32-a2c6-e5bbced978d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_177be5e1-e05c-47de-97ee-4510f6d69cd3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7604201d-dd69-4a32-a2c6-e5bbced978d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7604201d-dd69-4a32-a2c6-e5bbced978d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7604201d-dd69-4a32-a2c6-e5bbced978d9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7604201d-dd69-4a32-a2c6-e5bbced978d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7604201d-dd69-4a32-a2c6-e5bbced978d9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23e96c9f-a708-4c95-87bc-5ecdfe225543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23e96c9f-a708-4c95-87bc-5ecdfe225543" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5668108b-ec30-46ff-8aad-511712442473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_CommercialPaperMember_5668108b-ec30-46ff-8aad-511712442473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e528213c-73e7-40ed-90d3-59e1b3247a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e528213c-73e7-40ed-90d3-59e1b3247a47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BondsMember_05535ef4-6c54-4878-8c63-8f71627e0afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_BondsMember_05535ef4-6c54-4878-8c63-8f71627e0afa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_bfe116a4-cd65-4ea0-b9ed-e786c42b752a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_bfe116a4-cd65-4ea0-b9ed-e786c42b752a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_502923c5-3a70-4340-ba5f-c51cf6891e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_502923c5-3a70-4340-ba5f-c51cf6891e69" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4fc7bba5-6754-40e2-aa16-6b54c845bbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4fc7bba5-6754-40e2-aa16-6b54c845bbd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2424670-8d0f-41ae-a018-831c46abe1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2424670-8d0f-41ae-a018-831c46abe1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49cccf87-9c24-47c5-9014-8cf86d16fd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49cccf87-9c24-47c5-9014-8cf86d16fd5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8d3da7e3-5c2c-4594-ab3f-ab0f0c01db9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:to="loc_us-gaap_Depreciation_8d3da7e3-5c2c-4594-ab3f-ab0f0c01db9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d0792f0-db62-44fa-96d2-a1b30df71371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d0792f0-db62-44fa-96d2-a1b30df71371" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c03db18c-eb4a-484d-b503-a90e166f25cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d0792f0-db62-44fa-96d2-a1b30df71371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c03db18c-eb4a-484d-b503-a90e166f25cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c03db18c-eb4a-484d-b503-a90e166f25cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c03db18c-eb4a-484d-b503-a90e166f25cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c03db18c-eb4a-484d-b503-a90e166f25cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c03db18c-eb4a-484d-b503-a90e166f25cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_04ff2b3f-1507-40a4-bc2f-b62bc92fd1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_04ff2b3f-1507-40a4-bc2f-b62bc92fd1fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_389b200f-130e-40cd-b76a-ba8e2a09709b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:to="loc_us-gaap_ComputerEquipmentMember_389b200f-130e-40cd-b76a-ba8e2a09709b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1154ac9d-ca88-452b-bf39-b9e1206d14b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1154ac9d-ca88-452b-bf39-b9e1206d14b0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#IncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ebde43c3-9b65-4812-b732-2bd393e9c306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f40be5bb-0bd4-4337-a065-518ef1cd3aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ebde43c3-9b65-4812-b732-2bd393e9c306" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f40be5bb-0bd4-4337-a065-518ef1cd3aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ece7efce-dcf5-4098-acd3-1b34988a7571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ebde43c3-9b65-4812-b732-2bd393e9c306" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ece7efce-dcf5-4098-acd3-1b34988a7571" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a0bed404-e491-46ec-bc56-4811ad6c21e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ece7efce-dcf5-4098-acd3-1b34988a7571" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a0bed404-e491-46ec-bc56-4811ad6c21e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a0bed404-e491-46ec-bc56-4811ad6c21e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a0bed404-e491-46ec-bc56-4811ad6c21e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a0bed404-e491-46ec-bc56-4811ad6c21e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a0bed404-e491-46ec-bc56-4811ad6c21e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5081bf2-b324-4e14-b531-976f72e7c292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5081bf2-b324-4e14-b531-976f72e7c292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8063caf7-633e-49e8-a04e-4168eb684d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:to="loc_us-gaap_WarrantMember_8063caf7-633e-49e8-a04e-4168eb684d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1731310a-1d1f-4eb9-abe1-203ef3ba658a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1731310a-1d1f-4eb9-abe1-203ef3ba658a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e6e4a872-b6ef-4293-a3eb-4d8f8a295785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e6e4a872-b6ef-4293-a3eb-4d8f8a295785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_580bad5e-a17c-45ac-8832-108d17032081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_580bad5e-a17c-45ac-8832-108d17032081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_469a6e82-4c71-44bf-9bea-133c7588d458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_469a6e82-4c71-44bf-9bea-133c7588d458" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3eb30c0b-b194-4f5a-8820-e331787b6b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3eb30c0b-b194-4f5a-8820-e331787b6b08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dd1fed22-af4d-4919-8a2a-fc220f28bf03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3eb30c0b-b194-4f5a-8820-e331787b6b08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dd1fed22-af4d-4919-8a2a-fc220f28bf03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd1fed22-af4d-4919-8a2a-fc220f28bf03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dd1fed22-af4d-4919-8a2a-fc220f28bf03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd1fed22-af4d-4919-8a2a-fc220f28bf03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dd1fed22-af4d-4919-8a2a-fc220f28bf03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9d8c6b5c-6968-46cb-8462-3d2b6c769669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9d8c6b5c-6968-46cb-8462-3d2b6c769669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aac1dedd-8dae-4955-a308-2f9792462c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aac1dedd-8dae-4955-a308-2f9792462c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4039eaf4-0e04-4bf9-9c2b-be1f46658deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4039eaf4-0e04-4bf9-9c2b-be1f46658deb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beefb768-e9ef-4f3a-a3db-2e3639687321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3eb30c0b-b194-4f5a-8820-e331787b6b08" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beefb768-e9ef-4f3a-a3db-2e3639687321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_beefb768-e9ef-4f3a-a3db-2e3639687321_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beefb768-e9ef-4f3a-a3db-2e3639687321" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_beefb768-e9ef-4f3a-a3db-2e3639687321_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c465c17a-59da-4743-8a59-b5d2f9106973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beefb768-e9ef-4f3a-a3db-2e3639687321" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c465c17a-59da-4743-8a59-b5d2f9106973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_137fcf64-b6fe-4215-af71-f8cae842c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c465c17a-59da-4743-8a59-b5d2f9106973" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_137fcf64-b6fe-4215-af71-f8cae842c5ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_f526a118-f77c-4db8-9f2d-f3465b35ceaa" xlink:href="lsta-20230930.xsd#lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_f526a118-f77c-4db8-9f2d-f3465b35ceaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_80be0c7b-aa3c-4e52-86de-4cb25f4be5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_us-gaap_CommonStockValueOutstanding_80be0c7b-aa3c-4e52-86de-4cb25f4be5fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OutstandingStockThreshold_871d10c9-0a28-4e17-adf6-71f0f739fe6a" xlink:href="lsta-20230930.xsd#lsta_OutstandingStockThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_lsta_OutstandingStockThreshold_871d10c9-0a28-4e17-adf6-71f0f739fe6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSale_f3d762b8-0be8-4a16-80e1-398b8b9235ca" xlink:href="lsta-20230930.xsd#lsta_SaleOfStockAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_lsta_SaleOfStockAvailableForSale_f3d762b8-0be8-4a16-80e1-398b8b9235ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSalePercentage_a901a2dc-f8f6-4ad2-8ef5-9374804a6bed" xlink:href="lsta-20230930.xsd#lsta_SaleOfStockAvailableForSalePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_lsta_SaleOfStockAvailableForSalePercentage_a901a2dc-f8f6-4ad2-8ef5-9374804a6bed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa5c2827-92ae-4100-a35c-42cf921975e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa5c2827-92ae-4100-a35c-42cf921975e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_987ea7b0-5eb2-426e-9eb1-81144e8026e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_987ea7b0-5eb2-426e-9eb1-81144e8026e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e640e9d5-27b9-4c55-8087-7b73ee25c5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e640e9d5-27b9-4c55-8087-7b73ee25c5f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_42ff1c28-27fc-4a3a-98c9-29541bcb7f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_42ff1c28-27fc-4a3a-98c9-29541bcb7f62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e0d870c3-860c-4633-954a-a1a06a18aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42ff1c28-27fc-4a3a-98c9-29541bcb7f62" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e0d870c3-860c-4633-954a-a1a06a18aed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e0d870c3-860c-4633-954a-a1a06a18aed5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e0d870c3-860c-4633-954a-a1a06a18aed5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e0d870c3-860c-4633-954a-a1a06a18aed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dfda446a-6056-4dc4-9a2f-4024dcf73a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e0d870c3-860c-4633-954a-a1a06a18aed5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dfda446a-6056-4dc4-9a2f-4024dcf73a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AtTheMarketOfferingAgreementMember_3467d32a-1f68-4fbf-8800-cc5cebc6c8a4" xlink:href="lsta-20230930.xsd#lsta_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dfda446a-6056-4dc4-9a2f-4024dcf73a2a" xlink:to="loc_lsta_AtTheMarketOfferingAgreementMember_3467d32a-1f68-4fbf-8800-cc5cebc6c8a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6f895b84-9b28-42ae-a235-c9148e09c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42ff1c28-27fc-4a3a-98c9-29541bcb7f62" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6f895b84-9b28-42ae-a235-c9148e09c0da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6f895b84-9b28-42ae-a235-c9148e09c0da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6f895b84-9b28-42ae-a235-c9148e09c0da" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6f895b84-9b28-42ae-a235-c9148e09c0da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bedafcae-19ee-47c2-b92d-1b0ccf638502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6f895b84-9b28-42ae-a235-c9148e09c0da" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bedafcae-19ee-47c2-b92d-1b0ccf638502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_d2eeb14b-df48-409d-b3c6-34e08af82623" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bedafcae-19ee-47c2-b92d-1b0ccf638502" xlink:to="loc_lsta_CENDMember_d2eeb14b-df48-409d-b3c6-34e08af82623" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#StockholdersEquityStockOptionsandWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_585ee016-d064-4fe4-aa20-d6aa0157ea8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff1dfc66-1393-4d9f-afb6-6b27cf5054fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_585ee016-d064-4fe4-aa20-d6aa0157ea8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff1dfc66-1393-4d9f-afb6-6b27cf5054fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c537394c-a230-492c-9a91-f1fe0780a539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_585ee016-d064-4fe4-aa20-d6aa0157ea8e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c537394c-a230-492c-9a91-f1fe0780a539" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_526df9fd-c8ca-4867-a5a7-11ba6f6b8767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c537394c-a230-492c-9a91-f1fe0780a539" xlink:to="loc_us-gaap_AwardTypeAxis_526df9fd-c8ca-4867-a5a7-11ba6f6b8767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_526df9fd-c8ca-4867-a5a7-11ba6f6b8767_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_526df9fd-c8ca-4867-a5a7-11ba6f6b8767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_526df9fd-c8ca-4867-a5a7-11ba6f6b8767_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a13786af-76d8-4b53-97a1-6365d6b20de1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_526df9fd-c8ca-4867-a5a7-11ba6f6b8767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a13786af-76d8-4b53-97a1-6365d6b20de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ae572b76-e0d0-4bde-806e-d446191fb4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a13786af-76d8-4b53-97a1-6365d6b20de1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ae572b76-e0d0-4bde-806e-d446191fb4e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c09f354-b674-4f64-a819-d6b41c02bda2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c537394c-a230-492c-9a91-f1fe0780a539" xlink:to="loc_srt_RangeAxis_4c09f354-b674-4f64-a819-d6b41c02bda2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c09f354-b674-4f64-a819-d6b41c02bda2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4c09f354-b674-4f64-a819-d6b41c02bda2" xlink:to="loc_srt_RangeMember_4c09f354-b674-4f64-a819-d6b41c02bda2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82c5d920-6010-430e-a479-16733585ccfb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4c09f354-b674-4f64-a819-d6b41c02bda2" xlink:to="loc_srt_RangeMember_82c5d920-6010-430e-a479-16733585ccfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1599b74d-e199-4524-8d6f-ca790fb90d28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82c5d920-6010-430e-a479-16733585ccfb" xlink:to="loc_srt_MaximumMember_1599b74d-e199-4524-8d6f-ca790fb90d28" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2a28c054-8664-4a1f-a407-9ea942859091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2a28c054-8664-4a1f-a407-9ea942859091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_4c13285a-84a7-476a-95aa-00e863438ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_4c13285a-84a7-476a-95aa-00e863438ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cae14f48-b63a-4ea7-b5ef-d8f090e2a0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cae14f48-b63a-4ea7-b5ef-d8f090e2a0fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_84759eed-6270-45da-891f-e236c884ff52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_84759eed-6270-45da-891f-e236c884ff52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62bfce89-79e1-47ff-9c75-eb21b0689f06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62bfce89-79e1-47ff-9c75-eb21b0689f06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86f87103-5a7a-46d7-8324-5127295efdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62bfce89-79e1-47ff-9c75-eb21b0689f06" xlink:to="loc_us-gaap_AwardTypeAxis_86f87103-5a7a-46d7-8324-5127295efdd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86f87103-5a7a-46d7-8324-5127295efdd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_86f87103-5a7a-46d7-8324-5127295efdd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86f87103-5a7a-46d7-8324-5127295efdd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56add2c0-71c6-492a-bf12-dbfeba3e9cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_86f87103-5a7a-46d7-8324-5127295efdd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56add2c0-71c6-492a-bf12-dbfeba3e9cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d11cb3a9-ce16-4d8d-ad34-947e324f3439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56add2c0-71c6-492a-bf12-dbfeba3e9cf1" xlink:to="loc_us-gaap_RestrictedStockMember_d11cb3a9-ce16-4d8d-ad34-947e324f3439" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8c43dcb2-b5b4-41d3-adcb-94dd2d0124d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56add2c0-71c6-492a-bf12-dbfeba3e9cf1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8c43dcb2-b5b4-41d3-adcb-94dd2d0124d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f199dc05-78d7-4eec-8894-1a08dea252b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62bfce89-79e1-47ff-9c75-eb21b0689f06" xlink:to="loc_srt_RangeAxis_f199dc05-78d7-4eec-8894-1a08dea252b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f199dc05-78d7-4eec-8894-1a08dea252b6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f199dc05-78d7-4eec-8894-1a08dea252b6" xlink:to="loc_srt_RangeMember_f199dc05-78d7-4eec-8894-1a08dea252b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9e7fd93-42b2-4e01-a4e5-94afcfc430fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f199dc05-78d7-4eec-8894-1a08dea252b6" xlink:to="loc_srt_RangeMember_e9e7fd93-42b2-4e01-a4e5-94afcfc430fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9dff2ec8-45d6-42b6-91ce-ee650c5a6cd6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e9e7fd93-42b2-4e01-a4e5-94afcfc430fb" xlink:to="loc_srt_MinimumMember_9dff2ec8-45d6-42b6-91ce-ee650c5a6cd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_552ca770-c215-40bd-a82f-00f29fdd1466" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e9e7fd93-42b2-4e01-a4e5-94afcfc430fb" xlink:to="loc_srt_MaximumMember_552ca770-c215-40bd-a82f-00f29fdd1466" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_589bf434-0e2f-4ad3-866c-c5e3a0c71aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3e5dd97e-cf1a-42e0-8112-fafe8589c725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_589bf434-0e2f-4ad3-866c-c5e3a0c71aab" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3e5dd97e-cf1a-42e0-8112-fafe8589c725" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3d39b31-018d-4d90-bd61-fcaab27832de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_589bf434-0e2f-4ad3-866c-c5e3a0c71aab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3d39b31-018d-4d90-bd61-fcaab27832de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8d99933a-66a7-460a-8737-17ca2841fda4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3d39b31-018d-4d90-bd61-fcaab27832de" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8d99933a-66a7-460a-8737-17ca2841fda4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8d99933a-66a7-460a-8737-17ca2841fda4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8d99933a-66a7-460a-8737-17ca2841fda4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8d99933a-66a7-460a-8737-17ca2841fda4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ed4bb7fe-22a5-4139-b1a0-9e2bf6141aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8d99933a-66a7-460a-8737-17ca2841fda4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ed4bb7fe-22a5-4139-b1a0-9e2bf6141aee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2d89bc7c-9fa5-4d3d-8537-d512e0198f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ed4bb7fe-22a5-4139-b1a0-9e2bf6141aee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2d89bc7c-9fa5-4d3d-8537-d512e0198f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a953491-dfec-4574-b4eb-70287745cd36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ed4bb7fe-22a5-4139-b1a0-9e2bf6141aee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a953491-dfec-4574-b4eb-70287745cd36" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa5c364b-886b-4304-a43b-fb2b48848abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f30aa352-8554-4642-8424-b5fd74a9a9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa5c364b-886b-4304-a43b-fb2b48848abb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f30aa352-8554-4642-8424-b5fd74a9a9d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4e1ba161-fafe-4bdf-b20f-4cdeaf917f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa5c364b-886b-4304-a43b-fb2b48848abb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4e1ba161-fafe-4bdf-b20f-4cdeaf917f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90025e37-1032-4366-8ad2-14181fef4b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa5c364b-886b-4304-a43b-fb2b48848abb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90025e37-1032-4366-8ad2-14181fef4b16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4cfbfe7e-e198-43f1-a9eb-3401261db13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90025e37-1032-4366-8ad2-14181fef4b16" xlink:to="loc_us-gaap_AwardTypeAxis_4cfbfe7e-e198-43f1-a9eb-3401261db13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cfbfe7e-e198-43f1-a9eb-3401261db13f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4cfbfe7e-e198-43f1-a9eb-3401261db13f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cfbfe7e-e198-43f1-a9eb-3401261db13f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4cfbfe7e-e198-43f1-a9eb-3401261db13f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1fbc6bb7-6965-4634-add3-f2a433fd65af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1fbc6bb7-6965-4634-add3-f2a433fd65af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6f11b7f9-b391-4e64-87ab-bd79c08a02a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6f11b7f9-b391-4e64-87ab-bd79c08a02a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_fe335869-96a3-4703-b0d4-5a075aedd054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:to="loc_us-gaap_RestrictedStockMember_fe335869-96a3-4703-b0d4-5a075aedd054" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9afca9f-4251-4f7a-bb25-0a38eca59e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_49d58c93-b1b2-435c-9636-6d9477f082dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9afca9f-4251-4f7a-bb25-0a38eca59e90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_49d58c93-b1b2-435c-9636-6d9477f082dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b894ae14-97fd-4b06-993b-9cedcc4ce956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9afca9f-4251-4f7a-bb25-0a38eca59e90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b894ae14-97fd-4b06-993b-9cedcc4ce956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688bea78-37ab-4db2-8e22-26e4db620c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9afca9f-4251-4f7a-bb25-0a38eca59e90" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688bea78-37ab-4db2-8e22-26e4db620c4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3339dfbf-9630-4177-92ef-681c2ae8ffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688bea78-37ab-4db2-8e22-26e4db620c4d" xlink:to="loc_us-gaap_AwardTypeAxis_3339dfbf-9630-4177-92ef-681c2ae8ffdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3339dfbf-9630-4177-92ef-681c2ae8ffdd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3339dfbf-9630-4177-92ef-681c2ae8ffdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3339dfbf-9630-4177-92ef-681c2ae8ffdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_109b11ce-6839-46c7-aabb-394a72887574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3339dfbf-9630-4177-92ef-681c2ae8ffdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_109b11ce-6839-46c7-aabb-394a72887574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e9272ea4-a70d-414e-97a6-4d064516c934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_109b11ce-6839-46c7-aabb-394a72887574" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e9272ea4-a70d-414e-97a6-4d064516c934" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_55c41697-d975-404a-9a3d-c74131fd72c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_55c41697-d975-404a-9a3d-c74131fd72c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_a3e1be06-916a-46c7-876c-cd0adc89c1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_a3e1be06-916a-46c7-876c-cd0adc89c1f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_1eab6338-0e6b-467a-9bc3-4ee0e6272584" xlink:href="lsta-20230930.xsd#lsta_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_1eab6338-0e6b-467a-9bc3-4ee0e6272584" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FairValueMarketOfTaxNOLs_1cc04c10-a887-4822-8777-bcb400646999" xlink:href="lsta-20230930.xsd#lsta_FairValueMarketOfTaxNOLs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_FairValueMarketOfTaxNOLs_1cc04c10-a887-4822-8777-bcb400646999" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_482882b3-e88b-4a9a-8800-0aadb7ea17a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_482882b3-e88b-4a9a-8800-0aadb7ea17a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_3959ecf9-fb81-4f06-b151-e8e304c34324" xlink:href="lsta-20230930.xsd#lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_3959ecf9-fb81-4f06-b151-e8e304c34324" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsPostAcquisition_84456310-795e-4640-b678-c05f2890591b" xlink:href="lsta-20230930.xsd#lsta_OperatingLossCarryforwardsPostAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_OperatingLossCarryforwardsPostAcquisition_84456310-795e-4640-b678-c05f2890591b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9caeacb0-ef9e-4a50-8fd5-489bcb5776b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9caeacb0-ef9e-4a50-8fd5-489bcb5776b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_bf7b746c-93a1-4679-baf4-49df4de0ae73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_bf7b746c-93a1-4679-baf4-49df4de0ae73" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNOLS_8484d1dc-1170-4ddc-a5b9-53639ef105b0" xlink:href="lsta-20230930.xsd#lsta_ProceedsFromSaleOfNOLS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_ProceedsFromSaleOfNOLS_8484d1dc-1170-4ddc-a5b9-53639ef105b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bb44c452-e16d-42c7-b7a5-ec0bc7f31016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bb44c452-e16d-42c7-b7a5-ec0bc7f31016" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LossOnSaleOfNOL_f350face-db00-4ddc-a274-936ea2b2eab7" xlink:href="lsta-20230930.xsd#lsta_LossOnSaleOfNOL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_LossOnSaleOfNOL_f350face-db00-4ddc-a274-936ea2b2eab7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2252917a-465c-4fe0-a89a-f642a9b59aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2252917a-465c-4fe0-a89a-f642a9b59aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2252917a-465c-4fe0-a89a-f642a9b59aad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2252917a-465c-4fe0-a89a-f642a9b59aad" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2252917a-465c-4fe0-a89a-f642a9b59aad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2252917a-465c-4fe0-a89a-f642a9b59aad" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4bc941ff-1449-4518-99d0-5e52af3bbc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:to="loc_us-gaap_DomesticCountryMember_4bc941ff-1449-4518-99d0-5e52af3bbc6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_7e36a951-dd56-4eee-bad1-be6feb2979e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:to="loc_us-gaap_ForeignCountryMember_7e36a951-dd56-4eee-bad1-be6feb2979e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a1319cd3-109a-4f63-9d0d-408991d8863e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a1319cd3-109a-4f63-9d0d-408991d8863e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_14018f19-d188-4280-81f2-265b1e8e64e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_14018f19-d188-4280-81f2-265b1e8e64e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_14018f19-d188-4280-81f2-265b1e8e64e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_14018f19-d188-4280-81f2-265b1e8e64e1" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_14018f19-d188-4280-81f2-265b1e8e64e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_14018f19-d188-4280-81f2-265b1e8e64e1" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_61d5868a-7f3d-4275-8470-0ef7ce315961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_61d5868a-7f3d-4275-8470-0ef7ce315961" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_96f8b2df-ff06-4624-9c41-f82b510a7fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_96f8b2df-ff06-4624-9c41-f82b510a7fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_1c0fb41a-08c7-44bb-b23d-5bda3a682201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_1c0fb41a-08c7-44bb-b23d-5bda3a682201" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c9668a27-2d8c-4a7a-b73b-8ba51ef4f9b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:to="loc_dei_LegalEntityAxis_c9668a27-2d8c-4a7a-b73b-8ba51ef4f9b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c9668a27-2d8c-4a7a-b73b-8ba51ef4f9b8_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c9668a27-2d8c-4a7a-b73b-8ba51ef4f9b8" xlink:to="loc_dei_EntityDomain_c9668a27-2d8c-4a7a-b73b-8ba51ef4f9b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5a7a8548-4f94-47b3-8db3-118bd8b7ac85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c9668a27-2d8c-4a7a-b73b-8ba51ef4f9b8" xlink:to="loc_dei_EntityDomain_5a7a8548-4f94-47b3-8db3-118bd8b7ac85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_1a701672-e977-404c-b253-db15c6693a56" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5a7a8548-4f94-47b3-8db3-118bd8b7ac85" xlink:to="loc_lsta_CENDMember_1a701672-e977-404c-b253-db15c6693a56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AustraliaResearchandDevelopmentTaxIncentiveDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_04f64482-0c1a-4534-8c95-0a55cb7a1906" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_04f64482-0c1a-4534-8c95-0a55cb7a1906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncomeTaxIncentiveReceivable_32b30ec8-5cd9-41e5-89a7-7ec9a6ec362b" xlink:href="lsta-20230930.xsd#lsta_IncomeTaxIncentiveReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:to="loc_lsta_IncomeTaxIncentiveReceivable_32b30ec8-5cd9-41e5-89a7-7ec9a6ec362b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_78d3e957-c040-4dd1-8e69-665a466ef287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_78d3e957-c040-4dd1-8e69-665a466ef287" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_e00c06e4-e208-43c5-87d3-2975b21d0378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_e00c06e4-e208-43c5-87d3-2975b21d0378" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_472c8d7d-b53b-49c4-9688-1977305b01f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_e00c06e4-e208-43c5-87d3-2975b21d0378" xlink:to="loc_srt_RangeAxis_472c8d7d-b53b-49c4-9688-1977305b01f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_472c8d7d-b53b-49c4-9688-1977305b01f1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_472c8d7d-b53b-49c4-9688-1977305b01f1" xlink:to="loc_srt_RangeMember_472c8d7d-b53b-49c4-9688-1977305b01f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_839574cc-5686-428c-a842-6c5933918ac4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_472c8d7d-b53b-49c4-9688-1977305b01f1" xlink:to="loc_srt_RangeMember_839574cc-5686-428c-a842-6c5933918ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b908f51b-c341-471c-95c9-3d8c3a2a3cc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_839574cc-5686-428c-a842-6c5933918ac4" xlink:to="loc_srt_MinimumMember_b908f51b-c341-471c-95c9-3d8c3a2a3cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_552c6437-e011-43f8-9c98-0bcc94e16f0c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_839574cc-5686-428c-a842-6c5933918ac4" xlink:to="loc_srt_MaximumMember_552c6437-e011-43f8-9c98-0bcc94e16f0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_85c39a18-0811-4a75-b493-d0ba1f566ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_e00c06e4-e208-43c5-87d3-2975b21d0378" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_85c39a18-0811-4a75-b493-d0ba1f566ab1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_85c39a18-0811-4a75-b493-d0ba1f566ab1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_85c39a18-0811-4a75-b493-d0ba1f566ab1" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_85c39a18-0811-4a75-b493-d0ba1f566ab1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_499f912d-ee92-4ec6-8d4d-317074a1bb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_85c39a18-0811-4a75-b493-d0ba1f566ab1" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_499f912d-ee92-4ec6-8d4d-317074a1bb6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_53712d96-c992-414c-a709-9c4aac8a39ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_499f912d-ee92-4ec6-8d4d-317074a1bb6f" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_53712d96-c992-414c-a709-9c4aac8a39ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#TechnologyTransferAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_2a5b3cc3-d7e6-4741-914c-8d6a8ed72979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_2a5b3cc3-d7e6-4741-914c-8d6a8ed72979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InvestmentOwnedCanceledShares_bcc1c3c7-993f-4397-aa2e-bef123e379ff" xlink:href="lsta-20230930.xsd#lsta_InvestmentOwnedCanceledShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:to="loc_lsta_InvestmentOwnedCanceledShares_bcc1c3c7-993f-4397-aa2e-bef123e379ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_346ee908-db73-4eca-8efd-3e67599781c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_346ee908-db73-4eca-8efd-3e67599781c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_aed6fba7-ec31-46bb-b250-098b3ce4d942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_aed6fba7-ec31-46bb-b250-098b3ce4d942" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_aacc60d3-7af6-4684-81e7-153349e50062" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_aed6fba7-ec31-46bb-b250-098b3ce4d942" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_aacc60d3-7af6-4684-81e7-153349e50062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_aacc60d3-7af6-4684-81e7-153349e50062_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_aacc60d3-7af6-4684-81e7-153349e50062" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_aacc60d3-7af6-4684-81e7-153349e50062_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5288a5cc-d2dd-4294-9e85-6b9bca7dde1d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_aacc60d3-7af6-4684-81e7-153349e50062" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5288a5cc-d2dd-4294-9e85-6b9bca7dde1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_5521c02f-2f5f-4cfb-b5e5-2e1ad717b191" xlink:href="lsta-20230930.xsd#lsta_ImpiloMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5288a5cc-d2dd-4294-9e85-6b9bca7dde1d" xlink:to="loc_lsta_ImpiloMember_5521c02f-2f5f-4cfb-b5e5-2e1ad717b191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6a87cf26-a68a-4c14-9143-ff8633280036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_aed6fba7-ec31-46bb-b250-098b3ce4d942" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6a87cf26-a68a-4c14-9143-ff8633280036" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6a87cf26-a68a-4c14-9143-ff8633280036_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6a87cf26-a68a-4c14-9143-ff8633280036" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6a87cf26-a68a-4c14-9143-ff8633280036_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b53125e1-3652-4512-820f-fe82a8406865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6a87cf26-a68a-4c14-9143-ff8633280036" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b53125e1-3652-4512-820f-fe82a8406865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c12f8ca7-a361-4b1f-8bb8-b637107ac8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b53125e1-3652-4512-820f-fe82a8406865" xlink:to="loc_us-gaap_SubsequentEventMember_c12f8ca7-a361-4b1f-8bb8-b637107ac8cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesIssuedUnderLicenseAgreement_b0fb7718-a9ce-4eb6-b560-09e8b278bc1c" xlink:href="lsta-20230930.xsd#lsta_SharesIssuedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_SharesIssuedUnderLicenseAgreement_b0fb7718-a9ce-4eb6-b560-09e8b278bc1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_416d19e9-8751-4b83-a358-fe3195d1eb10" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_416d19e9-8751-4b83-a358-fe3195d1eb10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_9db53d10-4293-420a-b291-55d2264fe3b5" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_9db53d10-4293-420a-b291-55d2264fe3b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_5b817053-fb1b-4009-9385-7c107233a0c3" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_5b817053-fb1b-4009-9385-7c107233a0c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_ba7ac551-7c24-428f-a9d1-87c76f633746" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_ba7ac551-7c24-428f-a9d1-87c76f633746" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_878dcdf5-21aa-482b-819c-fdbd9c2ec3f0" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_878dcdf5-21aa-482b-819c-fdbd9c2ec3f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_4529cd08-f852-4c00-9e71-0bf1465b6de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_4529cd08-f852-4c00-9e71-0bf1465b6de0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_43e45977-4296-4d03-bda2-2bdb52f526f9" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_43e45977-4296-4d03-bda2-2bdb52f526f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesHeldByThirdParty_9b234e94-05ac-4d66-987b-d5aa0bf534da" xlink:href="lsta-20230930.xsd#lsta_SharesHeldByThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_SharesHeldByThirdParty_9b234e94-05ac-4d66-987b-d5aa0bf534da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_641c4d3f-fea6-4d9b-85ee-b2497550ed56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_us-gaap_SharesIssued_641c4d3f-fea6-4d9b-85ee-b2497550ed56" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_bb46af43-aec3-420c-91a1-92d5e3af7a6d" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_bb46af43-aec3-420c-91a1-92d5e3af7a6d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_a466803e-a4e8-498e-b492-c658d4032e86" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_a466803e-a4e8-498e-b492-c658d4032e86" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_49f06cf6-14a9-452f-92ee-9f52db7b4586" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_49f06cf6-14a9-452f-92ee-9f52db7b4586" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c2da32f-d0cf-4bb0-9200-a07f9b18c11b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_srt_CounterpartyNameAxis_0c2da32f-d0cf-4bb0-9200-a07f9b18c11b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c2da32f-d0cf-4bb0-9200-a07f9b18c11b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0c2da32f-d0cf-4bb0-9200-a07f9b18c11b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c2da32f-d0cf-4bb0-9200-a07f9b18c11b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0c2da32f-d0cf-4bb0-9200-a07f9b18c11b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SanfordBurnhamPrebysMember_e294ad3b-0be0-4aa9-82e1-297f3f04aa2c" xlink:href="lsta-20230930.xsd#lsta_SanfordBurnhamPrebysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:to="loc_lsta_SanfordBurnhamPrebysMember_e294ad3b-0be0-4aa9-82e1-297f3f04aa2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_UniversityOfCaliforniaAtSanDiegoMember_149fa143-72e1-4ae7-b244-3ebfd0c05889" xlink:href="lsta-20230930.xsd#lsta_UniversityOfCaliforniaAtSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:to="loc_lsta_UniversityOfCaliforniaAtSanDiegoMember_149fa143-72e1-4ae7-b244-3ebfd0c05889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_MassachusettsInstituteOfTechnologyMember_f4354c10-6b17-4d57-9de5-6f33652d7bc8" xlink:href="lsta-20230930.xsd#lsta_MassachusettsInstituteOfTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:to="loc_lsta_MassachusettsInstituteOfTechnologyMember_f4354c10-6b17-4d57-9de5-6f33652d7bc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6875d744-0448-4560-ae32-1dcb80422944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6875d744-0448-4560-ae32-1dcb80422944" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6875d744-0448-4560-ae32-1dcb80422944_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6875d744-0448-4560-ae32-1dcb80422944" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6875d744-0448-4560-ae32-1dcb80422944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc390099-3213-4634-85e9-e18460462aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6875d744-0448-4560-ae32-1dcb80422944" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc390099-3213-4634-85e9-e18460462aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8c5ed319-2a3f-47e9-9086-bcd821412e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc390099-3213-4634-85e9-e18460462aaf" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8c5ed319-2a3f-47e9-9086-bcd821412e0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bfc976a0-b733-4d99-8f4c-720c3d771ef0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_srt_RangeAxis_bfc976a0-b733-4d99-8f4c-720c3d771ef0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bfc976a0-b733-4d99-8f4c-720c3d771ef0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bfc976a0-b733-4d99-8f4c-720c3d771ef0" xlink:to="loc_srt_RangeMember_bfc976a0-b733-4d99-8f4c-720c3d771ef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02b40776-bd5d-4804-86c3-30c468aebce8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bfc976a0-b733-4d99-8f4c-720c3d771ef0" xlink:to="loc_srt_RangeMember_02b40776-bd5d-4804-86c3-30c468aebce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8baf7cbf-047d-40eb-91fd-11191013259b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_02b40776-bd5d-4804-86c3-30c468aebce8" xlink:to="loc_srt_MinimumMember_8baf7cbf-047d-40eb-91fd-11191013259b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f477abc-393c-453a-8099-04a98686820d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_02b40776-bd5d-4804-86c3-30c468aebce8" xlink:to="loc_srt_MaximumMember_5f477abc-393c-453a-8099-04a98686820d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a0c4ae48-4c09-4587-90a9-b732b15e9e53" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_dei_LegalEntityAxis_a0c4ae48-4c09-4587-90a9-b732b15e9e53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a0c4ae48-4c09-4587-90a9-b732b15e9e53_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a0c4ae48-4c09-4587-90a9-b732b15e9e53" xlink:to="loc_dei_EntityDomain_a0c4ae48-4c09-4587-90a9-b732b15e9e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_de0f0127-f9b4-4224-8c3f-6ad39953d8d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a0c4ae48-4c09-4587-90a9-b732b15e9e53" xlink:to="loc_dei_EntityDomain_de0f0127-f9b4-4224-8c3f-6ad39953d8d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_d8be10b3-7648-4d1e-9e93-fdec8f65e927" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_de0f0127-f9b4-4224-8c3f-6ad39953d8d4" xlink:to="loc_lsta_CENDMember_d8be10b3-7648-4d1e-9e93-fdec8f65e927" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9e91ae90-a3a6-4863-a471-67772823292a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9e91ae90-a3a6-4863-a471-67772823292a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9e91ae90-a3a6-4863-a471-67772823292a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9e91ae90-a3a6-4863-a471-67772823292a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9e91ae90-a3a6-4863-a471-67772823292a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3f68577b-7f53-4d0c-b824-1e5ced0e2e12" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9e91ae90-a3a6-4863-a471-67772823292a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3f68577b-7f53-4d0c-b824-1e5ced0e2e12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_f9b6843f-56cb-4bcc-ad59-cfb3b8794347" xlink:href="lsta-20230930.xsd#lsta_ImpiloMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3f68577b-7f53-4d0c-b824-1e5ced0e2e12" xlink:to="loc_lsta_ImpiloMember_f9b6843f-56cb-4bcc-ad59-cfb3b8794347" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_26b88aac-3124-496e-baac-a9a8fddaf4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_26b88aac-3124-496e-baac-a9a8fddaf4fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_08799051-7e84-4f36-9782-d29bdd94b9be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_08799051-7e84-4f36-9782-d29bdd94b9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_2ecb55e3-007b-4fe3-a6f5-04b4b6c32c3a" xlink:href="lsta-20230930.xsd#lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_2ecb55e3-007b-4fe3-a6f5-04b4b6c32c3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_f04ed1d8-f334-4f0a-b110-d0870a2f9c1a" xlink:href="lsta-20230930.xsd#lsta_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_f04ed1d8-f334-4f0a-b110-d0870a2f9c1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_e1903e83-7c0e-42bb-add3-52f88cb2a386" xlink:href="lsta-20230930.xsd#lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_e1903e83-7c0e-42bb-add3-52f88cb2a386" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_0108010b-bd29-4784-83f6-285ae25bab27" xlink:href="lsta-20230930.xsd#lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_0108010b-bd29-4784-83f6-285ae25bab27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bc47ce00-2173-4985-bf11-87fb7ac415cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bc47ce00-2173-4985-bf11-87fb7ac415cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc47ce00-2173-4985-bf11-87fb7ac415cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bc47ce00-2173-4985-bf11-87fb7ac415cb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc47ce00-2173-4985-bf11-87fb7ac415cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5be66a00-79f1-4bba-a3ba-109e78f75bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bc47ce00-2173-4985-bf11-87fb7ac415cb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5be66a00-79f1-4bba-a3ba-109e78f75bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_d1dc807c-90e3-4791-af01-2a6643d71ada" xlink:href="lsta-20230930.xsd#lsta_ExclusiveLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5be66a00-79f1-4bba-a3ba-109e78f75bf3" xlink:to="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_d1dc807c-90e3-4791-af01-2a6643d71ada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e671c1ed-e5a7-4040-8912-95febf2953e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:to="loc_srt_CounterpartyNameAxis_e671c1ed-e5a7-4040-8912-95febf2953e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e671c1ed-e5a7-4040-8912-95febf2953e7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e671c1ed-e5a7-4040-8912-95febf2953e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e671c1ed-e5a7-4040-8912-95febf2953e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684e06fb-5f3a-4604-9839-86a3253960e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e671c1ed-e5a7-4040-8912-95febf2953e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684e06fb-5f3a-4604-9839-86a3253960e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_QiluMember_4105b5a0-75a1-4513-a5e6-5bb387820c0a" xlink:href="lsta-20230930.xsd#lsta_QiluMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684e06fb-5f3a-4604-9839-86a3253960e2" xlink:to="loc_lsta_QiluMember_4105b5a0-75a1-4513-a5e6-5bb387820c0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7db895f-2df1-4382-b2b0-91f0e233c044" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:to="loc_srt_ProductOrServiceAxis_e7db895f-2df1-4382-b2b0-91f0e233c044" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7db895f-2df1-4382-b2b0-91f0e233c044_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e7db895f-2df1-4382-b2b0-91f0e233c044" xlink:to="loc_srt_ProductsAndServicesDomain_e7db895f-2df1-4382-b2b0-91f0e233c044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bc3e6f78-638b-4d68-bb20-1b6318bdd80b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e7db895f-2df1-4382-b2b0-91f0e233c044" xlink:to="loc_srt_ProductsAndServicesDomain_bc3e6f78-638b-4d68-bb20-1b6318bdd80b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_2310fd12-18af-405c-ba90-cbbd726edf46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bc3e6f78-638b-4d68-bb20-1b6318bdd80b" xlink:to="loc_us-gaap_LicenseMember_2310fd12-18af-405c-ba90-cbbd726edf46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_724fae46-659f-42d4-a973-bca0ac9ba3f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:to="loc_srt_RangeAxis_724fae46-659f-42d4-a973-bca0ac9ba3f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_724fae46-659f-42d4-a973-bca0ac9ba3f7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_724fae46-659f-42d4-a973-bca0ac9ba3f7" xlink:to="loc_srt_RangeMember_724fae46-659f-42d4-a973-bca0ac9ba3f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b82ee59c-d006-4b61-84cf-7fad49f5fd99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_724fae46-659f-42d4-a973-bca0ac9ba3f7" xlink:to="loc_srt_RangeMember_b82ee59c-d006-4b61-84cf-7fad49f5fd99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c0ba6864-be78-4f36-9764-7720f84b2407" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b82ee59c-d006-4b61-84cf-7fad49f5fd99" xlink:to="loc_srt_MinimumMember_c0ba6864-be78-4f36-9764-7720f84b2407" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d4372bb-bad4-4541-9c8d-ebb80048420c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b82ee59c-d006-4b61-84cf-7fad49f5fd99" xlink:to="loc_srt_MaximumMember_2d4372bb-bad4-4541-9c8d-ebb80048420c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>lsta-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b3932c72-a861-4a02-8e8c-886f49fbe91d,g:dd0049eb-adfc-4bb4-a64a-f5d2d3c1c00a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lsta_SaleOfStockAvailableForSalePercentage_c7651f07-95b7-41d0-9f91-3682805324c9_terseLabel_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage held by non-affiliates</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSalePercentage_label_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Available for Sale, Percentage</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSalePercentage_documentation_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Available for Sale, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSalePercentage" xlink:href="lsta-20230930.xsd#lsta_SaleOfStockAvailableForSalePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SaleOfStockAvailableForSalePercentage" xlink:to="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a9789554-898d-490b-a2a2-f2e4dd104856_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e1b86371-1e81-4c69-8901-e68d3104317d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ced4ac10-0fa3-4c1f-ba37-c0cb8237b255_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c2727097-b4f0-4d38-be8e-b7b388727d99_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0a8c8ab2-d509-4a33-873f-f421e6a15294_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a768fc7-a713-493b-ad59-76b062da4a0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_7d6975d6-bd28-42ff-b41f-9f0cb7cc701a_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_Sharesvestedandexpectedtovest_0b4ba75a-2ea2-4c4f-816f-7f30028d1b97_terseLabel_en-US" xlink:label="lab_lsta_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_lsta_Sharesvestedandexpectedtovest_label_en-US" xlink:label="lab_lsta_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:label id="lab_lsta_Sharesvestedandexpectedtovest_documentation_en-US" xlink:label="lab_lsta_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_Sharesvestedandexpectedtovest" xlink:href="lsta-20230930.xsd#lsta_Sharesvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_Sharesvestedandexpectedtovest" xlink:to="lab_lsta_Sharesvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_07a38611-b30b-4538-93bc-a14d6f7dda45_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_51c21f01-fb63-4cad-b9d6-e152b266e06c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_36f2650d-88d6-4463-81df-1682ae780c98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_90851f2d-fa6e-44db-9d81-bc2b262853f9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50f1882c-d05b-4041-ab24-8b294dafd837_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6902ad72-ff00-4536-be74-d450ce1fd000_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_413e68ca-3d2a-4990-8e4c-ca114e442a7c_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_483ade2d-0c33-47c4-a4fc-ec0aa44208b7_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_114c413a-eb8a-4e6a-a43a-83826662e494_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_14085270-df2e-42db-bd7b-13731749ca97_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_97273da0-a0d1-4599-8290-7d19c7ba4bb4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ba417503-1302-4c90-bb8b-7e2142a37092_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_9bff9c65-f2bf-4ba2-9e71-a5c8ce1db8d4_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9ba361a1-7094-49c0-85ac-7fcf442cf32b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_aa241a10-d164-4c0e-af42-0e28067eb878_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8748f595-5144-4f7b-8c74-ac02fcfbd5da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5da907f9-2dc2-41f6-ab1b-ac51e1b19699_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_f2f09ef3-1263-4479-968f-3f3f5b331b07_terseLabel_en-US" xlink:label="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to terminate</link:label>
    <link:label id="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_label_en-US" xlink:label="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreement, Option to Terminate</link:label>
    <link:label id="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_documentation_en-US" xlink:label="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreement, Option to Terminate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:href="lsta-20230930.xsd#lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:to="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_83f4c7c2-c0bb-45cf-b407-de544cf02dd0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable_c0024503-1d50-481e-8d4f-2e7332ea4c0e_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_664dc3b0-315e-4d21-9413-38f93e7f63e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayLineItems_bb47caa7-6276-46a4-b6e6-b5e84197b1c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems" xlink:to="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_249e21fa-ac91-4c68-a67f-ab0d23030363_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6b206303-6a40-4c66-a5ad-98be067036a4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_87117ba5-6e3d-4dc0-9fda-1d393737487a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger_a4bd6755-0837-4265-84c3-98c18c530214_terseLabel_en-US" xlink:label="lab_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with Merger</link:label>
    <link:label id="lab_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger_label_en-US" xlink:label="lab_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues Related to Merger</link:label>
    <link:label id="lab_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger_documentation_en-US" xlink:label="lab_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues Related to Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" xlink:href="lsta-20230930.xsd#lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" xlink:to="lab_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21c45e76-d357-45af-98bb-976533c704e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a6ae0a1d-7a05-4f3c-99ee-d94892f4a148_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c903f304-5206-4248-bd3f-413b2fab3631_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_d306fcb9-e21f-4419-8f90-003746cfdda2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_899a21bb-21f8-432a-862e-966ad4c961fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cf0029d5-c0a7-49f3-98f7-a988b67787be_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c54bf12-c7c6-4d75-9c9b-8bb063145d8f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7dc8325c-827d-48a8-bd8a-c6defe2f6629_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb17f9ac-49af-4aca-bcaa-18237f39dedc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_ee7dbb46-80cf-4d45-9e02-d3443c903791_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities - available for sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_1d6490b5-ca2a-45b9-9bf8-97c7cbbc4919_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicensing fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f956660c-97d2-4452-9b04-67e2ba06499e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c14d63ec-d536-47db-9f96-0d572a217903_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4daf8b2-f9d1-4150-b6b1-1e9d39e53dff_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_36113238-75f7-407c-af41-88a786bc7ad3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_InvestmentOwnedCanceledShares_c237f3e5-6cb8-4ac3-bb9d-6e33770aa143_terseLabel_en-US" xlink:label="lab_lsta_InvestmentOwnedCanceledShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares canceled (in shares)</link:label>
    <link:label id="lab_lsta_InvestmentOwnedCanceledShares_label_en-US" xlink:label="lab_lsta_InvestmentOwnedCanceledShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Canceled, Shares</link:label>
    <link:label id="lab_lsta_InvestmentOwnedCanceledShares_documentation_en-US" xlink:label="lab_lsta_InvestmentOwnedCanceledShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Canceled, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InvestmentOwnedCanceledShares" xlink:href="lsta-20230930.xsd#lsta_InvestmentOwnedCanceledShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_InvestmentOwnedCanceledShares" xlink:to="lab_lsta_InvestmentOwnedCanceledShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_997c4b23-11b9-443f-bc24-4b289c759758_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c357c907-b730-48c2-a0c5-2aaf47071f14_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ff026ffa-1093-40fe-ad5d-d456ae42b984_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_2c3878ef-f6e8-4888-a649-ef255d0fc1fd_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_1c832762-62e2-4f6f-801e-108a825fc3f3_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ec6d701c-83e2-4bef-a204-8af923f0fe78_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_a0f23abf-08e0-4024-880e-f4d010bb9d86_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_label_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_documentation_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:to="lab_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e10256c6-2129-4656-a2e6-666152084271_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6444d150-10cb-437b-a388-4a2cac905ace_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a47cd4fc-74c4-43d3-b7f7-a86cca3bc79e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_82e011a2-02d3-4737-be17-52c2e7eb66fe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0ac39b2b-99f1-4c85-a67e-f7dcf65c8733_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_650d26e1-886d-472c-830d-6a80c9e3b0d9_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_15b6049d-7d09-4fe5-801a-365d254d9220_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_bd69cc91-ae82-4dd5-b197-d86fb43d0485_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Compensation Cost Related to Nonvested Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dfd666ef-b1f9-4f7f-9ede-25632bd4609b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_a1b33893-519c-4c80-9d0b-10c358e44af1_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_768049b9-ac4a-4872-b877-af1a83c23767_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9dc1df28-ef11-42df-8a36-f8a013abb53c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a841e8e1-bcc9-457b-819a-ceb0d79c1895_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a9a77a13-8045-4bcb-8bff-9fa69a8438f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4904cf0a-49b0-4704-9d3c-c7167271e4ba_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_7b58db73-2d44-4ccc-ab48-bcac619eb4a8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_808c710a-8455-4e1e-bc91-f26180ce3302_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_20a363ad-e736-46e7-98b7-db7debfc7e99_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization, year four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_884a1cd3-21fa-4f9e-bd87-9a0517e1c0bb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_05868445-c715-42a0-964b-cb462b707506_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_481ca746-7d79-4ddb-8b1f-2dc3125d0365_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research and development expenses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8a15ce7f-2195-4822-a7d7-4eb0419492ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities - net unrealized gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6639181e-5a6d-4988-9ecf-f4af552ea82e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_4423794d-a82d-4388-af4b-0ea5c0b77c04_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_908fdabb-3dce-4704-8dab-59a26c82c62f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fb340e1b-e4a1-4919-82bc-178939924ddc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_376edd64-0f9b-43af-a418-4769d165da09_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change of control fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Change of Control Fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Change of Control Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_14c53303-4db9-4a1c-9e83-2be44defbefb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_30c040bf-4dae-4f39-9907-83c92889cbbf_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_b80cf5ec-82fe-42f7-a594-bc7508cb5637_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_29c397ab-1eb6-4617-b37c-dddb6e47829a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16924a76-de6a-4592-8da0-49d2f62182ed_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_6e198197-36d6-4286-bf18-3b32706055f6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2d00e96d-6cd8-4396-8dd1-de645296c6fd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_TechnologyTransferAgreementAbstract_label_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology Transfer Agreement [Abstract]</link:label>
    <link:label id="lab_lsta_TechnologyTransferAgreementAbstract_documentation_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology Transfer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementAbstract" xlink:href="lsta-20230930.xsd#lsta_TechnologyTransferAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_TechnologyTransferAgreementAbstract" xlink:to="lab_lsta_TechnologyTransferAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2b71bf77-3b12-4745-bd79-21bdc9cf783e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_cac99d5e-a6de-425c-a866-4e913744f22e_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AssetAcquisitionOtherLiabilities_05756855-9ff9-4ee1-bc84-9671e761338b_negatedTerseLabel_en-US" xlink:label="lab_lsta_AssetAcquisitionOtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_lsta_AssetAcquisitionOtherLiabilities_label_en-US" xlink:label="lab_lsta_AssetAcquisitionOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Liabilities</link:label>
    <link:label id="lab_lsta_AssetAcquisitionOtherLiabilities_documentation_en-US" xlink:label="lab_lsta_AssetAcquisitionOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionOtherLiabilities" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AssetAcquisitionOtherLiabilities" xlink:to="lab_lsta_AssetAcquisitionOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_1751fa75-1efa-4186-b3d6-71ee9e88af44_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5dbb872c-c01e-4925-8cfe-31736c73ac19_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_99907889-e655-4137-bb77-9ca56ea77cf2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2409f363-731d-4ebd-b45f-d4424b118d8b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ed3c97f0-f76c-4cd6-9bde-bb13d3a99961_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7a1bb0f9-cbfe-4c33-9f9d-9ca50e2db36e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_df2b7e17-435b-4a59-b125-b6334868382e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c144a70-500a-46d8-82c8-3bad0721ca8c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_bb8fe53f-0f3d-4e37-aaa7-388b1721252f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_67412263-759b-4fe6-8e9c-3ffc11249a2e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_848ff0bb-8021-4829-9fce-34083050501b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SharesHeldByThirdParty_4df38418-3340-4c16-a4ab-09f8ef3dde94_terseLabel_en-US" xlink:label="lab_lsta_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held by third party (in shares)</link:label>
    <link:label id="lab_lsta_SharesHeldByThirdParty_label_en-US" xlink:label="lab_lsta_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:label id="lab_lsta_SharesHeldByThirdParty_documentation_en-US" xlink:label="lab_lsta_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesHeldByThirdParty" xlink:href="lsta-20230930.xsd#lsta_SharesHeldByThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SharesHeldByThirdParty" xlink:to="lab_lsta_SharesHeldByThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_409c33f5-b01c-480a-8d1c-5970807e834b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_07845978-0252-408e-88da-64711d264bac_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0af29655-52d1-44a4-ae6b-f0d974954657_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1cf92ada-9b87-4e77-be87-37a4d0b7c177_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_IncomeTaxIncentiveReceivable_224ebd6b-bdef-43ba-a8cf-1c297b816411_terseLabel_en-US" xlink:label="lab_lsta_IncomeTaxIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax incentive receivable</link:label>
    <link:label id="lab_lsta_IncomeTaxIncentiveReceivable_label_en-US" xlink:label="lab_lsta_IncomeTaxIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Incentive Receivable</link:label>
    <link:label id="lab_lsta_IncomeTaxIncentiveReceivable_documentation_en-US" xlink:label="lab_lsta_IncomeTaxIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Incentive Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncomeTaxIncentiveReceivable" xlink:href="lsta-20230930.xsd#lsta_IncomeTaxIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_IncomeTaxIncentiveReceivable" xlink:to="lab_lsta_IncomeTaxIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_aa05c711-7585-47a1-9bad-d38cacc352ed_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization, remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_bb2af5df-b5c3-442f-98fa-200d7e72dd2a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6bb1265d-9e03-4c58-8656-10dfe46ab2f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_63575f72-7465-449e-a804-ce8271e1256f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_c238cf09-6fe9-4e30-bd00-0711b1212119_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4c2ea524-9f82-4b42-adea-af3282b8db36_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_da6a2171-6170-40ce-a068-154c4d6ae742_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_6167564f-47d3-44e3-b402-ea5e678d2808_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d2766f09-c042-4ec0-9e39-6fce58644a0d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities &#8212; current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2e0c8782-0332-498e-92a1-233cfc3485b2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_91d5cb22-c78b-4832-995d-997225fa71fd_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_4232f537-e529-4d3e-ba8a-554d2128ec3c_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsGranted_b7dee328-b2de-4835-aa1a-3a870e6cb439_terseLabel_en-US" xlink:label="lab_lsta_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsGranted_label_en-US" xlink:label="lab_lsta_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:label id="lab_lsta_WarrantsGranted_documentation_en-US" xlink:label="lab_lsta_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsGranted" xlink:href="lsta-20230930.xsd#lsta_WarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsGranted" xlink:to="lab_lsta_WarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_ab2d3380-1434-4bc5-a621-eca3ac41564b_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b992f56f-3c29-4697-bd82-d1c51eb81998_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_eee63763-426c-48ad-aab9-6354b9faf993_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d656247f-66b2-4a5d-b00b-473f8e80fb76_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5eacfe62-d371-433a-ac39-c37f62cb641e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired license - intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_18a08465-af28-46fc-bf42-cda124976be1_periodStartLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_73f81170-67c6-4887-8026-0e73b9c8e357_periodEndLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_394a49fe-5349-4139-86f0-d0c1016b314c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_796dad98-c4d5-40f4-b1fd-d6d643fa04ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f3aa023-b74e-4f8b-8653-5f6105b1a10a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ef0d175f-6da2-4fcc-aa08-06bca9769baa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_66a5609a-1308-4d22-a0c2-3df1f5c2958b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ffc15c7d-223d-4e7a-8098-0c8e4f6749f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c3e814e8-8136-49cf-95e7-e8c6a6f51e3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Share-based Compensation Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_fd2d26b3-d567-4b45-ba11-609b5723e5b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 738 shares at September 30, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_14d94241-5cd2-492f-89df-8523a654a8a7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ebe2a166-d176-4b05-964e-7fb63e9ba435_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f04c1166-60a3-4438-b5cf-5ea7f2da13e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_730cbf86-3409-4d95-91db-5a630a04c200_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7a7d894e-6b69-468b-9ca4-8efe5aecf887_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2673129e-2e7f-471b-82fe-abf80f2c0703_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_1bd2a00a-6374-4929-a16b-6f8319a280f4_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6a890c77-2036-4cc3-8559-06a9dad15c99_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OperatingLeaseRightOfUseAssetAbstract_ec743a13-65a1-4404-8e92-a810917d1d1e_terseLabel_en-US" xlink:label="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Assets:</link:label>
    <link:label id="lab_lsta_OperatingLeaseRightOfUseAssetAbstract_label_en-US" xlink:label="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset [Abstract]</link:label>
    <link:label id="lab_lsta_OperatingLeaseRightOfUseAssetAbstract_documentation_en-US" xlink:label="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:href="lsta-20230930.xsd#lsta_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:to="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d9d06511-fc91-424f-9087-05e34dafb824_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted-average period in years of compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_66ee9181-4f9c-4582-9ed0-eaa725b97b33_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8230a442-fb85-4762-9808-bf165db96d41_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_76e94cd1-806c-4b70-af8b-370bab69548d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CaladriusMember_a7466e0a-4a73-4d51-bf70-80048434cadf_terseLabel_en-US" xlink:label="lab_lsta_CaladriusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius</link:label>
    <link:label id="lab_lsta_CaladriusMember_label_en-US" xlink:label="lab_lsta_CaladriusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius [Member]</link:label>
    <link:label id="lab_lsta_CaladriusMember_documentation_en-US" xlink:label="lab_lsta_CaladriusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CaladriusMember" xlink:href="lsta-20230930.xsd#lsta_CaladriusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CaladriusMember" xlink:to="lab_lsta_CaladriusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e8076c58-fcec-447f-896a-e4a566829795_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_09063a3e-71cd-475c-9691-c7da4e888c23_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_56729004-82ac-4b99-801c-dc125ba19db0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8a40ac2d-e657-4568-b940-c8a2f5b5c4e7_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_06a0d4f7-14a2-4fbd-a04f-a3c3d8f3c55b_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_label_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_documentation_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:to="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7ba69e1b-d31f-49bd-b4d7-04b54e0c6ecf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_98817f07-0c8c-4d22-8f61-e1769b4d0304_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_ca5cacec-133a-40bd-ab10-d53e1af5539c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_192b54dd-6cf2-42ab-9160-b60dc7b5e3b6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember_5501d30e-d542-4dac-9170-45e2a3263aed_terseLabel_en-US" xlink:label="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive License and Collaboration Agreement</link:label>
    <link:label id="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive License and Collaboration Agreement [Member]</link:label>
    <link:label id="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive License and Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:href="lsta-20230930.xsd#lsta_ExclusiveLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:to="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_372c7428-a8a2-4865-88fe-cf90b7940ff1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4dd4179e-95b8-4f97-a6e0-066f5f388b8f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c80d6b37-ab86-4f24-8d19-70ffd6274bee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_d7099e01-b209-4db4-8b3b-3b7b7aaeed2d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OperatingLossCarryforwardsPostAcquisition_589df365-c7b0-4ae4-b020-24be5411c003_terseLabel_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, post acquisition</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsPostAcquisition_label_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Post Acquisition</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsPostAcquisition_documentation_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Post Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:href="lsta-20230930.xsd#lsta_OperatingLossCarryforwardsPostAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:to="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_357b8f22-2f35-4a05-9150-7b2c1afe8452_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4eb7840b-d084-44c7-9eb3-c7a3235ca38e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_3f5b24eb-4c05-4ea6-a3fa-62c274be21e7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding_e834da2c-a577-451b-a74b-2748a9f9d207_terseLabel_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding_label_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding_documentation_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:href="lsta-20230930.xsd#lsta_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:to="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_39ac1d27-fded-408e-9862-6a30586b5bdb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4e04e1c9-f344-4d57-9c64-8fa4019e0197_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuances of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35c0bbe6-f71c-48af-88e7-ae6fac548893_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1a68e3ac-7f80-4c2a-9586-651d4651ec09_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5f385d7c-a721-4118-9f14-27a701ef4c43_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_07f8e649-63e8-4c5e-9bc6-5a64ba315dc3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_39203d0b-1fe0-4953-afd0-c9e6a878609c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_5502132d-1bab-420f-a1c1-1d199d9370c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a1de591c-cc76-43c4-a7d5-1b7c00419b92_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3c8ef3f8-c850-4258-b259-f6aa2348a131_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_6fb59fad-55c3-473b-9475-a48378c09239_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental fair value of Cend's fully vested stock options assumed</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AtTheMarketOfferingAgreementMember_35b68d28-1045-4e8f-b699-a1cb923f93c8_terseLabel_en-US" xlink:label="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_lsta_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_lsta_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AtTheMarketOfferingAgreementMember" xlink:href="lsta-20230930.xsd#lsta_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AtTheMarketOfferingAgreementMember" xlink:to="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a534e0c2-9e44-461d-8c0c-8b46972f0990_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_265ac227-9de1-4d55-97ec-e6efd2f68f88_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_26602881-7d2b-4848-a531-87754cf20d3d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1dc2e60d-79a0-41bb-9b01-1029b09eadd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CommonStockWarrantsShares_dbf29413-64dd-427b-9e22-93e3c2ff0dc4_periodStartLabel_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_lsta_CommonStockWarrantsShares_2545331b-7032-4919-9ada-822fc91e1d7e_periodEndLabel_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_lsta_CommonStockWarrantsShares_label_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:label id="lab_lsta_CommonStockWarrantsShares_documentation_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CommonStockWarrantsShares" xlink:href="lsta-20230930.xsd#lsta_CommonStockWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CommonStockWarrantsShares" xlink:to="lab_lsta_CommonStockWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_518200b1-2aaa-42ab-9cac-e2c173dbfa05_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_bc51a672-b58e-497c-a94a-7e52209e9303_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_af98100a-200e-4c1e-a5ed-044f7f1568a4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AssetAcquisitionNetWorkingCapital_670079d3-7cca-4fb8-8886-8fe7f783cd9d_negatedTerseLabel_en-US" xlink:label="lab_lsta_AssetAcquisitionNetWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net working capital (excluding cash)</link:label>
    <link:label id="lab_lsta_AssetAcquisitionNetWorkingCapital_label_en-US" xlink:label="lab_lsta_AssetAcquisitionNetWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Net Working Capital</link:label>
    <link:label id="lab_lsta_AssetAcquisitionNetWorkingCapital_documentation_en-US" xlink:label="lab_lsta_AssetAcquisitionNetWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Net Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionNetWorkingCapital" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionNetWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AssetAcquisitionNetWorkingCapital" xlink:to="lab_lsta_AssetAcquisitionNetWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger_ffb45f5f-b408-483e-9727-5472cffe98e7_terseLabel_en-US" xlink:label="lab_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with Merger (in shares)</link:label>
    <link:label id="lab_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger_label_en-US" xlink:label="lab_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues Related to Merger</link:label>
    <link:label id="lab_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger_documentation_en-US" xlink:label="lab_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues Related to Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" xlink:href="lsta-20230930.xsd#lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" xlink:to="lab_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_ae310f86-1cd8-4ce1-a419-5691b25d2cb1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_4dd202cd-ba25-497b-9b8a-0ec3eadaf21d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4e2c0329-fb40-453f-808e-dab9a84d5941_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_7ddf3e00-d0c0-4f95-bb75-06b6d0b57faa_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_107568fb-5065-4637-9781-8c2863d2694b_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Lisata Therapeutics, Inc. Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_17aaa092-22ab-404c-94ae-720163da6f58_terseLabel_en-US" xlink:label="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL annual limitation</link:label>
    <link:label id="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_label_en-US" xlink:label="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carryforward Operating Loss Carryforward Annual Limitation</link:label>
    <link:label id="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_documentation_en-US" xlink:label="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carryforward Operating Loss Carryforward Annual Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:href="lsta-20230930.xsd#lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:to="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279a3de6-f6a3-4f66-80b4-bf199d5082a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_34e27a11-e076-48c4-8f68-ef26070c7ce6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_52fa30d7-60df-4692-a318-403544971fc5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_07b45fd2-873e-464d-9612-acba06ebb52d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55707e6d-0806-45b0-90d8-5a00ea826bfd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e9c24080-a27c-440a-9ed0-33e3a47e6a43_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b327dc32-e232-4c95-a2c5-5a8df24aa9df_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_fcca5c80-bd97-47e6-836a-6aeeb8056dcd_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, year four</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_1eb9b1b0-7123-4a44-aebd-7a8a84d644d0_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_EPSAbstract_c2fa9235-8ba3-41cd-8272-addeae8482ca_terseLabel_en-US" xlink:label="lab_lsta_EPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per share</link:label>
    <link:label id="lab_lsta_EPSAbstract_label_en-US" xlink:label="lab_lsta_EPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS [Abstract]</link:label>
    <link:label id="lab_lsta_EPSAbstract_documentation_en-US" xlink:label="lab_lsta_EPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_EPSAbstract" xlink:href="lsta-20230930.xsd#lsta_EPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_EPSAbstract" xlink:to="lab_lsta_EPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_05b2d225-adcc-4c88-9f54-5ffa2e52c845_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_050d3162-0c80-4386-9011-060957eafbca_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayTable_84d97de0-4c7e-441f-8aee-cd96a2d8407b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayTable" xlink:to="lab_us-gaap_IncomeTaxHolidayTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_274e17e2-7ea0-47a2-a273-f0b478987e4c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsOtherDisclosuresAbstract_0f484742-0b21-478e-b693-3084e8153a2d_terseLabel_en-US" xlink:label="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_lsta_WarrantsOtherDisclosuresAbstract_label_en-US" xlink:label="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures [Abstract]</link:label>
    <link:label id="lab_lsta_WarrantsOtherDisclosuresAbstract_documentation_en-US" xlink:label="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsOtherDisclosuresAbstract" xlink:href="lsta-20230930.xsd#lsta_WarrantsOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract" xlink:to="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_80bf092e-cd85-4b23-a035-0a07866df3cf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_36460b1d-ccdd-4426-ace7-51df82c7108c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization, year one</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d40a5f45-7f32-4f30-a5c2-e7753dc4fd77_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_67d532e4-292f-4fb7-ac79-29b26923d0b5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7dbb126e-a682-4db9-ad86-fdd9c2ef7ea7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9f411238-8233-42fd-8c19-a2faf019da1d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_35c1d784-80c4-46fd-b200-ff33c47e45bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares of the combined company owned by Cend stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_3d6b4b06-b5ac-4a26-b205-6d0cf9416267_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_1f5081c0-8283-4d7c-a704-8b67ea54240d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership after transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e3dde1b8-daf1-49bb-8dc1-8d37256377a1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_7aefac62-c4f7-41ce-983f-eee33f4cbfcb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a780d308-068d-4d12-a572-1e7feba3b430_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_3ada5e28-15fa-4533-afee-1bedb395ce21_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_a2256ae5-14f0-4830-a456-6409cc9c6e06_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c41ed3c9-4f6c-4ab1-8644-d83dd6f5e067_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_TechnologyTransferAgreementTextBlock_d81a131a-0e82-4ab5-ab6b-d4b7914dcfd6_terseLabel_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology Transfer Agreement</link:label>
    <link:label id="lab_lsta_TechnologyTransferAgreementTextBlock_label_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology Transfer Agreement [Text Block]</link:label>
    <link:label id="lab_lsta_TechnologyTransferAgreementTextBlock_documentation_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology Transfer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementTextBlock" xlink:href="lsta-20230930.xsd#lsta_TechnologyTransferAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_TechnologyTransferAgreementTextBlock" xlink:to="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_45b67dff-2827-46cd-af5b-9d413dcbbe12_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_32765aa6-0940-43eb-932a-69496d236fd1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f44353d5-22ec-466b-a81e-f8f12c7dc8e7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_993b19ee-4b2a-4f4d-88fc-7f0b22e46f31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_InProcessResearchAndDevelopment_53e3dc6e-b9de-45b0-a0b0-e2a611acef67_terseLabel_en-US" xlink:label="lab_lsta_InProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_lsta_InProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lsta_InProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_lsta_InProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lsta_InProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InProcessResearchAndDevelopment" xlink:href="lsta-20230930.xsd#lsta_InProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_InProcessResearchAndDevelopment" xlink:to="lab_lsta_InProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f9642659-f146-4107-925d-7c1aba4393c0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_cf3e1341-aa32-4f8f-a037-9abdf7da3ff3_terseLabel_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York</link:label>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_label_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_7bc3b2e8-7283-4ee2-889a-e7a6eb53d4e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_bd545d57-3a56-4cec-847f-b763ff53f203_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_90ae047a-ab72-460d-8272-8eaa7d97d5cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_44a164f7-75e0-427c-95b2-20ca7d3b81c8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_6e779dd7-a0e1-4956-a590-cf469e2d2e4d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_991b2a37-7ee3-4ad8-936b-377555b163d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_aafe537b-4ba6-44f3-8500-30e944efb694_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f8d7131f-f810-4735-b343-034179a1398d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8523a9fd-9137-48c6-93e8-32a088288a80_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SharesIssuedUnderLicenseAgreement_a3824950-a77b-4ede-a374-9c17e280951c_terseLabel_en-US" xlink:label="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under license agreement (in shares)</link:label>
    <link:label id="lab_lsta_SharesIssuedUnderLicenseAgreement_label_en-US" xlink:label="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:label id="lab_lsta_SharesIssuedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesIssuedUnderLicenseAgreement" xlink:href="lsta-20230930.xsd#lsta_SharesIssuedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SharesIssuedUnderLicenseAgreement" xlink:to="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_7d336e9d-93b0-4f9d-86c1-5139f0773bdd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SaleOfStockAvailableForSale_91384283-9925-4f92-9e83-cfde7dc7c876_terseLabel_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock available for sale</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSale_label_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Available for Sale</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSale_documentation_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Available for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSale" xlink:href="lsta-20230930.xsd#lsta_SaleOfStockAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SaleOfStockAvailableForSale" xlink:to="lab_lsta_SaleOfStockAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_dc48b6a9-5b42-4478-9d91-88aa2e22a65d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_cf2bde23-0605-4c85-b25e-a97bdb676ce1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9743b823-eb8f-4dd7-ab3e-948dbd0445cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,140,187 and 7,866,799 shares at September 30, 2023 and December 31, 2022, respectively; and outstanding, 8,139,449 and 7,866,061 shares at September 30, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AssetAcquisitionConsiderationTransferredEquityValue_b4eb856c-9513-45b6-8963-d86c1f008746_terseLabel_en-US" xlink:label="lab_lsta_AssetAcquisitionConsiderationTransferredEquityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lsta_AssetAcquisitionConsiderationTransferredEquityValue_label_en-US" xlink:label="lab_lsta_AssetAcquisitionConsiderationTransferredEquityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Value</link:label>
    <link:label id="lab_lsta_AssetAcquisitionConsiderationTransferredEquityValue_documentation_en-US" xlink:label="lab_lsta_AssetAcquisitionConsiderationTransferredEquityValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionConsiderationTransferredEquityValue" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionConsiderationTransferredEquityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AssetAcquisitionConsiderationTransferredEquityValue" xlink:to="lab_lsta_AssetAcquisitionConsiderationTransferredEquityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be7e811b-500b-4eac-815d-f3fc890ded09_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6ebc0428-69eb-4852-8cfa-c398d6d0b312_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_81c1e064-3b8a-433c-94da-d106623117f7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_e457b006-ce9e-46c0-83bc-b1b1a3b814e3_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, year seven</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_b185fdef-b8c7-4caf-897c-61992e407b58_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LossOnSaleOfNOL_0f95f5c9-c607-4def-845c-2f6533a4494f_terseLabel_en-US" xlink:label="lab_lsta_LossOnSaleOfNOL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of NOL</link:label>
    <link:label id="lab_lsta_LossOnSaleOfNOL_label_en-US" xlink:label="lab_lsta_LossOnSaleOfNOL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Sale of NOL</link:label>
    <link:label id="lab_lsta_LossOnSaleOfNOL_documentation_en-US" xlink:label="lab_lsta_LossOnSaleOfNOL" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Sale of NOL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LossOnSaleOfNOL" xlink:href="lsta-20230930.xsd#lsta_LossOnSaleOfNOL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LossOnSaleOfNOL" xlink:to="lab_lsta_LossOnSaleOfNOL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2cba3e60-eb99-40de-b6bd-deab62ecbeb9_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_eb0ed725-6641-46df-a38c-76edfa4c4ed9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_43388a61-dc6f-4593-be8c-8dba38341784_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c2bb563d-2ce0-4aa5-a4ef-4799ca28fb6c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercised_87f0f8c8-7d2a-4ce7-859d-a495d3995b8a_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercised_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercised_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_af419f5f-0a91-49a6-bfce-aa18039c3cb5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f4010c55-4725-44fc-a68f-e7a51cc584cf_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_52ef8983-b0b9-400e-bdba-461f06aa47f4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_155bec51-08d5-4c61-a9a6-d34a96d2d001_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, increase resulting from acquisition</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8357ef04-aa6d-49a3-b0cb-5f03253b85f7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_985e8c2c-ad95-43cb-9649-978bbf91c394_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale-Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_a8cbe041-1ca9-42cf-bea6-640ac5ecb547_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm_e4fc674b-98bb-4ec9-93d6-44ffff9ef03b_terseLabel_en-US" xlink:label="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:href="lsta-20230930.xsd#lsta_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:to="lab_lsta_OptionsVestedweightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsExpired_c67bdd26-8fb9-48e9-9575-609b00f49b3e_negatedTerseLabel_en-US" xlink:label="lab_lsta_WarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsExpired_label_en-US" xlink:label="lab_lsta_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:label id="lab_lsta_WarrantsExpired_documentation_en-US" xlink:label="lab_lsta_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExpired" xlink:href="lsta-20230930.xsd#lsta_WarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsExpired" xlink:to="lab_lsta_WarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30d4a7af-7878-4774-addf-86d12a6cb272_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsExercised_dfa89180-961c-4778-a974-6c7dc84bf744_negatedTerseLabel_en-US" xlink:label="lab_lsta_WarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsExercised_label_en-US" xlink:label="lab_lsta_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_lsta_WarrantsExercised_documentation_en-US" xlink:label="lab_lsta_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExercised" xlink:href="lsta-20230930.xsd#lsta_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsExercised" xlink:to="lab_lsta_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_64093fb6-a9ca-4c19-bd38-1ef85c576cb9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5759aa8-e991-4bc2-a742-4a8c7520e624_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ImpiloMember_363f3b51-7d19-4842-8c97-ad241c959697_terseLabel_en-US" xlink:label="lab_lsta_ImpiloMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impilo</link:label>
    <link:label id="lab_lsta_ImpiloMember_label_en-US" xlink:label="lab_lsta_ImpiloMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impilo [Member]</link:label>
    <link:label id="lab_lsta_ImpiloMember_documentation_en-US" xlink:label="lab_lsta_ImpiloMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impilo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember" xlink:href="lsta-20230930.xsd#lsta_ImpiloMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ImpiloMember" xlink:to="lab_lsta_ImpiloMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2d5aac22-1efc-4fd1-8fdc-462dca3a7e1a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_8393b611-8b09-4eb7-a8e2-953743e4805c_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_08db4756-a181-4d10-8e7f-f66e866e1ea8_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, net of sales</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c636901b-2152-48aa-9e12-430b150b5679_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_df1e42c3-86b2-4b0b-917c-6be322241d1a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Lisata Therapeutics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_5e572880-f609-442d-b29f-e51ac68e5879_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsVested_8e767847-e9f5-4884-88eb-f279805f6213_terseLabel_en-US" xlink:label="lab_lsta_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsVested_label_en-US" xlink:label="lab_lsta_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:label id="lab_lsta_WarrantsVested_documentation_en-US" xlink:label="lab_lsta_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsVested" xlink:href="lsta-20230930.xsd#lsta_WarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsVested" xlink:to="lab_lsta_WarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_81cfb304-441f-499a-b3de-3f9c9a18149e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_edc0e0f4-d227-4a44-b1c1-11fc9e3c6fce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1f1a9d17-9c55-4d87-9c4b-8143542a2171_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fa5f3806-a4da-462c-9df0-093b60e1c389_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustment arising during the period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7b703a77-7971-4c1e-8d9a-71eb4c29f91b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_bea5573e-96ef-46b7-b2a2-e550551f5953_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_da71d593-abce-4a5a-9c57-7ab972cc2b9f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before benefit from income taxes and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_BusinessTextBlock_101b22e5-3f44-4750-ab02-e301528a3b5f_terseLabel_en-US" xlink:label="lab_lsta_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business</link:label>
    <link:label id="lab_lsta_BusinessTextBlock_label_en-US" xlink:label="lab_lsta_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:label id="lab_lsta_BusinessTextBlock_documentation_en-US" xlink:label="lab_lsta_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_BusinessTextBlock" xlink:href="lsta-20230930.xsd#lsta_BusinessTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_BusinessTextBlock" xlink:to="lab_lsta_BusinessTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_92f8b1cb-0d0f-4448-a8d3-64f4cba37d40_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal debt securities</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6365cc09-45c3-4ea0-8983-2576f52cf903_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_637e1b12-b539-426d-9b94-8e64f227f67f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ce73dcaf-be7d-473f-a46d-3254f29efacd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_45fbd471-7a07-4d13-946a-053bfcffe0dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested_32fd11f8-21ea-4c44-9ac3-11257313cebb_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested_label_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested_documentation_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:to="lab_lsta_WeightedAverageRemainingContractualTermwarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_476933e7-e8e2-46a0-8ca5-37eff4b41ada_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_0a3a82ab-9d99-4810-88c1-e55c67e0e805_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_dd4ac842-f1e8-40b7-8c1b-46ace3f20b73_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of Lisata's cost method investment in Cend</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_609eba8e-3c0b-4723-a719-48c59f69699a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_3a2d4ef8-842f-446f-8cd1-7a1c587fadc6_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eec6ce8-23f9-48f5-918a-23a2e2577650_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_c7c32229-8233-4bad-b7fa-45235eff58c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less - net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f6b0d502-6f9f-453d-9852-0f5f6b25f81f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a49e0b02-1d2a-4460-9b00-f91062a8f9eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_01e6bc61-9958-4e65-a385-78362e9ea421_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_196183fb-6cbf-435d-8b45-80b1f4892f87_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4caf1c2c-8f51-4970-b13d-35e0db674d82_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding. Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_283f74f5-0410-485b-8a40-1f8cf80f7471_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6b08a96e-ec75-4525-8e4a-c8c2fd57d6c3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_744adb44-1ca4-4f37-81e0-07bbacbbb7ec_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_103dfe62-a978-40ad-b014-62ee96845827_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax refunds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_45daad50-26db-439c-87f3-57e2552029a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9cc4022e-f5a0-464c-a070-cedd535fd014_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c7b5fedc-ae54-492a-a5df-45708009350d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ba17a350-8cbe-4e1c-8f51-34b92f6d941b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2bfee70f-0528-43fb-978a-5985c43b0106_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5c0190fd-8c47-4e3c-9a29-58342b86d7fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_7deaa07c-741d-4117-ae2d-659e52e1d0f6_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_53f6c2a5-6285-4c1b-b91d-d73a7a6763ff_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_66587240-a87b-4121-9eaa-a3de6cc1e7cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb41c6ba-b1a5-4cf3-a5ff-74039b16b8e2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e79f879-262a-43b3-8e27-a9d6c9e41cb6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_934e7935-cf6a-410c-91ec-f36326b74210_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_UniversityOfCaliforniaAtSanDiegoMember_fae767a3-403b-4dad-9f0a-ed1643e9c493_terseLabel_en-US" xlink:label="lab_lsta_UniversityOfCaliforniaAtSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of California at San Diego</link:label>
    <link:label id="lab_lsta_UniversityOfCaliforniaAtSanDiegoMember_label_en-US" xlink:label="lab_lsta_UniversityOfCaliforniaAtSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of California at San Diego [Member]</link:label>
    <link:label id="lab_lsta_UniversityOfCaliforniaAtSanDiegoMember_documentation_en-US" xlink:label="lab_lsta_UniversityOfCaliforniaAtSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of California at San Diego</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_UniversityOfCaliforniaAtSanDiegoMember" xlink:href="lsta-20230930.xsd#lsta_UniversityOfCaliforniaAtSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_UniversityOfCaliforniaAtSanDiegoMember" xlink:to="lab_lsta_UniversityOfCaliforniaAtSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CENDMember_3d35abc3-16d3-4bb7-a148-3967ebe9cc7b_terseLabel_en-US" xlink:label="lab_lsta_CENDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEND</link:label>
    <link:label id="lab_lsta_CENDMember_label_en-US" xlink:label="lab_lsta_CENDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEND [Member]</link:label>
    <link:label id="lab_lsta_CENDMember_documentation_en-US" xlink:label="lab_lsta_CENDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CENDMember" xlink:to="lab_lsta_CENDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_57d85e88-59bf-4696-a917-1695f1b375b3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_25bb0268-91db-4eff-9f2f-339e2fe06217_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0623a38d-c491-4f96-8551-1d054a1fd405_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d8a96eed-1962-4306-9d93-78d1183b3c21_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c58c028d-040e-4da1-83ed-2da2599ada81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option and Warrants Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9764195-5179-4a9b-8568-ad1f4cf1303d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e518d606-74c1-4a63-93ca-ac4b48fb2f15_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b598d008-0e62-495c-a90d-2eb4c744ec18_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExpired_c1dc44e4-7e5a-47a1-8561-ce02c762bd59_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExpired_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExpired_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_55fd35b0-d067-44df-a4b0-fb07e134a9aa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental fair value of Cend's fully vested stock options</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_461a9b7e-edcc-4bab-b707-cf466cddcd3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding payments on net share settlement equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_2ea95079-adf5-4aee-9f86-d964396d0dcb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6efab97e-5045-453b-af91-58c2bbaef9d0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_173b5d63-a432-47d6-a96a-ed70736c2802_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0f787f50-f1d5-445a-a1ca-07df4aefc22e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e2428892-95ce-4821-a872-c61f437bd5a5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b0d0d303-eca6-49c8-ae83-764dd5312d07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e6f79b2f-2b40-4c1a-af99-5bddc4d11ebb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsCanceled_e903d720-b484-4a1b-b51a-1199a37b6280_negatedLabel_en-US" xlink:label="lab_lsta_WarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsCanceled_label_en-US" xlink:label="lab_lsta_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:label id="lab_lsta_WarrantsCanceled_documentation_en-US" xlink:label="lab_lsta_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsCanceled" xlink:href="lsta-20230930.xsd#lsta_WarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsCanceled" xlink:to="lab_lsta_WarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_9889cdfa-f887-4d4c-9f4f-73e4d7cc881e_terseLabel_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sublicensing revenues</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_label_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_documentation_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:href="lsta-20230930.xsd#lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:to="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_841ed81a-fdbb-4726-a395-48776dde950f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AssetAcquisitionIntangibles_91422e36-32fa-4e43-9af1-60de364b4cc0_terseLabel_en-US" xlink:label="lab_lsta_AssetAcquisitionIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_lsta_AssetAcquisitionIntangibles_label_en-US" xlink:label="lab_lsta_AssetAcquisitionIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Intangibles</link:label>
    <link:label id="lab_lsta_AssetAcquisitionIntangibles_documentation_en-US" xlink:label="lab_lsta_AssetAcquisitionIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionIntangibles" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AssetAcquisitionIntangibles" xlink:to="lab_lsta_AssetAcquisitionIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_84980855-9dcd-4b70-8148-fbd52a451028_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fd1fe3bb-5591-49ec-8153-cfb27aea86bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f9d440a5-9be2-4ee8-9427-35504431e4a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_31921961-68b4-4675-8c03-e245fbe6e599_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, non-controlling interests and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_b7d2a261-827e-492f-a903-cadf47aa0591_terseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_label_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AustralianTaxationOfficeMember" xlink:to="lab_us-gaap_AustralianTaxationOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a24491c1-c8bd-4a5a-9c27-1f7d6e1436dd_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_95fec409-bbb3-46a3-a40e-aaa59aed28f9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3e59c826-7e8f-4de1-ad55-f955cf9720c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale_ff916978-ff75-4aa9-87ac-fe743952bf9c_terseLabel_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sale</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale_label_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale_documentation_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:href="lsta-20230930.xsd#lsta_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:to="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9e43d90e-905a-4531-89e9-f6b7a18e3091_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_28c81d1b-3006-4324-b09d-3bf9526ac2d7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_dded74e0-1fa3-497b-8911-ff7cdc1685b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_59ac3ec1-5ab8-4cb5-ad81-7a50e67cedc2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d7c95284-1718-4ed3-81e4-3d905e777880_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6f5de916-2f05-48fc-aa6c-d2c5aea563dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_a368500e-40b4-490c-88ea-d342cb4e27de_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with merger</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d3a118c8-bda6-4dde-8b34-f526f82e80c3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_98415a93-1a92-4538-b682-10d48ae341aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_1271323a-54e9-4956-8611-427a5515684d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_87ce9b0c-65c2-4fdc-96d2-ef0ab2032b5b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Affiliates [Line Items]</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Affiliates [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_252d0043-16c6-43db-8071-2957a61a7f1b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_158ac100-cffc-4d0f-94ba-07470806b0bb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_740b947a-b344-4a48-afc4-455618418d27_terseLabel_en-US" xlink:label="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration amounts, milestones</link:label>
    <link:label id="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="lsta-20230930.xsd#lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_FairValueMarketOfTaxNOLs_eb839972-4978-4eaa-9cbb-a4b0c5d7433f_terseLabel_en-US" xlink:label="lab_lsta_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value market of tax NOLs</link:label>
    <link:label id="lab_lsta_FairValueMarketOfTaxNOLs_label_en-US" xlink:label="lab_lsta_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Market of Tax NOLs</link:label>
    <link:label id="lab_lsta_FairValueMarketOfTaxNOLs_documentation_en-US" xlink:label="lab_lsta_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Market of Tax NOLs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FairValueMarketOfTaxNOLs" xlink:href="lsta-20230930.xsd#lsta_FairValueMarketOfTaxNOLs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_FairValueMarketOfTaxNOLs" xlink:to="lab_lsta_FairValueMarketOfTaxNOLs" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AssetAcquisitionSharePrice_3c4c94bb-f31d-4d24-be31-2cf38acb5827_terseLabel_en-US" xlink:label="lab_lsta_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</link:label>
    <link:label id="lab_lsta_AssetAcquisitionSharePrice_label_en-US" xlink:label="lab_lsta_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Share Price</link:label>
    <link:label id="lab_lsta_AssetAcquisitionSharePrice_documentation_en-US" xlink:label="lab_lsta_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionSharePrice" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AssetAcquisitionSharePrice" xlink:to="lab_lsta_AssetAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f873d849-7943-4ba0-8300-4fe334d45b28_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c41cbc8f-17cb-470a-948e-6fe2fa6dc038_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a7d002a4-2b75-4508-a4d4-d29ebfe01e86_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d280436d-7922-43ec-bd16-09cd2d1d3590_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_8e148566-4a35-412a-ba8f-19dc0c3ebe5f_terseLabel_en-US" xlink:label="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering amount authorized per agreement</link:label>
    <link:label id="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_label_en-US" xlink:label="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:label id="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_documentation_en-US" xlink:label="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:href="lsta-20230930.xsd#lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:to="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_d17380bd-4ec8-473c-b225-4682a4e331cc_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, years two and three</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f09cc804-23aa-43bc-b0fb-6646228c9aaf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ff8e425-5e9b-46e9-8e6b-2c65aa13c5e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a373b0f6-9224-4953-9de8-bf49da5a43a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_9f686ab7-f763-4d06-9fb9-f433f0b43527_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_4688d479-c6dd-4b43-8c6b-bf56804370d6_terseLabel_en-US" xlink:label="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other liabilities</link:label>
    <link:label id="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:href="lsta-20230930.xsd#lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OutstandingStockThreshold_61b7cbbe-a442-4175-80bb-f410e46c9939_terseLabel_en-US" xlink:label="lab_lsta_OutstandingStockThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock threshold</link:label>
    <link:label id="lab_lsta_OutstandingStockThreshold_label_en-US" xlink:label="lab_lsta_OutstandingStockThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Stock Threshold</link:label>
    <link:label id="lab_lsta_OutstandingStockThreshold_documentation_en-US" xlink:label="lab_lsta_OutstandingStockThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Stock Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OutstandingStockThreshold" xlink:href="lsta-20230930.xsd#lsta_OutstandingStockThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OutstandingStockThreshold" xlink:to="lab_lsta_OutstandingStockThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_378041b2-b108-40d0-93be-6307d8a0d581_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown_7009dbd4-b009-4857-9ced-a7889ef1e87d_terseLabel_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, prior to write down</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown_label_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown_documentation_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:href="lsta-20230930.xsd#lsta_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:to="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_4c4a35ba-89f1-4b98-8b40-7ac0c1189d8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, value, outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward_e2fae709-82a3-45dc-929f-ac954c93fe1c_terseLabel_en-US" xlink:label="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:label id="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="lsta-20230930.xsd#lsta_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f86de508-b6ad-4213-8959-622053a9b1a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9e63eefa-46ee-471c-b540-84fd735cb096_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_d702aeef-77bd-4649-97fc-5f4cd9add72e_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, after first sale</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1ea242ad-aa22-4281-9c24-9d184797ce10_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_d2058a6f-2690-4b50-ad83-d2c9ee1a1a55_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_52404e57-9b9c-4113-a4a3-25798e3f961a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b52d4953-690b-427e-89ed-d845a82f3a9a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_5d23f30c-18ef-4cd5-97f2-553059f0c15b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones, Royalties</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3783f0f6-ef8c-4b90-b4d1-3d50d359e521_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b8b2531-dc86-4d99-a9d6-646b60b36ae0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c794ddab-3ac9-4d7c-b32f-6f19c7e65055_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization, year three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AccruedGrantFunding_ef27ccd8-d98a-4cca-9bab-0c63b191e02e_terseLabel_en-US" xlink:label="lab_lsta_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting &amp; tax consulting liabilities</link:label>
    <link:label id="lab_lsta_AccruedGrantFunding_label_en-US" xlink:label="lab_lsta_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Grant Funding</link:label>
    <link:label id="lab_lsta_AccruedGrantFunding_documentation_en-US" xlink:label="lab_lsta_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Grant Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AccruedGrantFunding" xlink:href="lsta-20230930.xsd#lsta_AccruedGrantFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AccruedGrantFunding" xlink:to="lab_lsta_AccruedGrantFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5758efed-fcf7-4b4d-b5cd-a8af0f8837eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_da25e432-81ce-4cd7-893a-7d6a9dff6289_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lisata transaction costs</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e8dba503-80e6-4d69-a49b-8475d5e2dcb2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_094b34a1-b5e3-4944-b54a-5e26f3e0c549_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_74921e99-bae1-4222-a699-b2d2f3960ecf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e103b19c-0a22-441a-b6d8-a247b02437dc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization, year two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_02c09359-2fb7-479c-9ef5-2c9b0cb78ce8_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_bf52de86-fe17-4b88-8117-31429344287f_terseLabel_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_label_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_documentation_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:href="lsta-20230930.xsd#lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:to="lab_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled_36c08e4d-46bb-42e0-bb05-0e5b3007fd10_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_0edf1163-669c-470f-9295-8bbf093d9433_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsGranted_d18d5760-5bd6-4026-a6b2-1a329a2163af_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsGranted_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsGranted_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SanfordBurnhamPrebysMember_5fff0e85-c497-4283-84bc-048013549e73_terseLabel_en-US" xlink:label="lab_lsta_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:label id="lab_lsta_SanfordBurnhamPrebysMember_label_en-US" xlink:label="lab_lsta_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys [Member]</link:label>
    <link:label id="lab_lsta_SanfordBurnhamPrebysMember_documentation_en-US" xlink:label="lab_lsta_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SanfordBurnhamPrebysMember" xlink:href="lsta-20230930.xsd#lsta_SanfordBurnhamPrebysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SanfordBurnhamPrebysMember" xlink:to="lab_lsta_SanfordBurnhamPrebysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_39a47087-766b-42ae-a3ec-5e91de91fac5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c9ea4687-4c13-4c1f-9198-6de0b78d44b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_b47706ef-7910-456f-8535-ff94eac58181_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_364de66b-da14-44ff-b3cc-f73690c60601_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ClinicalAndRDRelatedLiabilities_bd5830b4-ece8-4e39-8933-809847a329c5_terseLabel_en-US" xlink:label="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and R&amp;D related liabilities</link:label>
    <link:label id="lab_lsta_ClinicalAndRDRelatedLiabilities_label_en-US" xlink:label="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:label id="lab_lsta_ClinicalAndRDRelatedLiabilities_documentation_en-US" xlink:label="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalAndRDRelatedLiabilities" xlink:href="lsta-20230930.xsd#lsta_ClinicalAndRDRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ClinicalAndRDRelatedLiabilities" xlink:to="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_MassachusettsInstituteOfTechnologyMember_faf84433-acf6-47ba-a216-2d2fc958bebe_terseLabel_en-US" xlink:label="lab_lsta_MassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts Institute of Technology</link:label>
    <link:label id="lab_lsta_MassachusettsInstituteOfTechnologyMember_label_en-US" xlink:label="lab_lsta_MassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts Institute of Technology [Member]</link:label>
    <link:label id="lab_lsta_MassachusettsInstituteOfTechnologyMember_documentation_en-US" xlink:label="lab_lsta_MassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts Institute of Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_MassachusettsInstituteOfTechnologyMember" xlink:href="lsta-20230930.xsd#lsta_MassachusettsInstituteOfTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_MassachusettsInstituteOfTechnologyMember" xlink:to="lab_lsta_MassachusettsInstituteOfTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5c45c114-b2bc-433a-99ff-20df9a46598f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_738b58b1-231c-4d28-8d8b-bea4ef56c76f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_94201a04-cd1d-400c-a488-c9d81e42f48f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvested_c92d4343-e7d2-481f-b329-e7109e1e1619_terseLabel_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvested_label_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsvested_documentation_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsvested" xlink:href="lsta-20230930.xsd#lsta_AggregateIntrinsicValueWarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AggregateIntrinsicValueWarrantsvested" xlink:to="lab_lsta_AggregateIntrinsicValueWarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAbstract" xlink:to="lab_us-gaap_AssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_85df878c-d995-4016-83fd-263e197a7a20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5025ee5d-fb15-4372-ac0d-a50519ca939f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, employee benefits and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_22d14481-bf63-4336-af72-8582802777b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_bd98b524-de03-47ff-a229-920d9d34ce10_terseLabel_en-US" xlink:label="lab_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Acquired In-Process Research And Development</link:label>
    <link:label id="lab_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Acquired In-Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:to="lab_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_595c18ac-8970-4da0-8b46-42ffd95bc7bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_90c2eb67-1a78-48a6-9af6-90af944ea27e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_454da03d-2cde-45c9-8079-92704f5e567f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c50b04ae-a4f8-4b76-8bf2-8245afd8629a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bc4ebf50-3cb9-4bf5-8f57-7236fcd696a1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue excluding taxes</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_a452861c-0746-4b8b-8ddf-cda844c495c9_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a7777814-b506-41d4-9f59-21c4a43246e8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_846b8d41-d53f-49c5-a7d9-129692d18f6f_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0e4ebbc0-f3f9-4a25-bdaf-3feb1c64ae3d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_PaymentsForAssetAcquisitionCostsNet_ad550f5d-bf7d-47ef-bf40-3d7a979fbb75_negatedTerseLabel_en-US" xlink:label="lab_lsta_PaymentsForAssetAcquisitionCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition costs, net of cash acquired related to merger with Cend</link:label>
    <link:label id="lab_lsta_PaymentsForAssetAcquisitionCostsNet_label_en-US" xlink:label="lab_lsta_PaymentsForAssetAcquisitionCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisition Costs, Net</link:label>
    <link:label id="lab_lsta_PaymentsForAssetAcquisitionCostsNet_documentation_en-US" xlink:label="lab_lsta_PaymentsForAssetAcquisitionCostsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisition Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_PaymentsForAssetAcquisitionCostsNet" xlink:href="lsta-20230930.xsd#lsta_PaymentsForAssetAcquisitionCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_PaymentsForAssetAcquisitionCostsNet" xlink:to="lab_lsta_PaymentsForAssetAcquisitionCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b4b007e-7f65-4b08-9253-4914b17cfeeb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0c2f502a-b25a-43a4-9dd0-13533ea3003a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate for operating leases (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_31e812fb-fce1-4a67-84c8-dff8ba19a29f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8cbb041d-00ba-4d51-ae0b-0c34d9266364_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_ff07d8e7-21af-438b-8201-347d851b9176_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_98c03251-a6a1-4161-8772-8e860f4e72d0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_aa7fe800-2d63-4745-a927-ee0f257d289d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b95239a4-c392-44a8-8cae-99f00309a64a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2ef87c5c-22e0-4f74-9823-db816e93126f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a7976f50-8018-47db-8c6d-a0f3542f6921_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AssetAcquisitionCashAndCashEquivalents_34d2451d-8377-4a46-96d4-979206936430_terseLabel_en-US" xlink:label="lab_lsta_AssetAcquisitionCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_lsta_AssetAcquisitionCashAndCashEquivalents_label_en-US" xlink:label="lab_lsta_AssetAcquisitionCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash and Cash Equivalents</link:label>
    <link:label id="lab_lsta_AssetAcquisitionCashAndCashEquivalents_documentation_en-US" xlink:label="lab_lsta_AssetAcquisitionCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionCashAndCashEquivalents" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AssetAcquisitionCashAndCashEquivalents" xlink:to="lab_lsta_AssetAcquisitionCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e2a4183d-70df-47c0-8300-71d8265aed50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_eb082f7e-af52-4dc8-a24d-36863acf2fcf_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ProceedsFromSaleOfNOLS_4c20b312-908a-455b-8c0e-907da51a9fd8_terseLabel_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNOLS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of NOLs</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNOLS_label_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNOLS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of NOLS</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNOLS_documentation_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNOLS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of NOLS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNOLS" xlink:href="lsta-20230930.xsd#lsta_ProceedsFromSaleOfNOLS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ProceedsFromSaleOfNOLS" xlink:to="lab_lsta_ProceedsFromSaleOfNOLS" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_ef52a9fc-665b-48ce-83ed-49107201c17e_terseLabel_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia Research and Development Tax Incentive</link:label>
    <link:label id="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_label_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Tax Incentive [Text Block]</link:label>
    <link:label id="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_documentation_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Tax Incentive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:href="lsta-20230930.xsd#lsta_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:to="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8d700336-c0f8-4673-8aa5-7821230dec5d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b1202ead-7abc-4c82-a378-b3f26e1da931_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_49ab46f5-7e69-4028-9576-880f845afb52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_de6f51ed-1e71-4619-a912-1020d7e21a04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17090435-04c2-4173-9dc3-2bc0eec63bf6_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_e9342840-31af-499a-b3e5-380eabe8bcd3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_c23bf82f-6873-42bc-9829-b9fb90b33cd5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_0a1fc6d2-c000-49a6-ab48-d12c6129ee60_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6d01dd21-747e-47b7-a459-d70ee02503cd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_01f48a7b-4c46-4faf-8554-4153d2aa26e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_510f95af-4c3c-43bb-a093-f0a6e1e4eec5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_09fc393c-0dd5-4364-93d8-a4ccd101d434_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_9c432ee4-e756-419a-9406-29dfce846670_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_34e91907-6ae6-475f-8eea-7b73cf4b5b09_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e23a2b15-c079-46f2-abe3-55f6edcff525_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4c7e945c-3a94-4e64-9d8c-62e399b2dd84_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BondsMember_c1cb4241-0a11-4964-8d81-d5c1b7250ef3_terseLabel_en-US" xlink:label="lab_us-gaap_BondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_us-gaap_BondsMember_label_en-US" xlink:label="lab_us-gaap_BondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BondsMember" xlink:to="lab_us-gaap_BondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c6d5575a-70aa-4a89-9006-092ec654d9db_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_QiluMember_c8092516-971e-4db2-a7f8-a74bc88abeec_terseLabel_en-US" xlink:label="lab_lsta_QiluMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu</link:label>
    <link:label id="lab_lsta_QiluMember_label_en-US" xlink:label="lab_lsta_QiluMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu [Member]</link:label>
    <link:label id="lab_lsta_QiluMember_documentation_en-US" xlink:label="lab_lsta_QiluMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_QiluMember" xlink:href="lsta-20230930.xsd#lsta_QiluMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_QiluMember" xlink:to="lab_lsta_QiluMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_b37555ce-bf0f-4765-91f9-90766172a9e6_terseLabel_en-US" xlink:label="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</link:label>
    <link:label id="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_label_en-US" xlink:label="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:label id="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_documentation_en-US" xlink:label="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:href="lsta-20230930.xsd#lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:to="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e748c9e-6198-4cc1-8b9e-adb6a6f4e72d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_128e577f-dd3c-49af-b2ea-530296dd288f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_95d3dafd-4fa4-4797-a0cd-679a27e67af0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b5bdcfa7-9fd6-4894-bfaf-da31250a4987_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50f73f49-b4c2-4b5e-a7cd-3a59a0479289_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_50fd1905-4f21-4be5-a636-26e164771d76_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_77725d05-18ae-4f7b-bc42-8c270bfcaaf0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized to be repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_2380e757-dfda-4337-a6c0-dedd73663147_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest in Subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>lsta-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:b3932c72-a861-4a02-8e8c-886f49fbe91d,g:dd0049eb-adfc-4bb4-a64a-f5d2d3c1c00a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="lsta-20230930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d4f333c7-941b-4370-8c0e-4cb5ef410a22" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_DocumentType_d4f333c7-941b-4370-8c0e-4cb5ef410a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a1f22c9e-8fe7-4688-840c-025a721d5870" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_DocumentQuarterlyReport_a1f22c9e-8fe7-4688-840c-025a721d5870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7636011e-557b-41dd-a189-5f0effd632c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_DocumentPeriodEndDate_7636011e-557b-41dd-a189-5f0effd632c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1cb39fad-a9e5-415c-9e00-d2795a2c3526" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_DocumentTransitionReport_1cb39fad-a9e5-415c-9e00-d2795a2c3526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c4b42dc4-1cba-4255-8cec-fce6f8d87c8b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityFileNumber_c4b42dc4-1cba-4255-8cec-fce6f8d87c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fb9cdc96-1ce1-41b6-8959-fc5bc621fbe6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityRegistrantName_fb9cdc96-1ce1-41b6-8959-fc5bc621fbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a60224e0-bac0-4fac-9b23-a5502c4362a9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a60224e0-bac0-4fac-9b23-a5502c4362a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d11e9209-d587-4aec-bcac-ce8e8df7677f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityTaxIdentificationNumber_d11e9209-d587-4aec-bcac-ce8e8df7677f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1b4f9c9d-11dd-409a-8f2d-5ca411329443" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityAddressAddressLine1_1b4f9c9d-11dd-409a-8f2d-5ca411329443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f7590c09-417e-448b-958b-3170709d6a2b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityAddressCityOrTown_f7590c09-417e-448b-958b-3170709d6a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ce2a7b41-ff0a-441d-89c7-b8fd842c9346" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityAddressStateOrProvince_ce2a7b41-ff0a-441d-89c7-b8fd842c9346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6c249aca-5777-42e7-8dc5-5bfac336bec3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityAddressPostalZipCode_6c249aca-5777-42e7-8dc5-5bfac336bec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_19a41a19-ed5a-4fab-ba65-1ea2a1627e2d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_CityAreaCode_19a41a19-ed5a-4fab-ba65-1ea2a1627e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_74c7d3ce-5912-4831-9880-60b4f1c6b8ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_LocalPhoneNumber_74c7d3ce-5912-4831-9880-60b4f1c6b8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bb379382-ac1d-41aa-8fee-c2b68615f16d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_Security12bTitle_bb379382-ac1d-41aa-8fee-c2b68615f16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_870db739-0f0f-4d36-aaff-27b6579a2b51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_TradingSymbol_870db739-0f0f-4d36-aaff-27b6579a2b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_392e1915-bbae-4707-96d6-b53ec56f3731" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_SecurityExchangeName_392e1915-bbae-4707-96d6-b53ec56f3731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_da2bb138-2473-4c91-b8fe-597942dee725" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityCurrentReportingStatus_da2bb138-2473-4c91-b8fe-597942dee725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8b329b2f-d4f9-4806-80ae-404836747a27" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityInteractiveDataCurrent_8b329b2f-d4f9-4806-80ae-404836747a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4a132700-c9f8-46ed-9cbd-bf7a68989f4a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityFilerCategory_4a132700-c9f8-46ed-9cbd-bf7a68989f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5d67ea4c-32b1-48a3-89c9-c7e07362c653" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntitySmallBusiness_5d67ea4c-32b1-48a3-89c9-c7e07362c653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0af9cdff-0e99-448a-bf6a-24a0401b63fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityEmergingGrowthCompany_0af9cdff-0e99-448a-bf6a-24a0401b63fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3ea19f6b-18be-4557-92fe-8a668eed5711" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityShellCompany_3ea19f6b-18be-4557-92fe-8a668eed5711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1a31d90a-bc1e-4578-8133-52ad99429e0f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1a31d90a-bc1e-4578-8133-52ad99429e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fa68b032-45a8-4f1d-b1b1-3f7255471264" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_EntityCentralIndexKey_fa68b032-45a8-4f1d-b1b1-3f7255471264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fd59533a-7c30-4704-b4ad-a3f04ed5ddfd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_CurrentFiscalYearEndDate_fd59533a-7c30-4704-b4ad-a3f04ed5ddfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_20c8d555-d5c5-4621-bc32-966a2b1e0994" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_DocumentFiscalYearFocus_20c8d555-d5c5-4621-bc32-966a2b1e0994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_226a8c3e-b5df-4ab0-8729-16cfd29fcf5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_DocumentFiscalPeriodFocus_226a8c3e-b5df-4ab0-8729-16cfd29fcf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3cbb9d8f-a21d-434d-ae0e-a6b1827bea4b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78b5cea0-0e46-40a1-a277-ee0502806dda" xlink:to="loc_dei_AmendmentFlag_3cbb9d8f-a21d-434d-ae0e-a6b1827bea4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ce3e0398-f344-494d-af39-8a8d9484d8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce3e0398-f344-494d-af39-8a8d9484d8b9" xlink:to="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aaa804ee-dc9e-4852-b03a-7d97b7cb257a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aaa804ee-dc9e-4852-b03a-7d97b7cb257a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_48daefbe-8947-4e7b-b548-21ca041d9f08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:to="loc_us-gaap_MarketableSecurities_48daefbe-8947-4e7b-b548-21ca041d9f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fe1e82f6-c010-4a28-9071-180923896e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fe1e82f6-c010-4a28-9071-180923896e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_93052c9e-df8c-4564-b742-003a1b8408f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:to="loc_us-gaap_AssetsCurrent_93052c9e-df8c-4564-b742-003a1b8408f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_01b4742d-59a0-4237-b4f0-06433b3cb250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_01b4742d-59a0-4237-b4f0-06433b3cb250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1bdaded-9a2b-4fca-80c9-63acdb6805cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1bdaded-9a2b-4fca-80c9-63acdb6805cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3d49e5d7-4441-4a66-94af-4bb428d43f03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3d49e5d7-4441-4a66-94af-4bb428d43f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_62ee802f-b643-4421-86c5-fa6df95147b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c7a14e3-15d7-471a-95d9-b200c585e27a" xlink:to="loc_us-gaap_Assets_62ee802f-b643-4421-86c5-fa6df95147b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_995ad912-f9fb-4906-b39b-d12eb2a18f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce3e0398-f344-494d-af39-8a8d9484d8b9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_995ad912-f9fb-4906-b39b-d12eb2a18f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_9abff155-ea58-4d41-8b0f-b9b54d10e737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_995ad912-f9fb-4906-b39b-d12eb2a18f66" xlink:to="loc_us-gaap_LiabilitiesAbstract_9abff155-ea58-4d41-8b0f-b9b54d10e737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b9cae298-82a9-4740-b5b5-e4f2024fcbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9abff155-ea58-4d41-8b0f-b9b54d10e737" xlink:to="loc_us-gaap_AccountsPayableCurrent_b9cae298-82a9-4740-b5b5-e4f2024fcbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_84ba2c97-cc33-4fd3-b876-fbba6309cd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9abff155-ea58-4d41-8b0f-b9b54d10e737" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_84ba2c97-cc33-4fd3-b876-fbba6309cd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4da2d988-6196-48d8-a268-11d1b2496211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9abff155-ea58-4d41-8b0f-b9b54d10e737" xlink:to="loc_us-gaap_LiabilitiesCurrent_4da2d988-6196-48d8-a268-11d1b2496211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0ea18d35-393b-42d0-96f3-a42c48627097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9abff155-ea58-4d41-8b0f-b9b54d10e737" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0ea18d35-393b-42d0-96f3-a42c48627097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4bcda383-8cb0-4738-baae-ecf61c1f18aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_9abff155-ea58-4d41-8b0f-b9b54d10e737" xlink:to="loc_us-gaap_Liabilities_4bcda383-8cb0-4738-baae-ecf61c1f18aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9fb22daf-3d10-4f37-ad81-f4017a180802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_995ad912-f9fb-4906-b39b-d12eb2a18f66" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9fb22daf-3d10-4f37-ad81-f4017a180802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_995ad912-f9fb-4906-b39b-d12eb2a18f66" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_66996bc2-473a-4d79-8ea2-711349a31b93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:to="loc_us-gaap_CommonStockValue_66996bc2-473a-4d79-8ea2-711349a31b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a378e549-f2da-433f-af38-43f222291176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a378e549-f2da-433f-af38-43f222291176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_838816e8-34b4-43a3-b37f-6e51c63952f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:to="loc_us-gaap_TreasuryStockCommonValue_838816e8-34b4-43a3-b37f-6e51c63952f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c8994bcf-680d-4e08-84c6-04e821edc924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c8994bcf-680d-4e08-84c6-04e821edc924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_661b3039-6224-4002-8a5b-bc60b6482aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_661b3039-6224-4002-8a5b-bc60b6482aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7a837acd-b81b-4aad-b069-a0c2042332da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:to="loc_us-gaap_StockholdersEquity_7a837acd-b81b-4aad-b069-a0c2042332da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b2b75d5f-5db5-43c7-8c00-718686a8ef64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:to="loc_us-gaap_MinorityInterest_b2b75d5f-5db5-43c7-8c00-718686a8ef64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f69620f8-31df-4536-91c2-dd1cc97cfb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35cc5cf7-8c19-4df3-9edc-8a44f8d05d3a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f69620f8-31df-4536-91c2-dd1cc97cfb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c60fef0-7cfe-4e36-9343-72c7fc98ed25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_995ad912-f9fb-4906-b39b-d12eb2a18f66" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c60fef0-7cfe-4e36-9343-72c7fc98ed25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDBALANCESHEETSParentheticals"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5026f0d0-7a02-48f4-a2ad-596c41da4d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d7cabf6c-dbc5-4d4a-86d5-7fe5d009e241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5026f0d0-7a02-48f4-a2ad-596c41da4d27" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d7cabf6c-dbc5-4d4a-86d5-7fe5d009e241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2811b1bf-a207-4f20-9fb1-4ed311425410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5026f0d0-7a02-48f4-a2ad-596c41da4d27" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2811b1bf-a207-4f20-9fb1-4ed311425410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7ad0f091-3362-4787-a3d3-4849978a8d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5026f0d0-7a02-48f4-a2ad-596c41da4d27" xlink:to="loc_us-gaap_CommonStockSharesIssued_7ad0f091-3362-4787-a3d3-4849978a8d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0ccc9518-9529-45e1-96d6-2016b0a8aee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5026f0d0-7a02-48f4-a2ad-596c41da4d27" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0ccc9518-9529-45e1-96d6-2016b0a8aee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_a0e16422-8e95-4bdb-8dc4-bbfeba95507b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5026f0d0-7a02-48f4-a2ad-596c41da4d27" xlink:to="loc_us-gaap_TreasuryStockCommonShares_a0e16422-8e95-4bdb-8dc4-bbfeba95507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3293bf79-d0a2-4990-87da-ae8f4dc522a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3293bf79-d0a2-4990-87da-ae8f4dc522a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_813665af-4ae3-4668-8e5f-eeb0455bd057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3293bf79-d0a2-4990-87da-ae8f4dc522a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_813665af-4ae3-4668-8e5f-eeb0455bd057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InProcessResearchAndDevelopment_7668554b-585f-4f34-aa4e-b806ce885aa8" xlink:href="lsta-20230930.xsd#lsta_InProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3293bf79-d0a2-4990-87da-ae8f4dc522a4" xlink:to="loc_lsta_InProcessResearchAndDevelopment_7668554b-585f-4f34-aa4e-b806ce885aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1d7eb313-e30e-4a0e-ae83-6968c4b15197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3293bf79-d0a2-4990-87da-ae8f4dc522a4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1d7eb313-e30e-4a0e-ae83-6968c4b15197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4048618f-678e-4da2-902c-2ef195a4af72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3293bf79-d0a2-4990-87da-ae8f4dc522a4" xlink:to="loc_us-gaap_OperatingExpenses_4048618f-678e-4da2-902c-2ef195a4af72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f002108b-5972-4c57-82aa-4b9ac172064e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_us-gaap_OperatingIncomeLoss_f002108b-5972-4c57-82aa-4b9ac172064e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_30d701e6-1132-4ca6-bb60-f05979009bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_30d701e6-1132-4ca6-bb60-f05979009bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_0fccabfa-2aa9-46af-b9d8-67a5dd067d12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_30d701e6-1132-4ca6-bb60-f05979009bec" xlink:to="loc_us-gaap_InvestmentIncomeNet_0fccabfa-2aa9-46af-b9d8-67a5dd067d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5f3e59a4-4ab5-47ca-b0f9-45e878715167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_30d701e6-1132-4ca6-bb60-f05979009bec" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5f3e59a4-4ab5-47ca-b0f9-45e878715167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_edb80e73-d22d-4221-b6cd-dc7c81b316de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_30d701e6-1132-4ca6-bb60-f05979009bec" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_edb80e73-d22d-4221-b6cd-dc7c81b316de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1927c45c-c77f-4533-9030-681f88da4575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1927c45c-c77f-4533-9030-681f88da4575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1c438552-d792-47bc-83d5-d1bf1c1206d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1c438552-d792-47bc-83d5-d1bf1c1206d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2675aecc-5e98-4de1-9438-63bc8fe9611e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_us-gaap_ProfitLoss_2675aecc-5e98-4de1-9438-63bc8fe9611e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_b2bad89c-5824-4fc7-aabf-63dfa43a92b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_b2bad89c-5824-4fc7-aabf-63dfa43a92b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_22efcfa7-de12-4986-b38d-69e542bd3932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_us-gaap_NetIncomeLoss_22efcfa7-de12-4986-b38d-69e542bd3932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_EPSAbstract_eb353cc6-8807-42ba-866e-d1e3a8a9bb33" xlink:href="lsta-20230930.xsd#lsta_EPSAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_lsta_EPSAbstract_eb353cc6-8807-42ba-866e-d1e3a8a9bb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4c659a1e-b33a-4939-8304-23e618ee2d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_EPSAbstract_eb353cc6-8807-42ba-866e-d1e3a8a9bb33" xlink:to="loc_us-gaap_EarningsPerShareBasic_4c659a1e-b33a-4939-8304-23e618ee2d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c136a5c0-e801-47ad-be9d-f1af17aa5765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_EPSAbstract_eb353cc6-8807-42ba-866e-d1e3a8a9bb33" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c136a5c0-e801-47ad-be9d-f1af17aa5765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d3e4f3ce-7af1-47b4-ad30-8454643728f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c0ca75c-3f5c-4f95-827f-e496803c8ad4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d3e4f3ce-7af1-47b4-ad30-8454643728f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2b8a85a8-961e-46bd-ae56-2a71eff732eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d3e4f3ce-7af1-47b4-ad30-8454643728f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2b8a85a8-961e-46bd-ae56-2a71eff732eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fba9432-bc24-411f-a339-5b8209dc5a43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d3e4f3ce-7af1-47b4-ad30-8454643728f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fba9432-bc24-411f-a339-5b8209dc5a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a026095-afee-43c8-8ad6-9e177e73d3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c206b91f-6d06-48a4-8fa4-40f599041f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a026095-afee-43c8-8ad6-9e177e73d3f3" xlink:to="loc_us-gaap_ProfitLoss_c206b91f-6d06-48a4-8fa4-40f599041f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_01f4bc6b-f416-4e16-9c83-5ee6770d9587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a026095-afee-43c8-8ad6-9e177e73d3f3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_01f4bc6b-f416-4e16-9c83-5ee6770d9587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4eeb74a0-78b2-490b-a9f5-d338293cc28f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a026095-afee-43c8-8ad6-9e177e73d3f3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4eeb74a0-78b2-490b-a9f5-d338293cc28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7a4077e8-976c-4ed6-a85a-ff4c55a7c60e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a026095-afee-43c8-8ad6-9e177e73d3f3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7a4077e8-976c-4ed6-a85a-ff4c55a7c60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_67ec0645-6b73-4d0c-b670-1c2d8ac23b88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a026095-afee-43c8-8ad6-9e177e73d3f3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_67ec0645-6b73-4d0c-b670-1c2d8ac23b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a229ca41-2fb5-4ae8-b03d-d5d572171d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b16fef6d-d2c3-4b86-9809-193a71e09a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a229ca41-2fb5-4ae8-b03d-d5d572171d53" xlink:to="loc_us-gaap_StatementTable_b16fef6d-d2c3-4b86-9809-193a71e09a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aa54e3dc-d120-41e3-8304-75fb2069cb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b16fef6d-d2c3-4b86-9809-193a71e09a4c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aa54e3dc-d120-41e3-8304-75fb2069cb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21bcab2b-63a7-4e0d-b1e0-e4cdea9f81e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aa54e3dc-d120-41e3-8304-75fb2069cb85" xlink:to="loc_us-gaap_EquityComponentDomain_21bcab2b-63a7-4e0d-b1e0-e4cdea9f81e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21bcab2b-63a7-4e0d-b1e0-e4cdea9f81e0" xlink:to="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_784b1e80-a64c-4e9c-9f77-d2eb7bca764d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_CommonStockMember_784b1e80-a64c-4e9c-9f77-d2eb7bca764d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1a6681d7-865c-4619-bc19-3a4ff1304186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1a6681d7-865c-4619-bc19-3a4ff1304186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_76292277-4d0e-44ab-a77d-f949c3d03e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_76292277-4d0e-44ab-a77d-f949c3d03e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a135e16b-1cb7-4818-af81-481f7250844d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_RetainedEarningsMember_a135e16b-1cb7-4818-af81-481f7250844d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_228ca7ba-c9c4-46bb-9d5b-7eb89f50bea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a8a1b5ab-2697-4731-aa68-82847e2a8d51" xlink:to="loc_us-gaap_TreasuryStockCommonMember_228ca7ba-c9c4-46bb-9d5b-7eb89f50bea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7460d62e-443f-4ae7-bfb5-e6023045aa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21bcab2b-63a7-4e0d-b1e0-e4cdea9f81e0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7460d62e-443f-4ae7-bfb5-e6023045aa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f1c79462-b943-4e3d-96ee-6ddf00a43bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b16fef6d-d2c3-4b86-9809-193a71e09a4c" xlink:to="loc_us-gaap_StatementLineItems_f1c79462-b943-4e3d-96ee-6ddf00a43bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f1c79462-b943-4e3d-96ee-6ddf00a43bf7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2bbf31b3-3791-4422-b2d4-b3bbf08f3fad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2bbf31b3-3791-4422-b2d4-b3bbf08f3fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67546216-1d9b-49dd-b9e3-d7ce942df33c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67546216-1d9b-49dd-b9e3-d7ce942df33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_afad07cf-c985-4651-bd0d-8b825ec79071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_ProfitLoss_afad07cf-c985-4651-bd0d-8b825ec79071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7f901d7b-4ae7-42e6-9247-262ba7759348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7f901d7b-4ae7-42e6-9247-262ba7759348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d7aab36-6b72-49da-b9a9-6f64ede0f116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d7aab36-6b72-49da-b9a9-6f64ede0f116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76176240-b673-41a9-8c5c-31e15d95a15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76176240-b673-41a9-8c5c-31e15d95a15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_792237a8-20da-47cb-9e3d-e82ce97b9dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_792237a8-20da-47cb-9e3d-e82ce97b9dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger_fabc386a-70b7-4251-a45a-c9d0dc6eae26" xlink:href="lsta-20230930.xsd#lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger_fabc386a-70b7-4251-a45a-c9d0dc6eae26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger_866b7917-4c1f-4b82-8b01-b489f705e40f" xlink:href="lsta-20230930.xsd#lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger_866b7917-4c1f-4b82-8b01-b489f705e40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2be67fcd-2d25-4775-97b9-be65f8ad61fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2be67fcd-2d25-4775-97b9-be65f8ad61fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10687956-1a65-491b-b9c2-70b0a89fd855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10687956-1a65-491b-b9c2-70b0a89fd855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2b2102c0-8513-4f21-b939-3aff70e60477" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2b2102c0-8513-4f21-b939-3aff70e60477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_96c1a64f-088d-4cb0-85d0-d77d28b5bf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_96c1a64f-088d-4cb0-85d0-d77d28b5bf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_406eb2e3-ec82-49c3-aa50-40d18c7365c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_406eb2e3-ec82-49c3-aa50-40d18c7365c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bba30778-916d-44e7-a5b8-580d51ee5fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f37d33b7-65c3-4d74-8d2f-dc71caba53b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bba30778-916d-44e7-a5b8-580d51ee5fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lsta-20230930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3617a3e9-1646-42e8-a47b-afc5798d1780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28c93db6-b63f-4e4e-a39e-bf19a4ef5835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3617a3e9-1646-42e8-a47b-afc5798d1780" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28c93db6-b63f-4e4e-a39e-bf19a4ef5835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ace412cb-6275-432a-84e6-ec76ab6fcf77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28c93db6-b63f-4e4e-a39e-bf19a4ef5835" xlink:to="loc_us-gaap_ProfitLoss_ace412cb-6275-432a-84e6-ec76ab6fcf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_543b1c1c-6294-4c9a-85c0-25269d1d5c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28c93db6-b63f-4e4e-a39e-bf19a4ef5835" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_543b1c1c-6294-4c9a-85c0-25269d1d5c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1f6e508c-a4d7-4b1b-b245-9195486e5720" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_543b1c1c-6294-4c9a-85c0-25269d1d5c9c" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1f6e508c-a4d7-4b1b-b245-9195486e5720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3c965dae-bf4a-46ff-a8f1-bc6755194c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_543b1c1c-6294-4c9a-85c0-25269d1d5c9c" xlink:to="loc_us-gaap_DepreciationAndAmortization_3c965dae-bf4a-46ff-a8f1-bc6755194c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_af7a208b-ff8f-42c1-861d-ac5234c54eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_543b1c1c-6294-4c9a-85c0-25269d1d5c9c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_af7a208b-ff8f-42c1-861d-ac5234c54eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f00652eb-8b87-41f0-acfc-16bf51e9446a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_543b1c1c-6294-4c9a-85c0-25269d1d5c9c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f00652eb-8b87-41f0-acfc-16bf51e9446a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7246b50a-ed45-413b-9fc3-5455a61dce98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_543b1c1c-6294-4c9a-85c0-25269d1d5c9c" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7246b50a-ed45-413b-9fc3-5455a61dce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_93d6680d-1a2a-45ea-beb6-97d4dd4e8feb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28c93db6-b63f-4e4e-a39e-bf19a4ef5835" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_93d6680d-1a2a-45ea-beb6-97d4dd4e8feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_54e328b9-5b54-4683-9131-700df6c6b215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_93d6680d-1a2a-45ea-beb6-97d4dd4e8feb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_54e328b9-5b54-4683-9131-700df6c6b215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_84f98ba7-f89e-4376-beb1-c1f2d8c33e58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_93d6680d-1a2a-45ea-beb6-97d4dd4e8feb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_84f98ba7-f89e-4376-beb1-c1f2d8c33e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_a34e9df0-4e91-4135-8530-ea8580f67b75" xlink:href="lsta-20230930.xsd#lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_93d6680d-1a2a-45ea-beb6-97d4dd4e8feb" xlink:to="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_a34e9df0-4e91-4135-8530-ea8580f67b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c0430679-02fe-4966-b763-6a5fdecd604e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28c93db6-b63f-4e4e-a39e-bf19a4ef5835" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c0430679-02fe-4966-b763-6a5fdecd604e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3c1bb8e-bd5d-4e06-87eb-369996ee4236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3617a3e9-1646-42e8-a47b-afc5798d1780" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3c1bb8e-bd5d-4e06-87eb-369996ee4236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_530642ad-5f3b-4f41-a6a3-f649d21f68b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3c1bb8e-bd5d-4e06-87eb-369996ee4236" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_530642ad-5f3b-4f41-a6a3-f649d21f68b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_94ad35bb-f6ed-4ed8-a11e-c1939e4e684d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3c1bb8e-bd5d-4e06-87eb-369996ee4236" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_94ad35bb-f6ed-4ed8-a11e-c1939e4e684d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_PaymentsForAssetAcquisitionCostsNet_901279bd-3a6a-4438-afc0-612d85b025da" xlink:href="lsta-20230930.xsd#lsta_PaymentsForAssetAcquisitionCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3c1bb8e-bd5d-4e06-87eb-369996ee4236" xlink:to="loc_lsta_PaymentsForAssetAcquisitionCostsNet_901279bd-3a6a-4438-afc0-612d85b025da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2de8dc8f-cd26-4494-8d3d-2ddc90196504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3c1bb8e-bd5d-4e06-87eb-369996ee4236" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2de8dc8f-cd26-4494-8d3d-2ddc90196504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17301d1a-123b-48a9-8bf5-5f081af98429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3c1bb8e-bd5d-4e06-87eb-369996ee4236" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17301d1a-123b-48a9-8bf5-5f081af98429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75208c08-5da8-4127-9962-b91711ed7b52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3617a3e9-1646-42e8-a47b-afc5798d1780" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75208c08-5da8-4127-9962-b91711ed7b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fcc9eebd-d2f9-4a31-9bc5-6d94204a357a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75208c08-5da8-4127-9962-b91711ed7b52" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fcc9eebd-d2f9-4a31-9bc5-6d94204a357a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_698ad78f-74c6-4087-8454-74edad6436aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75208c08-5da8-4127-9962-b91711ed7b52" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_698ad78f-74c6-4087-8454-74edad6436aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6b456bbd-0f56-4ed6-a777-fdb5c4f6b0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75208c08-5da8-4127-9962-b91711ed7b52" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6b456bbd-0f56-4ed6-a777-fdb5c4f6b0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9288916-99f2-4ce0-951a-51113800e930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75208c08-5da8-4127-9962-b91711ed7b52" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9288916-99f2-4ce0-951a-51113800e930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a8ef099-3825-44d0-a53c-fcdad10bdad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3617a3e9-1646-42e8-a47b-afc5798d1780" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a8ef099-3825-44d0-a53c-fcdad10bdad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8d829ecb-d2d8-4277-b34f-6726179a8331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3617a3e9-1646-42e8-a47b-afc5798d1780" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8d829ecb-d2d8-4277-b34f-6726179a8331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62af68f0-ca99-4371-ada1-29ef42a515d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3617a3e9-1646-42e8-a47b-afc5798d1780" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62af68f0-ca99-4371-ada1-29ef42a515d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cb8f3712-48b9-429f-8bdd-ed120fb7f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3617a3e9-1646-42e8-a47b-afc5798d1780" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cb8f3712-48b9-429f-8bdd-ed120fb7f7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ea37b4d6-8bb1-497c-bc07-3641193a25bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3617a3e9-1646-42e8-a47b-afc5798d1780" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ea37b4d6-8bb1-497c-bc07-3641193a25bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_853d689c-159f-4314-8da0-058f186a042d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ea37b4d6-8bb1-497c-bc07-3641193a25bb" xlink:to="loc_us-gaap_StockIssued1_853d689c-159f-4314-8da0-058f186a042d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_2cd2159e-a219-4a07-a0c4-a7e9e6e72471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ea37b4d6-8bb1-497c-bc07-3641193a25bb" xlink:to="loc_us-gaap_LiabilitiesAssumed1_2cd2159e-a219-4a07-a0c4-a7e9e6e72471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusiness" xlink:type="simple" xlink:href="lsta-20230930.xsd#TheBusiness"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bd8154c-605b-48e2-a169-5c499885c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_BusinessTextBlock_7af2a23b-9f2d-45af-9df9-2f31c5f6fa04" xlink:href="lsta-20230930.xsd#lsta_BusinessTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bd8154c-605b-48e2-a169-5c499885c8ff" xlink:to="loc_lsta_BusinessTextBlock_7af2a23b-9f2d-45af-9df9-2f31c5f6fa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lsta-20230930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c1353595-b6be-404f-88ca-c42b21142d55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_718acf58-2cd3-4443-9f10-f9fabefb22cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1353595-b6be-404f-88ca-c42b21142d55" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_718acf58-2cd3-4443-9f10-f9fabefb22cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Merger" xlink:type="simple" xlink:href="lsta-20230930.xsd#Merger"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Merger" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_c55650ab-f0e7-43c3-8070-7f83fad8829c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_b54195af-be38-42d0-8b5d-84ff98ca7b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_c55650ab-f0e7-43c3-8070-7f83fad8829c" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_b54195af-be38-42d0-8b5d-84ff98ca7b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="lsta-20230930.xsd#AvailableforSaleSecurities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d22b5f8c-a339-4fa9-90c3-255eeb9cf99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_32473c16-e692-4240-990a-1655717423ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d22b5f8c-a339-4fa9-90c3-255eeb9cf99a" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_32473c16-e692-4240-990a-1655717423ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lsta-20230930.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_99e72963-7d11-4a56-8a6c-44f14ef9f52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_78c80b59-1a78-465d-86c7-c0d22078eddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_99e72963-7d11-4a56-8a6c-44f14ef9f52d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_78c80b59-1a78-465d-86c7-c0d22078eddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="simple" xlink:href="lsta-20230930.xsd#IncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_161be6ac-9c45-4951-92e1-526aedc0e99c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_867a3709-6186-47b8-a30d-ff6f06fb8c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_161be6ac-9c45-4951-92e1-526aedc0e99c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_867a3709-6186-47b8-a30d-ff6f06fb8c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lsta-20230930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fa5f3422-fc12-4a23-9758-f5c7bc659c67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3e40306f-c463-4a2a-a75b-a6add3345647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fa5f3422-fc12-4a23-9758-f5c7bc659c67" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3e40306f-c463-4a2a-a75b-a6add3345647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="lsta-20230930.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_bedd6f9a-547e-4d81-beeb-8f8c65e324d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_233e96eb-c5ae-4b22-af69-5151fa40782b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_bedd6f9a-547e-4d81-beeb-8f8c65e324d8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_233e96eb-c5ae-4b22-af69-5151fa40782b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="lsta-20230930.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f1723226-8057-464f-95e6-b137ec4e2ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_f970f18c-0f63-44a7-ada7-7daf1ebfc7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f1723226-8057-464f-95e6-b137ec4e2ac2" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_f970f18c-0f63-44a7-ada7-7daf1ebfc7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lsta-20230930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_10e33a1b-096b-4959-826b-0cabf6590e58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cccae899-63d6-47b7-9bd2-87827bbe29c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10e33a1b-096b-4959-826b-0cabf6590e58" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cccae899-63d6-47b7-9bd2-87827bbe29c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="lsta-20230930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc42a6f3-0d92-4c61-8e8a-5e8b41019cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3265ff8e-2c3c-4989-994f-05a37f342763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc42a6f3-0d92-4c61-8e8a-5e8b41019cd3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3265ff8e-2c3c-4989-994f-05a37f342763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lsta-20230930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_69291e4c-db11-48ef-8a73-697aa3a516d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8e703635-f4aa-457f-91e9-b99c86190b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_69291e4c-db11-48ef-8a73-697aa3a516d1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_8e703635-f4aa-457f-91e9-b99c86190b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="simple" xlink:href="lsta-20230930.xsd#AustraliaResearchandDevelopmentTaxIncentive"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_daa344f8-ab89-4bbf-a0a8-4a6bb247bf86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_abe01b40-4fe5-433e-899d-444262d9c512" xlink:href="lsta-20230930.xsd#lsta_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_daa344f8-ab89-4bbf-a0a8-4a6bb247bf86" xlink:to="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_abe01b40-4fe5-433e-899d-444262d9c512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="lsta-20230930.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eb1f1409-9736-428b-aaf9-bbadd4c031bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_068671e8-af3b-48b6-a94e-9dce1bd2d7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eb1f1409-9736-428b-aaf9-bbadd4c031bd" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_068671e8-af3b-48b6-a94e-9dce1bd2d7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TechnologyTransferAgreement" xlink:type="simple" xlink:href="lsta-20230930.xsd#TechnologyTransferAgreement"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TechnologyTransferAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementAbstract_2667c8e5-3255-464d-b487-10bbf016547b" xlink:href="lsta-20230930.xsd#lsta_TechnologyTransferAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementTextBlock_ab589b90-dbdc-4288-9213-b35a40b2daa8" xlink:href="lsta-20230930.xsd#lsta_TechnologyTransferAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_TechnologyTransferAgreementAbstract_2667c8e5-3255-464d-b487-10bbf016547b" xlink:to="loc_lsta_TechnologyTransferAgreementTextBlock_ab589b90-dbdc-4288-9213-b35a40b2daa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreements" xlink:type="simple" xlink:href="lsta-20230930.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c7897929-f985-469e-a4bc-8f1a4ecb9b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_50ef64fd-1200-4ebd-a1ee-7867470653e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c7897929-f985-469e-a4bc-8f1a4ecb9b54" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_50ef64fd-1200-4ebd-a1ee-7867470653e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="simple" xlink:href="lsta-20230930.xsd#ResearchCollaborationandLicenseAgreement"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69c6da0d-f7ca-4dd9-b912-2a4e530a70ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b4f3e223-d909-4a26-ad2b-a6c89d7d4fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69c6da0d-f7ca-4dd9-b912-2a4e530a70ec" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b4f3e223-d909-4a26-ad2b-a6c89d7d4fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lsta-20230930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c4419ecf-2dcc-41a4-96d1-a9831a63bc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c4419ecf-2dcc-41a4-96d1-a9831a63bc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a85f20d9-5fc6-4fb1-8cf5-71af4da7c353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_UseOfEstimates_a85f20d9-5fc6-4fb1-8cf5-71af4da7c353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_a3d59bd6-473d-4e2d-a2c9-e9d9d17d5b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_a3d59bd6-473d-4e2d-a2c9-e9d9d17d5b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5620d06e-f798-4804-b8ee-5509239b81dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5620d06e-f798-4804-b8ee-5509239b81dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_52ab82b8-5e09-42bd-b1e8-e34f24cd0326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_52ab82b8-5e09-42bd-b1e8-e34f24cd0326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_df656e28-2557-44a5-a175-b678b55feb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_df656e28-2557-44a5-a175-b678b55feb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c92f2c3f-c013-4796-922e-e7db4e53b239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c92f2c3f-c013-4796-922e-e7db4e53b239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_a147e595-afd1-468b-a89f-ac33c2c2a45f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_a147e595-afd1-468b-a89f-ac33c2c2a45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5cc2779c-6e01-40de-a392-5696506f03a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5cc2779c-6e01-40de-a392-5696506f03a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_d3f3d521-2b8c-428c-a1ff-1e978bc0c769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_d3f3d521-2b8c-428c-a1ff-1e978bc0c769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_089d6a8f-7014-4eab-a888-3dcd70d65f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_089d6a8f-7014-4eab-a888-3dcd70d65f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_fb0d7894-f9d6-4692-adb3-024b8e7fd778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_fb0d7894-f9d6-4692-adb3-024b8e7fd778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_c1d8b7c0-c5e7-4e61-9bed-591c09a926f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_c1d8b7c0-c5e7-4e61-9bed-591c09a926f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_e5de111a-aeda-476d-8b17-96ffef9045ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_e5de111a-aeda-476d-8b17-96ffef9045ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_64663521-8643-409b-bc3b-66e547a2c560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_64663521-8643-409b-bc3b-66e547a2c560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_936ad71b-cd0d-4cdc-8288-2529b605a2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_936ad71b-cd0d-4cdc-8288-2529b605a2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_37c98f88-5db5-44bd-996b-48135e8c72ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97499bd2-9eae-4414-ba2b-9828bc957b34" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_37c98f88-5db5-44bd-996b-48135e8c72ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_29e87372-b446-4434-9389-d4fd0d6b5a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_767b5f6f-29ab-4b3c-bdb5-90069710270d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_29e87372-b446-4434-9389-d4fd0d6b5a56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_767b5f6f-29ab-4b3c-bdb5-90069710270d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#MergerTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/MergerTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_fa20fcb5-ace2-4002-8a10-ce97c9dd6158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_cecde06d-df38-4db7-bfd0-362e4e4eb17b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_fa20fcb5-ace2-4002-8a10-ce97c9dd6158" xlink:to="loc_us-gaap_AssetAcquisitionTableTextBlock_cecde06d-df38-4db7-bfd0-362e4e4eb17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#AvailableforSaleSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10580844-4988-4ef1-a632-dc0f182bd853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9fd34171-be3e-4ad0-a231-74558c2746b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10580844-4988-4ef1-a632-dc0f182bd853" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9fd34171-be3e-4ad0-a231-74558c2746b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_ee397cf7-deed-48a1-99e0-b0b80d3a51a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10580844-4988-4ef1-a632-dc0f182bd853" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_ee397cf7-deed-48a1-99e0-b0b80d3a51a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4a61893b-4b0d-4997-abab-9f6cf643b71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_10580844-4988-4ef1-a632-dc0f182bd853" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4a61893b-4b0d-4997-abab-9f6cf643b71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_959e4dcf-10d5-4ca5-96fd-b4c3fd601862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6a7ec0d7-f7fe-4a06-8daf-2378b7655e32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_959e4dcf-10d5-4ca5-96fd-b4c3fd601862" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6a7ec0d7-f7fe-4a06-8daf-2378b7655e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#IncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_144bbf94-2383-4526-b236-b1c5dc99532b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_aca8c6c5-9dbb-4992-be22-fb354a5a6670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_144bbf94-2383-4526-b236-b1c5dc99532b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_aca8c6c5-9dbb-4992-be22-fb354a5a6670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_93e2fbd8-804c-4ce7-9def-19be0020bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_489cee14-4d3c-4dea-b469-6a47e9d3e1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93e2fbd8-804c-4ce7-9def-19be0020bc13" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_489cee14-4d3c-4dea-b469-6a47e9d3e1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_bd7b044c-e01d-4a7c-bea0-f647d5fa5590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_26f856d1-fb6a-4cac-86cc-2fad8f811068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_bd7b044c-e01d-4a7c-bea0-f647d5fa5590" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_26f856d1-fb6a-4cac-86cc-2fad8f811068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_58bf86b4-45d8-40dc-b349-1af6c5b01ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_bdc60a95-7428-4995-8f10-84a68e49963c" xlink:href="lsta-20230930.xsd#lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_58bf86b4-45d8-40dc-b349-1af6c5b01ae1" xlink:to="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_bdc60a95-7428-4995-8f10-84a68e49963c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e8abd704-3f11-4c3f-a720-bebdc03066ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_58bf86b4-45d8-40dc-b349-1af6c5b01ae1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e8abd704-3f11-4c3f-a720-bebdc03066ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_21924bf6-d16c-44cc-96b7-0d83984d110c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_98b047fb-aac5-4178-ac3b-96bdd8d3aac0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_21924bf6-d16c-44cc-96b7-0d83984d110c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_98b047fb-aac5-4178-ac3b-96bdd8d3aac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_17b5acd8-c63f-4cb7-a4e6-0ad2efdcfbde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_21924bf6-d16c-44cc-96b7-0d83984d110c" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_17b5acd8-c63f-4cb7-a4e6-0ad2efdcfbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_b5f39600-3fa9-404d-b048-ec7ea0e0ec43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_21924bf6-d16c-44cc-96b7-0d83984d110c" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_b5f39600-3fa9-404d-b048-ec7ea0e0ec43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="lsta-20230930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b6b6b5b3-6d9a-4b79-b51c-a95e96aae658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_816653a2-68ad-4541-8497-73b8e23e4b68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b6b6b5b3-6d9a-4b79-b51c-a95e96aae658" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_816653a2-68ad-4541-8497-73b8e23e4b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_b0c9015e-f9cc-4e8a-82a5-2e99d816bdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b6b6b5b3-6d9a-4b79-b51c-a95e96aae658" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_b0c9015e-f9cc-4e8a-82a5-2e99d816bdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f922d541-9a6d-4dfb-a3bc-5459f1b0c944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b6b6b5b3-6d9a-4b79-b51c-a95e96aae658" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f922d541-9a6d-4dfb-a3bc-5459f1b0c944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#TheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff36aca8-b994-4c1f-a25f-f89da7f67456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_1fbdfae3-3e5e-4e00-96ae-596d847e2893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff36aca8-b994-4c1f-a25f-f89da7f67456" xlink:to="loc_us-gaap_AssetAcquisitionTable_1fbdfae3-3e5e-4e00-96ae-596d847e2893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_84bc7a01-4e6c-48b0-98a8-10fed08709ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1fbdfae3-3e5e-4e00-96ae-596d847e2893" xlink:to="loc_us-gaap_AssetAcquisitionAxis_84bc7a01-4e6c-48b0-98a8-10fed08709ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_89c24d1c-1df5-45ea-815c-c6c4ac731a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_84bc7a01-4e6c-48b0-98a8-10fed08709ca" xlink:to="loc_us-gaap_AssetAcquisitionDomain_89c24d1c-1df5-45ea-815c-c6c4ac731a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_000822ad-c92b-4f62-9342-7cf0b2c0510b" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_89c24d1c-1df5-45ea-815c-c6c4ac731a03" xlink:to="loc_lsta_CENDMember_000822ad-c92b-4f62-9342-7cf0b2c0510b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f0e2700d-d893-4aec-b6dc-bc7bf5f468b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1fbdfae3-3e5e-4e00-96ae-596d847e2893" xlink:to="loc_dei_LegalEntityAxis_f0e2700d-d893-4aec-b6dc-bc7bf5f468b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_dfd7a49a-b4b5-4c20-9214-f5be5b89cf55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f0e2700d-d893-4aec-b6dc-bc7bf5f468b5" xlink:to="loc_dei_EntityDomain_dfd7a49a-b4b5-4c20-9214-f5be5b89cf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CaladriusMember_2d9e86da-c804-4c97-b803-204c37ffce3a" xlink:href="lsta-20230930.xsd#lsta_CaladriusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_dfd7a49a-b4b5-4c20-9214-f5be5b89cf55" xlink:to="loc_lsta_CaladriusMember_2d9e86da-c804-4c97-b803-204c37ffce3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1fbdfae3-3e5e-4e00-96ae-596d847e2893" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a2076d30-6226-4c2d-9c66-fe7c20569474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a2076d30-6226-4c2d-9c66-fe7c20569474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c1eb60a8-2f42-4dbf-b755-1b3530bfb292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:to="loc_us-gaap_SharesIssued_c1eb60a8-2f42-4dbf-b755-1b3530bfb292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_c24e75e2-221c-45a3-a348-14aaf74320c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_c24e75e2-221c-45a3-a348-14aaf74320c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c5052d7e-a47d-4096-99ba-885de08069c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_acd43969-58ab-498e-9e2f-6069def6461d" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c5052d7e-a47d-4096-99ba-885de08069c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cc761898-ef5e-4db1-b829-ea0c700a25a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dd5c975f-349f-40b7-bbd9-77bc7ee4a279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cc761898-ef5e-4db1-b829-ea0c700a25a3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dd5c975f-349f-40b7-bbd9-77bc7ee4a279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d960223-1bc3-4dbd-8007-fb70a6704845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dd5c975f-349f-40b7-bbd9-77bc7ee4a279" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d960223-1bc3-4dbd-8007-fb70a6704845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d960223-1bc3-4dbd-8007-fb70a6704845" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_929b62bb-cc0d-427a-a6ee-f4dc2f4b41c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_929b62bb-cc0d-427a-a6ee-f4dc2f4b41c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_599b65ff-f6e6-42a6-b906-e2763f5e0a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:to="loc_us-gaap_ComputerEquipmentMember_599b65ff-f6e6-42a6-b906-e2763f5e0a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_02d47cfc-f535-40ff-86b8-f09d78894571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e088b55-7c95-46e1-ab93-aec631cdcd29" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_02d47cfc-f535-40ff-86b8-f09d78894571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_009803dd-9945-4ec0-a5a5-0ee37a8ad5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dd5c975f-349f-40b7-bbd9-77bc7ee4a279" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_009803dd-9945-4ec0-a5a5-0ee37a8ad5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f969aff1-a971-4757-8214-7aea29038f52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_009803dd-9945-4ec0-a5a5-0ee37a8ad5a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f969aff1-a971-4757-8214-7aea29038f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b1325d6a-813b-4336-bab8-e86f861e5005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b1325d6a-813b-4336-bab8-e86f861e5005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5c9e2635-350b-4874-a263-37fd2f947970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5c9e2635-350b-4874-a263-37fd2f947970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_58882e3b-e026-48eb-b37c-56c9c6a162ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_58882e3b-e026-48eb-b37c-56c9c6a162ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_4d7a53da-a89e-4574-979d-8b1d6f2018ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_4d7a53da-a89e-4574-979d-8b1d6f2018ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c72b64c8-d7d9-4c4d-8e99-f88dc4004e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c72b64c8-d7d9-4c4d-8e99-f88dc4004e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_51917484-c558-4f28-a04a-7d3d8e4c2e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_51917484-c558-4f28-a04a-7d3d8e4c2e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7dd26b73-38bc-40ed-bd3a-5e553c7a66a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7dd26b73-38bc-40ed-bd3a-5e553c7a66a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9f57ad33-5e92-42bc-9f63-4b4d790c50a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9f57ad33-5e92-42bc-9f63-4b4d790c50a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_18be2b87-09bd-4210-aaf5-c128ba20e0da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_18be2b87-09bd-4210-aaf5-c128ba20e0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_77446056-de05-4cf0-ad63-4194469ec41a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_77446056-de05-4cf0-ad63-4194469ec41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6ef850b7-0b07-4858-a14c-7345d8161cae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd14d7c-9e97-45a8-b919-19fbbd10d96b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6ef850b7-0b07-4858-a14c-7345d8161cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f82ee625-a249-4904-822c-8229813b8643" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ef850b7-0b07-4858-a14c-7345d8161cae" xlink:to="loc_srt_ProductOrServiceAxis_f82ee625-a249-4904-822c-8229813b8643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25b2ad62-e1ab-40d6-80ee-b0b13d4eb153" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f82ee625-a249-4904-822c-8229813b8643" xlink:to="loc_srt_ProductsAndServicesDomain_25b2ad62-e1ab-40d6-80ee-b0b13d4eb153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_f812935a-1d79-4744-8fe8-ad00f19314f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_25b2ad62-e1ab-40d6-80ee-b0b13d4eb153" xlink:to="loc_us-gaap_RoyaltyMember_f812935a-1d79-4744-8fe8-ad00f19314f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_eb72edd4-6719-4528-aa79-5b5c10ba5f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ef850b7-0b07-4858-a14c-7345d8161cae" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_eb72edd4-6719-4528-aa79-5b5c10ba5f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_22b2b8e9-d555-415e-9030-a521b491a389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eb72edd4-6719-4528-aa79-5b5c10ba5f3a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_22b2b8e9-d555-415e-9030-a521b491a389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerNarrativeDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#MergerNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/MergerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_a8252a64-d64e-4e14-901f-5b9b6550de06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_18ce9505-c1b0-4743-8977-bbeda55c8939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_a8252a64-d64e-4e14-901f-5b9b6550de06" xlink:to="loc_us-gaap_AssetAcquisitionTable_18ce9505-c1b0-4743-8977-bbeda55c8939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_fe8042f8-670d-4daa-82cb-682229137aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_18ce9505-c1b0-4743-8977-bbeda55c8939" xlink:to="loc_us-gaap_AssetAcquisitionAxis_fe8042f8-670d-4daa-82cb-682229137aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bc3180c9-955f-42f4-83c5-fbe71f139485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_fe8042f8-670d-4daa-82cb-682229137aec" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bc3180c9-955f-42f4-83c5-fbe71f139485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_136df4ed-5c4e-45dc-97f6-713278714d26" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bc3180c9-955f-42f4-83c5-fbe71f139485" xlink:to="loc_lsta_CENDMember_136df4ed-5c4e-45dc-97f6-713278714d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_2ade814b-bcb9-455b-91c2-4f34cfe39b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_18ce9505-c1b0-4743-8977-bbeda55c8939" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_2ade814b-bcb9-455b-91c2-4f34cfe39b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_010e8ac4-2451-4547-b607-b170ac449b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2ade814b-bcb9-455b-91c2-4f34cfe39b7f" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_010e8ac4-2451-4547-b607-b170ac449b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#MergerDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/MergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_d3fc0cf7-696e-4678-ad1d-5a0b477b81bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_589284e8-2404-4110-8c0f-e7492a3127d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_d3fc0cf7-696e-4678-ad1d-5a0b477b81bb" xlink:to="loc_us-gaap_AssetAcquisitionTable_589284e8-2404-4110-8c0f-e7492a3127d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2a48784d-cc4e-4942-a9ea-21791cd0f1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_589284e8-2404-4110-8c0f-e7492a3127d1" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2a48784d-cc4e-4942-a9ea-21791cd0f1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_7544388f-3691-43ee-8e8e-325cfbd38acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2a48784d-cc4e-4942-a9ea-21791cd0f1f3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_7544388f-3691-43ee-8e8e-325cfbd38acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_75b6838c-be27-489b-b0d5-bec09a54c02b" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7544388f-3691-43ee-8e8e-325cfbd38acd" xlink:to="loc_lsta_CENDMember_75b6838c-be27-489b-b0d5-bec09a54c02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_589284e8-2404-4110-8c0f-e7492a3127d1" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e33a139f-18ea-4da0-9ce6-abd08688255e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e33a139f-18ea-4da0-9ce6-abd08688255e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionSharePrice_97c634ff-0043-449a-9361-408dfbc0b01e" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionSharePrice_97c634ff-0043-449a-9361-408dfbc0b01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionConsiderationTransferredEquityValue_b190954f-778f-419e-812e-fbf7acaa5279" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionConsiderationTransferredEquityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionConsiderationTransferredEquityValue_b190954f-778f-419e-812e-fbf7acaa5279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_6143f87f-551d-4f6d-9691-55df1ef866f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_6143f87f-551d-4f6d-9691-55df1ef866f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2a987cd8-e64b-4e67-b2c9-60640b071afc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2a987cd8-e64b-4e67-b2c9-60640b071afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_28e7525d-5ab2-4764-8aa8-16ae8e32c1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_28e7525d-5ab2-4764-8aa8-16ae8e32c1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1862328c-2cfa-4ca3-9161-7bb688fedcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1862328c-2cfa-4ca3-9161-7bb688fedcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionCashAndCashEquivalents_fd2d2d93-aa9d-428c-b132-49e1c766d145" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionCashAndCashEquivalents_fd2d2d93-aa9d-428c-b132-49e1c766d145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionNetWorkingCapital_59e5ae11-ca82-4a22-934a-d7bcbc4e9326" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionNetWorkingCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionNetWorkingCapital_59e5ae11-ca82-4a22-934a-d7bcbc4e9326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionOtherLiabilities_ef3c0023-5988-44d7-a741-9a00cd481389" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionOtherLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionOtherLiabilities_ef3c0023-5988-44d7-a741-9a00cd481389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_4e6fc687-c721-415f-a7cb-305f8fbe642e" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment_4e6fc687-c721-415f-a7cb-305f8fbe642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AssetAcquisitionIntangibles_f64dde64-ba11-4251-b950-9e7fa66a704d" xlink:href="lsta-20230930.xsd#lsta_AssetAcquisitionIntangibles"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_f1e7a0a5-eeac-47dc-8941-5f10e9e37cbe" xlink:to="loc_lsta_AssetAcquisitionIntangibles_f64dde64-ba11-4251-b950-9e7fa66a704d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74e7e92c-9d70-408b-a510-e2a4554309b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_177be5e1-e05c-47de-97ee-4510f6d69cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_74e7e92c-9d70-408b-a510-e2a4554309b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_177be5e1-e05c-47de-97ee-4510f6d69cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7604201d-dd69-4a32-a2c6-e5bbced978d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_177be5e1-e05c-47de-97ee-4510f6d69cd3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7604201d-dd69-4a32-a2c6-e5bbced978d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7604201d-dd69-4a32-a2c6-e5bbced978d9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23e96c9f-a708-4c95-87bc-5ecdfe225543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23e96c9f-a708-4c95-87bc-5ecdfe225543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5668108b-ec30-46ff-8aad-511712442473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_CommercialPaperMember_5668108b-ec30-46ff-8aad-511712442473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e528213c-73e7-40ed-90d3-59e1b3247a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e528213c-73e7-40ed-90d3-59e1b3247a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BondsMember_05535ef4-6c54-4878-8c63-8f71627e0afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_BondsMember_05535ef4-6c54-4878-8c63-8f71627e0afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_bfe116a4-cd65-4ea0-b9ed-e786c42b752a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_bfe116a4-cd65-4ea0-b9ed-e786c42b752a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_502923c5-3a70-4340-ba5f-c51cf6891e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9eccb8d-4354-4ba8-9e61-5ee1718148fd" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_502923c5-3a70-4340-ba5f-c51cf6891e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_177be5e1-e05c-47de-97ee-4510f6d69cd3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4f3021a7-b8bc-4e2f-aea0-75cfeb979834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4f3021a7-b8bc-4e2f-aea0-75cfeb979834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bbad768c-15d7-43cc-b95d-4a144e15bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bbad768c-15d7-43cc-b95d-4a144e15bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2cbf7cd2-8264-4a76-82fe-fe31afd1b04b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2cbf7cd2-8264-4a76-82fe-fe31afd1b04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7faab08f-4964-4e5f-b0cd-db90647c471d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c4ec381b-a788-45fb-9800-2ce824ad23aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7faab08f-4964-4e5f-b0cd-db90647c471d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_053c482d-1d6a-4f72-bdc7-11b7eb1c933d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_558fadd6-bf8b-4a79-9826-5e2493e1442a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_053c482d-1d6a-4f72-bdc7-11b7eb1c933d" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_558fadd6-bf8b-4a79-9826-5e2493e1442a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_63693d9c-b9d3-4eae-882d-42bd32e6ff6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_053c482d-1d6a-4f72-bdc7-11b7eb1c933d" xlink:to="loc_us-gaap_MarketableSecurities_63693d9c-b9d3-4eae-882d-42bd32e6ff6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_6ac34ade-415d-4c2f-96e3-056475437591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_053c482d-1d6a-4f72-bdc7-11b7eb1c933d" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_6ac34ade-415d-4c2f-96e3-056475437591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8fcd29a0-ce98-41d4-a41e-39efad332ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_733592c3-982f-47f7-ab6a-e99a836a781f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8fcd29a0-ce98-41d4-a41e-39efad332ec4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_733592c3-982f-47f7-ab6a-e99a836a781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_f3ae59f8-5908-46dd-b910-2df1658d25be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_733592c3-982f-47f7-ab6a-e99a836a781f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_f3ae59f8-5908-46dd-b910-2df1658d25be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_c9250ef3-831a-4d62-85cf-b420c01fc452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_733592c3-982f-47f7-ab6a-e99a836a781f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_c9250ef3-831a-4d62-85cf-b420c01fc452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f1618765-352b-457d-8d2e-6160455f1d75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_733592c3-982f-47f7-ab6a-e99a836a781f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f1618765-352b-457d-8d2e-6160455f1d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ec6157be-844c-4a86-bdf9-d1ee39a66c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8fcd29a0-ce98-41d4-a41e-39efad332ec4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ec6157be-844c-4a86-bdf9-d1ee39a66c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_78edc2ef-8b8e-48ea-9875-7a0cbf4fdaee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ec6157be-844c-4a86-bdf9-d1ee39a66c4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_78edc2ef-8b8e-48ea-9875-7a0cbf4fdaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_be0a9b78-5dd0-428b-8134-27e8d9c67fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ec6157be-844c-4a86-bdf9-d1ee39a66c4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_be0a9b78-5dd0-428b-8134-27e8d9c67fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_398bf2a4-3b87-416a-b2c5-ea2821d3305b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ec6157be-844c-4a86-bdf9-d1ee39a66c4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_398bf2a4-3b87-416a-b2c5-ea2821d3305b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_72123ee3-30e9-43dc-ad48-478c036c378a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d0792f0-db62-44fa-96d2-a1b30df71371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_72123ee3-30e9-43dc-ad48-478c036c378a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d0792f0-db62-44fa-96d2-a1b30df71371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c03db18c-eb4a-484d-b503-a90e166f25cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d0792f0-db62-44fa-96d2-a1b30df71371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c03db18c-eb4a-484d-b503-a90e166f25cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c03db18c-eb4a-484d-b503-a90e166f25cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_04ff2b3f-1507-40a4-bc2f-b62bc92fd1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_04ff2b3f-1507-40a4-bc2f-b62bc92fd1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_389b200f-130e-40cd-b76a-ba8e2a09709b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:to="loc_us-gaap_ComputerEquipmentMember_389b200f-130e-40cd-b76a-ba8e2a09709b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1154ac9d-ca88-452b-bf39-b9e1206d14b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_100cec15-0f38-4b05-95ed-eb979ebce715" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1154ac9d-ca88-452b-bf39-b9e1206d14b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d0792f0-db62-44fa-96d2-a1b30df71371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4fc7bba5-6754-40e2-aa16-6b54c845bbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4fc7bba5-6754-40e2-aa16-6b54c845bbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2424670-8d0f-41ae-a018-831c46abe1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2424670-8d0f-41ae-a018-831c46abe1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49cccf87-9c24-47c5-9014-8cf86d16fd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49cccf87-9c24-47c5-9014-8cf86d16fd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8d3da7e3-5c2c-4594-ab3f-ab0f0c01db9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2377d6c6-425b-4061-9c40-421bd0e8a4b8" xlink:to="loc_us-gaap_Depreciation_8d3da7e3-5c2c-4594-ab3f-ab0f0c01db9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#IncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_faea2b31-de46-4976-853a-7175b1070cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ece7efce-dcf5-4098-acd3-1b34988a7571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_faea2b31-de46-4976-853a-7175b1070cf9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ece7efce-dcf5-4098-acd3-1b34988a7571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a0bed404-e491-46ec-bc56-4811ad6c21e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ece7efce-dcf5-4098-acd3-1b34988a7571" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a0bed404-e491-46ec-bc56-4811ad6c21e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a0bed404-e491-46ec-bc56-4811ad6c21e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5081bf2-b324-4e14-b531-976f72e7c292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5081bf2-b324-4e14-b531-976f72e7c292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8063caf7-633e-49e8-a04e-4168eb684d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:to="loc_us-gaap_WarrantMember_8063caf7-633e-49e8-a04e-4168eb684d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1731310a-1d1f-4eb9-abe1-203ef3ba658a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8e23dec-20bd-4b80-94c9-b245882d5080" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1731310a-1d1f-4eb9-abe1-203ef3ba658a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ebde43c3-9b65-4812-b732-2bd393e9c306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ece7efce-dcf5-4098-acd3-1b34988a7571" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ebde43c3-9b65-4812-b732-2bd393e9c306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f40be5bb-0bd4-4337-a065-518ef1cd3aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ebde43c3-9b65-4812-b732-2bd393e9c306" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f40be5bb-0bd4-4337-a065-518ef1cd3aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ddc2fd41-a317-4988-9ae6-603072165e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3eb30c0b-b194-4f5a-8820-e331787b6b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ddc2fd41-a317-4988-9ae6-603072165e43" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3eb30c0b-b194-4f5a-8820-e331787b6b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dd1fed22-af4d-4919-8a2a-fc220f28bf03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3eb30c0b-b194-4f5a-8820-e331787b6b08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dd1fed22-af4d-4919-8a2a-fc220f28bf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dd1fed22-af4d-4919-8a2a-fc220f28bf03" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9d8c6b5c-6968-46cb-8462-3d2b6c769669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9d8c6b5c-6968-46cb-8462-3d2b6c769669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aac1dedd-8dae-4955-a308-2f9792462c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aac1dedd-8dae-4955-a308-2f9792462c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4039eaf4-0e04-4bf9-9c2b-be1f46658deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7531312c-3a58-44d3-82ab-ea7654991c5d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4039eaf4-0e04-4bf9-9c2b-be1f46658deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beefb768-e9ef-4f3a-a3db-2e3639687321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3eb30c0b-b194-4f5a-8820-e331787b6b08" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beefb768-e9ef-4f3a-a3db-2e3639687321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c465c17a-59da-4743-8a59-b5d2f9106973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beefb768-e9ef-4f3a-a3db-2e3639687321" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c465c17a-59da-4743-8a59-b5d2f9106973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_137fcf64-b6fe-4215-af71-f8cae842c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c465c17a-59da-4743-8a59-b5d2f9106973" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_137fcf64-b6fe-4215-af71-f8cae842c5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3eb30c0b-b194-4f5a-8820-e331787b6b08" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e6e4a872-b6ef-4293-a3eb-4d8f8a295785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e6e4a872-b6ef-4293-a3eb-4d8f8a295785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_580bad5e-a17c-45ac-8832-108d17032081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_580bad5e-a17c-45ac-8832-108d17032081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_469a6e82-4c71-44bf-9bea-133c7588d458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0b27ec-fe78-43ce-9bce-8a8a06a37b84" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_469a6e82-4c71-44bf-9bea-133c7588d458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_561da4a2-a164-4349-aa9d-3f87acba1d92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_66d031d2-3044-4a0c-9493-e82c9e26fa60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_561da4a2-a164-4349-aa9d-3f87acba1d92" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_66d031d2-3044-4a0c-9493-e82c9e26fa60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalAndRDRelatedLiabilities_449a87a9-1fe7-490a-98e7-d95c7ba1cab1" xlink:href="lsta-20230930.xsd#lsta_ClinicalAndRDRelatedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_561da4a2-a164-4349-aa9d-3f87acba1d92" xlink:to="loc_lsta_ClinicalAndRDRelatedLiabilities_449a87a9-1fe7-490a-98e7-d95c7ba1cab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AccruedGrantFunding_1da08600-228a-4011-a9ba-fe350780d19d" xlink:href="lsta-20230930.xsd#lsta_AccruedGrantFunding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_561da4a2-a164-4349-aa9d-3f87acba1d92" xlink:to="loc_lsta_AccruedGrantFunding_1da08600-228a-4011-a9ba-fe350780d19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_27f3f29a-ea0a-4c65-8f51-340eb2f4b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_561da4a2-a164-4349-aa9d-3f87acba1d92" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_27f3f29a-ea0a-4c65-8f51-340eb2f4b8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e499fc87-567c-42f9-be00-26b6b855f36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_561da4a2-a164-4349-aa9d-3f87acba1d92" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e499fc87-567c-42f9-be00-26b6b855f36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1fb12d63-5e3b-4d5c-876c-e3cddd5f2ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_561da4a2-a164-4349-aa9d-3f87acba1d92" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1fb12d63-5e3b-4d5c-876c-e3cddd5f2ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_997fd713-48f4-43ce-af98-134ab2cad7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5f259c78-f676-4f07-905b-a7d8b493e46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_997fd713-48f4-43ce-af98-134ab2cad7b3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5f259c78-f676-4f07-905b-a7d8b493e46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3ba5dfe6-9b33-483c-b2cd-36171b3cb9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_997fd713-48f4-43ce-af98-134ab2cad7b3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3ba5dfe6-9b33-483c-b2cd-36171b3cb9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4398106d-a2ee-4a86-bd76-37f0e240b212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLeaseRightOfUseAssetAbstract_01dcc7e3-9e25-44c4-9c88-db734725b0a3" xlink:href="lsta-20230930.xsd#lsta_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4398106d-a2ee-4a86-bd76-37f0e240b212" xlink:to="loc_lsta_OperatingLeaseRightOfUseAssetAbstract_01dcc7e3-9e25-44c4-9c88-db734725b0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b704823f-dff1-42d3-b6c9-2d0ac00115cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_OperatingLeaseRightOfUseAssetAbstract_01dcc7e3-9e25-44c4-9c88-db734725b0a3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b704823f-dff1-42d3-b6c9-2d0ac00115cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_66ded77d-695b-4b2d-9c21-9ccb572d3dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4398106d-a2ee-4a86-bd76-37f0e240b212" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_66ded77d-695b-4b2d-9c21-9ccb572d3dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_69d6972e-5622-4c34-9608-a0df0a475347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_66ded77d-695b-4b2d-9c21-9ccb572d3dfd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_69d6972e-5622-4c34-9608-a0df0a475347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c6a964f0-1eef-416d-9046-7f3afcbcefee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_66ded77d-695b-4b2d-9c21-9ccb572d3dfd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c6a964f0-1eef-416d-9046-7f3afcbcefee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bcdec736-b85b-4c45-94ce-e4c0dcada4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_66ded77d-695b-4b2d-9c21-9ccb572d3dfd" xlink:to="loc_us-gaap_OperatingLeaseLiability_bcdec736-b85b-4c45-94ce-e4c0dcada4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1a01494a-d6b2-4e51-a1c4-21e5d9ad94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4398106d-a2ee-4a86-bd76-37f0e240b212" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1a01494a-d6b2-4e51-a1c4-21e5d9ad94aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_317274c9-52e6-4601-acd7-0981d790a619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4398106d-a2ee-4a86-bd76-37f0e240b212" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_317274c9-52e6-4601-acd7-0981d790a619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_9caa2650-ac96-49e4-90df-4a6abe622584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4398106d-a2ee-4a86-bd76-37f0e240b212" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_9caa2650-ac96-49e4-90df-4a6abe622584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2f00a3e0-8e04-4e78-84bf-092d23e63c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4d033ad4-3c7b-41b5-ab8a-49053850896f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f00a3e0-8e04-4e78-84bf-092d23e63c1b" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4d033ad4-3c7b-41b5-ab8a-49053850896f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2b65b16b-e334-4e44-8fa6-066e03c5dd42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4d033ad4-3c7b-41b5-ab8a-49053850896f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2b65b16b-e334-4e44-8fa6-066e03c5dd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_17107af6-53d1-435e-b99d-0f914d233874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4d033ad4-3c7b-41b5-ab8a-49053850896f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_17107af6-53d1-435e-b99d-0f914d233874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f0583b04-efde-4038-a8c0-f603aa16fcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4d033ad4-3c7b-41b5-ab8a-49053850896f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f0583b04-efde-4038-a8c0-f603aa16fcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_77e18201-89c1-4677-ac23-6d38f603c84c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4d033ad4-3c7b-41b5-ab8a-49053850896f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_77e18201-89c1-4677-ac23-6d38f603c84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f65b8431-cf84-4627-a32e-6585c27bd3db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4d033ad4-3c7b-41b5-ab8a-49053850896f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f65b8431-cf84-4627-a32e-6585c27bd3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9d74c821-0ae7-44eb-a979-1418129c7e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4d033ad4-3c7b-41b5-ab8a-49053850896f" xlink:to="loc_us-gaap_OperatingLeaseLiability_9d74c821-0ae7-44eb-a979-1418129c7e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="lsta-20230930.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_06b4eb01-d34c-4334-acd9-6b31387a3f86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_42ff1c28-27fc-4a3a-98c9-29541bcb7f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_06b4eb01-d34c-4334-acd9-6b31387a3f86" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_42ff1c28-27fc-4a3a-98c9-29541bcb7f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e0d870c3-860c-4633-954a-a1a06a18aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42ff1c28-27fc-4a3a-98c9-29541bcb7f62" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e0d870c3-860c-4633-954a-a1a06a18aed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dfda446a-6056-4dc4-9a2f-4024dcf73a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e0d870c3-860c-4633-954a-a1a06a18aed5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dfda446a-6056-4dc4-9a2f-4024dcf73a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AtTheMarketOfferingAgreementMember_3467d32a-1f68-4fbf-8800-cc5cebc6c8a4" xlink:href="lsta-20230930.xsd#lsta_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dfda446a-6056-4dc4-9a2f-4024dcf73a2a" xlink:to="loc_lsta_AtTheMarketOfferingAgreementMember_3467d32a-1f68-4fbf-8800-cc5cebc6c8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6f895b84-9b28-42ae-a235-c9148e09c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42ff1c28-27fc-4a3a-98c9-29541bcb7f62" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6f895b84-9b28-42ae-a235-c9148e09c0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bedafcae-19ee-47c2-b92d-1b0ccf638502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6f895b84-9b28-42ae-a235-c9148e09c0da" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bedafcae-19ee-47c2-b92d-1b0ccf638502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_d2eeb14b-df48-409d-b3c6-34e08af82623" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bedafcae-19ee-47c2-b92d-1b0ccf638502" xlink:to="loc_lsta_CENDMember_d2eeb14b-df48-409d-b3c6-34e08af82623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42ff1c28-27fc-4a3a-98c9-29541bcb7f62" xlink:to="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_f526a118-f77c-4db8-9f2d-f3465b35ceaa" xlink:href="lsta-20230930.xsd#lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_f526a118-f77c-4db8-9f2d-f3465b35ceaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_80be0c7b-aa3c-4e52-86de-4cb25f4be5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_us-gaap_CommonStockValueOutstanding_80be0c7b-aa3c-4e52-86de-4cb25f4be5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OutstandingStockThreshold_871d10c9-0a28-4e17-adf6-71f0f739fe6a" xlink:href="lsta-20230930.xsd#lsta_OutstandingStockThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_lsta_OutstandingStockThreshold_871d10c9-0a28-4e17-adf6-71f0f739fe6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSale_f3d762b8-0be8-4a16-80e1-398b8b9235ca" xlink:href="lsta-20230930.xsd#lsta_SaleOfStockAvailableForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_lsta_SaleOfStockAvailableForSale_f3d762b8-0be8-4a16-80e1-398b8b9235ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSalePercentage_a901a2dc-f8f6-4ad2-8ef5-9374804a6bed" xlink:href="lsta-20230930.xsd#lsta_SaleOfStockAvailableForSalePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_lsta_SaleOfStockAvailableForSalePercentage_a901a2dc-f8f6-4ad2-8ef5-9374804a6bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa5c2827-92ae-4100-a35c-42cf921975e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa5c2827-92ae-4100-a35c-42cf921975e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_987ea7b0-5eb2-426e-9eb1-81144e8026e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_987ea7b0-5eb2-426e-9eb1-81144e8026e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e640e9d5-27b9-4c55-8087-7b73ee25c5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0e43bfb4-c35f-4bd0-8529-8de0a4b4346a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e640e9d5-27b9-4c55-8087-7b73ee25c5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#StockholdersEquityStockOptionsandWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_90fa866b-ac75-40a1-b2bd-956a26c63bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c537394c-a230-492c-9a91-f1fe0780a539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_90fa866b-ac75-40a1-b2bd-956a26c63bb2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c537394c-a230-492c-9a91-f1fe0780a539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_526df9fd-c8ca-4867-a5a7-11ba6f6b8767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c537394c-a230-492c-9a91-f1fe0780a539" xlink:to="loc_us-gaap_AwardTypeAxis_526df9fd-c8ca-4867-a5a7-11ba6f6b8767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a13786af-76d8-4b53-97a1-6365d6b20de1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_526df9fd-c8ca-4867-a5a7-11ba6f6b8767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a13786af-76d8-4b53-97a1-6365d6b20de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ae572b76-e0d0-4bde-806e-d446191fb4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a13786af-76d8-4b53-97a1-6365d6b20de1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ae572b76-e0d0-4bde-806e-d446191fb4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c09f354-b674-4f64-a819-d6b41c02bda2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c537394c-a230-492c-9a91-f1fe0780a539" xlink:to="loc_srt_RangeAxis_4c09f354-b674-4f64-a819-d6b41c02bda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82c5d920-6010-430e-a479-16733585ccfb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4c09f354-b674-4f64-a819-d6b41c02bda2" xlink:to="loc_srt_RangeMember_82c5d920-6010-430e-a479-16733585ccfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1599b74d-e199-4524-8d6f-ca790fb90d28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82c5d920-6010-430e-a479-16733585ccfb" xlink:to="loc_srt_MaximumMember_1599b74d-e199-4524-8d6f-ca790fb90d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_585ee016-d064-4fe4-aa20-d6aa0157ea8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c537394c-a230-492c-9a91-f1fe0780a539" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_585ee016-d064-4fe4-aa20-d6aa0157ea8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff1dfc66-1393-4d9f-afb6-6b27cf5054fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_585ee016-d064-4fe4-aa20-d6aa0157ea8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ff1dfc66-1393-4d9f-afb6-6b27cf5054fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#StockholdersEquityStockOptionsandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a9a32619-2999-49e1-99be-6eb3b30ce2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7448877a-3908-45c1-9241-e9f82a1d5d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a9a32619-2999-49e1-99be-6eb3b30ce2b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7448877a-3908-45c1-9241-e9f82a1d5d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bfffcfd8-74b1-40c4-bb10-013320150ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7448877a-3908-45c1-9241-e9f82a1d5d7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bfffcfd8-74b1-40c4-bb10-013320150ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d7be8e43-df2a-492c-8241-0584556e47de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bfffcfd8-74b1-40c4-bb10-013320150ae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d7be8e43-df2a-492c-8241-0584556e47de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_21d09844-4b0a-4468-aee6-0211bca487eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bfffcfd8-74b1-40c4-bb10-013320150ae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_21d09844-4b0a-4468-aee6-0211bca487eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e7f7292f-6de9-45df-b7d4-117fc51fac63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bfffcfd8-74b1-40c4-bb10-013320150ae7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e7f7292f-6de9-45df-b7d4-117fc51fac63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4e6b1102-927a-49a4-8f20-3e159732d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bfffcfd8-74b1-40c4-bb10-013320150ae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4e6b1102-927a-49a4-8f20-3e159732d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_85172a67-9319-4bc6-8680-2860805d53a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bfffcfd8-74b1-40c4-bb10-013320150ae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_85172a67-9319-4bc6-8680-2860805d53a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19eefa73-1457-4274-b72e-74d3a0e179f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bfffcfd8-74b1-40c4-bb10-013320150ae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19eefa73-1457-4274-b72e-74d3a0e179f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c2655230-2bef-4ef7-8274-8d6e6784dc54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7448877a-3908-45c1-9241-e9f82a1d5d7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c2655230-2bef-4ef7-8274-8d6e6784dc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_de981b98-4523-4649-bac6-5cf4b4c619d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7448877a-3908-45c1-9241-e9f82a1d5d7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_de981b98-4523-4649-bac6-5cf4b4c619d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b642bab-38ef-40fd-8826-a75410c0e046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7448877a-3908-45c1-9241-e9f82a1d5d7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b642bab-38ef-40fd-8826-a75410c0e046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3305b7a2-2414-4713-8434-08ad98724a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b642bab-38ef-40fd-8826-a75410c0e046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3305b7a2-2414-4713-8434-08ad98724a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dfac5373-491c-45d0-a951-a888f04ef62f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b642bab-38ef-40fd-8826-a75410c0e046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dfac5373-491c-45d0-a951-a888f04ef62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1383e799-5a88-4cc4-84a0-7ffd10e180fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b642bab-38ef-40fd-8826-a75410c0e046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1383e799-5a88-4cc4-84a0-7ffd10e180fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9907ca3f-a377-44e2-ad99-505c43330bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b642bab-38ef-40fd-8826-a75410c0e046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9907ca3f-a377-44e2-ad99-505c43330bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d25fe1ca-066c-46a8-bbce-9fe2cd3ce907" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b642bab-38ef-40fd-8826-a75410c0e046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d25fe1ca-066c-46a8-bbce-9fe2cd3ce907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dd892ce7-7d9c-4b20-b413-b4d569fcad57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b642bab-38ef-40fd-8826-a75410c0e046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dd892ce7-7d9c-4b20-b413-b4d569fcad57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_09b04956-c906-40fa-bbbf-9b7d2d28dfad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7448877a-3908-45c1-9241-e9f82a1d5d7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_09b04956-c906-40fa-bbbf-9b7d2d28dfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c9f1a06a-0d41-4f6c-9eb9-a035e0e9bdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7448877a-3908-45c1-9241-e9f82a1d5d7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c9f1a06a-0d41-4f6c-9eb9-a035e0e9bdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0806a1a9-3391-4db7-9c03-bdf24a0ebe90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_7448877a-3908-45c1-9241-e9f82a1d5d7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0806a1a9-3391-4db7-9c03-bdf24a0ebe90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_14d2429c-ab84-40a2-b59c-d07ebd53257e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0806a1a9-3391-4db7-9c03-bdf24a0ebe90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_14d2429c-ab84-40a2-b59c-d07ebd53257e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f7e1ed40-40f9-49ed-8fad-9c9988e8c833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0806a1a9-3391-4db7-9c03-bdf24a0ebe90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f7e1ed40-40f9-49ed-8fad-9c9988e8c833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OptionsVestedweightedAverageRemainingContractualTerm_09fd31f3-c146-4217-b0ad-b2f9efea4cb8" xlink:href="lsta-20230930.xsd#lsta_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0806a1a9-3391-4db7-9c03-bdf24a0ebe90" xlink:to="loc_lsta_OptionsVestedweightedAverageRemainingContractualTerm_09fd31f3-c146-4217-b0ad-b2f9efea4cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e254328-c957-405d-b9c4-027280696950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0806a1a9-3391-4db7-9c03-bdf24a0ebe90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e254328-c957-405d-b9c4-027280696950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8fe77498-4638-4e8e-ace2-ffec5b3ce9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0806a1a9-3391-4db7-9c03-bdf24a0ebe90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8fe77498-4638-4e8e-ace2-ffec5b3ce9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fe0e73aa-1156-4766-a5e2-8f8b3f45f162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0806a1a9-3391-4db7-9c03-bdf24a0ebe90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fe0e73aa-1156-4766-a5e2-8f8b3f45f162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6f6be45e-f493-43df-9ebb-f86afc91f6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a9a32619-2999-49e1-99be-6eb3b30ce2b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6f6be45e-f493-43df-9ebb-f86afc91f6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_52c88262-5341-405a-96f2-2760478b6f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6f6be45e-f493-43df-9ebb-f86afc91f6d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_52c88262-5341-405a-96f2-2760478b6f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CommonStockWarrantsShares_90220b08-0c7f-4eb1-a1b0-fce5516eebca" xlink:href="lsta-20230930.xsd#lsta_CommonStockWarrantsShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_52c88262-5341-405a-96f2-2760478b6f66" xlink:to="loc_lsta_CommonStockWarrantsShares_90220b08-0c7f-4eb1-a1b0-fce5516eebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsGranted_c0c3feb2-5a73-41b2-b3f1-d8343115869b" xlink:href="lsta-20230930.xsd#lsta_WarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_52c88262-5341-405a-96f2-2760478b6f66" xlink:to="loc_lsta_WarrantsGranted_c0c3feb2-5a73-41b2-b3f1-d8343115869b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExercised_a9416803-a939-423a-8f78-0012968d479b" xlink:href="lsta-20230930.xsd#lsta_WarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_52c88262-5341-405a-96f2-2760478b6f66" xlink:to="loc_lsta_WarrantsExercised_a9416803-a939-423a-8f78-0012968d479b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsCanceled_797c63c7-a84b-44dd-bf76-bba69942b9fd" xlink:href="lsta-20230930.xsd#lsta_WarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_52c88262-5341-405a-96f2-2760478b6f66" xlink:to="loc_lsta_WarrantsCanceled_797c63c7-a84b-44dd-bf76-bba69942b9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExpired_3195eb01-e184-42f8-bb45-6ccfa5d87f00" xlink:href="lsta-20230930.xsd#lsta_WarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_52c88262-5341-405a-96f2-2760478b6f66" xlink:to="loc_lsta_WarrantsExpired_3195eb01-e184-42f8-bb45-6ccfa5d87f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CommonStockWarrantsShares_95bbebcd-3cb1-4ae4-8c5f-0dc1e9e297fb" xlink:href="lsta-20230930.xsd#lsta_CommonStockWarrantsShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_52c88262-5341-405a-96f2-2760478b6f66" xlink:to="loc_lsta_CommonStockWarrantsShares_95bbebcd-3cb1-4ae4-8c5f-0dc1e9e297fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_Sharesvestedandexpectedtovest_7a1be9d6-6071-48fd-93b3-22ba96c7e572" xlink:href="lsta-20230930.xsd#lsta_Sharesvestedandexpectedtovest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6f6be45e-f493-43df-9ebb-f86afc91f6d4" xlink:to="loc_lsta_Sharesvestedandexpectedtovest_7a1be9d6-6071-48fd-93b3-22ba96c7e572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsVested_804dafea-30d4-4113-bfb7-9448bc2149a3" xlink:href="lsta-20230930.xsd#lsta_WarrantsVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6f6be45e-f493-43df-9ebb-f86afc91f6d4" xlink:to="loc_lsta_WarrantsVested_804dafea-30d4-4113-bfb7-9448bc2149a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_67152c1f-f1b2-4f88-a190-e6ff43ebc340" xlink:href="lsta-20230930.xsd#lsta_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6f6be45e-f493-43df-9ebb-f86afc91f6d4" xlink:to="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_67152c1f-f1b2-4f88-a190-e6ff43ebc340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_68caad9e-b12a-40b3-a43e-a525ade9ae7d" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_67152c1f-f1b2-4f88-a190-e6ff43ebc340" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_68caad9e-b12a-40b3-a43e-a525ade9ae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsGranted_695da15c-887c-4e13-b3bd-7681d9a2a5e5" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_67152c1f-f1b2-4f88-a190-e6ff43ebc340" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsGranted_695da15c-887c-4e13-b3bd-7681d9a2a5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercised_d489420c-f75f-4cd7-b4c3-b55603e43469" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_67152c1f-f1b2-4f88-a190-e6ff43ebc340" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsExercised_d489420c-f75f-4cd7-b4c3-b55603e43469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled_f6b0ab2b-1115-4711-8789-67b76dc0202e" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_67152c1f-f1b2-4f88-a190-e6ff43ebc340" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled_f6b0ab2b-1115-4711-8789-67b76dc0202e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExpired_7b7e1809-d0bb-44ec-8bbf-74fda638b3de" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_67152c1f-f1b2-4f88-a190-e6ff43ebc340" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsExpired_7b7e1809-d0bb-44ec-8bbf-74fda638b3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_70816de2-b61e-4fc6-8637-c4aae210695c" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_67152c1f-f1b2-4f88-a190-e6ff43ebc340" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_70816de2-b61e-4fc6-8637-c4aae210695c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_bf11c2f7-b974-412f-a223-48365e5e8da7" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6f6be45e-f493-43df-9ebb-f86afc91f6d4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_bf11c2f7-b974-412f-a223-48365e5e8da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable_51edad84-82ac-4976-ba68-9f632cc3258d" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6f6be45e-f493-43df-9ebb-f86afc91f6d4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable_51edad84-82ac-4976-ba68-9f632cc3258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsOtherDisclosuresAbstract_94f985f7-e37f-4024-ab45-a540b72b5b75" xlink:href="lsta-20230930.xsd#lsta_WarrantsOtherDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6f6be45e-f493-43df-9ebb-f86afc91f6d4" xlink:to="loc_lsta_WarrantsOtherDisclosuresAbstract_94f985f7-e37f-4024-ab45-a540b72b5b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_d03beca3-d28e-4392-8b32-3c307fb51126" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_94f985f7-e37f-4024-ab45-a540b72b5b75" xlink:to="loc_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding_d03beca3-d28e-4392-8b32-3c307fb51126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_57fcaaad-d28e-4666-a911-f887a23cc4e7" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_94f985f7-e37f-4024-ab45-a540b72b5b75" xlink:to="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_57fcaaad-d28e-4666-a911-f887a23cc4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermwarrantsvested_2a072087-f540-4918-ab15-e599c8886d1d" xlink:href="lsta-20230930.xsd#lsta_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_94f985f7-e37f-4024-ab45-a540b72b5b75" xlink:to="loc_lsta_WeightedAverageRemainingContractualTermwarrantsvested_2a072087-f540-4918-ab15-e599c8886d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding_a146cd3d-8515-4d81-b479-ef8900493f34" xlink:href="lsta-20230930.xsd#lsta_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_94f985f7-e37f-4024-ab45-a540b72b5b75" xlink:to="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding_a146cd3d-8515-4d81-b479-ef8900493f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_3167ecec-18f2-4ef4-922c-29993c3c3c33" xlink:href="lsta-20230930.xsd#lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_94f985f7-e37f-4024-ab45-a540b72b5b75" xlink:to="loc_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_3167ecec-18f2-4ef4-922c-29993c3c3c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsvested_7b6f6592-499e-430f-a7ba-58d23f140b32" xlink:href="lsta-20230930.xsd#lsta_AggregateIntrinsicValueWarrantsvested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_94f985f7-e37f-4024-ab45-a540b72b5b75" xlink:to="loc_lsta_AggregateIntrinsicValueWarrantsvested_7b6f6592-499e-430f-a7ba-58d23f140b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_85c5391a-de3b-42f4-bec2-48049c36f96d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62bfce89-79e1-47ff-9c75-eb21b0689f06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_85c5391a-de3b-42f4-bec2-48049c36f96d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62bfce89-79e1-47ff-9c75-eb21b0689f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86f87103-5a7a-46d7-8324-5127295efdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62bfce89-79e1-47ff-9c75-eb21b0689f06" xlink:to="loc_us-gaap_AwardTypeAxis_86f87103-5a7a-46d7-8324-5127295efdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56add2c0-71c6-492a-bf12-dbfeba3e9cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_86f87103-5a7a-46d7-8324-5127295efdd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56add2c0-71c6-492a-bf12-dbfeba3e9cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d11cb3a9-ce16-4d8d-ad34-947e324f3439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56add2c0-71c6-492a-bf12-dbfeba3e9cf1" xlink:to="loc_us-gaap_RestrictedStockMember_d11cb3a9-ce16-4d8d-ad34-947e324f3439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8c43dcb2-b5b4-41d3-adcb-94dd2d0124d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56add2c0-71c6-492a-bf12-dbfeba3e9cf1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8c43dcb2-b5b4-41d3-adcb-94dd2d0124d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f199dc05-78d7-4eec-8894-1a08dea252b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62bfce89-79e1-47ff-9c75-eb21b0689f06" xlink:to="loc_srt_RangeAxis_f199dc05-78d7-4eec-8894-1a08dea252b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9e7fd93-42b2-4e01-a4e5-94afcfc430fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f199dc05-78d7-4eec-8894-1a08dea252b6" xlink:to="loc_srt_RangeMember_e9e7fd93-42b2-4e01-a4e5-94afcfc430fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9dff2ec8-45d6-42b6-91ce-ee650c5a6cd6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e9e7fd93-42b2-4e01-a4e5-94afcfc430fb" xlink:to="loc_srt_MinimumMember_9dff2ec8-45d6-42b6-91ce-ee650c5a6cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_552ca770-c215-40bd-a82f-00f29fdd1466" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e9e7fd93-42b2-4e01-a4e5-94afcfc430fb" xlink:to="loc_srt_MaximumMember_552ca770-c215-40bd-a82f-00f29fdd1466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62bfce89-79e1-47ff-9c75-eb21b0689f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2a28c054-8664-4a1f-a407-9ea942859091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2a28c054-8664-4a1f-a407-9ea942859091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_4c13285a-84a7-476a-95aa-00e863438ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_4c13285a-84a7-476a-95aa-00e863438ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cae14f48-b63a-4ea7-b5ef-d8f090e2a0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cae14f48-b63a-4ea7-b5ef-d8f090e2a0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_84759eed-6270-45da-891f-e236c884ff52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cb0ba98-fe2a-4c7a-9b32-0288f0070f00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_84759eed-6270-45da-891f-e236c884ff52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba3afa95-648c-4f3c-bd3d-c412e8937ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3d39b31-018d-4d90-bd61-fcaab27832de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba3afa95-648c-4f3c-bd3d-c412e8937ed9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3d39b31-018d-4d90-bd61-fcaab27832de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8d99933a-66a7-460a-8737-17ca2841fda4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3d39b31-018d-4d90-bd61-fcaab27832de" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8d99933a-66a7-460a-8737-17ca2841fda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ed4bb7fe-22a5-4139-b1a0-9e2bf6141aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8d99933a-66a7-460a-8737-17ca2841fda4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ed4bb7fe-22a5-4139-b1a0-9e2bf6141aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2d89bc7c-9fa5-4d3d-8537-d512e0198f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ed4bb7fe-22a5-4139-b1a0-9e2bf6141aee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2d89bc7c-9fa5-4d3d-8537-d512e0198f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a953491-dfec-4574-b4eb-70287745cd36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ed4bb7fe-22a5-4139-b1a0-9e2bf6141aee" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a953491-dfec-4574-b4eb-70287745cd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_589bf434-0e2f-4ad3-866c-c5e3a0c71aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3d39b31-018d-4d90-bd61-fcaab27832de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_589bf434-0e2f-4ad3-866c-c5e3a0c71aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3e5dd97e-cf1a-42e0-8112-fafe8589c725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_589bf434-0e2f-4ad3-866c-c5e3a0c71aab" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3e5dd97e-cf1a-42e0-8112-fafe8589c725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aeaf68e2-8111-455d-9b81-0193e9d02dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90025e37-1032-4366-8ad2-14181fef4b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aeaf68e2-8111-455d-9b81-0193e9d02dfb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90025e37-1032-4366-8ad2-14181fef4b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4cfbfe7e-e198-43f1-a9eb-3401261db13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90025e37-1032-4366-8ad2-14181fef4b16" xlink:to="loc_us-gaap_AwardTypeAxis_4cfbfe7e-e198-43f1-a9eb-3401261db13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4cfbfe7e-e198-43f1-a9eb-3401261db13f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1fbc6bb7-6965-4634-add3-f2a433fd65af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1fbc6bb7-6965-4634-add3-f2a433fd65af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6f11b7f9-b391-4e64-87ab-bd79c08a02a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6f11b7f9-b391-4e64-87ab-bd79c08a02a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_fe335869-96a3-4703-b0d4-5a075aedd054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_788cce62-c61c-4a65-9774-265ed26642e3" xlink:to="loc_us-gaap_RestrictedStockMember_fe335869-96a3-4703-b0d4-5a075aedd054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa5c364b-886b-4304-a43b-fb2b48848abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90025e37-1032-4366-8ad2-14181fef4b16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa5c364b-886b-4304-a43b-fb2b48848abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f30aa352-8554-4642-8424-b5fd74a9a9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa5c364b-886b-4304-a43b-fb2b48848abb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f30aa352-8554-4642-8424-b5fd74a9a9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4e1ba161-fafe-4bdf-b20f-4cdeaf917f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa5c364b-886b-4304-a43b-fb2b48848abb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4e1ba161-fafe-4bdf-b20f-4cdeaf917f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea76b6b1-1cab-4977-bd79-85795e016dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688bea78-37ab-4db2-8e22-26e4db620c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea76b6b1-1cab-4977-bd79-85795e016dbc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688bea78-37ab-4db2-8e22-26e4db620c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3339dfbf-9630-4177-92ef-681c2ae8ffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688bea78-37ab-4db2-8e22-26e4db620c4d" xlink:to="loc_us-gaap_AwardTypeAxis_3339dfbf-9630-4177-92ef-681c2ae8ffdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_109b11ce-6839-46c7-aabb-394a72887574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3339dfbf-9630-4177-92ef-681c2ae8ffdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_109b11ce-6839-46c7-aabb-394a72887574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e9272ea4-a70d-414e-97a6-4d064516c934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_109b11ce-6839-46c7-aabb-394a72887574" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e9272ea4-a70d-414e-97a6-4d064516c934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9afca9f-4251-4f7a-bb25-0a38eca59e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_688bea78-37ab-4db2-8e22-26e4db620c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9afca9f-4251-4f7a-bb25-0a38eca59e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_49d58c93-b1b2-435c-9636-6d9477f082dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9afca9f-4251-4f7a-bb25-0a38eca59e90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_49d58c93-b1b2-435c-9636-6d9477f082dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b894ae14-97fd-4b06-993b-9cedcc4ce956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9afca9f-4251-4f7a-bb25-0a38eca59e90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b894ae14-97fd-4b06-993b-9cedcc4ce956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fe2a0e5c-dc40-4dde-9e21-80b953064c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe2a0e5c-dc40-4dde-9e21-80b953064c39" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2252917a-465c-4fe0-a89a-f642a9b59aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2252917a-465c-4fe0-a89a-f642a9b59aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2252917a-465c-4fe0-a89a-f642a9b59aad" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4bc941ff-1449-4518-99d0-5e52af3bbc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:to="loc_us-gaap_DomesticCountryMember_4bc941ff-1449-4518-99d0-5e52af3bbc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_7e36a951-dd56-4eee-bad1-be6feb2979e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:to="loc_us-gaap_ForeignCountryMember_7e36a951-dd56-4eee-bad1-be6feb2979e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a1319cd3-109a-4f63-9d0d-408991d8863e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69e42d72-bfe2-496a-ba16-fd13975520e3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a1319cd3-109a-4f63-9d0d-408991d8863e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_14018f19-d188-4280-81f2-265b1e8e64e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_14018f19-d188-4280-81f2-265b1e8e64e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_14018f19-d188-4280-81f2-265b1e8e64e1" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_61d5868a-7f3d-4275-8470-0ef7ce315961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_61d5868a-7f3d-4275-8470-0ef7ce315961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_96f8b2df-ff06-4624-9c41-f82b510a7fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_96f8b2df-ff06-4624-9c41-f82b510a7fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_1c0fb41a-08c7-44bb-b23d-5bda3a682201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_697e3ae5-3f03-4a25-8a46-07557d1197b8" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_1c0fb41a-08c7-44bb-b23d-5bda3a682201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c9668a27-2d8c-4a7a-b73b-8ba51ef4f9b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:to="loc_dei_LegalEntityAxis_c9668a27-2d8c-4a7a-b73b-8ba51ef4f9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5a7a8548-4f94-47b3-8db3-118bd8b7ac85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c9668a27-2d8c-4a7a-b73b-8ba51ef4f9b8" xlink:to="loc_dei_EntityDomain_5a7a8548-4f94-47b3-8db3-118bd8b7ac85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_1a701672-e977-404c-b253-db15c6693a56" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5a7a8548-4f94-47b3-8db3-118bd8b7ac85" xlink:to="loc_lsta_CENDMember_1a701672-e977-404c-b253-db15c6693a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c8852f37-b0fb-4ca2-8f7f-bef2b583ec76" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_55c41697-d975-404a-9a3d-c74131fd72c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_55c41697-d975-404a-9a3d-c74131fd72c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_a3e1be06-916a-46c7-876c-cd0adc89c1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_a3e1be06-916a-46c7-876c-cd0adc89c1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_1eab6338-0e6b-467a-9bc3-4ee0e6272584" xlink:href="lsta-20230930.xsd#lsta_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_1eab6338-0e6b-467a-9bc3-4ee0e6272584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FairValueMarketOfTaxNOLs_1cc04c10-a887-4822-8777-bcb400646999" xlink:href="lsta-20230930.xsd#lsta_FairValueMarketOfTaxNOLs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_FairValueMarketOfTaxNOLs_1cc04c10-a887-4822-8777-bcb400646999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_482882b3-e88b-4a9a-8800-0aadb7ea17a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_482882b3-e88b-4a9a-8800-0aadb7ea17a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_3959ecf9-fb81-4f06-b151-e8e304c34324" xlink:href="lsta-20230930.xsd#lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_3959ecf9-fb81-4f06-b151-e8e304c34324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsPostAcquisition_84456310-795e-4640-b678-c05f2890591b" xlink:href="lsta-20230930.xsd#lsta_OperatingLossCarryforwardsPostAcquisition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_OperatingLossCarryforwardsPostAcquisition_84456310-795e-4640-b678-c05f2890591b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9caeacb0-ef9e-4a50-8fd5-489bcb5776b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9caeacb0-ef9e-4a50-8fd5-489bcb5776b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_bf7b746c-93a1-4679-baf4-49df4de0ae73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_bf7b746c-93a1-4679-baf4-49df4de0ae73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNOLS_8484d1dc-1170-4ddc-a5b9-53639ef105b0" xlink:href="lsta-20230930.xsd#lsta_ProceedsFromSaleOfNOLS"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_ProceedsFromSaleOfNOLS_8484d1dc-1170-4ddc-a5b9-53639ef105b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bb44c452-e16d-42c7-b7a5-ec0bc7f31016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bb44c452-e16d-42c7-b7a5-ec0bc7f31016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LossOnSaleOfNOL_f350face-db00-4ddc-a274-936ea2b2eab7" xlink:href="lsta-20230930.xsd#lsta_LossOnSaleOfNOL"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_a0f71a01-d5ab-4a15-8ad2-8a8b040ee58a" xlink:to="loc_lsta_LossOnSaleOfNOL_f350face-db00-4ddc-a274-936ea2b2eab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#AustraliaResearchandDevelopmentTaxIncentiveDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3f10be73-b951-42b6-b710-a6eee2e4330d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_e00c06e4-e208-43c5-87d3-2975b21d0378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f10be73-b951-42b6-b710-a6eee2e4330d" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_e00c06e4-e208-43c5-87d3-2975b21d0378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_472c8d7d-b53b-49c4-9688-1977305b01f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_e00c06e4-e208-43c5-87d3-2975b21d0378" xlink:to="loc_srt_RangeAxis_472c8d7d-b53b-49c4-9688-1977305b01f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_839574cc-5686-428c-a842-6c5933918ac4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_472c8d7d-b53b-49c4-9688-1977305b01f1" xlink:to="loc_srt_RangeMember_839574cc-5686-428c-a842-6c5933918ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b908f51b-c341-471c-95c9-3d8c3a2a3cc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_839574cc-5686-428c-a842-6c5933918ac4" xlink:to="loc_srt_MinimumMember_b908f51b-c341-471c-95c9-3d8c3a2a3cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_552c6437-e011-43f8-9c98-0bcc94e16f0c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_839574cc-5686-428c-a842-6c5933918ac4" xlink:to="loc_srt_MaximumMember_552c6437-e011-43f8-9c98-0bcc94e16f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_85c39a18-0811-4a75-b493-d0ba1f566ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_e00c06e4-e208-43c5-87d3-2975b21d0378" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_85c39a18-0811-4a75-b493-d0ba1f566ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_499f912d-ee92-4ec6-8d4d-317074a1bb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_85c39a18-0811-4a75-b493-d0ba1f566ab1" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_499f912d-ee92-4ec6-8d4d-317074a1bb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_53712d96-c992-414c-a709-9c4aac8a39ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_499f912d-ee92-4ec6-8d4d-317074a1bb6f" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_53712d96-c992-414c-a709-9c4aac8a39ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_e00c06e4-e208-43c5-87d3-2975b21d0378" xlink:to="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_04f64482-0c1a-4534-8c95-0a55cb7a1906" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_04f64482-0c1a-4534-8c95-0a55cb7a1906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncomeTaxIncentiveReceivable_32b30ec8-5cd9-41e5-89a7-7ec9a6ec362b" xlink:href="lsta-20230930.xsd#lsta_IncomeTaxIncentiveReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:to="loc_lsta_IncomeTaxIncentiveReceivable_32b30ec8-5cd9-41e5-89a7-7ec9a6ec362b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_78d3e957-c040-4dd1-8e69-665a466ef287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_48659ad6-e10f-4cbe-afc3-5ad232a40b1c" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_78d3e957-c040-4dd1-8e69-665a466ef287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#TechnologyTransferAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementAbstract_b01689f3-5c16-45ad-9dc0-b2b089e398bd" xlink:href="lsta-20230930.xsd#lsta_TechnologyTransferAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_aed6fba7-ec31-46bb-b250-098b3ce4d942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_TechnologyTransferAgreementAbstract_b01689f3-5c16-45ad-9dc0-b2b089e398bd" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_aed6fba7-ec31-46bb-b250-098b3ce4d942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_aacc60d3-7af6-4684-81e7-153349e50062" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_aed6fba7-ec31-46bb-b250-098b3ce4d942" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_aacc60d3-7af6-4684-81e7-153349e50062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5288a5cc-d2dd-4294-9e85-6b9bca7dde1d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_aacc60d3-7af6-4684-81e7-153349e50062" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5288a5cc-d2dd-4294-9e85-6b9bca7dde1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_5521c02f-2f5f-4cfb-b5e5-2e1ad717b191" xlink:href="lsta-20230930.xsd#lsta_ImpiloMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5288a5cc-d2dd-4294-9e85-6b9bca7dde1d" xlink:to="loc_lsta_ImpiloMember_5521c02f-2f5f-4cfb-b5e5-2e1ad717b191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6a87cf26-a68a-4c14-9143-ff8633280036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_aed6fba7-ec31-46bb-b250-098b3ce4d942" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6a87cf26-a68a-4c14-9143-ff8633280036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b53125e1-3652-4512-820f-fe82a8406865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6a87cf26-a68a-4c14-9143-ff8633280036" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b53125e1-3652-4512-820f-fe82a8406865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c12f8ca7-a361-4b1f-8bb8-b637107ac8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b53125e1-3652-4512-820f-fe82a8406865" xlink:to="loc_us-gaap_SubsequentEventMember_c12f8ca7-a361-4b1f-8bb8-b637107ac8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_aed6fba7-ec31-46bb-b250-098b3ce4d942" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_2a5b3cc3-d7e6-4741-914c-8d6a8ed72979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_2a5b3cc3-d7e6-4741-914c-8d6a8ed72979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InvestmentOwnedCanceledShares_bcc1c3c7-993f-4397-aa2e-bef123e379ff" xlink:href="lsta-20230930.xsd#lsta_InvestmentOwnedCanceledShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:to="loc_lsta_InvestmentOwnedCanceledShares_bcc1c3c7-993f-4397-aa2e-bef123e379ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_346ee908-db73-4eca-8efd-3e67599781c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_53f31eb4-25a4-4ecd-8c51-0a6bec6f57d2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_346ee908-db73-4eca-8efd-3e67599781c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a60d4a1-22eb-48c8-8a70-13b8a01267c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a60d4a1-22eb-48c8-8a70-13b8a01267c7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c2da32f-d0cf-4bb0-9200-a07f9b18c11b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_srt_CounterpartyNameAxis_0c2da32f-d0cf-4bb0-9200-a07f9b18c11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0c2da32f-d0cf-4bb0-9200-a07f9b18c11b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SanfordBurnhamPrebysMember_e294ad3b-0be0-4aa9-82e1-297f3f04aa2c" xlink:href="lsta-20230930.xsd#lsta_SanfordBurnhamPrebysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:to="loc_lsta_SanfordBurnhamPrebysMember_e294ad3b-0be0-4aa9-82e1-297f3f04aa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_UniversityOfCaliforniaAtSanDiegoMember_149fa143-72e1-4ae7-b244-3ebfd0c05889" xlink:href="lsta-20230930.xsd#lsta_UniversityOfCaliforniaAtSanDiegoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:to="loc_lsta_UniversityOfCaliforniaAtSanDiegoMember_149fa143-72e1-4ae7-b244-3ebfd0c05889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_MassachusettsInstituteOfTechnologyMember_f4354c10-6b17-4d57-9de5-6f33652d7bc8" xlink:href="lsta-20230930.xsd#lsta_MassachusettsInstituteOfTechnologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f5b6201-7cde-47c8-bfdd-a4057c610b2e" xlink:to="loc_lsta_MassachusettsInstituteOfTechnologyMember_f4354c10-6b17-4d57-9de5-6f33652d7bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6875d744-0448-4560-ae32-1dcb80422944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6875d744-0448-4560-ae32-1dcb80422944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc390099-3213-4634-85e9-e18460462aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6875d744-0448-4560-ae32-1dcb80422944" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc390099-3213-4634-85e9-e18460462aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8c5ed319-2a3f-47e9-9086-bcd821412e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc390099-3213-4634-85e9-e18460462aaf" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8c5ed319-2a3f-47e9-9086-bcd821412e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bfc976a0-b733-4d99-8f4c-720c3d771ef0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_srt_RangeAxis_bfc976a0-b733-4d99-8f4c-720c3d771ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02b40776-bd5d-4804-86c3-30c468aebce8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bfc976a0-b733-4d99-8f4c-720c3d771ef0" xlink:to="loc_srt_RangeMember_02b40776-bd5d-4804-86c3-30c468aebce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8baf7cbf-047d-40eb-91fd-11191013259b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_02b40776-bd5d-4804-86c3-30c468aebce8" xlink:to="loc_srt_MinimumMember_8baf7cbf-047d-40eb-91fd-11191013259b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f477abc-393c-453a-8099-04a98686820d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_02b40776-bd5d-4804-86c3-30c468aebce8" xlink:to="loc_srt_MaximumMember_5f477abc-393c-453a-8099-04a98686820d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a0c4ae48-4c09-4587-90a9-b732b15e9e53" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_dei_LegalEntityAxis_a0c4ae48-4c09-4587-90a9-b732b15e9e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_de0f0127-f9b4-4224-8c3f-6ad39953d8d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a0c4ae48-4c09-4587-90a9-b732b15e9e53" xlink:to="loc_dei_EntityDomain_de0f0127-f9b4-4224-8c3f-6ad39953d8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_d8be10b3-7648-4d1e-9e93-fdec8f65e927" xlink:href="lsta-20230930.xsd#lsta_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_de0f0127-f9b4-4224-8c3f-6ad39953d8d4" xlink:to="loc_lsta_CENDMember_d8be10b3-7648-4d1e-9e93-fdec8f65e927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9e91ae90-a3a6-4863-a471-67772823292a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9e91ae90-a3a6-4863-a471-67772823292a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3f68577b-7f53-4d0c-b824-1e5ced0e2e12" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9e91ae90-a3a6-4863-a471-67772823292a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3f68577b-7f53-4d0c-b824-1e5ced0e2e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_f9b6843f-56cb-4bcc-ad59-cfb3b8794347" xlink:href="lsta-20230930.xsd#lsta_ImpiloMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3f68577b-7f53-4d0c-b824-1e5ced0e2e12" xlink:to="loc_lsta_ImpiloMember_f9b6843f-56cb-4bcc-ad59-cfb3b8794347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59139e1a-1a0e-4383-8a67-fdcc406f4229" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesIssuedUnderLicenseAgreement_b0fb7718-a9ce-4eb6-b560-09e8b278bc1c" xlink:href="lsta-20230930.xsd#lsta_SharesIssuedUnderLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_SharesIssuedUnderLicenseAgreement_b0fb7718-a9ce-4eb6-b560-09e8b278bc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_416d19e9-8751-4b83-a358-fe3195d1eb10" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_416d19e9-8751-4b83-a358-fe3195d1eb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_9db53d10-4293-420a-b291-55d2264fe3b5" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_9db53d10-4293-420a-b291-55d2264fe3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_5b817053-fb1b-4009-9385-7c107233a0c3" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_5b817053-fb1b-4009-9385-7c107233a0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_ba7ac551-7c24-428f-a9d1-87c76f633746" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_ba7ac551-7c24-428f-a9d1-87c76f633746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_878dcdf5-21aa-482b-819c-fdbd9c2ec3f0" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_878dcdf5-21aa-482b-819c-fdbd9c2ec3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_4529cd08-f852-4c00-9e71-0bf1465b6de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_4529cd08-f852-4c00-9e71-0bf1465b6de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_43e45977-4296-4d03-bda2-2bdb52f526f9" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_43e45977-4296-4d03-bda2-2bdb52f526f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesHeldByThirdParty_9b234e94-05ac-4d66-987b-d5aa0bf534da" xlink:href="lsta-20230930.xsd#lsta_SharesHeldByThirdParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_SharesHeldByThirdParty_9b234e94-05ac-4d66-987b-d5aa0bf534da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_641c4d3f-fea6-4d9b-85ee-b2497550ed56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_us-gaap_SharesIssued_641c4d3f-fea6-4d9b-85ee-b2497550ed56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_bb46af43-aec3-420c-91a1-92d5e3af7a6d" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_bb46af43-aec3-420c-91a1-92d5e3af7a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_a466803e-a4e8-498e-b492-c658d4032e86" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_a466803e-a4e8-498e-b492-c658d4032e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_49f06cf6-14a9-452f-92ee-9f52db7b4586" xlink:href="lsta-20230930.xsd#lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2c89fdbc-4559-453f-b50f-a07979a4ca77" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_49f06cf6-14a9-452f-92ee-9f52db7b4586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="lsta-20230930.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3717a170-64b2-4a9e-a4eb-c7d9b1e4c8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3717a170-64b2-4a9e-a4eb-c7d9b1e4c8fe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bc47ce00-2173-4985-bf11-87fb7ac415cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bc47ce00-2173-4985-bf11-87fb7ac415cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5be66a00-79f1-4bba-a3ba-109e78f75bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bc47ce00-2173-4985-bf11-87fb7ac415cb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5be66a00-79f1-4bba-a3ba-109e78f75bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_d1dc807c-90e3-4791-af01-2a6643d71ada" xlink:href="lsta-20230930.xsd#lsta_ExclusiveLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5be66a00-79f1-4bba-a3ba-109e78f75bf3" xlink:to="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_d1dc807c-90e3-4791-af01-2a6643d71ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e671c1ed-e5a7-4040-8912-95febf2953e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:to="loc_srt_CounterpartyNameAxis_e671c1ed-e5a7-4040-8912-95febf2953e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684e06fb-5f3a-4604-9839-86a3253960e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e671c1ed-e5a7-4040-8912-95febf2953e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684e06fb-5f3a-4604-9839-86a3253960e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_QiluMember_4105b5a0-75a1-4513-a5e6-5bb387820c0a" xlink:href="lsta-20230930.xsd#lsta_QiluMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684e06fb-5f3a-4604-9839-86a3253960e2" xlink:to="loc_lsta_QiluMember_4105b5a0-75a1-4513-a5e6-5bb387820c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7db895f-2df1-4382-b2b0-91f0e233c044" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:to="loc_srt_ProductOrServiceAxis_e7db895f-2df1-4382-b2b0-91f0e233c044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bc3e6f78-638b-4d68-bb20-1b6318bdd80b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e7db895f-2df1-4382-b2b0-91f0e233c044" xlink:to="loc_srt_ProductsAndServicesDomain_bc3e6f78-638b-4d68-bb20-1b6318bdd80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_2310fd12-18af-405c-ba90-cbbd726edf46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bc3e6f78-638b-4d68-bb20-1b6318bdd80b" xlink:to="loc_us-gaap_LicenseMember_2310fd12-18af-405c-ba90-cbbd726edf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_724fae46-659f-42d4-a973-bca0ac9ba3f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:to="loc_srt_RangeAxis_724fae46-659f-42d4-a973-bca0ac9ba3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b82ee59c-d006-4b61-84cf-7fad49f5fd99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_724fae46-659f-42d4-a973-bca0ac9ba3f7" xlink:to="loc_srt_RangeMember_b82ee59c-d006-4b61-84cf-7fad49f5fd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c0ba6864-be78-4f36-9764-7720f84b2407" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b82ee59c-d006-4b61-84cf-7fad49f5fd99" xlink:to="loc_srt_MinimumMember_c0ba6864-be78-4f36-9764-7720f84b2407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d4372bb-bad4-4541-9c8d-ebb80048420c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b82ee59c-d006-4b61-84cf-7fad49f5fd99" xlink:to="loc_srt_MaximumMember_2d4372bb-bad4-4541-9c8d-ebb80048420c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e2af081-728c-4900-aa32-210820d01a9a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_26b88aac-3124-496e-baac-a9a8fddaf4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_26b88aac-3124-496e-baac-a9a8fddaf4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_08799051-7e84-4f36-9782-d29bdd94b9be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_08799051-7e84-4f36-9782-d29bdd94b9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_2ecb55e3-007b-4fe3-a6f5-04b4b6c32c3a" xlink:href="lsta-20230930.xsd#lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_2ecb55e3-007b-4fe3-a6f5-04b4b6c32c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_f04ed1d8-f334-4f0a-b110-d0870a2f9c1a" xlink:href="lsta-20230930.xsd#lsta_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_f04ed1d8-f334-4f0a-b110-d0870a2f9c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_e1903e83-7c0e-42bb-add3-52f88cb2a386" xlink:href="lsta-20230930.xsd#lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_e1903e83-7c0e-42bb-add3-52f88cb2a386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_0108010b-bd29-4784-83f6-285ae25bab27" xlink:href="lsta-20230930.xsd#lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b177db4a-caab-4ae6-a843-5ada803c34b6" xlink:to="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_0108010b-bd29-4784-83f6-285ae25bab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>lsta-20230930_g1.jpg
<TEXT>
begin 644 lsta-20230930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV/N\H01BO?/^"C_A+X@W'@>Y\4:+XF73_ VGV,=MK&CB[E1[QY;E$0B-4*.
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M6OSB\+W_ ,:?V\/BAK$NF>)IM"TFQ_?&/[9+!9:=$[$1QJD?+R,%/.,G:22
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MHESK%S=I((HW _?1RS,LI9#]Z,[L@-@$E37VE0 4444""BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^3/^
M"E'Q,_X0WX"IX>MY=E]XGO%M=JG#?9X\22D>V1$I]I#7UG7PE^UA\%O'O[07
M[4?A+3AX;OQ\/M+^S6L^J8 @V.XEN9 <YSMVI]8Q0-'A_P  _P!L_P 5? 7X
M;67A/1_AW;W\$<LMS)>S&97N'D;.XA1CA=JCV45X[XF^+FJO\?%^*$6ACP]J
M+ZK%JXL4WB,RJRM)@L 2'8,3_OFOV]CC2&-8XU5(U 5548  Z "OE#_@H9\!
M-9^,7P]T#4?"^E2ZOXBT6]*BVMP/,>VE7$F.><,D1^FZD5<[[]J/7+/Q1^R+
MXRUG3Y/.L-0T);NWD'\4<FQE/X@BO#/^"4]G%'\._'-V%Q/+JL,3-ZJL.5'Y
MNWYUO^"?!_Q"U;]@7Q#X&USPQJ-KXKL;2;3+.QG4>;<P[U>(KSC 5BG_ &SK
M2_X)T_"WQ9\*_A[XJLO%NA76@W=UJBS0Q7:@%T$2C<,$\9&*8NA\]?\ !5+_
M )+#X2_[ (_]*):^KOV[?^3./&7_ %RT[_TNMJ\,_P""B?P+\??%3XG>&M0\
M)^%K_7;*WT<02S6J@JDGGR-M.2.<$'\:^M?CI\,KCXM_ OQ'X.MY$M[[4+!4
M@:8X03(5DC#'L-Z*">P-(.QXG_P3'_Y-PN?^P]=?^BX:\,_X*L_\E \"_P#8
M+F_]&U4_9SM_VE?V=]>@\&67@6];P]?ZI%/>M<:>;F"$,R1RR)/&VT911U8C
MY<XZUZ%_P48^"/COXK>-/"%WX2\,7VO6]II\L4\EHH(C8R9 .2.U'0?4[O\
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M,9. 65MWRD\AN.1@@]-C-\ _ 7]HKXGZ/8^(?&?QNU'PD][&+A-,TF &1%8
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M[ _CSP?=ZM;ZO=6\,UPEQ:QLB"!Y8V=<'G./,_.N<_X)2_9O^$ \=[=OVO\
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MO#X6\07HF\/:HL=E<7VSRXIK>4@PW(!)QLDX;DX D%>R_P#!5K[7_P *_P#
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MC9^Q+XK\9V]M]C_M/PCJIEMMV[RIDMYHY5![@.C8/<8->#?\$G_^1?\ B/\
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M[>1]GS)LQC_:\NE_;=LXM1_;@T2TG7?!.=)BD7U5G (_(U]0_L0_LCW'[/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \(_;2^%/B/XR_ ^Z\-^%;
M2.]U:2^MYUBDG2$;$8ECN8@5-^QG\+O$7P=^!6F^&O%%I'9:O#=W,KPQS)*
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M'M(_R+\?\SS_ /X69XC_ .B3>,/_  +T;_Y84?\ "S/$?_1)O&'_ (%Z-_\
M+"O0**/K-+_GQ'[Y_P#R8>TC_(OQ_P SS_\ X69XC_Z)-XP_\"]&_P#EA1_P
MLSQ'_P!$F\8?^!>C?_+"O0**/K-+_GQ'[Y__ "8>TC_(OQ_S//\ _A9GB/\
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M/^>G_CH_PH_M"X_YZ?\ CH_PH]K3_P"?$/OG_P#)AS1_D7X_YG,_\+,\1_\
M1)O&'_@7HW_RPH_X69XC_P"B3>,/_ O1O_EA73?VA<?\]/\ QT?X4?VA<?\
M/3_QT?X4>UI_\^(??/\ ^3#FC_(OQ_S.9_X69XC_ .B3>,/_  +T;_Y84?\
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M6%=-_:%Q_P ]/_'1_A1_:%Q_ST_\='^%'M:?_/B'WS_^3#FC_(OQ_P SF?\
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M_"CVM/\ Y\0^^?\ \F'-'^1?C_F<S_PLSQ'_ -$F\8?^!>C?_+"C_A9GB/\
MZ)-XP_\  O1O_EA73?VA<?\ /3_QT?X4?VA<?\]/_'1_A1[6G_SXA]\__DPY
MH_R+\?\ ,YG_ (69XC_Z)-XP_P# O1O_ )84?\+,\1_]$F\8?^!>C?\ RPKI
MO[0N/^>G_CH_PH_M"X_YZ?\ CH_PH]K3_P"?$/OG_P#)AS1_D7X_YG,_\+,\
M1_\ 1)O&'_@7HW_RPH_X69XC_P"B3>,/_ O1O_EA73?VA<?\]/\ QT?X4?VA
M<?\ /3_QT?X4>UI_\^(??/\ ^3#FC_(OQ_S.9_X69XC_ .B3>,/_  +T;_Y8
M4?\ "S/$?_1)O&'_ (%Z-_\ +"NF_M"X_P">G_CH_P */[0N/^>G_CH_PH]K
M3_Y\0^^?_P F'-'^1?C_ )G,_P#"S/$?_1)O&'_@7HW_ ,L*/^%F>(_^B3>,
M/_ O1O\ Y85TW]H7'_/3_P ='^%']H7'_/3_ ,='^%'M:?\ SXA]\_\ Y,.:
M/\B_'_,YG_A9GB/_ *)-XP_\"]&_^6%'_"S/$?\ T2;QA_X%Z-_\L*ZRSO)I
MKE$=\J<Y&!Z5J5$L12CHZ$?OG_\ )B=2*^POQ_S//_\ A9GB/_HDWC#_ ,"]
M&_\ EA1_PLSQ'_T2;QA_X%Z-_P#+"O0**GZS2_Y\1^^?_P F+VD?Y%^/^9Y_
M_P +,\1_]$F\8?\ @7HW_P L*/\ A9GB/_HDWC#_ ,"]&_\ EA7H%%'UFE_S
MXC]\_P#Y,/:1_D7X_P"9Y_\ \+,\1_\ 1)O&'_@7HW_RPH_X69XC_P"B3>,/
M_ O1O_EA7H%%'UFE_P ^(_?/_P"3#VD?Y%^/^9Y__P +,\1_]$F\8?\ @7HW
M_P L*/\ A9GB/_HDWC#_ ,"]&_\ EA7H%%'UFE_SXC]\_P#Y,/:1_D7X_P"9
MY_\ \+,\1_\ 1)O&'_@7HW_RPH_X69XC_P"B3>,/_ O1O_EA7H%%'UFE_P ^
M(_?/_P"3#VD?Y%^/^84445YY@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!6U#_ (\Y/P_F*Q:VM0_X\Y/P_F*Q:Z*>Q<=@
MHK+\51ZQ-X9U:/P]-:V^O/:2K837H)@CN"A$;2  DJ&P2 .0*_-/Q)IOQM^%
MGQ?^&OAK1?C-XC\?_&#4;^6[\3>'[749;S1+"T:5=C-$ZJL2;&;(9!@8*A/D
MW:-V*/U HK\W?[<^(7[4GQP^/UNWQ4\4_#W2OA_%<0Z1IOAZ_:RC+1M*BO/L
M(+KF LV3G]Y@, ,5[?\ L+_&SQW\?/V4]1OKJ\AF\;Z9-=:1::OJ2DQW$JQ(
M\$TH5?FV^:JM@$ML)/)-)2NQ7/K.BORX\96OQM^$'Q2^'FA:+\9/$?Q"^,%Y
M=SWWB;P[::C+>:)96GF*4+1,@6)"A;(9!@8*A/DW<*_QH^+OC+X*>-?V@H_B
MQXGTG6='\50:?:>';2XVZ4L#*IVM;'Y&QYB#YE.0AW!BV0N?R"Y^P-%?F%\;
M=1^+,WPSN/BWXL^,FK^%]9\46FG2^!/ W@G4[B'SFFV,T,]N%4NRJ_+ MR>2
M?E0Z/QR\/_&VP^%?ACQ?X]\9_%6YURY\-3,N@?#W2_L]MI=Y$BLLVISQ2C"L
M&R_[O((D"E0N"<WD%S]+**^=/V ?&NK^//V9?#NI:[XO7QKJJRSP3:@3*TL>
MU_EAE>159Y%4C+$'.1AF&&/T75K57&%%%% !17YJ?MW:7\1/ASX@\4>(_P#A
M8/Q:OIKB*"]TB;PQ926'AK0X3<%&BNIXIF+.$ P0BL24+%MV [Q-\8_'WQ:\
M;?LZ?">R^*6H:?IWB308=1UCQ9X9D>SN-1ES,&"2,B2*1]F*\A<L[%E.,5',
M*Y^E-%?#O[&7Q,\9>'_VG/BM\$?$/BO5O'FCZ"KWFG:QK4YN+J$+)&IC>4Y9
MMPF7@G ,9P!DBN._;$T'XH^!9/&WC3Q%\;=8T._O[R"T^'_@[P5J=Q$;K,N#
M'/;JJ[V"$992W)Y)^1"^;2X7/T3HK\KM"\=?'+X]?%RY^'/C/XA^)/A[J/A3
MP8^IW*>'9C933W@@CD5KCR]FXGSDWKT&PA=I):M+X+^-/B]^TK\&]&\5>-OC
M)/\ #SX9^$+BZL]>UK2[^2PUG4'2,/$_F)'M? ECCP6RQ4DJ[D4N8+GZ?T5^
M8WPEL?CS\3/V8]1UWQ!\0?B/!X1T_5XYM.B\/:6UWXFU^Q9E5A%*9DD"#=N#
M$N,;_O*@%>B?\$V_'WB76O'_ ,5?#FN^-/$.I6>FW .G^&?&CS2:U8QB5E\R
M8NNU#M**R(Q&_)*KP6.8+GWK1115C"BBOBC]OK]J*_\ "]U:_"3P1XDM?"WB
MS4[9K[5/$%U?+9#3+-59PD<K$?OY=I"A3NQ@ 9=2$W97 ^UZ*_)KPW^U]XX\
M*_L 7E_9>.+W5?'UUXK_ +,GU&^U$WE_I]K)$9$;]XS,@?R9%0GC[Y7D9'I,
MFO>/_P!D_P#:7^"FB_\ "S_%/Q'T/QU;V]OJFG^(]0>\"22R+&98=Y/EJ&=7
M7'.$8%B#4\PKGZ.45\Q_M8>!O&_B/Q#H^LW'Q;?X5_!O1;22YUVYT;49;'59
M9L/MV2*A#+S&H0MR2<*S%<?"6C_'SX_R>!/A_P"#-2\9^)-*T+QQXE^RZ5XH
MNRR:O+8!X4++,?GV%IU8-OR2I4-LZMRL%S]B:*_,7PKJ_P ?M4^+7Q=_9W\%
M_%*ZNTTQA>6_BKQ9=RO?6EJK1B2-+E4=P[B=/FX \HE-A8XU?@U9?%GQ=\>O
MB!X'^&GQL\5Z_P##BUT[['=>-]>SJZVM\(TW+:N[*"^\L!L8?*2?FVJY7-Y!
M<_26BORS^!/C+QEX+_; ^'_ARZ\>_$_2-(U"UV:A9?%>*XA?6;@^8K"UM\RH
MB,P38SOD$,-Y. WZF52=QFCH_P#RV_#^M:59NC_\MOP_K6E7-/XF9O<**X/X
MV67Q$U+P'<6OPOU+1-'\42RHHO\ 7HWDA@A.?,=%56W2 8VA@5SUKX=_8!^/
MWCF;]G/X]^-/$_B'5O&FK^'&GO;4:O>27 5H[6238@8G8A9>57  [5 C]'J*
M_'VX\7_%ZS_9'L/VEA\<O%\GBJ7Q%Y3:$]^?[),0E:()]D_U><KN*[=NTXVY
MYK[Z^)K?%/\ :"_9<\,WWPPUVP^'_B7Q+8V6H7M[?2RQM:VTL(DE2&1$9DDR
MR@-@$ '!4D$ 'T117Y :]\=/BW\#?$WQ=N_AE\3O%'Q-^&_A_3X;"?Q-XGN#
MJ,-OJ,AABS;RN&5G221B N%*CY@P"LVGH_Q(^-'P3\6_ &\T3XJ>(/&=]\6-
M'1KG3/%UW)>6-K=7#!(W13N*)&TT;_( Q\H@G:VT 'ZV45^4GC:/XU_!'XJ?
M#K1K#XY>(O'?Q:N;NXU+Q=H=OJ4MYH&F6'F*1))$ZJL,?EERP9!M'*A/DW>?
M?M)?MM>./BM\2=/\7^$?B)=>#_ $&M+H^G:'I6NM:7EQ A5I;V[AC=6"/D;3
M(, ?*/NL6 /V<HJII.K6.O:7::EIEY;ZCIUY$L]M>6DJRPS1L 5='4D,I!!!
M!P0:MT %%%9/BR+69_"^KQ^')K6VU][25=/FO@3!'<%"(VD !)4-@D <@4 :
MU%?E9XFTOXZ?"?XR?##PQHGQL\2?$/XRZE?RW?BCP]::E+>Z%86;2KL9HG55
MB0HS;@R# P5"?)NZ#^WOB-^U=\=_VAK=OBSXK^'.D_#N*XAT;2_#FH-91EXV
ME17N-A!D4F LV3N_>8# #% 'Z9T5\@_L$_'+Q_\ M!?LDZE?7=Y#-XZTN:[T
M:SUC5%)BN)5A1X)I@J_,%\U5; );RR3R37S'XTM?CI\&_BO\.- T3XU>)?B-
M\9;V[GO_ !1X;L]2EO=#L;,R*49HF15B0HS9#(,#!4)\FX _5JBOQH?XW?&/
MQK\#O''[1,?Q=\4Z/K6B^+8-.L_#=G<;=(6!U4[6MC^[;'F(/F4Y"'<&+9'I
M'QSU+XO3?"^X^,/B_P"-6L>%=:\56FFR^ / ?@75+F'SFFV.\,]L%0NRJ_+*
M6Y/)/R1D _4^BOR/_:&_;&^*FK?#+1?AROC%?!GCGPSHJZIXSUA=073;ZYN\
MCRK"W"%&:8*\;2K%_%N!P$8-]U_L"_$"7XC?LJ>"-1OO$C>*-<BAE@U.[N+X
MW=RDXE=MD[EF8.$:,X8YVLO8B@#Z%HHHH ***^"/^"@GA?QYHNL7?BR#QO\
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MX%76[:74;C4]-D-GK-S:_OC!YLN X;;;L!DG(D#.&.* /UVHK\J/@5XH^/\
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MW,FBBN?^($?BB7P9JR>"I-+A\5-"1I\FM"0VBRY',GE@MC&>@ZXKK-#H**^
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MO\";/XT_$/XTWOP[\'0^'IK?2K#PG?RV%_J.K1LT2M-&B(L@E>-GVJW .%V
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MQM-6;PGK(M(]0B(4%94>-P5.T9484GD@GFOI2B@#YQUC]@'X0:M\$=+^%_\
M9=_9:-I=RU_9ZE:WA74(KMEVO<"4@@LPQD%2G"X4;5QY_P#L\_L3^+_@'^T]
MKOC636])\;>&-2MVMX];\37=U<^)H$\L!4#;1 <LJ*SGDHH"[<D'[.HH ^:_
MC3^POX=^.GQ,M_'&M?$7XB:9JUB5.FPZ+J\%M!IF  3;#[.6C)(W%MQ8GOP
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MZ9HHY4%CRC]GW]F?P7^S7HNI6/A6.]NKO5)Q<:AJVK3B>\O'&=OF.%48&YL
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M  HGPA_SQUC_ ,*#4/\ X_7H%% 'G_\ PHGPA_SQUC_PH-0_^/T?\*)\(?\
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M2/A/_GEJW_@^O_\ X_7JNH?\><GX?S%8M=%/8N)PG_"D?"?_ #RU;_P?7_\
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M%BZ>.P\<12VE_P ,_P 3A/\ A2/A/_GEJW_@^O\ _P"/T?\ "D?"?_/+5O\
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M  HGPA_SQUC_ ,*#4/\ X_7H%% 'G_\ PHGPA_SQUC_PH-0_^/T?\*)\(?\
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M #QUC_PH-0_^/UZ!10!Y_P#\*)\(?\\=8_\ "@U#_P"/T?\ "B?"'_/'6/\
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MI'PG_P \M6_\'U__ /'Z[NBBR X3_A2/A/\ YY:M_P"#Z_\ _C]'_"D?"?\
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MHHHJAA1110 45\7^*M2UGQ%^V9\1M!N-,^(WB_1-/T+2I[72?!WBY](BLI)
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M1_\ EM^']:TJS='_ .6WX?UK2KEG\3,WN%%%%0(**** "BBB@ HHHH ****
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M#L>)> _V>]7TKXZ7GQ7\7>*M/UWQ))H:Z##!H>A_V5;"'S1(SRAKB>260E5
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M%\5:8/\ B;739E5;:"Z1)&5][!'CBESOPKXZ16WC[QE;?M,?LX?'CX[>'?\
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M)))9B222237XG?\ #1?Q7_Z*=XR_\']W_P#'*/\ AHOXK_\ 13O&7_@_N_\
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M_P#/^/W,/[(G_.C]\:*_ [_AI3XN_P#14_&O_A0WG_QRC_AI3XN_]%3\:_\
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MC+_P?W?_ ,<K;_4G$?\ /Z/W,K^RI_S(_=.BOPL_X:+^*_\ T4[QE_X/[O\
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MA_\ E8O_ /X_1_KIE_\ )/[H_P#R0?VI1[/\/\S\;Z*_9#_AW_\  3_H0_\
MRL7_ /\ 'Z/^'?\ \!/^A#_\K%__ /'Z/]=,O_DG]T?_ )(/[4H]G^'^9^-]
M%?LA_P ._P#X"?\ 0A_^5B__ /C]'_#O_P" G_0A_P#E8O\ _P"/T?ZZ9?\
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MB_\ _C]'^NF7_P D_NC_ /)!_:E'L_P_S/QOHK]D/^'?_P !/^A#_P#*Q?\
M_P ?H_X=_P#P$_Z$/_RL7_\ \?H_UTR_^2?W1_\ D@_M2CV?X?YGXWT5^R'_
M  [_ /@)_P!"'_Y6+_\ ^/T?\.__ ("?]"'_ .5B_P#_ (_1_KIE_P#)/[H_
M_)!_:E'L_P /\S\;Z*_9#_AW_P# 3_H0_P#RL7__ ,?H_P"'?_P$_P"A#_\
M*Q?_ /Q^C_73+_Y)_='_ .2#^U*/9_A_F?C?17[(?\.__@)_T(?_ )6+_P#^
M/T?\._\ X"?]"'_Y6+__ ./T?ZZ9?_)/[H__ "0?VI1[/\/\S\;Z*_9#_AW_
M / 3_H0__*Q?_P#Q^C_AW_\  3_H0_\ RL7_ /\ 'Z/]=,O_ ))_='_Y(/[4
MH]G^'^9^-]%?L[IO_!/?X 7'F>9X!W8QC_B<Z@/7_IXJ[_P[N_9\_P"B?_\
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M_D@_M:AV?X?YGXJUW7P6\46_A7QU;37;B.VNHVM7D/1-Q!!/MN49]C7ZX?\
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M4/\ Y(H_UXR[_GW/[H__ "0?VM0[/\/\S\5:*_:K_AW=^SY_T3__ ,K6H?\
MR11_P[N_9\_Z)_\ ^5K4/_DBC_7C+O\ GW/[H_\ R0?VM0[/\/\ ,_%6BOVJ
M_P"'=W[/G_1/_P#RM:A_\D4?\.[OV?/^B?\ _E:U#_Y(H_UXR[_GW/[H_P#R
M0?VM0[/\/\S\5:*_:K_AW=^SY_T3_P#\K6H?_)%'_#N[]GS_ *)__P"5K4/_
M )(H_P!>,N_Y]S^Z/_R0?VM0[/\ #_,_%6BOVJ_X=W?L^?\ 1/\ _P K6H?_
M "11_P .[OV?/^B?_P#E:U#_ .2*/]>,N_Y]S^Z/_P D']K4.S_#_,_%6BOV
MJ_X=W?L^?]$__P#*UJ'_ ,D4?\.[OV?/^B?_ /E:U#_Y(H_UXR[_ )]S^Z/_
M ,D']K4.S_#_ #/Q5HK]JO\ AW=^SY_T3_\ \K6H?_)%'_#N[]GS_HG_ /Y6
MM0_^2*/]>,N_Y]S^Z/\ \D']K4.S_#_,_%6BOVJ_X=W?L^?]$_\ _*UJ'_R1
M1_P[N_9\_P"B?_\ E:U#_P"2*/\ 7C+O^?<_NC_\D']K4.S_  _S/QE\/^'[
M[Q1K-II>FP-<7MR^R-!^I)[ #DGL!7V]\.M T7X7^'['PV-6MWOG?<ZRW"AY
MIFQNV(3G'& !Z>N37V!!_P $]_@#:L6A\"/$Q&TF/7-14D>G%Q3K'_@G[\!M
M+O(+RR\#M:WENZRPSIK-^6C=3E6 ,Y!((!Y!%>;C.+<!BTHVFDO[L=__  (]
MK+N),+@9.?LFY/KIHO0^:=0UBPTGRC?7MO9"5MD?VB58][>@R>37Q[\?/A2_
M@K6SK.G%KG0-2D+I+NW^3(<DH6[@\D$]1D=LG]0?#/['/@?XBZ'(_P 2/#S:
MU=6E]/#:+]NN;9416",V(I$W;F0X)SP!CK6JO_!/?X I"\*^!'6)^6C&N:B%
M;'J/M'-98?B7!8"H[\S>SLDT_1\R_(];.^)<'6J3PW(Y<KTDK;]?ET/Q1HK]
MJO\ AW=^SY_T3_\ \K6H?_)%'_#N[]GS_HG_ /Y6M0_^2*]?_7C+O^?<_NC_
M /)'Q_\ :U#L_P /\S\5:*_:K_AW=^SY_P!$_P#_ "M:A_\ )%5=0_X)Z_L_
MP0JR> =IW8_Y#.H>A_Z>*:XXRYNWLY_='_Y(?]K4.S_#_,_%^BOV0_X=_P#P
M$_Z$/_RL7_\ \?H_X=__  $_Z$/_ ,K%_P#_ !^M/]=,O_DG]T?_ )(?]J4>
MS_#_ #/QOHK]D/\ AW_\!/\ H0__ "L7_P#\?H_X=_\ P$_Z$/\ \K%__P#'
MZ/\ 73+_ .2?W1_^2#^U*/9_A_F?C?17[(?\._\ X"?]"'_Y6+__ ./T?\._
M_@)_T(?_ )6+_P#^/T?ZZ9?_ "3^Z/\ \D']J4>S_#_,_&^BOV0_X=__  $_
MZ$/_ ,K%_P#_ !^C_AW_ / 3_H0__*Q?_P#Q^C_73+_Y)_='_P"2#^U*/9_A
M_F?C?17[(?\ #O\ ^ G_ $(?_E8O_P#X_1_P[_\ @)_T(?\ Y6+_ /\ C]'^
MNF7_ ,D_NC_\D']J4>S_  _S/QOHK]D/^'?_ ,!/^A#_ /*Q?_\ Q^C_ (=_
M_ 3_ *$/_P K%_\ _'Z/]=,O_DG]T?\ Y(/[4H]G^'^9^2?A/1?,D6_N#Y<,
M9_=Y.-S>OT%=OM;RHI,'RY5WQOCAUR1D'N,@CZ@U^FW_  P%\!CMSX$SMZ9U
MB_/_ +7KF?VEOV9[7QMXV^%7]BZ;'9Z5'<+HE[#:QA$ALT#3*% X4*B3@>[*
M*_!.-:4L]K/,(592E=*,'%148WV34I-N[NWIZ6LE^\<#>(.69=*&5^P]G!J4
MIU'*[<E%RVMHK*R5^W5MGS%^SO\ $C7OV;?'<&K:WH%_;^'=5B2&^-Q9/&_D
MDY66)F49P3G .&''7!'Z>Z5JMGKFF6NHZ?<QWEC=1+-!<0MN21&&58'T(-3K
M#&L(A$:B$+L$84;=N,8QZ8IMK:PV4"PV\,<$*YVQQ*%49.3@#W-8Y;@)Y?!T
MO:<T>FFWXGY!Q?Q1A^*\1'&_5?95EI)J5U)+:ZY59K:]W=:=$2T445[)^?!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!9T__ (_(_P ?Y&MJL73_ /C\C_'^1K:KGJ;D2W"BBBLB0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH K:A_QYR?A_,5BUM:A_QYR?A_,5BUT4]BX[!1116I04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!HZ/\ \MOP_K6E6;H__+;\/ZUI5RS^)F;W"BBBH$%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52U;_CW7_?_ *&K
MM4M6_P"/=?\ ?_H:J/Q(:W,FBBBNLT"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** +.G_\ 'Y'^/\C6U6+I_P#Q^1_C_(UM5SU-R);A
M11161(4444 %%%% !1110 4444 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S[ZK_
M ."B[_\ C5;E% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N
M44 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\ C5;E% &'_P )C8?\
M^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+O_XU
M1_PF-A_S[ZK_ ."B[_\ C5;E% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_ #[Z
MK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\ C5;E
M% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N44 8?_"8V'_/
MOJO_ (*+O_XU1_PF-A_S[ZK_ ."B[_\ C5;E% &'_P )C8?\^^J_^"B[_P#C
M5'_"8V'_ #[ZK_X*+O\ ^-5N44 8?_"8V'_/OJO_ (*+O_XU1_PF-A_S[ZK_
M ."B[_\ C5;E% &'_P )C8?\^^J_^"B[_P#C5'_"8V'_ #[ZK_X*+O\ ^-5N
M44 <W?>+[%K5P(-4SQUTFZ'<?],JR?\ A*;+_GCJ7_@LN?\ XW78ZA_QYR?A
M_,5BUT4[V+B9'_"4V7_/'4O_  67/_QNC_A*;+_GCJ7_ (++G_XW6O16FI1D
M?\)39?\ /'4O_!9<_P#QNC_A*;+_ )XZE_X++G_XW6O11J!D?\)39?\ /'4O
M_!9<_P#QNC_A*;+_ )XZE_X++G_XW6O11J!D?\)39?\ /'4O_!9<_P#QNC_A
M*;+_ )XZE_X++G_XW6O11J!D?\)39?\ /'4O_!9<_P#QNC_A*;+_ )XZE_X+
M+G_XW6O11J!D?\)39?\ /'4O_!9<_P#QNC_A*;+_ )XZE_X++G_XW6O11J!D
M?\)39?\ /'4O_!9<_P#QNC_A*;+_ )XZE_X++G_XW6O11J!D?\)39?\ /'4O
M_!9<_P#QNC_A*;+_ )XZE_X++G_XW7GG[1'Q]L_@7X;MIEMEU'7-0+)8V3L5
M7Y1\TKD?P*2O Y).!CDCY6\*_MA?&#Q+XNL[/3(K'6+F[F"1:3'8+L?)QMR"
M& 'J6XZDU\]C<]PF!K+#SNY=DKV_$^8Q_$6"R_$+#5+RGVBKVOM_PRU/NS_A
M*;+_ )XZE_X++G_XW1_PE-E_SQU+_P %ES_\;K*^''C^#Q_I-W+Y4-IJFG73
MV.HV4-RMPMO.O4+(O#J000P]<'!! ZRO<I5(UH*I!W3/HJ56%>"J4W=,R/\
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M?\)C8?\ /OJO_@HN_P#XU6Y10!A_\)C8?\^^J_\ @HN__C5'_"8V'_/OJO\
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M?\)C8?\ /OJO_@HN_P#XU6Y10!A_\)C8?\^^J_\ @HN__C5'_"8V'_/OJO\
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M)I5N1IE[+;>>$T+>@?8PW!6 89Z$9KI?BY\9?B3\+/A5\)5T+XC^+YM2\?\
M@;S[V>\U,WDYO#)"R/!YC;XW*NT68?WA!!"NXR?KO_AO'_J1_P#RK_\ VBN9
M^(W[4_AKXM^$KOPSXM^&,>LZ)=%6DMI-:>,AE8,K*Z1*Z," 0RD$>M+_ %8S
M;_GU_P"31_\ D@_U!XD_Z!O_ ">G_P#)&A^Q'IMAI/Q4^)TVK:N7\:ZO'97:
MZ)JL>K2ZG96,<?E;C=ZK;07,\;R#.-I1"  >:^QZ^$/ ?Q^\&_#;Q%J/B#1?
MAQ>R:_J$"6MSJNK^+;S4[MX4.5B\ZZ61U0'G:"!GM7??\-X_]2/_ .5?_P"T
M5:X:S5+^#_Y-'_,?^H/$G_0+_P"3T_\ Y(^L:*^3O^&\?^I'_P#*O_\ :*/^
M&\?^I'_\J_\ ]HI_ZMYK_P ^?_)H_P"8?Z@\2?\ 0+_Y/3_^2/K&BOD[_AO'
M_J1__*O_ /:*/^&\?^I'_P#*O_\ :*/]6\U_Y\_^31_S#_4'B3_H%_\ )Z?_
M ,D?6-%?)W_#>/\ U(__ )5__M%'_#>/_4C_ /E7_P#M%'^K>:_\^?\ R:/^
M8?Z@\2?] O\ Y/3_ /DCZQHKY._X;Q_ZD?\ \J__ -HH_P"&\?\ J1__ "K_
M /VBC_5O-?\ GS_Y-'_,/]0>)/\ H%_\GI__ "1]8T5\G?\ #>/_ %(__E7_
M /M%'_#>/_4C_P#E7_\ M%'^K>:_\^?_ ":/^8?Z@\2?] O_ )/3_P#DCZQH
MKY._X;Q_ZD?_ ,J__P!HH_X;Q_ZD?_RK_P#VBC_5O-?^?/\ Y-'_ ##_ %!X
MD_Z!?_)Z?_R1]A:/_P MOP_K6E7P/XQ_X*=?\*]^R?\ %MOM_P!LW_\ ,=\O
M9LV_].QSG=^E<W_P^"_ZI+_Y<G_W)64N%LXD[JC_ .31_P#DCYC&9'F&!KRP
M^(I\LXVNKQ>ZOT;6S/T<HK\X_P#A\%_U27_RY/\ [DH_X?!?]4E_\N3_ .Y*
M7^JF<_\ /C_R:'_R1Q?V=BOY/Q7^9^CE%?G'_P /@O\ JDO_ )<G_P!R4?\
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MZ.45^<?_  ^"_P"J2_\ ER?_ ')1_P /@O\ JDO_ )<G_P!R4?ZJ9S_SX_\
M)H?_ "0?V=BOY/Q7^9^CE%?G'_P^"_ZI+_Y<G_W)1_P^"_ZI+_Y<G_W)1_JI
MG/\ SX_\FA_\D']G8K^3\5_F?HY17YQ_\/@O^J2_^7)_]R4?\/@O^J2_^7)_
M]R4?ZJ9S_P ^/_)H?_)!_9V*_D_%?YGZ.45^<?\ P^"_ZI+_ .7)_P#<E'_#
MX+_JDO\ Y<G_ -R4?ZJ9S_SX_P#)H?\ R0?V=BOY/Q7^9^CE%?G'_P /@O\
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M .2#^S\3_+^*_P S]"Z*_/3_ (>U?]4J_P#+B_\ N6C_ (>U?]4J_P#+B_\
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M_$_R_BO\S]"Z*_/3_A[5_P!4J_\ +B_^Y:/^'M7_ %2K_P N+_[EH_U7S?\
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M)_\ <E83X5SAO2A_Y-'_ .2)>7XG^3\5_F?HY17YQ_\ #X+_ *I+_P"7)_\
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MQ=_Z)7XU_P#"=O/_ (W7?]<PW_/R/WHV]I#^9'G%%>C_ /#-?Q=_Z)7XU_\
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MU_%W_HE?C7_PG;S_ .-T?7,-_P _(_>@]I#^9'G%%>C_ /#-?Q=_Z)7XU_\
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M^[>TA_,CSVBO0O\ AG7XK_\ 1,?&7_@@N_\ XW1_PSK\5_\ HF/C+_P07?\
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M)CXR_P#!!=__ !NCZWA_^?D?O0>TA_,CSVBO0O\ AG7XK_\ 1,?&7_@@N_\
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M\^+1_P"T;L;7\YIL^=YOFG]XS-@OCG'3B@#XE^.'[8GQ#TGP?\1_%7P[\?\
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M_#^8K%K:U#_CSD_#^8K%KHI[%QV"BBBM2@HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %G3_\
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M?_(E=%/8N)KT5D?\3_\ ZAO_ )$H_P")_P#]0W_R)6ERC7HK(_XG_P#U#?\
MR)1_Q/\ _J&_^1*+@:]%9'_$_P#^H;_Y$H_XG_\ U#?_ ")1<#7HK(_XG_\
MU#?_ ")1_P 3_P#ZAO\ Y$HN!KT5D?\ $_\ ^H;_ .1*/^)__P!0W_R)1<#7
MHK(_XG__ %#?_(E'_$__ .H;_P"1*+@:]%9'_$__ .H;_P"1*/\ B?\ _4-_
M\B47 UZ*R/\ B?\ _4-_\B4?\3__ *AO_D2BX&O161_Q/_\ J&_^1*/^)_\
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M7_Y$H W**P_^*D_ZA?\ Y$H_XJ3_ *A?_D2@#<HK#_XJ3_J%_P#D2C_BI/\
MJ%_^1* -RBL/_BI/^H7_ .1*/^*D_P"H7_Y$H W**P_^*D_ZA?\ Y$H_XJ3_
M *A?_D2@#<HK#_XJ3_J%_P#D2C_BI/\ J%_^1* -RBL/_BI/^H7_ .1*/^*D
M_P"H7_Y$H W**P_^*D_ZA?\ Y$H_XJ3_ *A?_D2@#<JEJW_'NO\ O_T-4/\
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M5BUM:A_QYR?A_,5BUT4]BX[!65XI\5:5X)T"\UO6[U-/TNT7?-<2 D*"0
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M/3+:WGBW!MDB1*K#()!P0>0<5T% !1110 4444 %%%% !1110 4444 %%%%
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MO;*EE-'IYN%GMO(A0QQ[G,6UBPP/49KY,^'OBB^\(VFD7VGQV,EPVC>#X?\
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M U#2_%<T-K<VVH1XW08#LLA((92A;*G/&"!ROQ(\&>+OA[^UEI?Q@T+PO?\
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MBCQE'9WMX\\0N!:6"&#,\JPE<DA1YC!,=&/M?[27[/.N_M"?\(#X2U%=%O/
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M,?'D%QJ>C:3XW?2H+GPKXK?0=4M,/!Y=I&\%AAX%#L3*[[WZ%,<U]/\ A/\
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M'[/[S]3?^'I_PH_Z%_QE_P" 5I_\E4?\/3_A1_T+_C+_ , K3_Y*K\LJ*/\
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MU_\  &S_ /DJOR<HI?ZFY5_++_P(/[,P_9_>?K'_ ,/9/A%_T+GC7_P!L_\
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M?\9?^ 5I_P#)5?EE11_JCE?:7WA_9N'[/[S]3?\ AZ?\*/\ H7_&7_@%:?\
MR51_P]/^%'_0O^,O_ *T_P#DJORRHH_U1ROM+[P_LW#]G]Y^IO\ P]/^%'_0
MO^,O_ *T_P#DJC_AZ?\ "C_H7_&7_@%:?_)5?EE11_JCE?:7WA_9N'[/[S]3
M?^'I_P */^A?\9?^ 5I_\E4?\/3_ (4?]"_XR_\  *T_^2J_+*BC_5'*^TOO
M#^S</V?WGZF_\/3_ (4?]"_XR_\  *T_^2J/^'I_PH_Z%_QE_P" 5I_\E5^6
M5%'^J.5]I?>']FX?L_O/U-_X>G_"C_H7_&7_ (!6G_R51_P]/^%'_0O^,O\
MP"M/_DJORRHH_P!4<K[2^\/[-P_9_>?J;_P]/^%'_0O^,O\ P"M/_DJC_AZ?
M\*/^A?\ &7_@%:?_ "57Y944?ZHY7VE]X?V;A^S^\_4W_AZ?\*/^A?\ &7_@
M%:?_ "51_P /3_A1_P!"_P",O_ *T_\ DJORRHH_U1ROM+[P_LW#]G]Y^IO_
M  ]/^%'_ $+_ (R_\ K3_P"2J/\ AZ?\*/\ H7_&7_@%:?\ R57Y944?ZHY7
MVE]X?V;A^S^\_4W_ (>G_"C_ *%_QE_X!6G_ ,E4?\/3_A1_T+_C+_P"M/\
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M'P?E4MU+[Q?V9A^S^\_6/_A[)\(O^A<\:_\ @#9__)5'_#V3X1?]"YXU_P#
M&S_^2J_)RBE_J;E7\LO_  (/[,P_9_>?K'_P]D^$7_0N>-?_  !L_P#Y*H_X
M>R?"+_H7/&O_ ( V?_R57Y.44?ZFY5_++_P(/[,P_9_>?K'_ ,/9/A%_T+GC
M7_P!L_\ Y*H_X>R?"+_H7/&O_@#9_P#R57Y.44?ZFY5_++_P(/[,P_9_>?K'
M_P /9/A%_P!"YXU_\ ;/_P"2J/\ A[)\(O\ H7/&O_@#9_\ R57Y.44?ZFY5
M_++_ ,"#^S,/V?WG[ ^!/^"G/P@\<>+-.T)K?Q#X>-])Y*:AK5M;QVD;'[HD
M=)W*@G W$8&>2!DU]; A@"#D&OYR*_3/_@F3^TCXS\9_:/AOK>GWFO:-I-KY
MMIKW7^SXQPMO,Q/S*<$1XRPP1@J,I\IQ!PK2P6'>*P3TC\2;_%/]/N/.QF7Q
MI0]I2V6Y^@M?.W@']NSX:_$C]HS6?@QI"ZL?$VFO<Q&_FAA%A<R08\V.*192
M[,/GZH!^[;GIGT[XZ>,M8^'_ ,'_ !=K_A[2-0U[Q!9Z=*VFZ=IEG)=SSW3#
M;"%BC5F8;V4GC 4$G@&OS1U+]C_XM_ OX3?!/XKZ-9MXJ\8^&-7CUS4O#>D:
M!<#69/MK))<QW$@GD,Y3:L1"P(5#N3G!-?EYX!^F%Q\=OAK::U<Z-/\ $+PK
M#J]K/]EGT^36[9;B*;./+:,ON5\\;2,U+X@^-GP[\)ZY<:+K?CWPQHVLVZJ\
MVGZAK%O!<1JPRI:-W# $<@D<U^4NL2+XVUC]L_PUIGPY\1^+?%/B;6;1-*.G
M>'IKHVK_ &EGVSRJA^S%>'Q(5'[L]QBMM+*;P#^TU\0O#/BWP?K/C_Q)_P *
M=L]$:WT719-6E^W?V?;1MN$2L45F!3S/NY89(!H _4OQ9\4_!?@'2++5?$WB
M_0?#FEWQ M;[5M3@M8)R5W#RWD8*V5YX)XYJAK7QR^''AO0=)US5_B!X6TK1
M=74MIVI7NM6T-M>@8R89&<+(!D?=)ZU^:OPV_9V^*OPO\3? /7?'EOXTM_#V
MF^$KO33<^$]%AUJ]T&ZEGN91'+:/;76T-#)'&76(D<+E0I%;6I?LS?8(?V:[
M3PEX"^)$WA)?B#-K.HV/C32X&N-/A=K7<\L5FGEVUNQC9@DH4CY\@# H _0_
M_A>?PW_X0\^+?^%@^%?^$5\_[+_;G]M6WV'SO^>?G[]F_P#V<YKYX\ ?\% 8
M_B9K&KV^B^&_#:Z=8^,E\+1:C?\ C:WM8[^%B=MU:[X0)W8 %8$)+9&'KXV\
M/_ WXB^#_P!J23QSJWPW\5:C\-=(^*>H7TVF6FA7$^4E/[B_AME0M-&NW=OC
M5@-H[LH-&'X)?$75/%$E_I'PV\7:1977QKAUJT%QX<NH/L]B2Y6X:,Q_)$N1
MEB-HQC- 'ZQM\:/AZGC,>$&\=^&5\6&7R1H)UBW^W^9C.SR-^_=CG&,XH;XT
M?#U/&8\(-X[\,KXL,ODC03K%O]O\S&=GD;]^['.,9Q7P[^RGX;D^%_PKE^&7
MQ(^"'BSQ;\09?&%U=R:A+X534-/-RX_=:I]NN-ML$4<;_,\P'.%YKR_X:_LW
M:HGPK;X=?$OP]\9;KQI%XOFU$6OA70=.-A-=$%H]3&KW%IM"$85BUUNSQLQP
M #]*H_CU\,Y?%@\+)\1?";^)C<?9?[%76[4WOG=/+\G?OW_[.,UP?[.'[4]I
M\>?#_P 0]9O]%B\(V/@[7KS1IYIM0$Z21VZAFN&8QH(Q@DE><8^\:_/3Q[\.
M_C'XE\">"+#7/ASXETK5M)\?Q7MQX3\*^![6WT'3+8$YN(9K6%I9BW.Y_,9>
MNX9V,WT9^RG\#?%VJ_ ']IOP=JFBZAX7U'Q7XDUN+3'UNREMEF2> )',N]06
MC)/WER.#C- 'I]O_ ,%%/A[-X=MO%S^&/&EO\-[C53I$?CN;3(1I9D!*B0@3
M_:!$6&W>80-W!P<BO:K?X_?#"\\4)X:@^(_A&?Q')-]F32(]=M6NVE_YYB$2
M;RW^SC-?%?PA\<?$3X8_LC^&_A!#\ M=\2?$O3+Z32FTG7M E;0'3[0\OVN2
M](%LT>&&"),EQZ8->&^//AU\8O$G@/P1I^M?#?Q%H^JZ3X^BO;CPCX1\"VMM
MX?TNV!/^D02VL32S%N<MYC+UW#(1F /T_P!3_:,^$^BZ_/H6H?$_P;8:W!/]
MFETVZ\06D=S'-G'EM&T@8-GC:1G-:/B3XT?#WP;XB@\/^(/'?AG0M>N-GDZ7
MJ6L6]O=2;SA-L3N&.X\# Y[5^9WQ8_9_\8ZQX;_;2NH?AUKU]JVM>)=,DT*1
M-%GDEOH%O6>1K7Y"9% (9C'D8P3VKKOV=?"FL?!>R^,>C?%WX/\ C#XB:]XN
MO+"YLI;;PH=8M=1MRG[A'>1?(B,#$,R3NFS QRM 'Z!M\:?A['XS'A!O'?AE
M?%AE\D:"=8MQ?^9C.SR-^_=CG&,XK%D_:@^#4)D$GQ;\"QF-F5PWB2R&TJ0&
M!_>\$$C/ID5^<'P5_9DN;3X.Z=\,?B5X3^,UCXEMO%9O5TOPCX>TO[#'-M!C
MU!-5EM3&JA0$;_2SR,!"M8?PO_8_5O@7K^N>,?A[\1=%\;P_$,S:?K6A^&5O
M-0M;9(T,4TEI/LDFM=\DC-Y*L2R D$+B@#]:_!_COPU\1-'_ +6\*^(=*\3:
M7YC1?;M'O8KN#>.J[XV*Y&1D9[UNU\E_L(CXBPZA\38O&?AFUMM);5$ETWQ>
MWA)?#-_XC<[Q+<7-EM5P>$(=U!.\\MV^M* "BBB@ HHHH \2_;1^'^O_ !2_
M9I\8^&/#%A_:>N7WV/[/:^='#OV7L$C_ #R,JC"(QY(Z8ZU^7/\ P[_^/?\
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M[_\ CW_T(?\ Y6+#_P"/U^R%%'^NF8?R0^Z7_P D']J5NR_'_,_&_P#X=_\
MQ[_Z$/\ \K%A_P#'Z/\ AW_\>_\ H0__ "L6'_Q^OV0HH_UTS#^2'W2_^2#^
MU*W9?C_F?C?_ ,.__CW_ -"'_P"5BP_^/T?\._\ X]_]"'_Y6+#_ ./U^R%%
M'^NF8?R0^Z7_ ,D']J5NR_'_ #/QO_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\
MZ$/_ ,K%A_\ 'Z_9"BC_ %TS#^2'W2_^2#^U*W9?C_F?C?\ \.__ (]_]"'_
M .5BP_\ C]'_  [_ /CW_P!"'_Y6+#_X_7[(44?ZZ9A_)#[I?_)!_:E;LOQ_
MS/QO_P"'?_Q[_P"A#_\ *Q8?_'Z/^'?_ ,>_^A#_ /*Q8?\ Q^OV0HH_UTS#
M^2'W2_\ D@_M2MV7X_YGXW_\._\ X]_]"'_Y6+#_ ./T?\.__CW_ -"'_P"5
MBP_^/U^R%%'^NF8?R0^Z7_R0?VI6[+\?\S\;_P#AW_\ 'O\ Z$/_ ,K%A_\
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M (]_]"'_ .5BP_\ C]'_  [_ /CW_P!"'_Y6+#_X_7[(45Q?ZZ9A_)#[I?\
MR1_07]J5NR_'_,_&_P#X=_\ Q[_Z$/\ \K%A_P#'Z/\ AW_\>_\ H0__ "L6
M'_Q^OV0HH_UTS#^2'W2_^2#^U*W9?C_F?CG#_P $]_C_ '&?+\ [L=?^)SIX
M_P#;BI?^'=W[0?\ T3__ ,K6G_\ R17[,:/_ ,MOP_K6E6,N-\Q3M[.'W2_^
M2)>:U^R_'_,_%7_AW=^T'_T3_P#\K6G_ /R11_P[N_:#_P"B?_\ E:T__P"2
M*_:JBI_UXS+_ )]P^Z7_ ,D+^UJ_9?C_ )GXJ_\ #N[]H/\ Z)__ .5K3_\
MY(H_X=W?M!_]$_\ _*UI_P#\D5^U5%'^O&9?\^X?=+_Y(/[6K]E^/^9^*O\
MP[N_:#_Z)_\ ^5K3_P#Y(H_X=W?M!_\ 1/\ _P K6G__ "17[544?Z\9E_S[
MA]TO_D@_M:OV7X_YGXJ_\.[OV@_^B?\ _E:T_P#^2*/^'=W[0?\ T3__ ,K6
MG_\ R17[544?Z\9E_P ^X?=+_P"2#^UJ_9?C_F?BK_P[N_:#_P"B?_\ E:T_
M_P"2*/\ AW=^T'_T3_\ \K6G_P#R17[544?Z\9E_S[A]TO\ Y(/[6K]E^/\
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M_)!_:U?LOQ_S/Q5_X=W?M!_]$_\ _*UI_P#\D4?\.[OV@_\ HG__ )6M/_\
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M1@N9IR?+=M+[-VW9>BZGXL_#SX&?$/XO6U[/X'\+/XAAL72.Z<7MO;",L"5
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M6+#_ ./U^R%%=7^NF8?R0^Z7_P D<O\ :E;LOQ_S/QO_ .'?_P >_P#H0_\
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M]$__ /*UI_\ \D5^U5%'^O&9?\^X?=+_ .2#^UJ_9?C_ )GXJ_\ #N[]H/\
MZ)__ .5K3_\ Y(H_X=W?M!_]$_\ _*UI_P#\D5^U5%'^O&9?\^X?=+_Y(/[6
MK]E^/^9^-W@[_@FO\;]=\3:=8ZUX<A\-:3-*%NM5GU*TG6WCZEO+BF9W..
M.21D@9(_5;X+_!?PQ\!_ MGX6\+6?V>SA^>>XDP9KN8@!I96Q\S''T
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110!HZ/_P MOP_K6E6;H_\
MRV_#^M:5<L_B9F]PHHHJ!!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %4M6_P"/=?\ ?_H:NU2U;_CW7_?_ *&JC\2&MS)HHHKK- HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"SI_P#Q^1_C_(UM
M5BZ?_P ?D?X_R-;5<]3<B6X4445D2%%%% !1110 4444 %%%% &'_P (9I?]
MVZ_\#I__ (NC_A#-+_NW7_@=/_\ %UN44#,/_A#-+_NW7_@=/_\ %T?\(9I?
M]VZ_\#I__BZW** ,/_A#-+_NW7_@=/\ _%T?\(9I?]VZ_P# Z?\ ^+K<HH P
M_P#A#-+_ +MU_P"!T_\ \71_PAFE_P!VZ_\  Z?_ .+K<HH P_\ A#-+_NW7
M_@=/_P#%T?\ "&:7_=NO_ Z?_P"+K<HH P_^$,TO^[=?^!T__P 71_PAFE_W
M;K_P.G_^+K<HH P_^$,TO^[=?^!T_P#\71_PAFE_W;K_ ,#I_P#XNMRB@##_
M .$,TO\ NW7_ ('3_P#Q='_"&:7_ ';K_P #I_\ XNMRB@##_P"$,TO^[=?^
M!T__ ,71_P (9I?]VZ_\#I__ (NMRB@##_X0S2_[MU_X'3__ !='_"&:7_=N
MO_ Z?_XNMRB@##_X0S2_[MU_X'3_ /Q='_"&:7_=NO\ P.G_ /BZW** ,/\
MX0S2_P"[=?\ @=/_ /%T?\(9I?\ =NO_  .G_P#BZW** .<OO!VF):N0MUGC
M_E]G]1_MUD?\(KIW]VY_\#)O_BZ['4/^/.3\/YBL6NBGL7$R/^$5T[^[<_\
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MIW]VY_\  R;_ .+H_P"$5T[^[<_^!DW_ ,76O119 9'_  BNG?W;G_P,F_\
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M?^!T_P#\76Y10!A_\(9I?]VZ_P# Z?\ ^+H_X0S2_P"[=?\ @=/_ /%UN44
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M_P"!T_\ \71_PAFE_P!VZ_\  Z?_ .+K<HH P_\ A#-+_NW7_@=/_P#%T?\
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M?_%UKT460&1_PBNG?W;G_P #)O\ XNC_ (173O[MS_X&3?\ Q=:]%%D!D?\
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M\(9I?]VZ_P# Z?\ ^+K<HH P_P#A#-+_ +MU_P"!T_\ \71_PAFE_P!VZ_\
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MD^'/@WXBWG@.^U+5KOQ?9V:ZA<:3HWAS4M3EBMVQB5OLMO( OS+DYX) .,T
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M_!-S6O!EKX-^$=EJWQ'\4:!XJNM8ULZ1X3TNYF72M:4<R-=HL31N4&2N]TY
MQFO0)K'Q5J/_  5:\<1>$-;TG0=3_P"$ A+W6LZ3+J47E^9;958H[FW(;.TA
MBY& 1M.<C[]KBO%?QN^'7@/59M,\3>/O"_AW4H85N);/5M9MK69(F8*LC)(X
M(4L0 Q&"3B@#\V_CU^Q[X>^">O?LW^!=3U.;QF/%'Q"GO]?N[N!;>.]DF:U6
M1%A4D1QE5 V[F/+<\@#S'PQX@M/#?C_QAX#N/!6EW_@:W^*6H1VNH^)A?7'A
MGPX-VT+-86\B13;E'R+*0J[#C +$?M)'*DT:21NLD;@,K*<@@]"#Z4^@#\)?
MA[I6G:WXDUJQN?B%X3T73O#_ (ZO)=*\*^-]&U&#P;?-(C8,GWTM !&VV.5M
MV#UR/FZ_X?\ BB7X@>//AO8^,=#T'X8_!/3;34+/1F\70:CK7A*\U#YV>=/M
M%U"0&C?$6Z4JA7Y1N8X_:NB@#Y-_9)T/P)X#_9-O;;Q#\1+'QW\+7NYO(U/Q
M9HTVD:=#92&-5M@FH.^^W#DA'+%6W[1DCGY4^$_Q6^&_AWXJ?MJ%/&/A72]'
MUG36M] VZG;0V]\!;W*JEI\P60#*@"//4#TK]7:* /Q'^"NO>"/A[X9_9D\1
M^!YX[/XA:1J6I:EX[N+!7%Q#HZRAYFO, ?NOL^-F[@@G&<FOT"_9C\-VNL?#
M_P"(/QZ^+=M9PR_$2W:^NK+5H@]OIOAZ*-A;6KJ^05,69'XPV\9&17O'QN^#
M.C_'OP'+X/\ $%_J=GH=Q<P3WD.ES)$UY'%()/(D9D;]TS*NX+M8@8W#FNZM
M[>*SMXH((UA@B4)''&,*J@8  [ "@#\O/&WQ>^'G[7'CCP)H/AOQ%X+^%OP0
M^'FK)JMN;_5+/2]0UBYBSLALK$NK01GD!G5?]9NQE0M>%>//%EG?6/@GQ9:^
M'-#^&GBN/XCQ_:--2VU.7Q1:J6.Z2_U:ZF+.K\XC* <94C:ZC]O** /ST_:R
M\,ZOXT_;L.@: "VMZG\'-6L[)5D\LM,YNU0;NV20,^]<9\&_C9\*?#W[#7A/
MX4>+/!<OC?QU;:HVE7?PO2-XM5EO1=O+YK18#JH4A]Y&.-N<Y%?<GB;]F_1/
M$G[07A[XPC7M=TOQ/HNF_P!D):V3VQL[BU,CNR2I) [_ #&0@LCJ< 8(/->M
M4 ?D)^SOX*U6\_8'_:4U&U\6^(?#&GV.J:VDOABV73YK6;;:0DI-++;2SDX(
M0F.9<A01@DL?+_@=\)_$7CK4KSQ=X&N9K?X@_#[P7H?B31%C8A;EH_\ 76[*
M/O"2+< O\1PI.&-?N710!^-OAW67\1?\$TY-6DC6&2_^+,=TT:G(0O+&Q /M
MFOV2KRO]H/\ 9YT?]I#PWI>@>(-=UO2M(L;^+46M]&>V3[3+&0T?F-+!(P"G
M/"%<[CG/&/5* "BBB@#%\8>(])\)^'+O5=<U2ST;2[?9YU]J%PD$$>YU5=SN
M0HRS*!D\D@=Z\S_X:+^%'_13O!O_ (/[3_XY7+_\%$?^3.OB!_W#_P#TX6U?
MBK7Z%P[P[2S?"RKSJ.+4FM/1/]3VL%@HXFFYMVU/W2_X:+^%'_13O!O_ (/[
M3_XY1_PT7\*/^BG>#?\ P?VG_P <K\Y?$W[%>DM^S[X%\?\ A?5K[4-9NK.U
MU'Q'HTTT3O!:3OL^TP(J!E1&# [MW&3D;#GSSXQ?LS3>$_BWXO\ #OA?5-'.
MBZ/??8X7\1^*=+L;MOW:.2R330L1\_W@@4XQU!KT:/#^65Y.,<2TU>]TE;E:
M3_-6[HVC@\/-V4WU_ _5W_AHOX4?]%.\&_\ @_M/_CE'_#1?PH_Z*=X-_P#!
M_:?_ !ROR.^&G[-^K^,OB5:^']3U#2K/1K>V;5=:UO3-6M-1MM.L(R?-E>6W
MDD17PI 1CDEEXP<UZ'\3_P!FOX;>"_VF- \#0>+=8LO!VJ6%C>Q7UU +F\N6
MN' 6*,)&BH6!&&=0%Y)STJY\-Y="K[+ZQ)OE<M%?1>G7R&\#04N7G=[7V/TN
M_P"&B_A1_P!%.\&_^#^T_P#CE'_#1?PH_P"BG>#?_!_:?_'*_&WX_P#P_P!.
M^%7QG\7^$=)FNKC3='OWM8);UE:9E &"Y55!//8"O/Z[Z7!N%K4XU85I6DDU
MHNIM'+*<HJ2D]3]TO^&B_A1_T4[P;_X/[3_XY7.^+?B5\#_&4EG?7>M^ ?&.
MNZ0)+C2(I+NROKJ*; ;_ $<$LRL2B\I@_*/2OQR\ ^+D\'>((KNYT^WU;3G_
M '=U8W42R)+&>N P(##J#_0FOLGP7X+\#W3Z?XL\.Z5:0O+&6@N;<%  P*L-
M@. >H/&1R*XL5PMA\&TY3DT]M%:_9GOY;PS2QTDU5V>JZV\C[1\*_M">"K?P
MWIP\5>-?#^A:UY7[ZVU35(+:5L$J)-CN#AL9SC'7TK5_X:+^%'_13O!O_@_M
M/_CE?%?BSP'X7\27$>J>(--MKM[*)@)KAB%2,98[AG! Y//3FOCWXM^-],\4
MZU]E\/Z9::5H%FQ6!+6W6(SMT,KX )SV!Z#W)I8;AG#XV;Y9R7?167DCHS;A
MFEA:DZRJ64F^6*_K9'[+?\-%_"C_ **=X-_\']I_\<H_X:+^%'_13O!O_@_M
M/_CE?A;17I_ZDX?_ )_2^Y'S7]E0_F9^Z7_#1?PH_P"BG>#?_!_:?_'*/^&B
M_A1_T4[P;_X/[3_XY7X6T4?ZDX?_ )_2^Y!_94/YF?NE_P -%_"C_HIW@W_P
M?VG_ ,<H_P"&B_A1_P!%.\&_^#^T_P#CE?A;11_J3A_^?TON0?V5#^9G[I?\
M-%_"C_HIW@W_ ,']I_\ '*/^&B_A1_T4[P;_ .#^T_\ CE?A;11_J3A_^?TO
MN0?V5#^9G[I?\-%_"C_HIW@W_P ']I_\<H_X:+^%'_13O!O_ (/[3_XY7X6T
M4?ZDX?\ Y_2^Y!_94/YF?NE_PT7\*/\ HIW@W_P?VG_QRC_AHOX4?]%.\&_^
M#^T_^.5^%M%'^I.'_P"?TON0?V5#^9G[I?\ #1?PH_Z*=X-_\']I_P#'*/\
MAHOX4?\ 13O!O_@_M/\ XY7X6T4?ZDX?_G]+[D']E0_F9^Z7_#1?PH_Z*=X-
M_P#!_:?_ !RC_AHOX4?]%.\&_P#@_M/_ (Y7X6T4?ZDX?_G]+[D']E0_F9^Z
M7_#1?PH_Z*=X-_\ !_:?_'*/^&B_A1_T4[P;_P"#^T_^.5^%M%'^I.'_ .?T
MON0?V5#^9G[I?\-%_"C_ **=X-_\']I_\<H_X:+^%'_13O!O_@_M/_CE?A;1
M1_J3A_\ G]+[D']E0_F9^Z7_  T7\*/^BG>#?_!_:?\ QRC_ (:+^%'_ $4[
MP;_X/[3_ ..5^%M%'^I.'_Y_2^Y!_94/YF?O%I?[2'PEC\W?\4?!:YQC=X@M
M!Z_]-*O_ /#2GPB_Z*GX*_\ "AL__CE?@=16<N!L-)W]M+[D+^R8?SL_?'_A
MI3X1?]%3\%?^%#9__'*/^&E/A%_T5/P5_P"%#9__ !ROP.HI?ZBX;_G_ "^Y
M"_LB'\[/WQ_X:4^$7_14_!7_ (4-G_\ '*/^&E/A%_T5/P5_X4-G_P#'*_ Z
MBC_47#?\_P"7W(/[(A_.S]\?^&E/A%_T5/P5_P"%#9__ !RC_AI3X1?]%3\%
M?^%#9_\ QROP.HH_U%PW_/\ E]R#^R(?SL_?'_AI3X1?]%3\%?\ A0V?_P <
MH_X:4^$7_14_!7_A0V?_ ,<K\#J*/]1<-_S_ )?<@_LB'\[/WQ_X:4^$7_14
M_!7_ (4-G_\ '*/^&E/A%_T5/P5_X4-G_P#'*_ ZBC_47#?\_P"7W(/[(A_.
MS]\?^&E/A%_T5/P5_P"%#9__ !RC_AI3X1?]%3\%?^%#9_\ QROP.HH_U%PW
M_/\ E]R#^R(?SL_?'_AI3X1?]%3\%?\ A0V?_P <H_X:4^$7_14_!7_A0V?_
M ,<K\#J*/]1<-_S_ )?<@_LB'\[/WQ_X:4^$7_14_!7_ (4-G_\ '*/^&E/A
M%_T5/P5_X4-G_P#'*_ ZBC_47#?\_P"7W(/[(A_.S]\?^&E/A%_T5/P5_P"%
M#9__ !RC_AI3X1?]%3\%?^%#9_\ QROP.HH_U%PW_/\ E]R#^R(?SL_?'_AI
M3X1?]%3\%?\ A0V?_P <H_X:4^$7_14_!7_A0V?_ ,<K\#J*/]1<-_S_ )?<
M@_LB'\[/WQ_X:4^$7_14_!7_ (4-G_\ '*:_[2WPC1&8?%'P;(0,[(M>M7=O
M8*)"2?8<FOP6L[IK.X2555]IY5QD,/0UWFF6>EZE'#>P6L:.IS\HQM8=L"O@
M^*,MPW#$(UJT:DZ<M%*/+92Z*2=K)][OKVU^WX:X#I\23E2I8I0G'5Q:U<>K
MBU>[7:W;N?K]^R-\?)/COX1\07-X0NI:?JTX\DXW):RNTEOG'HI:/_ME7O%?
MBA\/?BWXO^%,FH2>$]<GT634(UAN6@5&+JI)7[RG!!)Y&#R>:_2']DGX6>,]
M.T=/&WQ(\0:SJ_B/4HLV>G:E>R2)I\##.?+8[5D8=>/E''!+"ORS*<TGBHQH
MN+<EN^A[OB#P'A\@JULSC7C3HS?[NFDW-NRNK:)).[O=V5NMD_HZBBBOJC\$
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:M_Q[K_ +_]#5VJ
M6K?\>Z_[_P#0U4?B0UN9-%%%=9H%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 6=/\ ^/R/\?Y&MJL73_\ C\C_ !_D:VJYZFY$MPHH
MHK(D**** "BBB@ HHHH **** .0^,7_)(_&__8#OO_2=Z^"/^"8/PX\(^*/@
M#X5N]9^!6F^([O\ M.[)\:WVG:3.8RLS%#NDD^T_(0%&$R".!@ U^C6L:3:>
M(-(OM+OXO/L;V"2VN(MQ7?&ZE67(((R"1D$&N9^$OP?\(_ OP5;>$O ^D_V)
MX>MY))HK/[3-<;6=BSG?*[L<DD\F@#\T-<_:R^*7@?\ 9?\ BOXK\.Z]9:-X
M@T_XJRZ';75GH>GQ@6GEL=C((-CMD#]XX+_[5=?XP^*W[47P/UW7!\4_'?BV
M#PK!:VMSI_C/PGX%TO4]*B9BCSB^CVK(D2Y>($2(Q(#=P#]A:A^Q3\&-6\%Z
MUX3NO!OF^']9UL^(KZS_ +4O1YVH$$&;>)MR\$_*I"_[-6?&7['?PC\>>(M9
MUO5_"LC7^MQPQ:L+'5KVR@U)8B#&+J&"9(Y\$#_6*V<#.: /C#]BGX@0/^T?
M\?O',_CWQ9XHT>2_T@FXT#PU]O\ [;22WN?*>>WMK*6:%$5?E\OR@IPKEC@'
MQG]NSXW7NC_M8^*/&7@Y+BQN5\'6-O&/$OAEHW -[&K9M-1MP?HQC]U-?J1X
M9_9>^&?@GQ]_PF7AKPXWAK76@AMI#HNHW=E:SQ0IY<22VL4JP2A5X >,] >H
M!K)^*W[&OP>^-WBJ\\2>-?"']M:U>6<6GSW/]IWD&^"-Q(B;8IE4890<@9..
M3B@#X4\:?M4_'?3],_:)\4:9\3'T[3/AOJ^FV>E:&FAZ<\$T<]P8V25VM_,V
MA!QA@<GKQ74>"_VHOVD/VFH_B+KGPSM=7L9]!U"WL-(T/3;/0SII9/FF^WR7
MTZ7691G:8,!/5CFOL:^_8Y^$&I:/XXTJY\(^98>-KF"[U^'^T[P?;987WQ-D
M39CPW.(RH/?-5M<_8H^#'B&^O+J[\&[?M\=M%?VUIJM[;6VH+;D&'[5!%,L=
MP5(!S*K$]\T >,_M4?&;XOZ#XN_9C\,:)KS?#76/'MXUIXD@MK.SOS;R8M-Z
M(TR2KE#+* 5)!R,EABOGAOVO_CWH/PK\0>.[CXD+J8\+?$9/"']FS:'8)'J=
ML#(SO<,D*LKD>6H,)CP%;J2&'Z/>*O@+X"\::YX&U?5O#T4U]X(E\[P\T$\M
MO'I[80?+'$ZHR@11@*ZL %X%<E=?L7_!N\\(ZMX8F\';]#U77?\ A);RU_M2
M\'FZCC'G[A-N7_<!"?[- 'PMX?\  =E\2/VA_P!L?3&^#7_"U]8N;B.#3)O^
M):G]E3R17*J_GW<\3P[FVG? &8>7D@87.-8?!'6_#7[5G[)_P\^,/V'QKJ,7
MAV\CU"TU(+J%OY>^]DA@?S01)Y2^6O((!0;<@ U^FW@CX)^"_AQXR\7>*O#N
MC?V=KWBR:.XUJ[^U32_:I(]VP['=E3&]N$"@YY[5C?$C]F;X=_%CQQHWC+Q'
MI%])XJT>W:UT_5M-UN_TVXMHR6)"-;3QXSO;GKAB,XH _-+XE?&O4_V4_BI^
MTK\*?AU]J?PEJ5K;6GA_2+/?-'IFKWHA#Q6R<["5FNV$:CDPH .*\_\ #_Q.
M\3_L9^"/CE\*=!O]<TMM7T6PUC0]3U32KO2[SS6:"&]:&*XCBD7Y7G D"\?9
MMP/&:_5#2/V*_@MH-SH-S9>"(8KG1-5_MRTN&O[MY'OL@BXG=I2;EU(^4S%]
MNYL8W-GI?B)^SC\-_BSXQT3Q5XM\+6VMZ[HT$UK9W,TLJJ(95*R121JX29&#
M,-LBL,,W'S'(!\E>$_@'\'?AY\,_V=/'FG>-(?ACXLG-A(GB&T4O/XEFN8TD
MFM;D@_O5D<\[L[1P,"OOZO%/!?[&/P=\ >(-#UG1_"+B\T%I'TA+_5KV^M]-
M9VW,UM!/,\4)+#.44$'IBO:Z "BBB@ HHHH **** "BBB@#YQ_X*(_\ )G7Q
M _[A_P#Z<+:OQ5K^B_4/^/.3\/YBL6OO,AXC_L?#2H>RY[R;OS6Z)=GV/7P>
M.^K4W#EOK??_ (!^.GA;]LW6O!/C#X6Z]HNC_93X-T-/#]Y:M>%DU:VWEI W
MR#R\Y&/O[656YQBN<^(W[5OCSQ5\1?$WB3PUXD\1>!M/UJ\^VMH^E:[.D4;F
M-$))C,88D(/FV@]/2OVNHKT8\38.%3VJP2O:WQWTO?K'N;K'4D^;V6OK\^Q^
M(.E_M4_%/3;'5K.;Q;-KMOJT<<-\OB2TM]8,\<99HXV-Y'*=BL[,$SM!8G&3
MFNV\=_M8Z7\3_B9X:\5>(_!#K#X?M;-;.ST:]M+*5[B!E.^6X^PL[Q-MXAX"
M9.TCG/[$44Y<3824_:?4DGKJI6>MD]HKHK>@/'TV[^RU]?\ @'X9_'SXGZ%\
M8O'^I>+M,\.ZAX>U'5KF2ZOX;O5H[Z%G;;@1!;:(H!@YW%\Y'(QSYM7]"M%=
ME'C.%"G&E3PWNK1>^W^<;FL<T4(J,:>B\_\ @'X'> ="TK7?$$2:[JL.D:1#
M^\N9I&^=U'\" <EC]..OH#]=^#/B_P"!M2U33_"_AVZ)/EF.VCCMWCB 12=H
M+ =@?K7Z;51UW28=>T:]TZX'[FZA:)O;(QGZCK^%<N)XJAC&O:46E_BT7G;E
MU^\]W+N)W@9)*DK-J[OK;R/SI\;?%KPQX#U2WTW7;MX);F+S0%A:10A)7+!0
M3R0>W8U\E_%S1?#%KK7]I>$=5M[W2;UBWV5,K):OU*[6 .P]N..GIG]L_ASX
M5_X0SP?I^F/M^T(I>=E.09&.6Y[XZ?0"NEI4.*(8.;]G2;Z?%H_.W+I]YT9K
MQ0L54G25).*;Y7?7U^9_/517]"M%>C_KQ_U#?^3_ /VI\Y_:W]S\?^ ?SU45
M_0K11_KQ_P!0W_D__P!J']K?W/Q_X!_/517]"M%'^O'_ %#?^3__ &H?VM_<
M_'_@'\]5%?T*T4?Z\?\ 4-_Y/_\ :A_:W]S\?^ ?SU45_0K11_KQ_P!0W_D_
M_P!J']K?W/Q_X!_/517]"M%'^O'_ %#?^3__ &H?VM_<_'_@'\]5%?T*T4?Z
M\?\ 4-_Y/_\ :A_:W]S\?^ ?SU45_0K11_KQ_P!0W_D__P!J']K?W/Q_X!_/
M517]"M%'^O'_ %#?^3__ &H?VM_<_'_@'\]5%?T*T4?Z\?\ 4-_Y/_\ :A_:
MW]S\?^ ?SU45_0K11_KQ_P!0W_D__P!J']K?W/Q_X!_/517]$VC_ /+;\/ZU
MI5E+CSE=OJW_ )/_ /:DO-_^G?X_\ _G'HK^CBBI_P!??^H;_P G_P#M0_MC
M_IW^/_ /YQZ*_HXHH_U]_P"H;_R?_P"U#^V/^G?X_P# /YQZ*_HXHH_U]_ZA
MO_)__M0_MC_IW^/_  #^<>BOZ.**/]??^H;_ ,G_ /M0_MC_ *=_C_P#^<>B
MOZ.**/\ 7W_J&_\ )_\ [4/[8_Z=_C_P#^<>BOZ.**/]??\ J&_\G_\ M0_M
MC_IW^/\ P#^<>BOZ.**/]??^H;_R?_[4/[8_Z=_C_P  _G'HK^CBBC_7W_J&
M_P#)_P#[4/[8_P"G?X_\ _G'HK^CBBC_ %]_ZAO_ "?_ .U#^V/^G?X_\ _G
M'HK^CBBC_7W_ *AO_)__ +4/[8_Z=_C_ , _G-LX%N;A(WE6%"?FD<\ 5W&G
MZYI-J(+*UD)R0BX0\D]R2*_?JHKFVBO+>6WGC66"5#')&XR&4C!!'H17Q'$F
M94>)U&&*A.,(WM&,TH\W\TO<;=NFJMKW9]IP[Q]5X<E*>&PT7*35Y2;<N7^6
M.R7W.^G9'XU?"'X"^,/CE+JT?A.RANVTR-)+CSYUB'SDA5!;C)VMQ[&OT,_9
M)U#XH>%='7P)\2_#-_:_8(O^)7K.]+B)HA_RPDDC9@"H^Z2>1\O4#=UG[,GP
M&A^ ?A/6M-#+-<W^K7%SYN<G[.'*6ZD_]<U#$=B["O8J_-LKRGZI&-9R:GU7
M3T/<X\\0%Q!5KY=3HPGADU[.33YTTE>2=[6;OI;5?>%%%%?3GX8%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 52U;_CW7_?_H:NU2U;_CW7_?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!9T_P#X_(_Q_D:VJQ=/_P"/R/\ '^1K:KGJ;D2W
M"BBBLB0HHHH **** "BBB@ HHHH P_\ A,;#_GWU7_P47?\ \:H_X3&P_P"?
M?5?_  47?_QJMRB@##_X3&P_Y]]5_P#!1=__ !JC_A,;#_GWU7_P47?_ ,:K
M<HH P_\ A,;#_GWU7_P47?\ \:H_X3&P_P"??5?_  47?_QJMRB@##_X3&P_
MY]]5_P#!1=__ !JC_A,;#_GWU7_P47?_ ,:K<HH P_\ A,;#_GWU7_P47?\
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M )]]5_\ !1=__&J/^$QL/^??5?\ P47?_P :K<HH P_^$QL/^??5?_!1=_\
MQJC_ (3&P_Y]]5_\%%W_ /&JW** ,/\ X3&P_P"??5?_  47?_QJC_A,;#_G
MWU7_ ,%%W_\ &JW** ,/_A,;#_GWU7_P47?_ ,:H_P"$QL/^??5?_!1=_P#Q
MJMRB@##_ .$QL/\ GWU7_P %%W_\:H_X3&P_Y]]5_P#!1=__ !JMRB@##_X3
M&P_Y]]5_\%%W_P#&J/\ A,;#_GWU7_P47?\ \:K<HH P_P#A,;#_ )]]5_\
M!1=__&J/^$QL/^??5?\ P47?_P :K<HH P_^$QL/^??5?_!1=_\ QJC_ (3&
MP_Y]]5_\%%W_ /&JW** ,/\ X3&P_P"??5?_  47?_QJC_A,;#_GWU7_ ,%%
MW_\ &JW** ,/_A,;#_GWU7_P47?_ ,:H_P"$QL/^??5?_!1=_P#QJMRB@##_
M .$QL/\ GWU7_P %%W_\:H_X3&P_Y]]5_P#!1=__ !JMRB@##_X3&P_Y]]5_
M\%%W_P#&J/\ A,;#_GWU7_P47?\ \:K<HH P_P#A,;#_ )]]5_\ !1=__&J/
M^$QL/^??5?\ P47?_P :K<HH P_^$QL/^??5?_!1=_\ QJC_ (3&P_Y]]5_\
M%%W_ /&JW** ,/\ X3&P_P"??5?_  47?_QJJFI^+K&2W4"#5/O=])NAV/K'
M73U2U;_CW7_?_H:J.Z&MSDO^$ILO^>.I?^"RY_\ C='_  E-E_SQU+_P67/_
M ,;K7HKJU-#(_P"$ILO^>.I?^"RY_P#C='_"4V7_ #QU+_P67/\ \;K7HHU
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M(R.?E"8,N0,(3PN85SZD_P"$ILO^>.I?^"RY_P#C='_"4V7_ #QU+_P67/\
M\;K\]/C5^UM\0-6_M#PB^JR6%UIVL>';VVUS1-&U3PQ-/;W-PR3026UW(92A
M(X8'8Z]NP]8_:1\1?$#QQ^UYX*^%GAR&XD\.Q^'9M>O+=?$-WH4%Q(96B#S7
M%J#-(D>U-L28R\@+<"CF"Y]9_P#"4V7_ #QU+_P67/\ \;H_X2FR_P">.I?^
M"RY_^-U\1:%^UU=_"']F;X@"SM?%&H^/O!NK7>FR0^*+>^UW3H)XYT5HO[4B
M@C0PA6.P3RK*,J"6RNZUXK_:M^//@O4OB-97=O\ #N]_X0?PY9^)KNX@TZ^C
M%W'.J'[,BFZ)1A^^_>DL/E3Y!N.TY@N?:?\ PE-E_P \=2_\%ES_ /&Z/^$I
MLO\ GCJ7_@LN?_C=?$:?MN?$C6/@WXL^.5C;>';/P1X<\11Z0WA*:UDDO;JV
M#Q1RR&[\X!)2TX*J(L +SFJMO^V?\6/$'PM\(Z_<Q^$-*M_&^KZEX>LIK2QO
M&FL6A\P1SL/M(W%O+==H8;25?<>4!S!<^YO^$ILO^>.I?^"RY_\ C='_  E-
ME_SQU+_P67/_ ,;K\_? GQ ^,%YX1_9$>W\<K?ZKXDN;\RO?"[\JXMUMLXO_
M /2B;QTP[JV4&=HVC!)^O_V8_C'J7QN^&T^M:SI]KIVKV.K7VCW:6+,;>22V
MF:,R1AOF56 !P22/4T)W"YZ'_P )39?\\=2_\%ES_P#&Z/\ A*;+_GCJ7_@L
MN?\ XW6O15:C,C_A*;+_ )XZE_X++G_XW1_PE-E_SQU+_P %ES_\;K7HHU R
M/^$ILO\ GCJ7_@LN?_C='_"4V7_/'4O_  67/_QNM>BC4#(_X2FR_P">.I?^
M"RY_^-T?\)39?\\=2_\ !9<__&ZUZ*-0,C_A*;+_ )XZE_X++G_XW1_PE-E_
MSQU+_P %ES_\;K7HHU R/^$ILO\ GCJ7_@LN?_C='_"4V7_/'4O_  67/_QN
MM>BC4#(_X2FR_P">.I?^"RY_^-T?\)39?\\=2_\ !9<__&ZUZ*-0,C_A*;+_
M )XZE_X++G_XW1_PE-E_SQU+_P %ES_\;K7HHU R/^$ILO\ GCJ7_@LN?_C=
M'_"4V7_/'4O_  67/_QNM>BC4#(_X2FR_P">.I?^"RY_^-T?\)39?\\=2_\
M!9<__&ZUZ*-0,^Q\5V2W2$P:ECGII=T>Q_Z9UK_\)C8?\^^J_P#@HN__ (U3
MM/\ ^/R/\?Y&MJL*FY$C#_X3&P_Y]]5_\%%W_P#&J/\ A,;#_GWU7_P47?\
M\:K<HK(DP_\ A,;#_GWU7_P47?\ \:H_X3&P_P"??5?_  47?_QJMRB@##_X
M3&P_Y]]5_P#!1=__ !JC_A,;#_GWU7_P47?_ ,:K<HH P_\ A,;#_GWU7_P4
M7?\ \:H_X3&P_P"??5?_  47?_QJMRB@##_X3&P_Y]]5_P#!1=__ !JC_A,;
M#_GWU7_P47?_ ,:K<HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH K:A_QYR?A_,5BUM:A_QYR?A_,5BUT4]BX['D
M?[4&H:/8_#6&+Q)'?OX:O-1AM-3DTUPDL,3*^V3H<A91$VWOC'/0_)R_!KPO
M\$9)/%OC75;'Q5I#?O?#6E:=,"=;! *32_\ /*%<@,.NX$<@#=][>+O"FF^.
M?#.HZ#J\'VC3K^(PRIW'<,I[," 0>Q -?&WB;_@G]XD;5-NA^*M-N=)0XA_M
M3S8YHT))VX1&4D$GH5!)S@9KXC/L!B*E=8BC1]IIIY/S75=5V>^FC_/.(LNQ
M5;$+$T:"JZ:?W7YK[2ZI='OHVGE_LQ_%'Q1\1/VGK34M1N3(EU974$UO -D%
MM;+&62.-.BHKK$ /IR:^]*\:_9[_ &:]+^!=O=7;7AU?Q#>1B*>]\O8D<><F
M.->2 3C))YVC@=*]EKV\BPF(P>%:Q3]^3;?6USWN'<%BL%@W'&.\Y2<GK>U[
M?Y7"BBBOH3Z<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** -'1_P#EM^']:TJS='_Y;?A_6M*N6?Q,S>X4445
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6K?\>Z_[_\
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M.?C3HOP*_9FTL> IK[6_ OBN\UC6],MM5T\2Q6[7B3)L=[A8W9E4X ?@]<4
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M?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_<SZ.HKYQ_X>(_L^?]%
M_P#*+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\ @$O\@^K5_P"1_<SZ
M.HKYQ_X>(_L^?]% _P#*+J'_ ,CT?\/$?V?/^B@?^474/_D>C^R,R_Z!I_\
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MC_P\1_9\_P"B@?\ E%U#_P"1Z/\ AXC^SY_T4#_RBZA_\CT?V1F7_0-/_P
ME_D;?5J_\C^YGT=5+5O^/=?]_P#H:^?O^'B/[/G_ $4#_P HNH?_ "/574/^
M"A7[/\\*JGC[<=V?^0-J'H?^G>JCE&8W7^S3_P# )?Y#6&KW^!_<SW6BOGK_
M (> ? 3_ *'S_P H]_\ _&*/^'@'P$_Z'S_RCW__ ,8KJ_LG,/\ H'G_ . R
M_P B_J];^1_<SZ%HKYZ_X> ? 3_H?/\ RCW_ /\ &*/^'@'P$_Z'S_RCW_\
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MB?XI?L52:;KEK!XA_P"$8UJ&WU'7+234(8TC>^15>)9X6<"-=B@2+MPO4#!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG)^'\Q6+7=0K5:<;0DTO)G;0Q6(H1Y:51Q7DVOR.3_X5'X%_Z$OP]_X*H/\
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M"C_HF/@W_P $%I_\;H_X9U^%'_1,?!O_ ((+3_XW7H=%'UO$?\_)?>P]I/\
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M"C_HF/@W_P $%I_\;H_X9U^%'_1,?!O_ ((+3_XW7H=%'UO$?\_)?>P]I/\
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M2OP5_P"$[9__ !NO1Z*/KF)_Y^2^]A[2?\S/./\ AFOX1?\ 1*_!7_A.V?\
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M $2OP5_X3MG_ /&Z]'HH^N8G_GY+[V'M)_S,\X_X9K^$7_1*_!7_ (3MG_\
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M16C_ &/_ --O_'?_ *]']C_]-O\ QW_Z]'/$+HSJ*T?['_Z;?^.__7H_L?\
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M '_Z&KM07=M]JC";MN#G.,U4=&-&'16C_8__ $V_\=_^O1_8_P#TV_\ '?\
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M\=_^O1_8_P#TV_\ '?\ Z]'/$+HSJ*T?['_Z;?\ CO\ ]>C^Q_\ IM_X[_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=<-:A%(!#7(0PH^3PC.&(Y (% &I1110 4444 %%%,FF2")Y9&"1HI9F8X
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MZ)IGK91B:>#S+#8FK\,)PD_1239^3U%?>G_#!?P__P"@QXD_\";?_P",4?\
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M9W0Q3P]*CSQOI)-6:[N[T\T_Q.@_8GTFZAT/Q5J#HPM+J:"&%B.&:-9"^/\
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M;#P_>P17D-W=7,30I#"X?[PQEL= ,]^M<A\#=/E;5M0O]I$"0>1N[%F8-C\
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M.T$\</FL)XW(WR,J#Y5)Y8=*]JDC2:,I(BR(W!5AD'\*6.-8T5$4(BC 51@
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M^!?$'PR_9I^'GA7Q39G3O$&DZ6EK>6K3I-Y3AF^7>C,IP,?=)%>O44 %%%%
M!1110!\@_M8^-;OX/_&SPOXLN-'M==\.ZIH\NCWUE<Q*XDB$I:502/D8K(N.
MQP0<C-><3> _@A\/&7XGC6/^$E\.78WZ)X1;'GFZ7EXY\DG8A SN&/G&=W&[
M[+^,WPBTCXU>"+GP[JY:'+":VNHP"]O, 0KC/7@D$=P2..M?!/BS]A'XIZ'J
MLEOI.GVGB2SR3'=VMY%#E<\;EF92#CL-P'K7P&;8;%4:\JE.C[6+UCI=QEUT
M6ZZVVV^?YAG>#QE#$RK4J'MH2?-'2[A+9Z+=/>STO;MKY5\5OBUX@^,7B=]9
MUZYW%1Y=M9Q9$%K'V2->P]3U)ZU].^,OV<_$/Q@_8N^$/@N+1&UB)O$EAJFJ
MVOVM+=ETQ[B:25MS.AR(IAPIW^@R*J_!/]@76IM:L]4^(<EO8Z; ZR-HUO*)
M9IR#G9(Z_*JYQG:6)&1QUK[OCC2&-(XU"(@"JHZ #H*WX?R_%4ZM3&8NZE)6
MUW[MO[CIX7RO&4:U3'XU-2DK:[N[3;?;96/ROF_X)^_&.X^V1:W;-XFM/ ^K
M:;I7P_CDU&V4KHZZ@;BXN&&]0&$6Q,/\Y *@$*E>F_$;]E?XHZ]_PM[[#X8\
M_P#M[XH:3XBT[_B86J^?I\./-FYE&W;_ '6PQ[*:_0:BON#]&/SH\4_L;_$.
MYA^*7@.[T;Q+XD\->-?%TVO?;--US0[#2Y8I9EE1[J:XLY]0CEB*X(B213@;
M>&:N>\1?LG?&+5? =IX(\)?#Z?0-#M="UJQ>R\::AH6IPV#3*3#%I-_;QK>C
MS7+%C<!%PV&Q7Z<44 ?F_I'PH^+6E:1\=]-U'X)ZY?7GQ(\.Z;H^E3S:CI<B
MVLT&GK:NMPZWC".)9&\Q&&20GW5.!6%I/["OQ6\._LP>.?",>A0W?CVX\::7
M?Z?K-O>6HGGM;:.!3=)*\@*A2)F57*OR?E^;G]/:* /SV^"?[(_Q#\(P_##P
M1XCTCQ//I?@GQ,=;75X-9T*#1=Z2R.MQ"$LWU&5I%?:T4I3)8YD "D=A\1/V
M/?%_[1'C#XX>)/%>I:EX0EU.W7P[X6L+1M/GBNK"V430SS,\<SQ![O$F(WAD
M 7G'&/MFB@#\W-/_ &>?C;J6F_$/_A+_ (0Z5XRU_P"(]CX?6:^U?6H1;Z3<
M6:)%<?:C#=)/M#1F9/LKL3E02#D"/0?V,/B5H?P'^$FBQ>#88_%>C^)-<OM9
M>*^M1((+B&YCB<RF8[PX: ;0[,!C=T-?I/10!^67PA_8I^,/PM\$^)M)U/P[
MXFU1/&GAZSTZ]L?#NL>'XUA\N%H9+2\EOH9G1!G<LEH7P#]W<!C1\7?\$Z?B
M-K>L3_"K3BMG\%Y86\21ZA=:E%,T6N_V8;5(GV+'(Z^>!*7$"J58\ _+7Z>4
M4 ?EQ\1/V(OBQ\5_AEX3\/2>&O$%OJO@G2%M[)?$.O:%#I4^UX?-L[=+"T\^
M:.4195KJ2/:0I;)+5],_L^_#GQC#^U=\0_B)J_PQE^&_AW6?#NG:=;0SW]A/
M)<7$)_>,4M9I N!A03U5%/!.T?5U% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<#KWQX\!>%_BM
MH/PUU3Q);V?C?78&N=/TEHY"TT:[^=X4HI/EO@,P+;3@&N^H X#XW?!'PU\?
MO [>&/$ZW<=NES'?6=_ITY@O+"ZC),=Q!)@[)%R<$@CD@@@UPR?L=^$]<\0:
MMKGC[6]>^*&K7^BR^'EN/$TELJVEC)GS$@CM8($1W!^:7!DXX89(J]^U5\=M
M5^!W@_P\/#.D6NM^,?%6NVOAO1+6_D9+5;J?=B6?;\QC0*20N">.1U'#ZQ^T
M!\1?@[\8M(\ ^/SX:\0Q^*-#U'4="UK0=-N; 1WEG$TTMO<023S;D*8VR+(I
MXP5YS0!TFF?L<:#'=>"4USQMXS\8:)X+O(]0T'0M<O+5K6TGC&('+Q6T<\WE
M#A/-E? '.>:]5L_ ?G:#KVB^(]<U#QIINL&9)H-:AM%6.WE7:ULHMX(@8]I(
M^?<_)RQKXC\#_M^>-]?^'WPV\2Q>(/AOXR\3>)]3AL;OX9>'+"XCUN!'D=69
M9/M\VS8J>86E@5=IZC@GI/%W[:WB72/B+\;=$N?'_P +_ EOX$G6/2=/\3:=
M<37NL V_FD+MU")BP8!?W<3GYAQG@@'J6D_L,^%+/2?#/AS4?&'C#Q%X!\-7
MZZCI7@W5KNVDT^*1&9HDD=;=9YHHRWRQRRLHV@$$<5?\3?L._"_QC\>M5^+&
MLV=]?ZYJFE2Z3=Z;),@L)8Y+<V[R;0@D$AA)3<),8.<9YKK/@7\6_$_Q0\(^
M%]2\0?#C6O"5QJFD1ZC<7%Q+;&TAE8X\@(9A<AB,.-T(4 X+9KR?0?CM\7_C
M5J7Q5U'X:Q>$-&\->"=4N=#L8O$5A=7EQKE[;*3.3)%<1+;Q$E I"2MG)(XV
MT =%<_L4Z+J7@:X\&ZG\2/B)J?A8Z3)HEII,VK01P65LZA %6.W3SV10%5KG
MSMN,CGFG>*/V)?"VO:Q8ZOIOB[Q=X3U:W\*1^#9;[1+FT$USIR  *S36TGEN
M<<O#Y9KQ[X$_\%&M>^,WC34DL_AIJ>M>'+;PM!K;VWAY(&O;.X#M'<K+)=74
M*2('1A&(UWMZ=<=%X'_X*/>"_$OACQ#XCMGU+Q/:/XEM/#GA[2M.T,6-Y>W-
MRA:*$&6\=9",'=*P@ VG"'(R 7M)_P""9/POT>PMK2'7O%S1V\>G1*9+RU)(
MLIVGBSBV')9R&]1C&#S7MOQ6^ >B?%3Q%X:\3'5M9\*^+O#C2_V9X@\/SQQW
M44<N!+$RRQR12QMM&5DC8=<8R:\KF_;TT&W\:?\ "O9/ GB@?%@ZHNF+X)5K
M-KA@T'V@70G$_D_9_*Y+[\@\;< FO+?%'_!0SQGI'Q$^)6CW?PVUGPCH_A/P
M['J<SZMH\%S>V<XN%CDE>/\ M*!+JU;.V-H'RQ(;.T&@#UN^_8(\$:EK$WB:
MX\3^+I/B%+K,.N-XW^V6PU(3PQF.- @M_LPB",5V"#&#["F^$_V!?!/A?6M.
MUB3Q5XQUS5K/Q;_PFC7NJWMK))<W_E^61)LMU!C(YVJ%.>A XK';_@I%\,M%
M^#;>/->M/$%@EIKR>&;S39+"%+U;PPB5I!"+AU$.S+9$C' P-QZ]C\,?VP-*
M^(7BKP3H]_X+\1^$(O'6G3ZIX6O]8-HT6I0Q*)'7$,[M%)Y;+(%<<J3SD8(
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M"6W_ ,D4?\/&/AM_T!/%7_@);?\ R11]5K?RA_J?G_\ T"2_#_,^IZ*^6/\
MAXQ\-O\ H">*O_ 2V_\ DBC_ (>,?#;_ * GBK_P$MO_ )(H^JUOY0_U/S__
M *!)?A_F?4]%?+'_  \8^&W_ $!/%7_@);?_ "11_P /&/AM_P! 3Q5_X"6W
M_P D4?5:W\H?ZGY__P! DOP_S/J>BOEC_AXQ\-O^@)XJ_P# 2V_^2*/^'C'P
MV_Z GBK_ ,!+;_Y(H^JUOY0_U/S_ /Z!)?A_F?4]%?+'_#QCX;?] 3Q5_P"
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M^6/^'C'PV_Z GBK_ ,!+;_Y(H_X>,?#;_H">*O\ P$MO_DBCZK6_E#_4_/\
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M+'_#QCX;?] 3Q5_X"6W_ ,D4?\/&/AM_T!/%7_@);?\ R11]5K?RA_J?G_\
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M\-O^@)XJ_P# 2V_^2*/JM;^4/]3\_P#^@27X?YGU/17RQ_P\8^&W_0$\5?\
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MS_\ Z!)?A_F?4]%?+'_#QCX;?] 3Q5_X"6W_ ,D4?\/&/AM_T!/%7_@);?\
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M_P"2*/JM;^4/]3\__P"@27X?YGU/17RQ_P /&/AM_P! 3Q5_X"6W_P D4?\
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M*H_X6;JG_/"S_P"^'_\ BJY&BC^R,!_SZ0?ZR9O_ -!$CKO^%FZI_P \+/\
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MY&BC^R,!_P ^D'^LF;_]!$CKO^%FZI_SPL_^^'_^*H_X6;JG_/"S_P"^'_\
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M*H_X6;JG_/"S_P"^'_\ BJY&BC^R,!_SZ0?ZR9O_ -!$CKO^%FZI_P \+/\
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MY&BC^R,!_P ^D'^LF;_]!$CKO^%FZI_SPL_^^'_^*H_X6;JG_/"S_P"^'_\
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M*H_X6;JG_/"S_P"^'_\ BJY&BC^R,!_SZ0?ZR9O_ -!$CKO^%FZI_P \+/\
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MY&BC^R,!_P ^D'^LF;_]!$CKO^%FZI_SPL_^^'_^*H_X6;JG_/"S_P"^'_\
MBJY&BC^R,!_SZ0?ZR9O_ -!$@KVKP#\9O!>G_!,_#OQGX0U;7K5/$,FOPW>E
M:PEDRN]M'!L(:"3( C)SQ]X>G/BM%=]?#PQ$5&I?1WT;6OJCYB4%-69[/HGQ
MF\(^!9_'4/A+PGJEEI?B?PM+H!@U+5DN98)I)4<S[UA0,N(U&S .<G=VJ#PM
MXV^#2^'].@\2?#?73K5E#LDU#0_$9A2^D!R'DCEB?RS_ +AQZ"O'Z*P>!I6=
MG)-]5*5W96U=]="/8Q\_O9].S?M>:R^O>-_''A_P@FF^)M6M;31;#56(O8M(
MT^%%5XL2QL)995C4,[]@V%YK-A_:>\=:SX5\3>&OB!HJ^(O"FL:>8VM;32K7
M3'M;@,&M[M7A@7+(R]&X92PKP+2]<O\ 16=K&Y>U=^KQX#?=9>#U'#L./6M:
M?XB>(+GS?,OE8RB,2'[/$"^S.S/R\D9//O7)_9>'C\-*.EK-WNK6M9ZM6MT>
M^N[9G]7@MHK]=#JM:\3W^M_"'PAX/E\-ZA%!X;U'4;VXOUSB19S"K)M*?(4,
M!&23R>@Q7H_B7]KCXCWUQ9)X)TFW\,>#+&&*PT726T6TU#[-&B*,">:W+.[$
M%V/'+&O"O^$^U\VLMLVH-)!+"('CDC1PR[MV3E3\V>=WWN3S4*^,-56X$RSQ
M(P5D");1+'M90K+L"[=I P1C!Y]36DL#3J6]I3B[-M7NU[SNW9Z7OUZ+;<IT
M5+XDGO\ B?67P=_:(\)7W[3WA3X@_$_3[SPMJO\ 8[V>I:M&I-O?:@H$4=X\
M2(-GR##8#*'1& &#C0_;6TGQ=\.;'1/&/A'XX^(_&7@3Q/)+##G79)/)=1DI
MNB<(Z8+#A05Q@CO7QEJ6N7>K0V\-RT1CM]WEK%!''MW')'RJ,CV/3M37UO4)
M-%BTAKR9M+BG:ZCLRY\M96559PO0,5103_LBN)9/&.)IXBG*R2Y7%JZY5>UK
MZJS?Z&/U5*HII[:6W5OT*1)8DDY)HHHKZ0[@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>lsta-20230930_g2.jpg
<TEXT>
begin 644 lsta-20230930_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV/N\H01BO?/^"C_A+X@W'@>Y\4:+XF73_ VGV,=MK&CB[E1[QY;E$0B-4*.
M9$SN8< ]:0['M?[*/QWOOVB/AA-XJU#2K?1YDU&:R%O;2,Z[45&!R>_S_I7E
M?[;'B#XZZ-XH\-I\)(M<DTY[.0WW]DV"7"^;O^7<2C8.WM7@'[#/PG^,'B33
M_#_B;POXX@TCP#8^(HVU+1'U"XB:Y6-XGG B2,HV^/"\L,]#@<UWW_!2/XO>
M-OAOXV\'6WA;Q3JOA^WN=.FDFCT^Z:)9&$N 2 >3B@.I]X:2T[:79M<[OM)A
M0R[A@[MHSD?6K=</XV^)6G_"WX17GC+7)&>UTW3DN)!GYYI"JA$!/\3NRJ/=
MJ_/KX?ZM^TC^VEKVLZWH'C:X\(:'93>7FUU"?3[.)B,B%! "\C!2"2V<9&3R
M!3%8_3VOCOX[>(OCY8_M/:'9^#8M>;X>M-IXNVL]/26VVF0>?ND*$CY<YYXK
MCOV<_CU\3OA/^T(OP8^+NI/K?VQO)L]1GE\YTE9=\3+,0&DCD'R@-R&('RX8
M5E_M0?&/QSX7_;6\->'-(\5ZMIN@SW&DK+IMM=.D#B250X* X.X=?6@=C]":
M*^<_V]_&FO> ?V>[O5O#FKWFB:FNHVL8N[&4Q2!68[AN'8U\Q?!OQ=^T/^U%
M\-[+PYX1\43:%8Z+YJZOXKU"^DCN+VY>5W2)9D5I $B:,87&/XCRHH%8_2FB
MOS(^%/[1'Q5_9F_:"C\!_%7Q#>:WH\UU';7SZI>/=B%),>7=0S/E]@W!B.FW
M<"H8<?77[8GQH\9?!_X?VK^!/#M]K&NZE*\0OH+&2ZAT^-0"TCA5*[CD!0W!
MPQYVD$"Q[[17PCI'[+'[27C;P_#KFM_'/5= UF[B$_\ 94%]=(D1;YMCF)T5
M",\A5('09 JC^Q_^T1\2-%_: O/@Q\1M3D\0RK)=6L5U<2>;-!<0(\C8FQND
MC9(VQOY^[TY%(+'T%^UY^TK=?LT^#M&U:QT:WUN[U*]-JL-S.8E11&6+\ D]
M ,<=>M>O>!?$$GBSP3X>UR:)8)=3TZWO7B0DJC21*Y4$]@6Q7YC?\%$O"7Q!
M\+^/K>]\3^)EU;PMKE]>7.A:8EW++]A2/R@P9'0*A(E7&TMT/X_3_P"Q=\*?
MC!X.N+#Q!XU\<0:]X*OO#D:Z;I*:A<3-;,Y@>$F-XU1=L2NO#'&[ R.: Z'U
MM17Y[>*OCM\4OVNOC=J7@/X0^(&\*^$=-#F76;:1H6EC1MIN&E4;P&8X1$(R
M"">Y7*^*=C^T+^Q?=:5XNE^(]]\0/#$MPL%RFI7$UQ&&()$<D<K,45@" Z-G
M(P<'&0+'Z/45Y_X3^-7A_P 4?!6V^)BS?9]!;3'U*XRP9H/+4F6,],LC*Z^Y
M6OSB\+W_ ,:?V\/BAK$NF>)IM"TFQ_?&/[9+!9:=$[$1QJD?+R,%/.,G:22
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M[5'QPN? 7P?UF?0]!MWD6&ZL+AK4RQ1D![J:=?G5"?NA>S*,%C4?B#QK\?\
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M5>B2,@+K^#;A^% '5T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM\*X]$O)X;S7[Z=K[4[F#)0RD!1&I(R515 R>I+' SBO:Z*!W"BBB@04444
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MSQ'_ -$F\8?^!>C?_+"C_A9GB/\ Z)-XP_\  O1O_EA7H%%'UFE_SXC]\_\
MY,/:1_D7X_YGG_\ PLSQ'_T2;QA_X%Z-_P#+"C_A9GB/_HDWC#_P+T;_ .6%
M>@44?6:7_/B/WS_^3#VD?Y%^/^9Y_P#\+,\1_P#1)O&'_@7HW_RPH_X69XC_
M .B3>,/_  +T;_Y85Z!11]9I?\^(_?/_ .3#VD?Y%^/^9Y__ ,+,\1_]$F\8
M?^!>C?\ RPH_X69XC_Z)-XP_\"]&_P#EA7H%%'UFE_SXC]\__DP]I'^1?C_F
M>?\ _"S/$?\ T2;QA_X%Z-_\L*/^%F>(_P#HDWC#_P "]&_^6%>@44?6:7_/
MB/WS_P#DP]I'^1?C_F>?_P#"S/$?_1)O&'_@7HW_ ,L*/^%F>(_^B3>,/_ O
M1O\ Y85Z!11]9I?\^(_?/_Y,/:1_D7X_YGG_ /PLSQ'_ -$F\8?^!>C?_+"C
M_A9GB/\ Z)-XP_\  O1O_EA7H%%'UFE_SXC]\_\ Y,/:1_D7X_YGG_\ PLSQ
M'_T2;QA_X%Z-_P#+"C_A9GB/_HDWC#_P+T;_ .6%>@44?6:7_/B/WS_^3#VD
M?Y%^/^9Y_P#\+,\1_P#1)O&'_@7HW_RPH_X69XC_ .B3>,/_  +T;_Y85Z!1
M1]9I?\^(_?/_ .3#VD?Y%^/^9Y__ ,+,\1_]$F\8?^!>C?\ RPH_X69XC_Z)
M-XP_\"]&_P#EA7H%%'UFE_SXC]\__DP]I'^1?C_F>?\ _"S/$?\ T2;QA_X%
MZ-_\L*/^%F>(_P#HDWC#_P "]&_^6%=S>2-#;.Z'##&#^-9G]H7'_/3_ ,='
M^%7&O3EJJ$?OG_\ )C4XO["_'_,YG_A9GB/_ *)-XP_\"]&_^6%'_"S/$?\
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M%'_"S/$?_1)O&'_@7HW_ ,L*Z;^T+C_GI_XZ/\*/[0N/^>G_ (Z/\*/:T_\
MGQ#[Y_\ R8<T?Y%^/^9S/_"S/$?_ $2;QA_X%Z-_\L*/^%F>(_\ HDWC#_P+
MT;_Y85TW]H7'_/3_ ,='^%']H7'_ #T_\='^%'M:?_/B'WS_ /DPYH_R+\?\
MSF?^%F>(_P#HDWC#_P "]&_^6%'_  LSQ'_T2;QA_P"!>C?_ "PKIO[0N/\
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MS.9_X69XC_Z)-XP_\"]&_P#EA1_PLSQ'_P!$F\8?^!>C?_+"NF_M"X_YZ?\
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M_ O1O_EA1_PLSQ'_ -$F\8?^!>C?_+"O0**7UFE_SXC]\_\ Y,7M(_R+\?\
M,\__ .%F>(_^B3>,/_ O1O\ Y84?\+,\1_\ 1)O&'_@7HW_RPKT"BCZS2_Y\
M1^^?_P F'M(_R+\?\SS_ /X69XC_ .B3>,/_  +T;_Y84?\ "S/$?_1)O&'_
M (%Z-_\ +"O0**/K-+_GQ'[Y_P#R8>TC_(OQ_P SS_\ X69XC_Z)-XP_\"]&
M_P#EA1_PLSQ'_P!$F\8?^!>C?_+"O0**/K-+_GQ'[Y__ "8>TC_(OQ_S//\
M_A9GB/\ Z)-XP_\  O1O_EA1_P +,\1_]$F\8?\ @7HW_P L*] HH^LTO^?$
M?OG_ /)A[2/\B_'_ #//_P#A9GB/_HDWC#_P+T;_ .6%'_"S/$?_ $2;QA_X
M%Z-_\L*] HH^LTO^?$?OG_\ )A[2/\B_'_,\_P#^%F>(_P#HDWC#_P "]&_^
M6%'_  LSQ'_T2;QA_P"!>C?_ "PKT"BCZS2_Y\1^^?\ \F'M(_R+\?\ ,\__
M .%F>(_^B3>,/_ O1O\ Y84?\+,\1_\ 1)O&'_@7HW_RPKT"BCZS2_Y\1^^?
M_P F'M(_R+\?\SS_ /X69XC_ .B3>,/_  +T;_Y84?\ "S/$?_1)O&'_ (%Z
M-_\ +"O0**/K-+_GQ'[Y_P#R8>TC_(OQ_P SS_\ X69XC_Z)-XP_\"]&_P#E
MA1_PLSQ'_P!$F\8?^!>C?_+"O0**/K-+_GQ'[Y__ "8>TC_(OQ_S//\ _A9G
MB/\ Z)-XP_\  O1O_EA1_P +,\1_]$F\8?\ @7HW_P L*] HH^LTO^?$?OG_
M /)A[2/\B_'_ #//_P#A9GB/_HDWC#_P+T;_ .6%'_"S/$?_ $2;QA_X%Z-_
M\L*] HH^LTO^?$?OG_\ )A[2/\B_'_,\_P#^%F>(_P#HDWC#_P "]&_^6%'_
M  LSQ'_T2;QA_P"!>C?_ "PKT"BCZS2_Y\1^^?\ \F'M(_R+\?\ ,\__ .%F
M>(_^B3>,/_ O1O\ Y84?\+,\1_\ 1)O&'_@7HW_RPKT"BCZS2_Y\1^^?_P F
M'M(_R+\?\SS_ /X69XC_ .B3>,/_  +T;_Y84?\ "S/$?_1)O&'_ (%Z-_\
M+"O0**/K-+_GQ'[Y_P#R8>TC_(OQ_P SS_\ X69XC_Z)-XP_\"]&_P#EA1_P
MLSQ'_P!$F\8?^!>C?_+"O0**/K-+_GQ'[Y__ "8>TC_(OQ_S//\ _A9GB/\
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M"]&_^6%'_"S/$?\ T2;QA_X%Z-_\L*Z;^T+C_GI_XZ/\*/[0N/\ GI_XZ/\
M"CVM/_GQ#[Y__)AS1_D7X_YG,_\ "S/$?_1)O&'_ (%Z-_\ +"C_ (69XC_Z
M)-XP_P# O1O_ )85TW]H7'_/3_QT?X4?VA<?\]/_ !T?X4>UI_\ /B'WS_\
MDPYH_P B_'_,YG_A9GB/_HDWC#_P+T;_ .6%'_"S/$?_ $2;QA_X%Z-_\L*Z
M;^T+C_GI_P".C_"C^T+C_GI_XZ/\*/:T_P#GQ#[Y_P#R8<T?Y%^/^9S/_"S/
M$?\ T2;QA_X%Z-_\L*/^%F>(_P#HDWC#_P "]&_^6%=-_:%Q_P ]/_'1_A1_
M:%Q_ST_\='^%'M:?_/B'WS_^3#FC_(OQ_P SF?\ A9GB/_HDWC#_ ,"]&_\
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M_1)O&'_@7HW_ ,L*Z;^T+C_GI_XZ/\*/[0N/^>G_ (Z/\*/:T_\ GQ#[Y_\
MR8<T?Y%^/^9S/_"S/$?_ $2;QA_X%Z-_\L*/^%F>(_\ HDWC#_P+T;_Y85TW
M]H7'_/3_ ,='^%']H7'_ #T_\='^%'M:?_/B'WS_ /DPYH_R+\?\SF?^%F>(
M_P#HDWC#_P "]&_^6%'_  LSQ'_T2;QA_P"!>C?_ "PKIO[0N/\ GI_XZ/\
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M'M(_R+\?\PHHHKSS **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_LG_ +2_P4T7_A9_BGXCZ'XZM[>WU33_ !'J#W@22618S+#O)\M0SJZXYPC
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M.^(?C%_L>FWVHW*6UMI<)8+)>2RR81 N<+N/7YN0A!^-/V<_VM/&W@/]FO\
M:&U&\^(MYXP\::-):1Z+)JVKMJ$D<3S&W>[A29W)C5I8VR 5W&,'J* /USHK
M\D_%7CCXI?LV_#3X$?&R'XP>+_&=WXNF6?6/#6L:D]S82QR*)3%#"Q(0!24)
MP2K$%=O2ONS]K#P'\2OB1H/AJV\&_$.W^&7A2"Y^U^*M66]DL[\6:[6_T>94
M(0J!(3ED!^7)V@@@'T!17XNZ]^TY\;OA?\.?B/<^%/'OBCQ'\,M0\0+HGAWQ
MGXC=IKUP#*SO;SR*6.8X=I88"E@5",3CUFWU[X\?"?\ :6?X&^"?BOJGBRZ\
M7>&8[JTU3QU<O=_V9=&W:5YD<K(R@>3*J@#:/-7<&*!B ?J317Y6Z-XY\>?L
M\_M(Z%8VOQG\5?$KP]X9T=;WXG3:E?RZGI>FN-YFBA9_NL=JK&H DWD+GEE7
M@])_;"\=^.OVLOAOXTUSXF?\(UX$U_6D<^%[+Q)LL]+TZ.;8JWT:2"-7< LW
MF@$CG 4J  ?L=5+5O^/=?]_^AJXK!E#*<@\@BJ>K?\>Z_P"__0U4?B0UN9-%
M%<_\0(_%$O@S5D\%2:7#XJ:$C3Y-:$AM%ER.9/+!;&,]!UQ76:'045\!?L'_
M !#^(^L?M*_&[0O'_C+4?%ESH:O"83<.;-)H[ED9K> X2(';@!5'%>/:#XR^
M*/QY^"OQC^.$_P 8?%GA?4_#%^1IGA_2-1:VTZ.--LGER1*0&RL@12>25^;=
MG%1S"N?J]17S9\*_B#\2?VB/V*=)\0>&-0L-"^)&KZ>UO'J>HH5@6:.9H9)]
MJ(V"ZQLRX0@%AP0,5\>ZKXR^+7P#^+PLO!7Q3\3?%B;PSX:EU#QTFJW\NHZ1
M8W*1RN\2,X.SE%VC ?/!/+*KY@N?JK17Y!1_&CXN_#KX1_#/X]#XI^)_$.K>
M(_$-W:7_ (9U"Y+Z9)#&Y'EI!RB;A&XRJC&\;-I7)[O]H+2_C?\ "^33[^\^
M-GB#6/C7XC\0+)HO@GP??S2:>-/V$[FLV10N& 'S*4(!SO\ G95SA<_4*BOR
M;^)FH?M"Z5X^^)/B'Q;8_%[_ (1O25CN9)_"WBR70M.MT50LKP^9;RI-'D9Q
M$!M&2<@Y'Z'?LL>.-&^(GP"\':WH.I:WJVGRVAB^U>)+G[3J+21NR2">7 WN
M'5AN  (P0 *:E?0+GJU%%%4,**1]VQM@!;'&XX&:_,']HC1_C?\ "JYLKR\^
M-NOZS\:O$/B$-HO@OP??S2:=_9X4G<UFR*%PP ^92A .=_SLJ;L#/T_HK\]_
M$'B/XE_M!?MCCX/:I\0M?^'>F^'O#D%Y??\ "(WGV.:[O3;0O*PD7DKYD_"G
M*[8^ "<UW7_!./XT^,?'VE_$;P7XMUBX\4W?@W4Q:VFO7KEY+F)VE4([G+/A
MH2VYB3B0#/ I<VMA7/LZBOS _:(T?XW_  JN;*\O/C;K^L_&KQ#XA#:+X+\'
MW\TFG?V>%)W-9LBA<, /F4H0#G?\[+SE_P#$SXP_&>Y^/'B75/B=XB\&ZE\,
M;.+[+HWAN[:VL9)XY6242HI7S 3#(<MDYD'\*[2N;R"Y^L5%?F)=>*_BK\5_
M@39_&GXA_&F]^'?@Z'P]-;Z58>$[^6PO]1U:-FB5IHT1%D$KQL^U6X!PNP!F
MKE;J;]J_Q;H?PCCU"T^)U_'<6=R;C_A&]4ET>XFB,C"#[7=>6T<<F%!#3*24
M*YY;-'-Y!<_66BOD'_@G?\5+'QQH7C?19M2\=S^*M&U%4U.P\=Z]_;$UKG>B
MK#-Y46%W1ON78"&'4@BOKZJ3NKC"BBBF 45\*_M[>&?'.CZM=>*8/&GQ4NM(
METJY&E:#\.M.:*STNXAC0B?4+E)L^4S,Q),>[ ;#*%P?%-2_:2^)%]^S?\"O
M"NG?$ZXN-7\9ZY<:9J?BRS>47EK$DT,:V[32*LAD47 9I!@G:N'8'<8<K"N?
MJK17P1\)?%_C7X"_MX+\%[SQYXB^(OA+7-,^U1R>)KTWEU92B!I0WF-R!^Z=
M=HP")%)&1FM_]LOPOX\T[6?%/COQ'\:K[X=?#32]'>/P_I?A74YK34+O4R@V
M),JJHF#.&X#DA<8V ,U/FT"Y]L45^3W@OXG_ !\^)GC?X+_!KQQXU\3>"%UF
MWEU"XU+3Y#::O<6W[XP^;+@,&VP,!DG(<,X8XK=^"/B;X\?';0_%OP]/Q<?0
M?#/@/Q %USQE?7LEKJLNG[Y%*1W(5B"OD2.3(X/[P N57!7,%S]1**_(Z+Q5
M^T'K_P -?BBGPW\3_$7QWX$AUV&W\/\ B!9+F75;A5E?>\,J#S7CV( ^W"@E
M?E4EEKU[]DSXB:IX1_:;T[P+\1[CXM:-XJU#2VET_3?%_C5=:T^XW1F3<T2V
M\6QML;[26;!#*0&%',%S]$Z***L8445\P_MQ?M-R_!;POI?A'PUJ-GI_C_Q<
M_P!DTZ]U"X2WMM,A)"R7DLLF$0+G"[CUYY"D$;MJ!]/45^4'[/?[57C/P-^S
MG\?]0O/B%=^+O&.CR6J:-)JNJM?R1QO,;=[J%)68F-6EC;(!7)0'J*G\4>-?
MB;^SI\./@?\ &:+XM^+/&%WXLF6;5O#FKZBUQ8RI(HE,4,3$A!M)0G!(8@KM
MZ5'/U%<_5BBO!OVI_ WQ&^(FA^'+;PA\0+?X;>%H;G[5XHU5;R2SOA:+M;]Q
M,JD(0 Y.60'Y<G (/YV:Y^TI\:/AI\/?B'<>%O'7B;Q#\-M0UY=&\/\ C#Q"
M[37K@&5G>WFD4L<QQ;2PP%+ J$8G#<K!<_8RBOS'M]=^./PL_:.?X)^#/BEJ
MGBFY\6>&X[JTU/QM</=?V;<F RO,KE9&4#RI%4 ;?WJ[@Q4$U+"3XQ> _CU8
M^#?A_P#%7Q?\5M0T_P /2R>-4N-0EU"PL;PQ2EHH'<'8^50( -^_ R<LJKF\
M@N?J'17X^^$_'OQ)^$-OX,U_XVS?'C1-(N]6^SS:HWC62"!RC[MC:?+;F4KM
M'(:4;P'*GM7Z_P ,R7$*2QL'C=0RL.A!&0:<9<P7+FG_ /'Y'^/\C6U6+I__
M !^1_C_(UM5C4W)EN%%4]8^W_P!DWO\ 9?V?^T_(?[+]LW>3YVT[/,V\[=V,
MXYQG%?G7\ _'WQGA_P""D6H^"/B9X[DUI[;1Y)I]*T:XFBT9&:VCE016YV@[
M!)C>R[B1DFLB3](**_,S^WOB-^U=\=_VAK=OBSXK^'.D_#N*XAT;2_#FH-91
MEXVE17N-A!D4F LV3N_>8# #%>Z_L$_'+Q_^T%^R3J5]=WD,WCK2YKO1K/6-
M44F*XE6%'@FF"K\P7S55L EO+)/)- 'U]17Y2^-+7XZ?!OXK_#C0-$^-7B7X
MC?&6]NY[_P 4>&[/4I;W0[&S,BE&:)D58D*,V0R# P5"?)NX)_C=\8_&OP.\
M<?M$Q_%WQ3H^M:+XM@TZS\-V=QMTA8'53M:V/[ML>8@^93D(=P8MD '[+T5^
M6'QSU+XO3?"^X^,/B_XU:QX5UKQ5::;+X \!^!=4N8?.:;8[PSVP5"[*K\LI
M;D\D_)&>&\8?&_\ :3^(7Q9T/X>:NWC4ZOX<\.17NKZ-X+UR/P_?3NUNL[W$
M\XB=0P66-2A0C<N% 9J /V(HKYK_ & /B]I7QB^ -OJ&G:SXHU>XL;R2RO1X
MPOX[Z^@F"H^S[0D4?G)M=2KLH;D@],5]*4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 5M0_X\Y/P_F*Q:VM0_P"/
M.3\/YBL6NBGL7'8SO$6D2>(-!U#3(M2O='DO('@74-.9%N;?<"-\9=64.,Y!
M*G![5\U?#_\ X)]>&_AGXC.LZ%\4_BI:S37R:A?0)XBCCBU&17W'[2$@4RAN
M0V3DACSS7U-16EDRCY4_:&_8#\-_%C4O%?BKPKKVM>"/&VN63P7+Z=?M%I^H
M,0HQ=Q!2S(P4!@A /WB&/7M?V;/@;XB^%_[.Z_#S7IM'\-ZDBSP1ZAX%DFW*
MKJ/](\RZ1B;@L78L5*CY<   #W:BCE5[A8^6? '_  3Y\-?#3Q$=8T+XI?%2
MUFFODU"^MU\11QPZC(K[C]I"0*90W(;)R0QYYJOKO_!-/X0Z]XJO=3>?Q-9Z
M-?7ZZE=^%;/5?+TF><;OF,>SS!]]_NR#:&(7:.*^KJ*7*@LCY;\2?\$^_#'B
M/XB3>-A\3/B7I&OLIAMY](UJWM?L-OR%MK?9;9CA4':$!QCKDDDGB+_@GGX'
MU_4CJD/C;XB:-K%SIRZ9JFIZ=X@VW&L1A5!-VSQMO+;06 "JQR2N>:^I**?*
M@L<-\&?@QX6^ G@.S\(^$+.2TTJW9I6:>4RRS2MC?(['JQP.@ &    !7<T4
M4P"BBB@#Y9\9?\$Z_AUXNU[Q'?V_B3QOX:L/$4RW&K:'H>M+%I][(&+9DB>)
MR1ECA=V%S\H6NE^('[#OPQ\>>%_!VCP0ZMX4D\(Q^5HFJ>';\P7MHFX.0)'#
M[LL-VY@6!)(()-?0-%+E061\H_L<?LI>+OV;/&WCFXUR[\.^(-,UN1IH?$"2
MW4NN7!\S*+<F0"(+@NQV9)<Y)( Q?\8?L#^'_&?Q/O?B!<_%'XG6'BBX9Q'>
M:9KD%LUK$Q/[B$K;;HX@"0%!Z=<DDGZ?HHY5L%CYE^(7_!/_ , ?$BXTG4+[
MQ'XTLO$5GI@TBZ\0V.L 7^JV^PH1=N\;"1BI(8A5W X.0 !G^*O^"<GPY\3>
M&O#?ARW\2>-/#WAW0!OL]*TC4X4A-R69GNW\R!V:=BWW\_* %4*!BOJJBCE0
M61\QZO\ L!^$?$>D:?#K/C_XDZSKFFWOV[3O$U_XD,NIV)PO[N&0Q[53*;A\
MA8$L01FNU^ G[*'@S]GO5-<UG1KO6]?\2:T?]/U[Q'??:KR9<[MI8*JXW<D[
M=Q.,DX&/9Z*.5!8****8!7G_ ,0/@#\.OB@U_<>)/!/A_5-4O+8VK:M=:5;3
M7D:[2JE)7C9@5!^7T(%>@44 ?.7A#]@;X3>$_@WK?PV.G7>KZ1K%RMU=:A?O
M$-09TYB_?Q1QG$9W%000-[CD,0?+_!W[ _B+X4?M)>$_&OA_Q!9>-?">DV\5
MHJ^/KVYN=3TV,9#?8_*18B54G8' 5=Q^7(#5]NT5/*@L>#_M$?L@:!^TMK&E
MWGB7QEXRTRUTT*UKI>B7\$%I'*"3Y^QX')EYQN+< <8YSCZY^PGX,\8?#X^%
MO%?B[QWXPDAO_P"T;#7M=UW[3J6G2;%4K;RF/:J$+DJR,,G/4 CZ0HI\J"Q\
MM6?_  3O\ :;X-\1:%9^*_'%M=^)+@3:YKZZM$VI:G&-Q\B:5H2IB+.68*H+
MG&\L !2^'_\ @GGX'T?PO=>%[_QM\1/$GA2:T:TC\/ZOX@W6-MEPRRQ111H$
M=2#@],,P(()KZDHHY4%CYJ^&_P"P/X"^'WCO0?%MWXA\8^-M4T")(='7Q5JZ
MW4.GA.$\I4C3 4=%)*CJ!D U]*T44TK; :.C_P#+;\/ZUI5FZ/\ \MOP_K6E
M7+/XF9O<X3XR?"C_ (7%X6@T0^,/%G@D172W7]H>#M3_ +/NWVJZ^6TFQLQG
M?DKCDJI[5XI\%?\ @GEX*^ ^O_;_  ]XY^(-QITK2-?>'[[6(3IFH[XFC(N8
M(X$$ORN<9/4"OJ:BH$?GU\9_^"5]N]CIR?"?7Y4TV'5QJ4_@KQIJUR^@,-N#
ML6!/.5N-I8L6*DC>N*^J_BA\!Q\</@]IO@CQ%X@U7PE"UO"FIQ^![A+6*?;%
MM>W4RQ.?L^2<)@$A5!XR*]:HH ^9?A[^P)X,\":#?^&[KQK\0/%_@V\TV72W
M\*^(M>$NEQQNRMOCABCCV2*5RK*1M))'/-9'@'_@FS\-?AYKT6MV/B/QK?:M
M864MEHEUJ.JQ3'0@^_Y[-?)"JR^8Y7>'56;<!N^:OK&B@#Y*\#_\$W_"/P_U
MJXU#2_BC\5 E[=K>:I8OXAB%MJS!LLMVB6Z^<K@LK!CDAF&>:Z/XN_\ !/?X
M+?%N'18_^$7L_!?]F7)N=WA'3[*P:[Z?NYS]G;>G'W>.IKZ2HH J:3I-CH.E
MVFFZ99V^G:=9Q+!;6=I$L4,,:@!41% "J    , "K=%% !6;XDT>3Q#X?U'2
MXM3OM&DO+=X%U#361+FVW*1YD3.K*'&<@E3@]JTJ* /D_P"'G_!.OPS\+_$I
MUK0/BO\ %BUFFOX]1O[=/$D<<.I2J^X_:A';J90W(;)R0QYYJ+]HW_@GKX9^
M+FI>+O%GA/Q!K?@7QUKUD]O=/INH-#IVHN0HQ=Q!69D8* P0@'[Q#'K]:T4
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MAHRI52?E^3*XX(RV?IJB@#Y(OO\ @F?\,IOA?;> ;#Q'XTT30#=-?:DNGZG
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MK'_A0:A_\?H_X43X0_YXZQ_X4&H?_'Z] HH \_\ ^%$^$/\ GCK'_A0:A_\
M'Z/^%$^$/^>.L?\ A0:A_P#'Z] HH \WOO@7X16U<B'5\\?\S!J![C_IO63_
M ,*1\)_\\M6_\'U__P#'Z]5U#_CSD_#^8K%KHI[%Q.$_X4CX3_YY:M_X/K__
M ./T?\*1\)_\\M6_\'U__P#'Z[NBM;(HX3_A2/A/_GEJW_@^O_\ X_1_PI'P
MG_SRU;_P?7__ ,?KNZ*+(#A/^%(^$_\ GEJW_@^O_P#X_1_PI'PG_P \M6_\
M'U__ /'Z[NBBR X3_A2/A/\ YY:M_P"#Z_\ _C]'_"D?"?\ SRU;_P 'U_\
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M\(?\\=8_\*#4/_C]>@44 >?_ /"B?"'_ #QUC_PH-0_^/T?\*)\(?\\=8_\
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MF']J;PS-\;?&?PT&C:ZM]X/TY-5UK6FBM_[/MK=H!,K#]]YSDA@N$B)S[<T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,CT?\/$?V@_^B@?^473_P#Y'KYQHKN_LC+O^@:'_@$?\C;ZM0_D7W(^CO\
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M\Q6+713V+CL%%%%:E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!#'X*_\#KS_P"1:_6.BC_7+-?YH_\ @(?VGB.Z^X_)S_ATW\7?^AC\%?\
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M -#!X-_\#;O_ .1:_4VBNK_6[-.\?N/T7^TL1W7W'Y9?\.L/BO\ ]#!X-_\
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MX/[2Q'=?<?EE_P .L/BO_P!#!X-_\#;O_P"1:/\ AUA\5_\ H8/!O_@;=_\
MR+7ZFT4?ZW9IWC]P?VEB.Z^X_++_ (=8?%?_ *&#P;_X&W?_ ,BT?\.L/BO_
M -#!X-_\#;O_ .1:_4VBC_6[-.\?N#^TL1W7W'Y9?\.L/BO_ -#!X-_\#;O_
M .1:/^'6'Q7_ .A@\&_^!MW_ /(M?J;11_K=FG>/W!_:6([K[C\LO^'6'Q7_
M .A@\&_^!MW_ /(M'_#K#XK_ /0P>#?_  -N_P#Y%K]3:*/];LT[Q^X/[2Q'
M=?<?EE_PZP^*_P#T,'@W_P #;O\ ^1:/^'6'Q7_Z&#P;_P"!MW_\BU^IM%'^
MMV:=X_<']I8CNON/RR_X=8?%?_H8/!O_ (&W?_R+1_PZP^*__0P>#?\ P-N_
M_D6OU-HH_P!;LT[Q^X/[2Q'=?<?EE_PZP^*__0P>#?\ P-N__D6C_AUA\5_^
MA@\&_P#@;=__ "+7ZFT4?ZW9IWC]P?VEB.Z^X_++_AUA\5_^A@\&_P#@;=__
M "+1_P .L/BO_P!#!X-_\#;O_P"1:_4VBC_6[-.\?N#^TL1W7W'Y<6?_  2Z
M^+-E<),FO^"V=>5WWEV0#Z_\>U>I?#__ ()V:SI'A+Q7=^-M<L]7\2-92)HM
MIH\DGV:*4+N621F1&9BPV[<8 )/)(V_>M%?/YGF$\X3^N4X2DUR\W*N9+LF[
MM?*Q[&#XIS?+U&.%KN$5)2LFTFU;=+?;KT/BK]B?]F7PKXZ^&]]KGC;0(M5&
MJ7C16BSLZ-'#$"I964@J3)O!P?X!7UK\*?@3X7^"LFI)X3%_8:??D/+ILMVT
M]NL@X#J'RP;'!.[D8SG QO>&M)L]$6WL["WCM+6,N4AC&%4L68X'N23^-=+7
MQV'R^C@X4XJ*YHK>VOF='$7%N99[B\34E6DJ-65_9\S<4E\/N[722U2WU"BB
MBO0/A@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH K:A_QYR?A_,5BUM:A_P ><GX?S%8M
M=%/8N.P4445J4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 :.C_P#+;\/ZUI5FZ/\ \MOP_K6E
M7+/XF9O<****@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=:]%&H&1_P )39?\\=2_\%ES_P#&Z/\ A*;+_GCJ7_@LN?\ XW6O11J!D?\
M"4V7_/'4O_!9<_\ QNC_ (2FR_YXZE_X++G_ .-UKT4:@9'_  E-E_SQU+_P
M67/_ ,;H_P"$ILO^>.I?^"RY_P#C=:]%&H&1_P )39?\\=2_\%ES_P#&Z/\
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M\%%W_P#&J/\ A,;#_GWU7_P47?\ \:K<HJ"3#_X3&P_Y]]5_\%%W_P#&J/\
MA,;#_GWU7_P47?\ \:K<HH P_P#A,;#_ )]]5_\ !1=__&J/^$QL/^??5?\
MP47?_P :K<HH P_^$QL/^??5?_!1=_\ QJC_ (3&P_Y]]5_\%%W_ /&JW**
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MY]]5_P#!1=__ !JMRB@##_X3&P_Y]]5_\%%W_P#&J/\ A,;#_GWU7_P47?\
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M_P""RY_^-T?\)39?\\=2_P#!9<__ !NM>BC4#/L?%=DMTA,&I8YZ:7='L?\
MIG6O_P )C8?\^^J_^"B[_P#C5.T__C\C_'^1K:K"IN1(P_\ A,;#_GWU7_P4
M7?\ \:H_X3&P_P"??5?_  47?_QJMRBLB3#_ .$QL/\ GWU7_P %%W_\:H_X
M3&P_Y]]5_P#!1=__ !JMRB@##_X3&P_Y]]5_\%%W_P#&J/\ A,;#_GWU7_P4
M7?\ \:K<HH P_P#A,;#_ )]]5_\ !1=__&J/^$QL/^??5?\ P47?_P :K<HH
M P_^$QL/^??5?_!1=_\ QJC_ (3&P_Y]]5_\%%W_ /&JW** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *VH?\><G
MX?S%8M;6H?\ 'G)^'\Q6+713V+CL%%%%:E!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &CH_\
MRV_#^M:59NC_ /+;\/ZUI5RS^)F;W"BBBH$%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<MT4 9[5]6UQ'PW^"_@WX17&NS^$M'_LF77)X[G4&^U33>=(D8C1OWCMMPH
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MZ:G9SE&58U4\0F56*@CJ2;7_  RS\5_"WQC\6>-O&'A35OB]+XP\+V5O??\
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M3\N=N<#5_:P_;V/[+>@^#'N/AU?:UXIU^VFOKKPW)J<<,VF6\2@R22RPI.C
M,<94[<*QSQ7D/Q4_8[A\8>#-2TG4/V:)Y_'^F:9'I^A^-_"/BFRA@NYHX52*
M[N?-EMG5]R@L&MYB!T8UA_LZ_L$?%_QEK?BRZ^/WBG6]-FM= _X1#1[ZPOK#
M47O].E:8SAFGBG9%PRA6Q'+ACR,4 ?1GQ+_:GU[2?%'[/%]X0?0M0\%?$^_M
M[.=+RSEDNX4D19/,BG2=4!VN%VM$<%2<]A]15^4_AWX<_$GX,S_LN_#WXBZ2
MMD?#OQ.N(-%OH[N&=;ZP?;(CC8[,GSL^%<*0I48X-?JQ0 4444 %%%% !111
M0!6U#_CSD_#^8K%K:U#_ (\Y/P_F*Q:Z*>Q<=@HHHK4H**** "BBB@ HHHH
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MXG\QHH&:"X:/[SR;&9>I.1GIK'X6>(;?X,^+O#=_X#\02?M%WGBVRO= U_\
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MA)()%^;EU7.1D%9I/V>I/V(/WDTEQ\?#X<U1[Z33UU#^UC=F7_2AJ9M^L8;
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M$4=[,+QG7;EVD#ASNV\C=T.*\K^(&L>+OA5X9>_UCXU>/]3U"7,=G:6^NW$
MFDQU(,C':."3GVSDBO;:^;/VJOAWJ5U-#XLMIIKNQAC6"XMR<BV&>'4?W23S
MZ'V/'@X%0J5E3J62?DONO;0^NS; T%0=:-%2E%)+R7IUL>7_ /#1?Q7_ .BG
M>,O_  ?W?_QRC_AHOXK_ /13O&7_ (/[O_XY7GM%?9_5,/\ \^X_<C\T]G#^
M5'H7_#1?Q7_Z*=XR_P#!_=__ !RC_AHOXK_]%.\9?^#^[_\ CE>>T4?5,/\
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MC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\
MP[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_
M / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:
MA_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DB
MC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\
MP[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_
M / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:
MA_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DB
MC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\
MP[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_
M / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:
MA_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DB
MC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\
MP[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_
M / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:
MA_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DB
MC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\
MP[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_
M / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:
MA_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DB
MC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\
MP[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:A_\ )%?1U%']KYE_T$S_
M / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DBC_AW=^SY_P!$_P#_ "M:
MA_\ )%?1U%']KYE_T$S_ / Y?YA]9K_SO[V?./\ P[N_9\_Z)_\ ^5K4/_DB
MK6E_L!_ C1;Z*\L/!$EI=1G*RQ:WJ((_\F.GM7T)11_:^8_]!,__  .7^9G4
MJU*L'3J2;B]&F[IKS/"[C]CGP+->&=+G68(BV[[-'<QF,#TRT9;'_ LUF>+/
MV%_@GX@D2\U/P?-?77">9+K-^.,=E$X5?7@ 5]#U2U;_ (]U_P!_^AK;^VLR
MFTGB):=I-?D>'E^3Y?E=9U\#1C3F^J5GZ>2\D?,G_#O_ . G_0A_^5B__P#C
M]'_#O_X"?]"'_P"5B_\ _C]?0M%;?VMF'_01/_P*7^9])]8K?SO[V?/7_#O_
M . G_0A_^5B__P#C]'_#O_X"?]"'_P"5B_\ _C]?0M%']K9A_P!!$_\ P*7^
M8?6*W\[^]GSU_P ._P#X"?\ 0A_^5B__ /C]'_#O_P" G_0A_P#E8O\ _P"/
MU]"T4?VMF'_01/\ \"E_F'UBM_._O9\]?\.__@)_T(?_ )6+_P#^/T?\._\
MX"?]"'_Y6+__ ./U]"T4?VMF'_01/_P*7^8?6*W\[^]GSU_P[_\ @)_T(?\
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M3YVN6*CHWTZ_-GSU_P ._P#X"?\ 0A_^5B__ /C]'_#O_P" G_0A_P#E8O\
M_P"/U]"T4?VMF'_01/\ \"E_F>7]8K?SO[V?/7_#O_X"?]"'_P"5B_\ _C]'
M_#O_ . G_0A_^5B__P#C]?0M%']K9A_T$3_\"E_F'UBM_._O9\]?\.__ ("?
M]"'_ .5B_P#_ (_1_P ._P#X"?\ 0A_^5B__ /C]?0M%']K9A_T$3_\  I?Y
MA]8K?SO[V?/7_#O_ . G_0A_^5B__P#C]'_#O_X"?]"'_P"5B_\ _C]?0M%'
M]K9A_P!!$_\ P*7^8?6*W\[^]GSU_P ._P#X"?\ 0A_^5B__ /C]'_#O_P"
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M=W_A_P /:=H=U>*%N&TZV6W$V#D%E0 $@D\D9Y/J:GTF&.WN(DBC6- 6(5
M.<D\?6MVO"HX2GA:4*25^5;_ )G;GF?8O.<?B<;.;BJSNXINUNB?>R27R"BB
MBND^8"BBB@ HHHH **** "BBB@ HK#_XJ3_J%_\ D2C_ (J3_J%_^1* -RBL
M/_BI/^H7_P"1*/\ BI/^H7_Y$H W**P_^*D_ZA?_ )$H_P"*D_ZA?_D2@#<H
MK#_XJ3_J%_\ D2C_ (J3_J%_^1* -RBL/_BI/^H7_P"1*/\ BI/^H7_Y$H W
M**P_^*D_ZA?_ )$H_P"*D_ZA?_D2@#<HK#_XJ3_J%_\ D2C_ (J3_J%_^1*
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M -0W_P B4?\ $_\ ^H;_ .1*+@:]%9'_ !/_ /J&_P#D2C_B?_\ 4-_\B47
MUZ*R/^)__P!0W_R)1_Q/_P#J&_\ D2BX&O161_Q/_P#J&_\ D2C_ (G_ /U#
M?_(E%P->BLC_ (G_ /U#?_(E'_$__P"H;_Y$HN!KT5D?\3__ *AO_D2C_B?_
M /4-_P#(E%P->BLC_B?_ /4-_P#(E'_$_P#^H;_Y$HN!KT5D?\3_ /ZAO_D2
MC_B?_P#4-_\ (E%P.HT?_EM^']:TJY32O^$A_>[?[,[=?,]ZO_\ %2?]0O\
M\B5S3^(A[FY16'_Q4G_4+_\ (E'_ !4G_4+_ /(E02;E%8?_ !4G_4+_ /(E
M'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_
M /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G
M_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_
M !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E
M%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B
M4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O
M_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2
M?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E
M'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_
M /(E'_%2?]0O_P B4 ;E%8?_ !4G_4+_ /(E'_%2?]0O_P B4 ;E%8?_ !4G
M_4+_ /(E'_%2?]0O_P B4 ;E4M6_X]U_W_Z&J'_%2?\ 4+_\B54U3_A(OLZ[
MO[,QN[>9Z&JCNAK<DHK(_P")_P#]0W_R)1_Q/_\ J&_^1*ZKFAKT5D?\3_\
MZAO_ )$H_P")_P#]0W_R)1<#7HK(_P")_P#]0W_R)1_Q/_\ J&_^1*+@:]%9
M'_$__P"H;_Y$H_XG_P#U#?\ R)1<#7HK(_XG_P#U#?\ R)1_Q/\ _J&_^1*+
M@:]%9'_$_P#^H;_Y$H_XG_\ U#?_ ")1<#7HK(_XG_\ U#?_ ")1_P 3_P#Z
MAO\ Y$HN!KT5D?\ $_\ ^H;_ .1*/^)__P!0W_R)1<#7HK(_XG__ %#?_(E'
M_$__ .H;_P"1*+@:]%9'_$__ .H;_P"1*/\ B?\ _4-_\B47 UZ*R/\ B?\
M_4-_\B4?\3__ *AO_D2BX&O161_Q/_\ J&_^1*/^)_\ ]0W_ ,B47 UZ*R/^
M)_\ ]0W_ ,B4?\3_ /ZAO_D2BX&O161_Q/\ _J&_^1*/^)__ -0W_P B47 U
MZ*R/^)__ -0W_P B4?\ $_\ ^H;_ .1*+@:]%9'_ !/_ /J&_P#D2C_B?_\
M4-_\B47 UZ*R/^)__P!0W_R)1_Q/_P#J&_\ D2BX&O161_Q/_P#J&_\ D2C_
M (G_ /U#?_(E%P->BLC_ (G_ /U#?_(E'_$__P"H;_Y$HN!KT5D?\3__ *AO
M_D2C_B?_ /4-_P#(E%P->BLC_B?_ /4-_P#(E'_$_P#^H;_Y$HN!KT5D?\3_
M /ZAO_D2C_B?_P#4-_\ (E%P.@T__C\C_'^1K:KC+'_A(/M2;?[-SSU\ST-:
M_P#Q4G_4+_\ (E85-R)&Y16'_P 5)_U"_P#R)1_Q4G_4+_\ (E9$FY16'_Q4
MG_4+_P#(E'_%2?\ 4+_\B4 ;E%8?_%2?]0O_ ,B4?\5)_P!0O_R)0!N45A_\
M5)_U"_\ R)1_Q4G_ %"__(E &Y16'_Q4G_4+_P#(E'_%2?\ 4+_\B4 ;E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU=,&FFVJ!O<J "QQDX &2>!5NNLT"BBB@ HHHH **** "BBB@ HHHH ****
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MYJ'PWTN]TC5-0U"TU?Q#I&IK9P:2L!Q"/LDS22SESP2C8&<XKS3XB>.GN/\
M@HKXN\*>*?$'Q&E\%6_@Z"\M=$\%WNN'R[LM"!*(-,;>/E9P68;,L,G)6@#]
M Z*_'?Q-_P +S_L_]F@>-3?+XF/Q&N1X6;QTCO>K9EK00M?J&65B'WDAF$A
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M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY3;3_P"-5X[11_9.7_\ 0/#_ ,!C_D'^KN2_] 5+_P %P_R/8O\ AKOXM?\
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MG_=,54I/_EU':^R^[U_JQ\L?\/$?V@_^B@?^473_ /Y'H_X>(_M!_P#10/\
MRBZ?_P#(]?.MRR-<2F(8C+DJ/;/%1U]Y_9&7?] T/_ (_P"1['U:A_(ON1]'
M?\/$?V@_^B@?^473_P#Y'H_X>(_M!_\ 10/_ "BZ?_\ (]?.-%']D9=_T#0_
M\ C_ )!]6H?R+[D?1W_#Q']H/_HH'_E%T_\ ^1Z/^'B/[0?_ $4#_P HNG__
M "/7SC11_9&7?] T/_ (_P"0?5J'\B^Y'T=_P\1_:#_Z*!_Y1=/_ /D>C_AX
MC^T'_P!% _\ *+I__P CU\XT4?V1EW_0-#_P"/\ D'U:A_(ON1]'?\/$?V@_
M^B@?^473_P#Y'H_X>(_M!_\ 10/_ "BZ?_\ (]?.-%']D9=_T#0_\ C_ )!]
M6H?R+[D?2$?_  40_:!:10_Q"*H3RPT33R0/7'D5ZNOQ]_:JU#2[?4M%^)>F
M:Y87""2&2VTVP0LI]0]L #VQGC%?#%?4_P"R;I_B&WT*_N+I]GAR9O\ 1(9
M=S2@X9T]%['U(XZ'/G8[+<#AZ7M84*>G1PCK^![&5Y=@\56]C5I7OU26G_ /
M=-1^)'Q=M?"TNMZ7XG8?$F:RACGOC:VI29@4+Q^6T?E 87 (4= <\G/ ZY^T
M+^T]X>\.W&K^(_B=INE64"[BC:78R2LW9%"VV"QZ?>_3FO2*^8OVM=/\1-J&
MFW<K^;X94;(DB! BGQSYGJ2.A] 1ZY\7!8?#UZJISI0UZN*;]%I]R/J\WRG
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MV'_QBOGJBC^R<O\ ^@>'_@,?\@^KT?Y%]R/H7_AX!\>_^A\_\H]A_P#&*/\
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M7W(^A?\ AX!\>_\ H?/_ "CV'_QBC_AX!\>_^A\_\H]A_P#&*^>J*/[)R_\
MZ!X?^ Q_R#ZO1_D7W(^A?^'@'Q[_ .A\_P#*/8?_ !BC_AX!\>_^A\_\H]A_
M\8KYZHH_LG+_ /H'A_X#'_(/J]'^1?<CZ%_X> ?'O_H?/_*/8?\ QBC_ (>
M?'O_ *'S_P H]A_\8KYZHH_LG+_^@>'_ (#'_(/J]'^1?<CZ%_X> ?'O_H?/
M_*/8?_&*/^'@'Q[_ .A\_P#*/8?_ !BOGJBC^R<O_P"@>'_@,?\ (/J]'^1?
M<CZ%_P"'@'Q[_P"A\_\ */8?_&*/^'@'Q[_Z'S_RCV'_ ,8KYZHH_LG+_P#H
M'A_X#'_(/J]'^1?<CZ%_X> ?'O\ Z'S_ ,H]A_\ &*/^'@'Q[_Z'S_RCV'_Q
MBOGJBC^R<O\ ^@>'_@,?\@^KT?Y%]R/H7_AX!\>_^A\_\H]A_P#&*/\ AX!\
M>_\ H?/_ "CV'_QBOGJBC^R<O_Z!X?\ @,?\@^KT?Y%]R/H7_AX!\>_^A\_\
MH]A_\8H_X> ?'O\ Z'S_ ,H]A_\ &*^>J*/[)R__ *!X?^ Q_P @^KT?Y%]R
M/H7_ (> ?'O_ *'S_P H]A_\8H_X> ?'O_H?/_*/8?\ QBOGJBC^R<O_ .@>
M'_@,?\@^KT?Y%]R/H7_AX!\>_P#H?/\ RCV'_P 8H_X> ?'O_H?/_*/8?_&*
M^>J*/[)R_P#Z!X?^ Q_R#ZO1_D7W(^A?^'@'Q[_Z'S_RCV'_ ,8H_P"'@'Q[
M_P"A\_\ */8?_&*^>J*/[)R__H'A_P" Q_R#ZO1_D7W(^Y/V9?\ @I'XJT?Q
M]#:?%G5!K?AN](B.HQV4,,NG-R!)MA1=\?/S @L ,KT*M^I>G:C:ZQI]M?6-
MS#>65S&LT%Q;N'CE1AE65AP000017\Z%?K)_P3$\-_$[1?A;=7'BFX,/@:[Q
M+H&GWB,;E<G+RH2?D@;.0I!W'++M!R_YUQ;D>$H4OKM"T'MR[)^B77OY:^OB
M9EA*<(^UAIY=_0^U****_)CYT**** "BBB@ HHHH **** ,'Q[H-QXI\"^(]
M%M'CCNM1TVYLXGF)"*\D3(I8@$@9(S@'Z5\^_L2_L<V7[.?PDT;2O%^A>$M5
M\=V-Y<7)U_3;-9I '<F/;/)"DN0A"]!C&!Q7U!10!^='BK_@G/\ $G7/V??B
M#X%@UOPJNK>(?B&_BVUFDN[D6Z6A0KLD(MRPER>@4K_M5VO[2O[#_BGXS>,=
M=U32_#GPXMKZXM[:/1_&,%]J>D:UIDB;5=YD@$D5X0@VIDQ8&,_=%?<5% 'Q
M'\#_ -A_QW\*?B9XNN->\3IXV\,^+!IL^HZY:^)]4T#6X[JV@D1Y,6B_OU=I
M6.UYUSPS99>?.OVJO^"9/C?XM?$[6]:\$^(=+AT2\T.UTZ%?%OB#4[Z]$T=R
MDKEY9DG<IA2%'F''3 %?I#10!^?WB3_@G[\0]8\ _M&Z'#K/AE;OXCZMIU_I
M+R75P(X([><R.+@B E6(/&P.,]2*C^'_ /P3S\3?"&X\3VNE>%/@_P#$2TUR
MXM[VWU/X@:?+=7.CRG'VJ-(Q;M]HB/.P>; <\GJ17Z"T4 ?,7QK_ &6_$'C[
MXD_LYZWH$WAS2]'^&M\UQJ-G%%)91M%BW 2S@1)%11Y+81G 4;1N/6O#=8_X
M)W_$?4/@;XW\&1ZUX775-<^)'_"86TS7=SY"6>TCRW/V?<)>>@4K_M5^A]%
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M#P;_ .!MW_\ (M?J;11_K=FG>/W!_:6([K[C\LO^'6'Q7_Z&#P;_ .!MW_\
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MC]P?VEB.Z^X_++_AUA\5_P#H8/!O_@;=_P#R+1_PZP^*_P#T,'@W_P #;O\
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MN_\ Y%H_X=8?%?\ Z&#P;_X&W?\ \BU^IM%'^MV:=X_<']I8CNON/@C]F_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"SI__ !^1_C_(UM5BZ?\
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M /Q='_"&:7_=NO\ P.G_ /BZW** ,/\ X0S2_P"[=?\ @=/_ /%T?\(9I?\
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M +MU_P"!T_\ \76Y10!A_P#"&:7_ ';K_P #I_\ XNC_ (0S2_[MU_X'3_\
MQ=;E% &'_P (9I?]VZ_\#I__ (NC_A#-+_NW7_@=/_\ %UN44 8?_"&:7_=N
MO_ Z?_XNC_A#-+_NW7_@=/\ _%UN44 8?_"&:7_=NO\ P.G_ /BZ/^$,TO\
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MZ/\ \\;C_P #)_\ XNM^B@+LP/\ A!='_P">-Q_X&3__ !='_""Z/_SQN/\
MP,G_ /BZWZ* NS _X071_P#GC<?^!D__ ,71_P (+H__ #QN/_ R?_XNM^B@
M+LP/^$%T?_GC<?\ @9/_ /%T?\(+H_\ SQN/_ R?_P"+K?HH"[,#_A!='_YX
MW'_@9/\ _%T?\(+H_P#SQN/_  ,G_P#BZWZ* NS!7P/I"G(BN ?:]G_^+IW_
M  AFE_W;K_P.G_\ BZW**07,/_A#-+_NW7_@=/\ _%T?\(9I?]VZ_P# Z?\
M^+K<HH P_P#A#-+_ +MU_P"!T_\ \71_PAFE_P!VZ_\  Z?_ .+K<HH P_\
MA#-+_NW7_@=/_P#%T?\ "&:7_=NO_ Z?_P"+K<HH P_^$,TO^[=?^!T__P 7
M1_PAFE_W;K_P.G_^+K<HH P_^$,TO^[=?^!T_P#\71_PAFE_W;K_ ,#I_P#X
MNMRB@ HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0:>T$\ G@NUF>T+[=NX,ACRNT$%BP4==)^W)I=GH/Q&TO7G\&^!_B9X1O)+
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M)$+ %&C(YSGI7V;\/=4NM<\ ^&=2OI?/O;S3+:XGEVA=\CQ*S'   R2> ,4
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M7;^,OCE\./ASJ<6G>+/B!X6\,:A+"+B.TUG6K:TE>(D@.$D=25)5AG&.#Z4
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MVL:#XCU3P_X?^%?_  DNMP>/'\"V=I_PD*VOVN40B19]S6Y$8).-IR!UW=J
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M<C\-W%IY%^RH(UE:.YMYA'*$&/,BV-U))/->T44 ?+$?_!.OX=Z)I\EEX/\
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M+P[;_#.]TJ3P3:W=EJVKZ:?#MWK.YE;RFTV:]FDBBA<[1*719,8 5@,U[O\
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M$L^WYC&@4DA<$\<CJ.'UC]H#XB_!WXQ:1X!\?GPUXAC\4:'J.HZ%K6@Z;<V
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MY;NAZ@AE8@A@>.@ /1**^6/^'C'PV_Z GBK_ ,!+;_Y(H_X>,?#;_H">*O\
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ME#_4_/\ _H$E^'^9]3T5\L?\/&/AM_T!/%7_ ("6W_R11_P\8^&W_0$\5?\
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M;^4/]3\__P"@27X?YGU/17RQ_P /&/AM_P! 3Q5_X"6W_P D4?\ #QCX;?\
M0$\5?^ EM_\ )%'U6M_*'^I^?_\ 0)+\/\SZGHKY8_X>,?#;_H">*O\ P$MO
M_DBC_AXQ\-O^@)XJ_P# 2V_^2*/JM;^4/]3\_P#^@27X?YGU/17RQ_P\8^&W
M_0$\5?\ @);?_)%'_#QCX;?] 3Q5_P" EM_\D4?5:W\H?ZGY_P#] DOP_P S
MZGHKY8_X>,?#;_H">*O_  $MO_DBC_AXQ\-O^@)XJ_\  2V_^2*/JM;^4/\
M4_/_ /H$E^'^9]3T5\L?\/&/AM_T!/%7_@);?_)%'_#QCX;?] 3Q5_X"6W_R
M11]5K?RA_J?G_P#T"2_#_,^IZ*^6/^'C'PV_Z GBK_P$MO\ Y(H_X>,?#;_H
M">*O_ 2V_P#DBCZK6_E#_4_/_P#H$E^'^9]3T5\L?\/&/AM_T!/%7_@);?\
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M]%?+'_#QCX;?] 3Q5_X"6W_R11_P\8^&W_0$\5?^ EM_\D4?5:W\H?ZGY_\
M] DOP_S/J>BOEC_AXQ\-O^@)XJ_\!+;_ .2*/^'C'PV_Z GBK_P$MO\ Y(H^
MJUOY0_U/S_\ Z!)?A_F?4]%?+'_#QCX;?] 3Q5_X"6W_ ,D4?\/&/AM_T!/%
M7_@);?\ R11]5K?RA_J?G_\ T"2_#_,^IZ*^6/\ AXQ\-O\ H">*O_ 2V_\
MDBC_ (>,?#;_ * GBK_P$MO_ )(H^JUOY0_U/S__ *!)?A_F?4]%?+'_  \8
M^&W_ $!/%7_@);?_ "11_P /&/AM_P! 3Q5_X"6W_P D4?5:W\H?ZGY__P!
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M?ZGY_P#] DOP_P SZGHKY8_X>,?#;_H">*O_  $MO_DBC_AXQ\-O^@)XJ_\
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MM_T!/%7_ ("6W_R11_P\8^&W_0$\5?\ @);?_)%'U6M_*'^I^?\ _0)+\/\
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M4?5:W\H?ZGY__P! DOP_S/J>BOEC_AXQ\-O^@)XJ_P# 2V_^2*/^'C'PV_Z
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MU[Q+;W(AFCM;S4M=M8 A6X>\$A:)I&2/<&CW9CR -QS[%_P\8^&W_0$\5?\
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M>XN;R]DOKB30_#UIHEJ&8* D=O;K]U0H :1I)".KG QY'_P\8^&W_0$\5?\
M@);?_)%'_#QCX;?] 3Q5_P" EM_\D4?5:W\H?ZGY_P#] DOP_P S\G/^%FZI
M_P \+/\ [X?_ .*H_P"%FZI_SPL_^^'_ /BJY&O8IO!VBK^Q]:>*QI\?_"1/
MX[FTMM0RV\VJZ?%((L9QC>Q;IGGK7]$ULNR^CRWHKWFE]Y]K+B;-HVOB):G%
M_P#"S=4_YX6?_?#_ /Q5'_"S=4_YX6?_ 'P__P 57<?L[>#=$\6Z#\7Y]8TZ
M*_ET?P7=ZC8-(6'D7"S0*LBX(Y =NN1S7K/PS^'>@ZQ\(/"ES\//A_X2^*?B
MJXCE;Q):Z]J\D>HVTHD(6*"U%Q#\FS!#IO))/'%<&(I99AY2C*ALTNB6JOJV
MTDNFO4QGQ5FL&T\1+\/4^;O^%FZI_P \+/\ [X?_ .*H_P"%FZI_SPL_^^'_
M /BJZ:3X8:C\2/C]_P (;H_A&3P%=WMZ(6T2\DED&E1J@:5Y'E^?8BAY"6_A
M'&>*[SXR^#? /A.Z\-?$KX;Z;%XH^'\-XVA:AINJERAOK9=H>4HP8)<Q!9UP
M1SOZ8P-98;+(SA3]BN:2O_DF[VUL[:V=GJ4^*<U34?K$KOT_K4\=_P"%FZI_
MSPL_^^'_ /BJ/^%FZI_SPL_^^'_^*KZ%\2_$+P'HOP5\$>-(O@CX+>^U[4=2
MLYX'>]\J-;86^PK^_P Y/G-G)/08K#^!/P3\&:YX).I?$&Z_L6]\>74F@^#2
M20EM.IW-?2#.3"LPBM\\_P"LD],CG]GE\:3K5<-RI.W1MM-IV2;VLV_)$?ZU
MYLHN4J\E]QXM_P +-U3_ )X6?_?#_P#Q5'_"S=4_YX6?_?#_ /Q5>X>+OV<]
M!\3_  ?&L^$+A[+XC>#A%I'B_P %S1M]I>X^T?9Q<0 9+;G= 0,@^QX;Z;_9
M]_X)::!I^D6NJ_%>ZGU75ID#MH6GSF*WM\@'9)*OS2,.^TJHYQNZUR8G%9%@
MZ3JU:=G=JUM6UV\K--.]FFM3.IQAF-./-+$R].I^>G_"S=4_YX6?_?#_ /Q5
M'_"S=4_YX6?_ 'P__P 57N_[>(^$GA3QM9^!OA;X;T_3VT8DZOJEK+)*9)R,
M"W#L[9"#.X_WCCJAKY:KV,'@<!C*$<0L/RJ6J3WM]_7<Z:7$^;U8*?MY*_H=
M=_PLW5/^>%G_ -\/_P#%4?\ "S=4_P">%G_WP_\ \57(T5V_V1@/^?2-?]9,
MW_Z")'7?\+-U3_GA9_\ ?#__ !5'_"S=4_YX6?\ WP__ ,57(T4?V1@/^?2#
M_63-_P#H(D==_P +-U3_ )X6?_?#_P#Q5'_"S=4_YX6?_?#_ /Q5<C11_9&
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M4?V1@/\ GT@_UDS?_H(D==_PLW5/^>%G_P!\/_\ %4?\+-U3_GA9_P#?#_\
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M11_9& _Y](/]9,W_ .@B1UW_  LW5/\ GA9_]\/_ /%4?\+-U3_GA9_]\/\
M_%5R-%']D8#_ )](/]9,W_Z")'7?\+-U3_GA9_\ ?#__ !5'_"S=4_YX6?\
MWP__ ,57(T4?V1@/^?2#_63-_P#H(D==_P +-U3_ )X6?_?#_P#Q5'_"S=4_
MYX6?_?#_ /Q5<C11_9& _P"?2#_63-_^@B1UW_"S=4_YX6?_ 'P__P 51_PL
MW5/^>%G_ -\/_P#%5R-%']D8#_GT@_UDS?\ Z")'7?\ "S=4_P">%G_WP_\
M\51_PLW5/^>%G_WP_P#\57(T4?V1@/\ GT@_UDS?_H(D==_PLW5/^>%G_P!\
M/_\ %4?\+-U3_GA9_P#?#_\ Q5<C11_9& _Y](/]9,W_ .@B1UW_  LW5/\
MGA9_]\/_ /%4?\+-U3_GA9_]\/\ _%5R-%']D8#_ )](/]9,W_Z")'7?\+-U
M3_GA9_\ ?#__ !5'_"S=4_YX6?\ WP__ ,57(T4?V1@/^?2#_63-_P#H(D==
M_P +-U3_ )X6?_?#_P#Q5'_"S=4_YX6?_?#_ /Q5<C11_9& _P"?2#_63-_^
M@B1UW_"S=4_YX6?_ 'P__P 51_PLW5/^>%G_ -\/_P#%5R-%']D8#_GT@_UD
MS?\ Z")'7?\ "S=4_P">%G_WP_\ \51_PLW5/^>%G_WP_P#\57(T4?V1@/\
MGT@_UDS?_H(D==_PLW5/^>%G_P!\/_\ %4?\+-U3_GA9_P#?#_\ Q5<C11_9
M& _Y](/]9,W_ .@B1UW_  LW5/\ GA9_]\/_ /%4?\+-U3_GA9_]\/\ _%5R
M-%']D8#_ )](/]9,W_Z")'7?\+-U3_GA9_\ ?#__ !5'_"S=4_YX6?\ WP__
M ,57(T4?V1@/^?2#_63-_P#H(D==_P +-U3_ )X6?_?#_P#Q5'_"S=4_YX6?
M_?#_ /Q5<C11_9& _P"?2#_63-_^@B1UW_"S=4_YX6?_ 'P__P 51_PLW5/^
M>%G_ -\/_P#%5R-%']D8#_GT@_UDS?\ Z")'7?\ "S=4_P">%G_WP_\ \51_
MPLW5/^>%G_WP_P#\57(T4?V1@/\ GT@_UDS?_H(D==_PLW5/^>%G_P!\/_\
M%4?\+-U3_GA9_P#?#_\ Q5<C11_9& _Y](/]9,W_ .@B1UW_  LW5/\ GA9_
M]\/_ /%4?\+-U3_GA9_]\/\ _%5R-%']D8#_ )](/]9,W_Z")'7?\+-U3_GA
M9_\ ?#__ !5'_"S=4_YX6?\ WP__ ,57(T4?V1@/^?2#_63-_P#H(D==_P +
M-U3_ )X6?_?#_P#Q5'_"S=4_YX6?_?#_ /Q5<C11_9& _P"?2#_63-_^@B1U
MW_"S=4_YX6?_ 'P__P 51_PLW5/^>%G_ -\/_P#%5R-%']D8#_GT@_UDS?\
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M /%4?\+-U3_GA9_]\/\ _%5R-%']D8#_ )](/]9,W_Z")'7?\+-U3_GA9_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139443055488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LISATA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2343568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 Allen Road, 2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basking Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LSTA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,139,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000320017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139443075024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 32,428<span></span>
</td>
<td class="nump">$ 32,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">21,966<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,839<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">57,233<span></span>
</td>
<td class="nump">71,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Acquired license - intangible</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">58,089<span></span>
</td>
<td class="nump">73,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,312<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,820<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,132<span></span>
</td>
<td class="nump">6,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,385<span></span>
</td>
<td class="nump">6,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,140,187 and 7,866,799 shares at September 30, 2023 and December 31, 2022, respectively; and outstanding, 8,139,449 and 7,866,061 shares at September 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">576,474<span></span>
</td>
<td class="nump">574,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 738 shares at September 30, 2023 and December 31, 2022</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(522,716)<span></span>
</td>
<td class="num">(507,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Lisata Therapeutics, Inc. stockholders' equity</a></td>
<td class="nump">52,958<span></span>
</td>
<td class="nump">66,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">52,704<span></span>
</td>
<td class="nump">66,324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, non-controlling interests and stockholders' equity</a></td>
<td class="nump">$ 58,089<span></span>
</td>
<td class="nump">$ 73,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139443062000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">33,333,333<span></span>
</td>
<td class="nump">33,333,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">8,140,187<span></span>
</td>
<td class="nump">7,866,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">8,139,449<span></span>
</td>
<td class="nump">7,866,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139439326192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 3,380<span></span>
</td>
<td class="nump">$ 3,335<span></span>
</td>
<td class="nump">$ 9,721<span></span>
</td>
<td class="nump">$ 9,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_InProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,393<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,584<span></span>
</td>
<td class="nump">3,992<span></span>
</td>
<td class="nump">9,962<span></span>
</td>
<td class="nump">10,815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,964<span></span>
</td>
<td class="nump">37,720<span></span>
</td>
<td class="nump">19,683<span></span>
</td>
<td class="nump">51,061<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,964)<span></span>
</td>
<td class="num">(37,720)<span></span>
</td>
<td class="num">(19,683)<span></span>
</td>
<td class="num">(51,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before benefit from income taxes and noncontrolling interests</a></td>
<td class="num">(5,261)<span></span>
</td>
<td class="num">(37,383)<span></span>
</td>
<td class="num">(17,805)<span></span>
</td>
<td class="num">(50,714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,330)<span></span>
</td>
<td class="num">(2,479)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,261)<span></span>
</td>
<td class="num">(37,383)<span></span>
</td>
<td class="num">(15,475)<span></span>
</td>
<td class="num">(48,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less - net income attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (5,261)<span></span>
</td>
<td class="num">$ (37,383)<span></span>
</td>
<td class="num">$ (15,475)<span></span>
</td>
<td class="num">$ (48,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_EPSAbstract', window );"><strong>Basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (7.88)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (11.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (7.88)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (11.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares (in shares)</a></td>
<td class="nump">8,141<span></span>
</td>
<td class="nump">4,747<span></span>
</td>
<td class="nump">8,050<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares (in shares)</a></td>
<td class="nump">8,141<span></span>
</td>
<td class="nump">4,747<span></span>
</td>
<td class="nump">8,050<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_EPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_EPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_InProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_InProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139443064304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,261)<span></span>
</td>
<td class="num">$ (37,383)<span></span>
</td>
<td class="num">$ (15,475)<span></span>
</td>
<td class="num">$ (48,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Available for sale securities - net unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment arising during the period</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (5,311)<span></span>
</td>
<td class="num">$ (37,403)<span></span>
</td>
<td class="num">$ (15,546)<span></span>
</td>
<td class="num">$ (48,255)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139438890560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Lisata Therapeutics, Inc. Stockholders' Equity</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- Controlling Interest in Subsidiary</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 92,000<span></span>
</td>
<td class="nump">$ 92,254<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 546,044<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (453,016)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(48,235)<span></span>
</td>
<td class="num">(48,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuances of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuances of common stock</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger', window );">Issuance of common stock in connection with Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,773,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger', window );">Issuance of common stock in connection with Merger</a></td>
<td class="nump">26,098<span></span>
</td>
<td class="nump">26,098<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">26,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">71,771<span></span>
</td>
<td class="nump">72,025<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">574,066<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(501,251)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,038,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">82,137<span></span>
</td>
<td class="nump">82,391<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">547,032<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(463,868)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(37,383)<span></span>
</td>
<td class="num">(37,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">939<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger', window );">Issuance of common stock in connection with Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,773,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger', window );">Issuance of common stock in connection with Merger</a></td>
<td class="nump">26,098<span></span>
</td>
<td class="nump">26,098<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">26,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 71,771<span></span>
</td>
<td class="nump">72,025<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">574,066<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(501,251)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">7,866,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,867,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 66,324<span></span>
</td>
<td class="nump">66,578<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">574,548<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(507,241)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from option exercises (in shares)</a></td>
<td class="nump">1,227,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 57,714<span></span>
</td>
<td class="nump">57,968<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">576,173<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(517,455)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">7,866,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,867,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 66,324<span></span>
</td>
<td class="nump">66,578<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">574,548<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(507,241)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(15,475)<span></span>
</td>
<td class="num">(15,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuances of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuances of common stock</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from option exercises (in shares)</a></td>
<td class="nump">82,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from option exercises</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">$ (72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">8,139,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 52,704<span></span>
</td>
<td class="nump">52,958<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">576,474<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(522,716)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="nump">57,714<span></span>
</td>
<td class="nump">57,968<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">576,173<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(517,455)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,261)<span></span>
</td>
<td class="num">(5,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">$ (50)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">8,139,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 52,704<span></span>
</td>
<td class="nump">$ 52,958<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 576,474<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (522,716)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, New Issues Related to Merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, New Issues Related to Merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139543512016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (15,475)<span></span>
</td>
<td class="num">$ (48,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based compensation</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">In process research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion on marketable securities</a></td>
<td class="num">(709)<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(314)<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued liabilities and other liabilities</a></td>
<td class="num">(1,305)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,963)<span></span>
</td>
<td class="num">(14,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(77,355)<span></span>
</td>
<td class="num">(68,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">93,171<span></span>
</td>
<td class="nump">93,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_PaymentsForAssetAcquisitionCostsNet', window );">Asset acquisition costs, net of cash acquired related to merger with Cend</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">15,816<span></span>
</td>
<td class="nump">21,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from option exercises</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments on net share settlement equity awards</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">361<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">60<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">6,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">32,154<span></span>
</td>
<td class="nump">24,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">32,428<span></span>
</td>
<td class="nump">31,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock in connection with merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Incremental fair value of Cend's fully vested stock options assumed</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_PaymentsForAssetAcquisitionCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisition Costs, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_PaymentsForAssetAcquisitionCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440783888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_BusinessTextBlock', window );">The Business</a></td>
<td class="text">The Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. LSTA1 also has the potential to modify the tumor microenvironment (&#8220;TME&#8221;), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, the Company has development programs based on its autologous CD34+ cell therapy technology platform that it is seeking to partner while incurring no additional capital outlay.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs. The Company&#8217;s current development pipeline includes: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including, metastatic pancreatic ductal adenocarcinoma (mPDAC) and other forms of pancreatic cancer, cholangiocarcinoma, esophageal cancer, head and neck cancer, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#8220;Caladrius&#8221;), completed its acquisition of Cend Therapeutics, Inc. (&#8220;Cend&#8221;), a Delaware corporation (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#8220;Merger Sub&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#8220;Effective Time&#8221;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc., and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#8220;Reverse Stock Split&#8221;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#8217;s common stock based on an exchange ratio of 0.5338, after taking into account the Reverse Stock Split (the &#8220;Exchange Ratio&#8221;). In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#8220;Cend Plan&#8221;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#8217;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team provided a vast majority of the individuals on the management team and holds the chief executive officer (&#8220;CEO&#8221;), chief medical officer (&#8220;CMO&#8221;) and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#8217;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no alternative future use being expensed as reported in the consolidated statement of operations. Operating results presented in the consolidated statements of operations and comprehensive loss prior to the Merger are solely related to Caladrius Biosciences, Inc. and subsidiaries.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company&#8217;s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company&#8217;s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_BusinessTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Business [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_BusinessTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139446572240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, Cend&#8217;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18&#160;thousand for the three months ended September&#160;30, 2023 and $53&#160;thousand for the nine months ended September&#160;30, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next five years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September&#160;30, 2023 and 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September&#160;30, 2023 and September&#160;30, 2022, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139441632560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Merger</a></td>
<td class="text">Merger<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;D. Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D being expensed. The fair value of total consideration was $36.1&#160;million. The following table is a summary of the purchase price calculation (in thousands except per share data).</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772,768&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.25</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23,580</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,062</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139558447152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Available-for-Sale-Securities</a></td>
<td class="text">Available-for-Sale-Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440796400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results included depreciation expense of approximately $89&#160;thousand and $22&#160;thousand for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440799920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text">Income (Loss) Per Share<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2023 and 2022, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At September&#160;30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139543624368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts payable and accrued expenses approximate fair value as of September&#160;30, 2023 and December&#160;31, 2022, due to the short maturity nature of these items.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440770464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September&#160;30, 2023 and December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440799920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating LeasesThe Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-566"><span style="-sec-ix-hidden:f-567">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-572"><span style="-sec-ix-hidden:f-573">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-576"><span style="-sec-ix-hidden:f-577">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the weighted average remaining lease term for our operating lease was 2.0 years, and the weighted average discount rate for our operating lease was 9.625%. As of December&#160;31, 2022, the weighted average remaining lease term for our operating leases was 1.5 years, and the weighted average discount rate for our operating leases was 9.625%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of September&#160;30, 2023 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139439990368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6&#160;million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0&#160;million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. During the nine months ended September&#160;30, 2023, the Company issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.  </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger closing on September 15, 2022, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding of Cend. The options granted under the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.03</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144,594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320,551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,316,134&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.84&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,229,103&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:f-660">one</span> and four years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The weighted average estimated fair value of restricted stock units issued for services in the nine months ended September&#160;30, 2023 and 2022 was $3.00 and $12.46 per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139532572976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2023 and 2022 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2023 and 2022 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440796400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had approximately $281.0&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $168.8&#160;million of the $281.0&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112.3&#160;million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173&#160;thousand under Internal Revenue Code Section 382. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had approximately $34.0&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $34.0&#160;million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Cend Therapeutics had approximately $10.9&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $10.7&#160;million of Federal and $15.0&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $36.1&#160;million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917&#160;thousand each year. The Federal NOL of $106&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. Cend&#8217;s wholly owned Australian subsidiary has $1.8&#160;million of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had State NOLs available in New Jersey of $35.5&#160;million and $97.0&#160;million, respectively, California of $10.0&#160;million and $69.5&#160;million, respectively, and New York City of $1.9&#160;million and $13.0&#160;million, respectively, to offset future taxable income expiring from 2032 through 2042. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs is limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company&#8217;s uncertain tax positions were $344&#160;thousand and $0, respectively. Due to the acquisition of Cend, the Company&#8217;s uncertain tax positions increased by $344&#160;thousand related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. As of September&#160;30, 2023, the Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2019, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from the date of filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, the Company received final approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) under the Technology Business Tax Certificate Transfer Program (&#8220;Program&#8221;) to sell a percentage of its New Jersey net operating losses (&#8220;NJ NOLs&#8221;), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.2&#160;million. The $2.3&#160;million of NJ NOLs related tax benefits has been recorded as a benefit from income taxes and the loss on sale of $0.1&#160;million recorded in other income (expense).</span></div>On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company&#8217;s results of operations for the year ended December 31, 2022. The Company will continue to monitor the future impact of changes in tax legislation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440603616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Australia Research and Development Tax Incentive<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock', window );">Australia Research and Development Tax Incentive</a></td>
<td class="text">Australia Research and Development Tax IncentiveThe Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the nine months ended September&#160;30, 2023, $0.5&#160;million was recorded as an income tax incentive receivable in  prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed. On September 4, 2023 the Company's Australian subsidiary received a $0.6&#160;million tax refund from the Australian Taxation Office related to the 2022 tax year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Tax Incentive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ResearchAndDevelopmentTaxIncentiveTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139442895744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. </span></div>In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022. Lingmed filed an answer to Cend&#8217;s response on July 11, 2022. At a Case Management Conference held on August 4, 2023, the Court set a trial date in the matter for August 2, 2024. The Company denies these allegations made by Lingmed and intends to vigorously defend itself.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139445269440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Technology Transfer Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_TechnologyTransferAgreementAbstract', window );"><strong>Technology Transfer Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_TechnologyTransferAgreementTextBlock', window );">Technology Transfer Agreement</a></td>
<td class="text">Technology Transfer Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impilo Therapeutics </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (&#8220;Impilo&#8221;) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023 in connection with the Sanford Burnham Prebys license agreement (Note 16) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_TechnologyTransferAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technology Transfer Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_TechnologyTransferAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_TechnologyTransferAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technology Transfer Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_TechnologyTransferAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139439990368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend&#8217;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company&#8217;s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2&#160;million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. On September 14, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned 382,030 shares of the Company&#8217;s common stock as of September&#160;30, 2023 and is a related party. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#8220;UCSD&#8221;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2&#160;million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#8217; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0&#160;million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement expires upon the expiration or abandonment of all valid claims. The agreement may be earlier terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may also be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, in accordance with the provisions of the license agreement, the Company provided notice to MIT that the license agreement would terminate effective December 30, 2023. Until such date, the license remains in full force and effect.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIT owned 43,236 shares of the Company&#8217;s common stock as of September&#160;30, 2023.</span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95&#160;million and $125&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139442885232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreement</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend&#8217;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company&#8217;s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2&#160;million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. On September 14, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned 382,030 shares of the Company&#8217;s common stock as of September&#160;30, 2023 and is a related party. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#8220;UCSD&#8221;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2&#160;million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#8217; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0&#160;million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement expires upon the expiration or abandonment of all valid claims. The agreement may be earlier terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may also be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, in accordance with the provisions of the license agreement, the Company provided notice to MIT that the license agreement would terminate effective December 30, 2023. Until such date, the license remains in full force and effect.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIT owned 43,236 shares of the Company&#8217;s common stock as of September&#160;30, 2023.</span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95&#160;million and $125&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139441772368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Accordingly, actual results could differ from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risks</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentThe cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span>The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text">Loss Per ShareBasic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-process Research and Development Expense</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div>If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Milestones, Royalties</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September&#160;30, 2023 and September&#160;30, 2022, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -SubTopic 50<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482610/350-50-25-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -SubTopic 40<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482633/350-40-30-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139445791360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139442885232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Asset Acquisition</a></td>
<td class="text">The following table is a summary of the purchase price calculation (in thousands except per share data).<div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772,768&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.25</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23,580</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,062</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139441707072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440567856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440643904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">At September&#160;30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139442880320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,103&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,069&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139440726784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September&#160;30, 2023 and December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139441795328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock', window );">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-566"><span style="-sec-ix-hidden:f-567">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-572"><span style="-sec-ix-hidden:f-573">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-576"><span style="-sec-ix-hidden:f-577">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Lease Agreements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of September&#160;30, 2023 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139443124576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option and Warrants Activity</a></td>
<td class="text">The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.03</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144,594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,320,551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,316,134&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.84&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,229,103&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139443124576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule Share-based Compensation Expense</a></td>
<td class="text">The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2023 and 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Total Compensation Cost Related to Nonvested Awards</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2023 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Share-based Compensation Awards</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2023 and 2022 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139438361776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Business (Details)<br></strong></div></th>
<th class="th"><div>Jul. 01, 2023</div></th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized to be repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,227,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=lsta_CaladriusMember', window );">Caladrius</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">0.067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lsta_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,772,768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lsta_CaladriusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lsta_CaladriusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lsta_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lsta_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139543533744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139437381456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected amortization, remainder of fiscal year</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected amortization, year one</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected amortization, year two</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected amortization, year three</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected amortization, year four</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139443140384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lsta_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase price</a></td>
<td class="nump">$ 36,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lsta_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lsta_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139441931472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of common shares of the combined company owned by Cend stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,139,449<span></span>
</td>
<td class="nump">7,866,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lsta_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of common shares of the combined company owned by Cend stockholders (in shares)</a></td>
<td class="nump">3,772,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AssetAcquisitionSharePrice', window );">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AssetAcquisitionConsiderationTransferredEquityValue', window );">Total</a></td>
<td class="nump">$ 23,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Carrying value of Lisata's cost method investment in Cend</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Incremental fair value of Cend's fully vested stock options</a></td>
<td class="nump">2,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Lisata transaction costs</a></td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase price</a></td>
<td class="nump">36,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AssetAcquisitionCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">7,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AssetAcquisitionNetWorkingCapital', window );">Net working capital (excluding cash)</a></td>
<td class="num">(1,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AssetAcquisitionOtherLiabilities', window );">Other liabilities</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">30,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AssetAcquisitionIntangibles', window );">License</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Acquired In-Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AssetAcquisitionCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash and Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AssetAcquisitionCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AssetAcquisitionConsiderationTransferredEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Equity Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AssetAcquisitionConsiderationTransferredEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AssetAcquisitionIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Intangibles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AssetAcquisitionIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AssetAcquisitionNetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Net Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AssetAcquisitionNetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AssetAcquisitionOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AssetAcquisitionOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AssetAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AssetAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lsta_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lsta_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139438787952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 51,086<span></span>
</td>
<td class="nump">$ 64,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">51,069<span></span>
</td>
<td class="nump">64,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">28,828<span></span>
</td>
<td class="nump">44,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">28,812<span></span>
</td>
<td class="nump">44,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">7,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">7,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">13,572<span></span>
</td>
<td class="nump">4,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">13,572<span></span>
</td>
<td class="nump">4,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_BondsMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">1,987<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,986<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">3,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">3,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">7,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 725<span></span>
</td>
<td class="nump">$ 7,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139445824960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 29,103<span></span>
</td>
<td class="nump">$ 27,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">21,966<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total</a></td>
<td class="nump">$ 51,069<span></span>
</td>
<td class="nump">$ 64,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139433916576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis', window );">Less than one year</a></td>
<td class="nump">$ 51,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">51,086<span></span>
</td>
<td class="nump">$ 64,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">Less than one year</a></td>
<td class="nump">51,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total estimated fair value</a></td>
<td class="nump">$ 51,069<span></span>
</td>
<td class="nump">$ 64,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139439299920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(417)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139445618320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139441892336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 29,103<span></span>
</td>
<td class="nump">$ 27,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">21,966<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">51,069<span></span>
</td>
<td class="nump">64,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">29,103<span></span>
</td>
<td class="nump">27,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">29,103<span></span>
</td>
<td class="nump">27,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">21,966<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">21,966<span></span>
</td>
<td class="nump">37,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139437177376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries, employee benefits and related taxes</a></td>
<td class="nump">$ 2,366<span></span>
</td>
<td class="nump">$ 2,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ClinicalAndRDRelatedLiabilities', window );">Clinical and R&amp;D related liabilities</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AccruedGrantFunding', window );">Accounting &amp; tax consulting liabilities</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8212; current</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 3,820<span></span>
</td>
<td class="nump">$ 3,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AccruedGrantFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Grant Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AccruedGrantFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ClinicalAndRDRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical and R&amp;D Related Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ClinicalAndRDRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139443160208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases (percent)</a></td>
<td class="nump">9.625%<span></span>
</td>
<td class="nump">9.625%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139445630096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Balance Sheet Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Right-of-Use Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Right-of-use assets, balance sheet line item</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, current, balance sheet line item</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, noncurrent, balance sheet line item</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139437262528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139439183744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Issuances (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">28 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Mar. 22, 2022</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OutstandingStockThreshold', window );">Outstanding stock threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 297,000<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of common shares of the combined company owned by Cend stockholders (in shares)</a></td>
<td class="nump">8,139,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,139,449<span></span>
</td>
<td class="nump">7,866,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lsta_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of common shares of the combined company owned by Cend stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,772,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SaleOfStockAvailableForSale', window );">Sale of stock available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,698,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SaleOfStockAvailableForSalePercentage', window );">Percentage held by non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="nump">64,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 270,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OutstandingStockThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding Stock Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OutstandingStockThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SaleOfStockAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Available for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SaleOfStockAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SaleOfStockAvailableForSalePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Available for Sale, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SaleOfStockAvailableForSalePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lsta_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lsta_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139442992080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Warrants Narrative (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139434024784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">1,391,352<span></span>
</td>
<td class="nump">1,391,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="num">(1,227,776)<span></span>
</td>
<td class="num">(82,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, End of Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,320,551<span></span>
</td>
<td class="nump">1,391,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,229,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding. Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding, End of Period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.82<span></span>
</td>
<td class="nump">$ 10.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and expected to vest (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options, Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OptionsVestedweightedAverageRemainingContractualTerm', window );">Options, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,700<span></span>
</td>
<td class="nump">$ 187,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options, Vested, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CommonStockWarrantsShares', window );">Warrants, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">1,423,774<span></span>
</td>
<td class="nump">1,423,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsGranted', window );">Warrants, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsExercised', window );">Warrants, Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsCanceled', window );">Warrants, Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsExpired', window );">Warrants, Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CommonStockWarrantsShares', window );">Warrants, Outstanding, End of Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,744<span></span>
</td>
<td class="nump">1,423,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_Sharesvestedandexpectedtovest', window );">Warrants, Vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsVested', window );">Warrants, Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Warrants, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 42.57<span></span>
</td>
<td class="nump">$ 42.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsGranted', window );">Warrants, Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsExercised', window );">Warrants, Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsCanceled', window );">Warrants, Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsExpired', window );">Warrants, Expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, End of Period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.51<span></span>
</td>
<td class="nump">$ 42.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest', window );">Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsExercisable', window );">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsOtherDisclosuresAbstract', window );"><strong>Warrants, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding', window );">Warrants, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 1 day<span></span>
</td>
<td class="text">3 years 4 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest', window );">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageRemainingContractualTermwarrantsvested', window );">Warrants, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AggregateIntrinsicValueWarrantsOutstanding', window );">Warrants Outstanding, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest', window );">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AggregateIntrinsicValueWarrantsvested', window );">Warrants, Vested, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AggregateIntrinsicValueWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AggregateIntrinsicValueWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AggregateIntrinsicValueWarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AggregateIntrinsicValueWarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OptionsVestedweightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Vested, weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OptionsVestedweightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_Sharesvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>shares, vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_Sharesvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Other Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageRemainingContractualTermwarrantoutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term warrant outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageRemainingContractualTermwarrantoutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageRemainingContractualTermwarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>weighted Average Remaining Contractual Term, warrants vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageRemainingContractualTermwarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139437216464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued (in shares)</a></td>
<td class="nump">159,950<span></span>
</td>
<td class="nump">70,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value (usd per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 12.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued (in shares)</a></td>
<td class="nump">188,850<span></span>
</td>
<td class="nump">111,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 567<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139432646800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 1,040<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
<td class="nump">$ 2,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 769<span></span>
</td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="nump">$ 1,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139439183328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 10 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 8 months 8 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139442963936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 1,001<span></span>
</td>
<td class="nump">$ 853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of shares granted</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139432113296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2023</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Unrecognized tax benefits, increase resulting from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ProceedsFromSaleOfNOLS', window );">Proceeds from sale of NOLs</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,330)<span></span>
</td>
<td class="num">$ (2,479)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LossOnSaleOfNOL', window );">Loss on sale of NOL</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=lsta_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_FairValueMarketOfTaxNOLs', window );">Fair value market of tax NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate reconciliation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation', window );">NOL annual limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,300<span></span>
</td>
<td class="nump">281,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OperatingLossCarryforwardsBeforeWriteDown', window );">Net operating loss carryforwards, prior to write down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OperatingLossCarryforwardsPostAcquisition', window );">Operating loss carryforwards, post acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_FairValueMarketOfTaxNOLs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Market of Tax NOLs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_FairValueMarketOfTaxNOLs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LossOnSaleOfNOL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Sale of NOL</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LossOnSaleOfNOL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Carryforward Operating Loss Carryforward Annual Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OperatingLossCarryforwardsBeforeWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Before Write Down</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OperatingLossCarryforwardsBeforeWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OperatingLossCarryforwardsPostAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Post Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OperatingLossCarryforwardsPostAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ProceedsFromSaleOfNOLS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of NOLS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ProceedsFromSaleOfNOLS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lsta_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lsta_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139439124064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Australia Research and Development Tax Incentive (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 04, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_IncomeTaxIncentiveReceivable', window );">Income tax incentive receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refunds</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research tax credit rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research tax credit rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_IncomeTaxIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Incentive Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_IncomeTaxIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139439172640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Technology Transfer Agreement (Details) - Impilo - shares<br></strong></div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems', window );"><strong>Investments in and Advances to Affiliates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems', window );"><strong>Investments in and Advances to Affiliates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_InvestmentOwnedCanceledShares', window );">Shares canceled (in shares)</a></td>
<td class="nump">766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">574,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_InvestmentOwnedCanceledShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Canceled, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_InvestmentOwnedCanceledShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139438636944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember', window );">Impilo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Impilo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven', window );">Annual license maintenance fee, year seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour', window );">Annual license maintenance fee, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SharesHeldByThirdParty', window );">Shares held by third party (in shares)</a></td>
<td class="nump">382,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_UniversityOfCaliforniaAtSanDiegoMember', window );">University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_UniversityOfCaliforniaAtSanDiegoMember', window );">University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_UniversityOfCaliforniaAtSanDiegoMember', window );">University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour', window );">Annual license maintenance fee, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SharesHeldByThirdParty', window );">Shares held by third party (in shares)</a></td>
<td class="nump">43,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree', window );">Annual license maintenance fee, years two and three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale', window );">Annual license maintenance fee, after first sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee', window );">Change of control fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">43,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Change of Control Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SharesHeldByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Held by Third Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SharesHeldByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SharesIssuedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SharesIssuedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lsta_UniversityOfCaliforniaAtSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lsta_UniversityOfCaliforniaAtSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lsta_MassachusettsInstituteOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lsta_MassachusettsInstituteOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lsta_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lsta_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140139438790928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 14, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Qilu | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from contract</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate', window );">Option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Qilu | License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Qilu | License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration and License Agreement, Option to Terminate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_RevenuePerformanceObligationPercentageOfNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_RevenuePerformanceObligationPercentageOfNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Sublicensing Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lsta_QiluMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lsta_QiluMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>lsta-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lsta="http://www.caladrius.com/20230930"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lsta-20230930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CaladriusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-03-22</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-04</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2023-04-05</startDate>
            <endDate>2023-04-05</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-04</startDate>
            <endDate>2023-09-04</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000320017</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-78"
      decimals="INF"
      id="f-376"
      unitRef="number">0.067</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-566">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-567">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-572">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-573">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-576">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-577">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-123" id="f-660">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <lsta:SaleOfStockAvailableForSalePercentage contextRef="c-113" decimals="2" id="f-670" unitRef="number">0.33</lsta:SaleOfStockAvailableForSalePercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33650</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">LISATA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">22-2343568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">110 Allen Road, 2nd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Basking Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">07920</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">842-0100</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">LSTA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">8139449</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">32428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">32154000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">21966000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">37072000</us-gaap:MarketableSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">2839000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">2650000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">57233000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">71876000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">204000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">296000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">281000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">334000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">371000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">528000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">58089000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">73034000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">1312000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">2655000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">3820000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">3728000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">5132000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">6383000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">253000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">327000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">5385000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">6710000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-56" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-57" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-58"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-59"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-60" unitRef="shares">33333333</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-61" unitRef="shares">33333333</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-62" unitRef="shares">8140187</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-63" unitRef="shares">7866799</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-64" unitRef="shares">8139449</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-65" unitRef="shares">7866061</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">576474000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">574548000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-70" unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-3" decimals="INF" id="f-71" unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">-522716000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">-507241000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">-100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">-29000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">52958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">66578000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-82" unitRef="usd">52704000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">66324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-84" unitRef="usd">58089000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">73034000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">3380000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-6" decimals="-3" id="f-87" unitRef="usd">3335000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-88" unitRef="usd">9721000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-7" decimals="-3" id="f-89" unitRef="usd">9853000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <lsta:InProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">0</lsta:InProcessResearchAndDevelopment>
    <lsta:InProcessResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-91" unitRef="usd">30393000</lsta:InProcessResearchAndDevelopment>
    <lsta:InProcessResearchAndDevelopment contextRef="c-1" decimals="-3" id="f-92" unitRef="usd">0</lsta:InProcessResearchAndDevelopment>
    <lsta:InProcessResearchAndDevelopment contextRef="c-7" decimals="-3" id="f-93" unitRef="usd">30393000</lsta:InProcessResearchAndDevelopment>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-94" unitRef="usd">2584000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-95" unitRef="usd">3992000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-96" unitRef="usd">9962000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-97" unitRef="usd">10815000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">5964000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">37720000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">19683000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-101" unitRef="usd">51061000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">-5964000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-103" unitRef="usd">-37720000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">-19683000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-105" unitRef="usd">-51061000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">714000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-6" decimals="-3" id="f-107" unitRef="usd">337000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">2053000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-7" decimals="-3" id="f-109" unitRef="usd">496000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">-11000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-111" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">-175000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-113" unitRef="usd">-149000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">703000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">337000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">1878000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-117" unitRef="usd">347000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">-5261000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">-37383000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-17805000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-121" unitRef="usd">-50714000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">-2330000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-125" unitRef="usd">-2479000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-126" unitRef="usd">-5261000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">-37383000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">-15475000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-3" id="f-129" unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-5" decimals="-3" id="f-130" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-7" decimals="-3" id="f-133" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-134" unitRef="usd">-5261000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">-37383000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-15475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-137" unitRef="usd">-48235000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-138"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-139"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-140"
      unitRef="usdPerShare">-7.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-141"
      unitRef="usdPerShare">-7.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-144"
      unitRef="usdPerShare">-11.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-145"
      unitRef="usdPerShare">-11.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-146" unitRef="shares">8141000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-147" unitRef="shares">8141000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-148" unitRef="shares">4747000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-149" unitRef="shares">4747000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-150" unitRef="shares">8050000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-151" unitRef="shares">8050000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-152" unitRef="shares">4276000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-153" unitRef="shares">4276000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-154" unitRef="usd">-5261000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-3" id="f-155" unitRef="usd">-37383000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">-15475000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-3" id="f-157" unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-158" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-6" decimals="-3" id="f-159" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-7" decimals="-3" id="f-161" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-162" unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-163" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">-72000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-165" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-166" unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-167" unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">-71000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-169" unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-170" unitRef="usd">-5311000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-171" unitRef="usd">-37403000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">-15546000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-173" unitRef="usd">-48255000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="-3" id="f-174" unitRef="shares">4038000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-175" unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-176" unitRef="usd">547032000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-177" unitRef="usd">-70000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-178" unitRef="usd">-463868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-179" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-180" unitRef="usd">82391000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-181" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-182" unitRef="usd">82137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-183" unitRef="usd">-37383000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-184" unitRef="usd">-37383000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-3" id="f-185" unitRef="usd">-37383000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-18" decimals="-3" id="f-186" unitRef="shares">52000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-3" id="f-187" unitRef="usd">940000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-188" unitRef="usd">939000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-189" unitRef="usd">939000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <lsta:StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger contextRef="c-18" decimals="-3" id="f-190" unitRef="shares">3773000</lsta:StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger>
    <lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger contextRef="c-18" decimals="-3" id="f-191" unitRef="usd">4000</lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger>
    <lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger contextRef="c-19" decimals="-3" id="f-192" unitRef="usd">26094000</lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger>
    <lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger contextRef="c-17" decimals="-3" id="f-193" unitRef="usd">26098000</lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger>
    <lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger contextRef="c-6" decimals="-3" id="f-194" unitRef="usd">26098000</lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-20" decimals="-3" id="f-195" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-17" decimals="-3" id="f-196" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-197" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-20" decimals="-3" id="f-198" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-17" decimals="-3" id="f-199" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-200" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-21" decimals="-3" id="f-201" unitRef="shares">7863000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-202" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-203" unitRef="usd">574066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-204" unitRef="usd">-90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-205" unitRef="usd">-501251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-206" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-207" unitRef="usd">72025000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-208" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-209" unitRef="usd">71771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-29" decimals="-3" id="f-210" unitRef="shares">3986000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-211" unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-212" unitRef="usd">546044000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-213" unitRef="usd">-70000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-214" unitRef="usd">-453016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-215" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-216" unitRef="usd">92254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-217" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-218" unitRef="usd">92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-37" decimals="-3" id="f-219" unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-38" decimals="-3" id="f-220" unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-3" id="f-221" unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-39" decimals="-3" id="f-222" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-40" decimals="-3" id="f-223" unitRef="usd">1899000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-38" decimals="-3" id="f-224" unitRef="usd">1899000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-225" unitRef="usd">1899000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-39" decimals="-3" id="f-226" unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-40" decimals="-3" id="f-227" unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-38" decimals="-3" id="f-228" unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-7" decimals="-3" id="f-229" unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <lsta:StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger contextRef="c-39" decimals="-3" id="f-230" unitRef="shares">3773000</lsta:StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger>
    <lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger contextRef="c-39" decimals="-3" id="f-231" unitRef="usd">4000</lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger>
    <lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger contextRef="c-40" decimals="-3" id="f-232" unitRef="usd">26094000</lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger>
    <lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger contextRef="c-38" decimals="-3" id="f-233" unitRef="usd">26098000</lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger>
    <lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger contextRef="c-7" decimals="-3" id="f-234" unitRef="usd">26098000</lsta:StockIssuedDuringPeriodValueNewIssuesRelatedToMerger>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-41" decimals="-3" id="f-235" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-236" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-237" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-41" decimals="-3" id="f-238" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-239" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-240" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-21" decimals="-3" id="f-241" unitRef="shares">7863000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-242" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-243" unitRef="usd">574066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-244" unitRef="usd">-90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-245" unitRef="usd">-501251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-246" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-247" unitRef="usd">72025000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-248" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-249" unitRef="usd">71771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-3" id="f-250" unitRef="shares">8133000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-251" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-252" unitRef="usd">576173000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-253" unitRef="usd">-50000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-254" unitRef="usd">-517455000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-255" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-256" unitRef="usd">57968000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-257" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-258" unitRef="usd">57714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-50" decimals="-3" id="f-259" unitRef="usd">-5261000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-51" decimals="-3" id="f-260" unitRef="usd">-5261000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-261" unitRef="usd">-5261000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-52" decimals="-3" id="f-262" unitRef="shares">7000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-53" decimals="-3" id="f-263" unitRef="usd">301000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-51" decimals="-3" id="f-264" unitRef="usd">301000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-265" unitRef="usd">301000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-54" decimals="-3" id="f-266" unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-51" decimals="-3" id="f-267" unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-268" unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-55" decimals="-3" id="f-269" unitRef="shares">8140000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-270" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-271" unitRef="usd">576474000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-272" unitRef="usd">-100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-273" unitRef="usd">-522716000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-274" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-275" unitRef="usd">52958000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-276" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-277" unitRef="usd">52704000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-62" decimals="-3" id="f-278" unitRef="shares">7867000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-3" id="f-279" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-3" id="f-280" unitRef="usd">574548000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-281" unitRef="usd">-29000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-3" id="f-282" unitRef="usd">-507241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="-3" id="f-283" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-3" id="f-284" unitRef="usd">66578000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="-3" id="f-285" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-286" unitRef="usd">66324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-69" decimals="-3" id="f-287" unitRef="usd">-15475000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-70" decimals="-3" id="f-288" unitRef="usd">-15475000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">-15475000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-71" decimals="-3" id="f-290" unitRef="shares">114000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-72" decimals="-3" id="f-291" unitRef="usd">1474000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-70" decimals="-3" id="f-292" unitRef="usd">1474000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">1474000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-71" decimals="-3" id="f-294" unitRef="shares">76000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-72" decimals="-3" id="f-295" unitRef="usd">297000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-70" decimals="-3" id="f-296" unitRef="usd">297000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">297000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-71" decimals="-3" id="f-298" unitRef="shares">83000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-72" decimals="-3" id="f-299" unitRef="usd">155000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-70" decimals="-3" id="f-300" unitRef="usd">155000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">155000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-73" decimals="-3" id="f-302" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-70" decimals="-3" id="f-303" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-73" decimals="-3" id="f-305" unitRef="usd">-72000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">-72000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">-72000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-55" decimals="-3" id="f-308" unitRef="shares">8140000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-309" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-310" unitRef="usd">576474000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-311" unitRef="usd">-100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-312" unitRef="usd">-522716000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-313" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-314" unitRef="usd">52958000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-315" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-316" unitRef="usd">52704000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">-15475000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-3" id="f-318" unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">1565000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-7" decimals="-3" id="f-320" unitRef="usd">2168000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">142000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-3" id="f-322" unitRef="usd">22000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">-3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-7" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-7" decimals="-3" id="f-326" unitRef="usd">-30393000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">709000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-7" decimals="-3" id="f-328" unitRef="usd">-893000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">314000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-330" unitRef="usd">-29000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">-130000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-7" decimals="-3" id="f-332" unitRef="usd">-178000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">-1305000</lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="c-7" decimals="-3" id="f-334" unitRef="usd">-150000</lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">-15963000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-336" unitRef="usd">-14702000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">77355000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-7" decimals="-3" id="f-338" unitRef="usd">68481000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">93171000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-7" decimals="-3" id="f-340" unitRef="usd">93865000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <lsta:PaymentsForAssetAcquisitionCostsNet contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">0</lsta:PaymentsForAssetAcquisitionCostsNet>
    <lsta:PaymentsForAssetAcquisitionCostsNet contextRef="c-7" decimals="-3" id="f-342" unitRef="usd">3320000</lsta:PaymentsForAssetAcquisitionCostsNet>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-344" unitRef="usd">259000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">15816000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-346" unitRef="usd">21805000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">155000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-348" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">91000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-7" decimals="-3" id="f-350" unitRef="usd">267000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">297000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-352" unitRef="usd">29000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">361000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-354" unitRef="usd">-238000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">60000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-356" unitRef="usd">-34000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">274000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-358" unitRef="usd">6831000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-359" unitRef="usd">32154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-36" decimals="-3" id="f-360" unitRef="usd">24647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-361" unitRef="usd">32428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-3" id="f-362" unitRef="usd">31478000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-7" decimals="-3" id="f-364" unitRef="usd">23580000</us-gaap:StockIssued1>
    <us-gaap:LiabilitiesAssumed1 contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1 contextRef="c-7" decimals="-3" id="f-366" unitRef="usd">2136000</us-gaap:LiabilitiesAssumed1>
    <lsta:BusinessTextBlock contextRef="c-1" id="f-367">The Business&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lisata Therapeutics, Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. LSTA1 also has the potential to modify the tumor microenvironment (&#x201c;TME&#x201d;), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). The Company and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, the Company has development programs based on its autologous CD34+ cell therapy technology platform that it is seeking to partner while incurring no additional capital outlay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs. The Company&#x2019;s current development pipeline includes: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;LSTA1, the subject of Phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including, metastatic pancreatic ductal adenocarcinoma (mPDAC) and other forms of pancreatic cancer, cholangiocarcinoma, esophageal cancer, head and neck cancer, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merger with Cend Therapeutics, Inc. and Name Change&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#x201c;Caladrius&#x201d;), completed its acquisition of Cend Therapeutics, Inc. (&#x201c;Cend&#x201d;), a Delaware corporation (the &#x201c;Merger&#x201d;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#x201c;Merger Sub&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#x201c;Effective Time&#x201d;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc., and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#x201c;Reverse Stock Split&#x201d;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#x2019;s common stock based on an exchange ratio of 0.5338, after taking into account the Reverse Stock Split (the &#x201c;Exchange Ratio&#x201d;). In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#x201c;Cend Plan&#x201d;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#x2019;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team provided a vast majority of the individuals on the management team and holds the chief executive officer (&#x201c;CEO&#x201d;), chief medical officer (&#x201c;CMO&#x201d;) and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#x2019;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Cend&#x2019;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;amp;D with no alternative future use being expensed as reported in the consolidated statement of operations. Operating results presented in the consolidated statements of operations and comprehensive loss prior to the Merger are solely related to Caladrius Biosciences, Inc. and subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company&#x2019;s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company&#x2019;s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#x201c;common stock&#x201d; to &#x201c;additional paid-in capital&#x201d; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of September&#160;30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</lsta:BusinessTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-74"
      decimals="INF"
      id="f-368"
      unitRef="number">0.5338</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SharesIssued
      contextRef="c-75"
      decimals="INF"
      id="f-369"
      unitRef="shares">3772768</us-gaap:SharesIssued>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c-76"
      decimals="INF"
      id="f-370"
      unitRef="shares">1227776</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="c-77" decimals="2" id="f-371" unitRef="number">0.52</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-372">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of September&#160;30, 2023, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2022 and 2021 included in our 2022 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-373">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-374">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-375">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-377">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible asset consists of a single asset, Cend&#x2019;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#x201c;Qilu&#x201d;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $18&#160;thousand for the three months ended September&#160;30, 2023 and $53&#160;thousand for the nine months ended September&#160;30, 2023. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September&#160;30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September&#160;30, 2023 and September&#160;30, 2022, the Company has not recognized revenue related to milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-378">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-379">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-380">Property and EquipmentThe cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-381">The estimated useful lives of property and equipment are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:358.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-79" id="f-382">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-80" id="f-383">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-81" id="f-384">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="c-1" id="f-385">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-386">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-387">Loss Per ShareBasic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-388">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="c-1" id="f-389">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c-1" id="f-390">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-5" id="f-391" unitRef="usd">400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-3" id="f-392">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-3" id="f-393" unitRef="usd">18000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-394" unitRef="usd">53000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-395">The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-396" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-3" id="f-397" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-398" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-3" id="f-399" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-400" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-401">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="INF" id="f-402" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="INF" id="f-403" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="INF" id="f-404" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="INF" id="f-405" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-406">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three and nine months ended September&#160;30, 2023 and September&#160;30, 2022, the Company has not recognized revenue related to milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-6" decimals="INF" id="f-407" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-5" decimals="INF" id="f-408" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-7" decimals="INF" id="f-409" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="INF" id="f-410" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="INF" id="f-411" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AssetAcquisitionTextBlock contextRef="c-1" id="f-412">Merger&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;amp;D. Cend&#x2019;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;amp;D being expensed. The fair value of total consideration was $36.1&#160;million. The following table is a summary of the purchase price calculation (in thousands except per share data).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of common shares of the combined company owned by Cend stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,772,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multiplied by the fair value per share of Lisata common stock on September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$23,580&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of Lisata's cost method investment in Cend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental fair value of Cend's fully vested stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lisata transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The allocation of the purchase price was as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7,062&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net working capital (excluding cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-74" decimals="-5" id="f-413" unitRef="usd">36100000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionTableTextBlock contextRef="c-1" id="f-414">The following table is a summary of the purchase price calculation (in thousands except per share data).&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of common shares of the combined company owned by Cend stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,772,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multiplied by the fair value per share of Lisata common stock on September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$23,580&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of Lisata's cost method investment in Cend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental fair value of Cend's fully vested stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lisata transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The allocation of the purchase price was as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7,062&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net working capital (excluding cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-75"
      decimals="INF"
      id="f-415"
      unitRef="shares">3772768</us-gaap:CommonStockSharesOutstanding>
    <lsta:AssetAcquisitionSharePrice
      contextRef="c-75"
      decimals="2"
      id="f-416"
      unitRef="usdPerShare">6.25</lsta:AssetAcquisitionSharePrice>
    <lsta:AssetAcquisitionConsiderationTransferredEquityValue contextRef="c-75" decimals="-3" id="f-417" unitRef="usd">23580000</lsta:AssetAcquisitionConsiderationTransferredEquityValue>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-74" decimals="-3" id="f-418" unitRef="usd">10000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable contextRef="c-74" decimals="-3" id="f-419" unitRef="usd">2136000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost contextRef="c-74" decimals="-3" id="f-420" unitRef="usd">382000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-74" decimals="-3" id="f-421" unitRef="usd">36098000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <lsta:AssetAcquisitionCashAndCashEquivalents contextRef="c-75" decimals="-3" id="f-422" unitRef="usd">7062000</lsta:AssetAcquisitionCashAndCashEquivalents>
    <lsta:AssetAcquisitionNetWorkingCapital contextRef="c-75" decimals="-3" id="f-423" unitRef="usd">1690000</lsta:AssetAcquisitionNetWorkingCapital>
    <lsta:AssetAcquisitionOtherLiabilities contextRef="c-75" decimals="-3" id="f-424" unitRef="usd">22000</lsta:AssetAcquisitionOtherLiabilities>
    <lsta:AssetAcquisitionAcquiredInProcessResearchAndDevelopment contextRef="c-75" decimals="-3" id="f-425" unitRef="usd">30393000</lsta:AssetAcquisitionAcquiredInProcessResearchAndDevelopment>
    <lsta:AssetAcquisitionIntangibles contextRef="c-75" decimals="-3" id="f-426" unitRef="usd">355000</lsta:AssetAcquisitionIntangibles>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-74" decimals="-3" id="f-427" unitRef="usd">36098000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-428">Available-for-Sale-Securities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:94.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:360.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:361.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-429">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:94.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-83" decimals="-3" id="f-430" unitRef="usd">28828000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-83" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-83" decimals="-3" id="f-432" unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-83" decimals="-3" id="f-433" unitRef="usd">28812000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-84" decimals="-3" id="f-434" unitRef="usd">44308000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-84" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-84" decimals="-3" id="f-436" unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-84" decimals="-3" id="f-437" unitRef="usd">44291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-85" decimals="-3" id="f-438" unitRef="usd">1978000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-85" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-85" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-85" decimals="-3" id="f-441" unitRef="usd">1978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-86" decimals="-3" id="f-442" unitRef="usd">7953000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-86" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-86" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-86" decimals="-3" id="f-445" unitRef="usd">7953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-87" decimals="-3" id="f-446" unitRef="usd">13572000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-87" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-87" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-87" decimals="-3" id="f-449" unitRef="usd">13572000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-88" decimals="-3" id="f-450" unitRef="usd">4871000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-88" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-88" decimals="-3" id="f-452" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-88" decimals="-3" id="f-453" unitRef="usd">4871000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-89" decimals="-3" id="f-454" unitRef="usd">1987000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-89" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-89" decimals="-3" id="f-456" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="-3" id="f-457" unitRef="usd">1986000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-90" decimals="-3" id="f-458" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-90" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-90" decimals="-3" id="f-460" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-91" decimals="-3" id="f-462" unitRef="usd">3996000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-91" decimals="-3" id="f-463" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-91" decimals="-3" id="f-464" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-91" decimals="-3" id="f-465" unitRef="usd">3996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-92" decimals="-3" id="f-466" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-92" decimals="-3" id="f-467" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-92" decimals="-3" id="f-468" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-93" decimals="-3" id="f-470" unitRef="usd">725000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-93" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-93" decimals="-3" id="f-472" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-93" decimals="-3" id="f-473" unitRef="usd">725000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-94" decimals="-3" id="f-474" unitRef="usd">7626000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-94" decimals="-3" id="f-475" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-94" decimals="-3" id="f-476" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-94" decimals="-3" id="f-477" unitRef="usd">7625000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-478" unitRef="usd">51086000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-479" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-480" unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-481" unitRef="usd">51069000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-482" unitRef="usd">64758000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-483" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-484" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-485" unitRef="usd">64740000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-486">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:360.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-487" unitRef="usd">29103000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-488" unitRef="usd">27668000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities contextRef="c-3" decimals="-3" id="f-489" unitRef="usd">21966000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-4" decimals="-3" id="f-490" unitRef="usd">37072000</us-gaap:MarketableSecurities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="-3" id="f-491" unitRef="usd">51069000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-4" decimals="-3" id="f-492" unitRef="usd">64740000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-493">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:361.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-494" unitRef="usd">51086000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue contextRef="c-3" decimals="-3" id="f-495" unitRef="usd">51069000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-496" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue contextRef="c-3" decimals="-3" id="f-497" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-498" unitRef="usd">51086000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-499" unitRef="usd">51069000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-500">Property and Equipment&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:358.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results included depreciation expense of approximately $89&#160;thousand and $22&#160;thousand for the nine months ended September&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-79" decimals="-3" id="f-501" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-95" decimals="-3" id="f-502" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-80" decimals="-3" id="f-503" unitRef="usd">589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-96" decimals="-3" id="f-504" unitRef="usd">589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-97" decimals="-3" id="f-505" unitRef="usd">72000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-98" decimals="-3" id="f-506" unitRef="usd">99000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-507" unitRef="usd">661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-508" unitRef="usd">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-509" unitRef="usd">457000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-510" unitRef="usd">417000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-511" unitRef="usd">204000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-512" unitRef="usd">296000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-513" unitRef="usd">89000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-514" unitRef="usd">22000</us-gaap:Depreciation>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-515">Income (Loss) Per Share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September&#160;30, 2023 and 2022, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At September&#160;30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-516">At September&#160;30, 2023 and 2022, the Company excluded the following potentially dilutive securities (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-99" decimals="-3" id="f-517" unitRef="shares">1321000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-100"
      decimals="-3"
      id="f-518"
      unitRef="shares">1399000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-101"
      decimals="-3"
      id="f-519"
      unitRef="shares">1422000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-102"
      decimals="-3"
      id="f-520"
      unitRef="shares">1424000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-103"
      decimals="-3"
      id="f-521"
      unitRef="shares">202000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-104"
      decimals="-3"
      id="f-522"
      unitRef="shares">48000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-523">Fair Value Measurements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 inputs are defined as unobservable inputs for the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:116.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:12.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of accounts payable and accrued expenses approximate fair value as of September&#160;30, 2023 and December&#160;31, 2022, due to the short maturity nature of these items.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-524">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:116.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:12.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-525" unitRef="usd">29103000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-526" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-527" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-528" unitRef="usd">29103000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-109" decimals="-3" id="f-529" unitRef="usd">27668000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-530" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-531" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-532" unitRef="usd">27668000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-533" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-534" unitRef="usd">21966000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-535" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-536" unitRef="usd">21966000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-109" decimals="-3" id="f-537" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-538" unitRef="usd">37072000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-539" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-540" unitRef="usd">37072000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-541" unitRef="usd">29103000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-542" unitRef="usd">21966000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-543" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-544" unitRef="usd">51069000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-109" decimals="-3" id="f-545" unitRef="usd">27668000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-546" unitRef="usd">37072000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-547" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-548" unitRef="usd">64740000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-549">Accrued Liabilities&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of September&#160;30, 2023 and December&#160;31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:313.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:97.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounting &amp;amp; tax consulting liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-550">&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of September&#160;30, 2023 and December&#160;31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:313.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:97.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounting &amp;amp; tax consulting liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-551" unitRef="usd">2366000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-552" unitRef="usd">2586000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lsta:ClinicalAndRDRelatedLiabilities contextRef="c-3" decimals="-3" id="f-553" unitRef="usd">915000</lsta:ClinicalAndRDRelatedLiabilities>
    <lsta:ClinicalAndRDRelatedLiabilities contextRef="c-4" decimals="-3" id="f-554" unitRef="usd">785000</lsta:ClinicalAndRDRelatedLiabilities>
    <lsta:AccruedGrantFunding contextRef="c-3" decimals="-3" id="f-555" unitRef="usd">230000</lsta:AccruedGrantFunding>
    <lsta:AccruedGrantFunding contextRef="c-4" decimals="-3" id="f-556" unitRef="usd">0</lsta:AccruedGrantFunding>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-557" unitRef="usd">164000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-558" unitRef="usd">180000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-559" unitRef="usd">145000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-560" unitRef="usd">177000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-561" unitRef="usd">3820000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-562" unitRef="usd">3728000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-563">Operating LeasesThe Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:325.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-566"&gt;&lt;span style="-sec-ix-hidden:f-567"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-572"&gt;&lt;span style="-sec-ix-hidden:f-573"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-576"&gt;&lt;span style="-sec-ix-hidden:f-577"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, the weighted average remaining lease term for our operating lease was 2.0 years, and the weighted average discount rate for our operating lease was 9.625%. As of December&#160;31, 2022, the weighted average remaining lease term for our operating leases was 1.5 years, and the weighted average discount rate for our operating leases was 9.625%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the lease agreement as of September&#160;30, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-564">The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has an operating lease for one office which expires in 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</us-gaap:LesseeLeasesPolicyTextBlock>
    <lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock contextRef="c-1" id="f-565">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:325.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-566"&gt;&lt;span style="-sec-ix-hidden:f-567"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-572"&gt;&lt;span style="-sec-ix-hidden:f-573"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-576"&gt;&lt;span style="-sec-ix-hidden:f-577"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-568" unitRef="usd">348000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-569" unitRef="usd">487000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-570" unitRef="usd">348000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-571" unitRef="usd">487000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-574" unitRef="usd">164000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-575" unitRef="usd">180000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-578" unitRef="usd">181000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-579" unitRef="usd">305000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-580" unitRef="usd">345000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-581" unitRef="usd">485000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-582">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="5" id="f-583" unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-584">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="5" id="f-585" unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-586">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the lease agreement as of September&#160;30, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-587" unitRef="usd">48000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-588" unitRef="usd">190000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-589" unitRef="usd">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-590" unitRef="usd">381000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-591" unitRef="usd">36000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-592" unitRef="usd">345000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-593">Stockholders' Equity&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 14, 2022, in connection with the Merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#x201c;common stock&#x201d; to &#x201c;additional paid-in capital&#x201d; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;At The Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC, as sales agent, in connection with an &#x201c;at the market offering&#x201d; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. Subsequent to the filing of our Form 10-K on March 22, 2022, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $43.6&#160;million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0&#160;million at the time of such Form 10-K filing, the aggregate amount of securities that we are permitted to offer and sell was reduced to $17,698,943, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of September 21, 2022. During the nine months ended September&#160;30, 2023, the Company issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774. Since inception, the Company has issued 64,394 shares of common stock under the ATM Agreement for net proceeds of $270,774.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger closing on September 15, 2022, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding of Cend. The options granted under the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144,594)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,320,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at September 30, 2023&lt;br/&gt;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,316,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,229,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:322.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:4.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vesting terms of restricted stock issuances are generally between &lt;span style="-sec-ix-hidden:f-660"&gt;one&lt;/span&gt; and four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:343.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted average estimated fair value of restricted stock units issued for services in the nine months ended September&#160;30, 2023 and 2022 was $3.00 and $12.46 per share, respectively. The fair value of the restricted stock units was determined using the Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <lsta:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement contextRef="c-113" decimals="-5" id="f-594" unitRef="usd">50000000</lsta:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <us-gaap:CommonStockValueOutstanding contextRef="c-113" decimals="-5" id="f-595" unitRef="usd">43600000</us-gaap:CommonStockValueOutstanding>
    <lsta:OutstandingStockThreshold contextRef="c-114" decimals="-5" id="f-596" unitRef="usd">75000000</lsta:OutstandingStockThreshold>
    <lsta:SaleOfStockAvailableForSale contextRef="c-113" decimals="0" id="f-597" unitRef="usd">17698943</lsta:SaleOfStockAvailableForSale>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-115"
      decimals="INF"
      id="f-598"
      unitRef="shares">64394</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-115" decimals="0" id="f-599" unitRef="usd">270774</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-116"
      decimals="INF"
      id="f-600"
      unitRef="shares">64394</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-116" decimals="0" id="f-601" unitRef="usd">270774</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-75"
      decimals="INF"
      id="f-602"
      unitRef="shares">3772768</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-117"
      decimals="INF"
      id="f-603"
      unitRef="shares">1227776</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-118" id="f-604">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-119" id="f-605">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-606">The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2023:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144,594)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,320,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at September 30, 2023&lt;br/&gt;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,316,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,229,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-607" unitRef="shares">1391352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-608"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-120" id="f-609">P7Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-2" id="f-610" unitRef="usd">187600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <lsta:CommonStockWarrantsShares contextRef="c-4" decimals="INF" id="f-611" unitRef="shares">1423774</lsta:CommonStockWarrantsShares>
    <lsta:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="c-4"
      decimals="2"
      id="f-612"
      unitRef="usdPerShare">42.57</lsta:WeightedAverageExercisePriceWarrantsOutstanding>
    <lsta:WeightedAverageRemainingContractualTermwarrantoutstanding contextRef="c-120" id="f-613">P3Y4M13D</lsta:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <lsta:AggregateIntrinsicValueWarrantsOutstanding contextRef="c-4" decimals="-3" id="f-614" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c-1" decimals="INF" id="f-615" unitRef="shares">180896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-616"
      unitRef="usdPerShare">3.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsGranted contextRef="c-1" decimals="INF" id="f-617" unitRef="shares">0</lsta:WarrantsGranted>
    <lsta:WeightedAverageExercisePriceWarrantsGranted
      contextRef="c-1"
      decimals="2"
      id="f-618"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-619" unitRef="shares">82500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-620"
      unitRef="usdPerShare">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsExercised contextRef="c-1" decimals="INF" id="f-621" unitRef="shares">0</lsta:WarrantsExercised>
    <lsta:WeightedAverageExercisePriceWarrantsExercised
      contextRef="c-1"
      decimals="2"
      id="f-622"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-623" unitRef="shares">144594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-624"
      unitRef="usdPerShare">3.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsCanceled contextRef="c-1" decimals="INF" id="f-625" unitRef="shares">0</lsta:WarrantsCanceled>
    <lsta:WeightedAverageExercisePriceWarrantsCanceled
      contextRef="c-1"
      decimals="2"
      id="f-626"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-627" unitRef="shares">24603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-628"
      unitRef="usdPerShare">29.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsExpired contextRef="c-1" decimals="INF" id="f-629" unitRef="shares">2000</lsta:WarrantsExpired>
    <lsta:WeightedAverageExercisePriceWarrantsExpired
      contextRef="c-1"
      decimals="2"
      id="f-630"
      unitRef="usdPerShare">88.35</lsta:WeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-631" unitRef="shares">1320551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-632"
      unitRef="usdPerShare">10.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-633">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-2" id="f-634" unitRef="usd">78700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <lsta:CommonStockWarrantsShares contextRef="c-3" decimals="INF" id="f-635" unitRef="shares">1421744</lsta:CommonStockWarrantsShares>
    <lsta:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="c-3"
      decimals="2"
      id="f-636"
      unitRef="usdPerShare">42.51</lsta:WeightedAverageExercisePriceWarrantsOutstanding>
    <lsta:WeightedAverageRemainingContractualTermwarrantoutstanding contextRef="c-1" id="f-637">P2Y8M1D</lsta:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <lsta:AggregateIntrinsicValueWarrantsOutstanding contextRef="c-3" decimals="-3" id="f-638" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-3" decimals="INF" id="f-639" unitRef="shares">1316134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-640"
      unitRef="usdPerShare">10.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-641">P6Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-3" decimals="-2" id="f-642" unitRef="usd">78700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <lsta:Sharesvestedandexpectedtovest contextRef="c-3" decimals="INF" id="f-643" unitRef="shares">1421744</lsta:Sharesvestedandexpectedtovest>
    <lsta:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
      contextRef="c-3"
      decimals="2"
      id="f-644"
      unitRef="usdPerShare">42.51</lsta:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest>
    <lsta:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest contextRef="c-1" id="f-645">P2Y8M1D</lsta:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest>
    <lsta:AggregateIntrinsicValueWarrantsvestedandexpectedtovest contextRef="c-3" decimals="-3" id="f-646" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsvestedandexpectedtovest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-3" decimals="INF" id="f-647" unitRef="shares">1229103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-648"
      unitRef="usdPerShare">11.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <lsta:OptionsVestedweightedAverageRemainingContractualTerm contextRef="c-1" id="f-649">P6Y1M2D</lsta:OptionsVestedweightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-3" decimals="-2" id="f-650" unitRef="usd">78200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <lsta:WarrantsVested contextRef="c-3" decimals="INF" id="f-651" unitRef="shares">1421744</lsta:WarrantsVested>
    <lsta:WeightedAverageExercisePriceWarrantsExercisable
      contextRef="c-3"
      decimals="2"
      id="f-652"
      unitRef="usdPerShare">42.51</lsta:WeightedAverageExercisePriceWarrantsExercisable>
    <lsta:WeightedAverageRemainingContractualTermwarrantsvested contextRef="c-1" id="f-653">P2Y8M1D</lsta:WeightedAverageRemainingContractualTermwarrantsvested>
    <lsta:AggregateIntrinsicValueWarrantsvested contextRef="c-3" decimals="-3" id="f-654" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsvested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-655">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:322.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:4.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-121"
      decimals="INF"
      id="f-656"
      unitRef="shares">159950</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-122"
      decimals="INF"
      id="f-657"
      unitRef="shares">70740</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-121" decimals="-3" id="f-658" unitRef="usd">480000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-122" decimals="-3" id="f-659" unitRef="usd">973000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-124" id="f-661">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-662">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2023 and 2022, the Company issued restricted stock units for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:343.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-125"
      decimals="INF"
      id="f-663"
      unitRef="shares">188850</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-126"
      decimals="INF"
      id="f-664"
      unitRef="shares">111170</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-125" decimals="-3" id="f-665" unitRef="usd">567000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-126" decimals="-3" id="f-666" unitRef="usd">1386000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-121"
      decimals="2"
      id="f-667"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-122"
      decimals="2"
      id="f-668"
      unitRef="usdPerShare">12.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-125" id="f-669">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-671">Share-Based Compensation&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2023 and 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:378.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#x2019;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-672">The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2023 and 2022 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="-3" id="f-673" unitRef="usd">103000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-128" decimals="-3" id="f-674" unitRef="usd">271000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-129" decimals="-3" id="f-675" unitRef="usd">517000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-130" decimals="-3" id="f-676" unitRef="usd">631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-131" decimals="-3" id="f-677" unitRef="usd">203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-3" id="f-678" unitRef="usd">769000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-3" id="f-679" unitRef="usd">1048000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-134" decimals="-3" id="f-680" unitRef="usd">1537000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-681" unitRef="usd">306000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-682" unitRef="usd">1040000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-683" unitRef="usd">1565000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-684" unitRef="usd">2168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-685">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-135" decimals="-3" id="f-686" unitRef="usd">221000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-136" decimals="-3" id="f-687" unitRef="usd">161000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-137" decimals="-3" id="f-688" unitRef="usd">483000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-119" id="f-689">P1Y10M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-125" id="f-690">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-121" id="f-691">P1Y8M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-692">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2023 and 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:378.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-119" decimals="-3" id="f-693" unitRef="usd">1001000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-138" decimals="-3" id="f-694" unitRef="usd">853000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-119"
      decimals="2"
      id="f-695"
      unitRef="usdPerShare">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-138"
      decimals="2"
      id="f-696"
      unitRef="usdPerShare">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-697">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had approximately $281.0&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021. As a result, $168.8&#160;million of the $281.0&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112.3&#160;million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173&#160;thousand under Internal Revenue Code Section 382. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had approximately $34.0&#160;million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $34.0&#160;million of remaining Federal NOLs. The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, Cend Therapeutics had approximately $10.9&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $10.7&#160;million of Federal and $15.0&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $36.1&#160;million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917&#160;thousand each year. The Federal NOL of $106&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation and does not expire. Cend&#x2019;s wholly owned Australian subsidiary has $1.8&#160;million of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the Company had State NOLs available in New Jersey of $35.5&#160;million and $97.0&#160;million, respectively, California of $10.0&#160;million and $69.5&#160;million, respectively, and New York City of $1.9&#160;million and $13.0&#160;million, respectively, to offset future taxable income expiring from 2032 through 2042. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#x2019;s NOLs is limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the FASB&#x2019;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the Company&#x2019;s uncertain tax positions were $344&#160;thousand and $0, respectively. Due to the acquisition of Cend, the Company&#x2019;s uncertain tax positions increased by $344&#160;thousand related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. As of September&#160;30, 2023, the Company does not believe there will be any material changes in its unrecognized tax positions over the next year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For years prior to 2019, the federal statute of limitations is closed for assessing tax. The Company&#x2019;s state tax returns remain open to examination for a period of three to four years from the date of filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2023, the Company received final approval from the New Jersey Economic Development Authority (&#x201c;NJEDA&#x201d;) under the Technology Business Tax Certificate Transfer Program (&#x201c;Program&#x201d;) to sell a percentage of its New Jersey net operating losses (&#x201c;NJ NOLs&#x201d;), which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.2&#160;million. The $2.3&#160;million of NJ NOLs related tax benefits has been recorded as a benefit from income taxes and the loss on sale of $0.1&#160;million recorded in other income (expense).&lt;/span&gt;&lt;/div&gt;On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for tax years beginning on or after January 1, 2023. For tax years beginning after December 31, 2021, the Tax Cuts &amp;amp; Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or 15 years beginning in 2022. Since the Company is in a net operating loss position, the capitalization of research and development costs did not have a material impact on the Company&#x2019;s results of operations for the year ended December 31, 2022. The Company will continue to monitor the future impact of changes in tax legislation.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c-139" decimals="-5" id="f-698" unitRef="usd">281000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-139" decimals="-5" id="f-699" unitRef="usd">168800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-139" decimals="-5" id="f-700" unitRef="usd">281000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-140" decimals="-5" id="f-701" unitRef="usd">112300000</us-gaap:OperatingLossCarryforwards>
    <lsta:OperatingLossCarryforwardsBeforeWriteDown contextRef="c-141" decimals="-5" id="f-702" unitRef="usd">34000000</lsta:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-4" decimals="-5" id="f-703" unitRef="usd">88200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <lsta:OperatingLossCarryforwardsBeforeWriteDown contextRef="c-141" decimals="-5" id="f-704" unitRef="usd">34000000</lsta:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:OperatingLossCarryforwards contextRef="c-142" decimals="-5" id="f-705" unitRef="usd">10900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-143" decimals="-5" id="f-706" unitRef="usd">10700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-144" decimals="-5" id="f-707" unitRef="usd">15000000</us-gaap:OperatingLossCarryforwards>
    <lsta:FairValueMarketOfTaxNOLs contextRef="c-145" decimals="-5" id="f-708" unitRef="usd">36100000</lsta:FairValueMarketOfTaxNOLs>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-145" decimals="4" id="f-709" unitRef="number">0.0254</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <lsta:NetCarryforwardOperatingLossCarryforwardAnnualLimitation contextRef="c-146" decimals="-3" id="f-710" unitRef="usd">917000</lsta:NetCarryforwardOperatingLossCarryforwardAnnualLimitation>
    <lsta:OperatingLossCarryforwardsPostAcquisition contextRef="c-142" decimals="-3" id="f-711" unitRef="usd">106000</lsta:OperatingLossCarryforwardsPostAcquisition>
    <us-gaap:OperatingLossCarryforwards contextRef="c-147" decimals="-5" id="f-712" unitRef="usd">1800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-148" decimals="-5" id="f-713" unitRef="usd">35500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-149" decimals="-5" id="f-714" unitRef="usd">97000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-150" decimals="-5" id="f-715" unitRef="usd">10000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-151" decimals="-5" id="f-716" unitRef="usd">69500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-152" decimals="-5" id="f-717" unitRef="usd">1900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-153" decimals="-5" id="f-718" unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-719" unitRef="usd">344000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-36" decimals="-3" id="f-720" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition contextRef="c-77" decimals="-3" id="f-721" unitRef="usd">344000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <lsta:ProceedsFromSaleOfNOLS contextRef="c-154" decimals="-5" id="f-722" unitRef="usd">2200000</lsta:ProceedsFromSaleOfNOLS>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-154" decimals="-5" id="f-723" unitRef="usd">2300000</us-gaap:IncomeTaxExpenseBenefit>
    <lsta:LossOnSaleOfNOL contextRef="c-154" decimals="-5" id="f-724" unitRef="usd">100000</lsta:LossOnSaleOfNOL>
    <lsta:ResearchAndDevelopmentTaxIncentiveTextBlock contextRef="c-1" id="f-725">Australia Research and Development Tax IncentiveThe Company&#x2019;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of the nine months ended September&#160;30, 2023, $0.5&#160;million was recorded as an income tax incentive receivable in  prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed. On September 4, 2023 the Company's Australian subsidiary received a $0.6&#160;million tax refund from the Australian Taxation Office related to the 2022 tax year.</lsta:ResearchAndDevelopmentTaxIncentiveTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-155" decimals="3" id="f-726" unitRef="number">0.435</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-156" decimals="3" id="f-727" unitRef="number">0.485</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <lsta:IncomeTaxIncentiveReceivable contextRef="c-3" decimals="-5" id="f-728" unitRef="usd">500000</lsta:IncomeTaxIncentiveReceivable>
    <us-gaap:ProceedsFromIncomeTaxRefunds contextRef="c-157" decimals="-5" id="f-729" unitRef="usd">600000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-730">Contingencies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. &lt;/span&gt;&lt;/div&gt;In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#x201c;Lingmed&#x201d;) claiming Lingmed was entitled to a success fee based on Cend&#x2019;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#x2019;s response to the complaint was filed on June 6, 2022. Lingmed filed an answer to Cend&#x2019;s response on July 11, 2022. At a Case Management Conference held on August 4, 2023, the Court set a trial date in the matter for August 2, 2024. The Company denies these allegations made by Lingmed and intends to vigorously defend itself.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lsta:TechnologyTransferAgreementTextBlock contextRef="c-1" id="f-731">Technology Transfer Agreement&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impilo Therapeutics &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (&#x201c;Impilo&#x201d;) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023 in connection with the Sanford Burnham Prebys license agreement (Note 16) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company.&lt;/span&gt;&lt;/div&gt;</lsta:TechnologyTransferAgreementTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-158"
      decimals="INF"
      id="f-732"
      unitRef="shares">766000</us-gaap:InvestmentOwnedBalanceShares>
    <lsta:InvestmentOwnedCanceledShares
      contextRef="c-159"
      decimals="INF"
      id="f-733"
      unitRef="shares">766000</lsta:InvestmentOwnedCanceledShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-159"
      decimals="INF"
      id="f-734"
      unitRef="shares">574500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-735">License Agreements&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanford Burnham Prebys&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#x201c;SBP&#x201d;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of LSTA1. At the time the license agreement was entered into, Cend&#x2019;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company&#x2019;s pre-seed preferred stock in Impilo on October 3, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#x2019; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2&#160;million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. On September 14, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SBP owned 382,030 shares of the Company&#x2019;s common stock as of September&#160;30, 2023 and is a related party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;University of California at San Diego&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#x201c;UCSD&#x201d;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2&#160;million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#x2019; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2023, pursuant to the technology transfer agreement with Impilo, the license was assigned in full to Impilo.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Massachusetts Institute of Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 43,236 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0&#160;million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, depending on when the related milestones are reached. In connection with the close of the Merger, the Company was required to pay MIT a change of control fee of $0.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement expires upon the expiration or abandonment of all valid claims. The agreement may be earlier terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may also be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2023, in accordance with the provisions of the license agreement, the Company provided notice to MIT that the license agreement would terminate effective December 30, 2023. Until such date, the license remains in full force and effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MIT owned 43,236 shares of the Company&#x2019;s common stock as of September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;Research Collaboration and License Agreement&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exclusive License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#x201c;Qilu Agreement&#x201d;) in which Cend granted an exclusive license to Qilu for the development and commercialization of LSTA1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of LSTA1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $95&#160;million and $125&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lsta:SharesIssuedUnderLicenseAgreement
      contextRef="c-160"
      decimals="INF"
      id="f-736"
      unitRef="shares">382030</lsta:SharesIssuedUnderLicenseAgreement>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-160" decimals="-3" id="f-737" unitRef="usd">10000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven contextRef="c-160" decimals="-3" id="f-738" unitRef="usd">20000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven>
    <lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-160" decimals="-5" id="f-739" unitRef="usd">10600000</lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="c-160"
      decimals="INF"
      id="f-740"
      unitRef="number">0.04</lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="c-160"
      decimals="INF"
      id="f-741"
      unitRef="number">0.25</lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-161"
      decimals="INF"
      id="f-742"
      unitRef="shares">191500</us-gaap:InvestmentOwnedBalanceShares>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-162" decimals="-3" id="f-743" unitRef="usd">20000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour contextRef="c-162" decimals="-3" id="f-744" unitRef="usd">30000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour>
    <lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-162" decimals="-5" id="f-745" unitRef="usd">23200000</lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="c-162"
      decimals="INF"
      id="f-746"
      unitRef="number">0.04</lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="c-163"
      decimals="INF"
      id="f-747"
      unitRef="number">0.10</lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="c-164"
      decimals="INF"
      id="f-748"
      unitRef="number">0.25</lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <lsta:SharesHeldByThirdParty
      contextRef="c-165"
      decimals="INF"
      id="f-749"
      unitRef="shares">382030</lsta:SharesHeldByThirdParty>
    <lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-166" decimals="-5" id="f-750" unitRef="usd">1200000</lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="c-166"
      decimals="INF"
      id="f-751"
      unitRef="number">0.015</lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="c-167"
      decimals="INF"
      id="f-752"
      unitRef="number">0.10</lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="c-168"
      decimals="INF"
      id="f-753"
      unitRef="number">0.20</lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <us-gaap:SharesIssued
      contextRef="c-169"
      decimals="INF"
      id="f-754"
      unitRef="shares">43236</us-gaap:SharesIssued>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-170" decimals="-3" id="f-755" unitRef="usd">20000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree contextRef="c-170" decimals="-3" id="f-756" unitRef="usd">25000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour contextRef="c-170" decimals="-3" id="f-757" unitRef="usd">50000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale contextRef="c-170" decimals="-3" id="f-758" unitRef="usd">150000000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale>
    <lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-170" decimals="-5" id="f-759" unitRef="usd">5000000</lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="c-170"
      decimals="INF"
      id="f-760"
      unitRef="number">0.02</lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="c-171"
      decimals="INF"
      id="f-761"
      unitRef="number">0.03</lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="c-172"
      decimals="INF"
      id="f-762"
      unitRef="number">0.20</lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <lsta:CollaborativeArrangementRightsAndObligationsChangeOfControlFee contextRef="c-170" decimals="-5" id="f-763" unitRef="usd">300000</lsta:CollaborativeArrangementRightsAndObligationsChangeOfControlFee>
    <lsta:SharesHeldByThirdParty
      contextRef="c-173"
      decimals="INF"
      id="f-764"
      unitRef="shares">43236</lsta:SharesHeldByThirdParty>
    <us-gaap:ContractWithCustomerLiability contextRef="c-174" decimals="-6" id="f-765" unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-175" decimals="-6" id="f-766" unitRef="usd">5000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-176" decimals="-6" id="f-767" unitRef="usd">95000000</lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-177" decimals="-6" id="f-768" unitRef="usd">125000000</lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <lsta:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="c-176"
      decimals="INF"
      id="f-769"
      unitRef="number">0.10</lsta:RevenuePerformanceObligationPercentageOfNetSale>
    <lsta:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="c-177"
      decimals="INF"
      id="f-770"
      unitRef="number">0.15</lsta:RevenuePerformanceObligationPercentageOfNetSale>
    <lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="c-176"
      decimals="INF"
      id="f-771"
      unitRef="number">0.12</lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="c-177"
      decimals="INF"
      id="f-772"
      unitRef="number">0.35</lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <lsta:ResearchCollaborationAndLicenseAgreementOptionToTerminate contextRef="c-178" id="f-773">P60D</lsta:ResearchCollaborationAndLicenseAgreementOptionToTerminate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M*]WW1HV<J'E(+&:AZW3-&MXA/MQ+ M><WO.DL]Z4WF]$!6\5;3_7FN]P+]?
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M,;/U8^.=;Y+F@_ 7*E<\4RAA#^#GG(0P,7+[C75[H\6F^$QY+[06:7&Y9A1
M&P-X_R! :I4WYLMG]:5[]B]02P,$%     @ <(%B5UM=AQW0 @  _ <  !@
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MBBF[C: 6]:FA^R1/>(KG0/6P5CWL5/V%IWJ_Q852-M<M/Y(JWW];#HD=MI9
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MN@7]%M!X *VO-&W:=N 3M#^:R5]02P,$%     @ <(%B5T1OFF'I!   6 P
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M"@7".201H5-04JREDEY2M'PN/ B+L$:I-U#4<&F0LU@:ZWE#]]08Q(+6K(.
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MEY9:4LO:-ZR'((?]CPN3 Y>2-=[TT%!34.XY5-;W.I*:2Y'<GB^23$M.@X>
MDHJ/!0J=HFPZY/X<;#0=/6K/;@NYA>9D5]0=(:-^H$F1XG0@0P38#'=XH;;O
MWHSC:/3!-HP?(3ND;KY+^\Z9AS;TDF^Z)B2$3%=G1>;(*X*1HF2Y);H:43UR
MGPL$[] DN?6K.W@V)Z0$+$JIMXCV%"=J"PSVF%1S0RA_DWLZV-Q*ARJ=8Y=R
M]^ 55:!9^[>B):Q*N>9!M5_=/T<OFU?8O7CSEOTLS#HG?R2N2#7LC 8!F.9]
MV/PX7?HWV5([>N'Y:49/:C0L0/LKK=WNAPWL'^FS_P!02P,$%     @ <(%B
M5\[DI %-"0  T1H  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULW5EM
M;]LX$OXKA#>[V *)XY<D3=HD0)*VV!:[W:+IWN%PN ^T-+)YE425I.*XO_Z>
M&4JRG-CI%7M?;K\DEDS./#/SS OI\Z5UG_V"**C[(B_]Q6 10O7B\- G"RJT
M']J*2GR365?H@$<W/_25(YW*IB(_G(Q&)X>%-N7@\ES>?7"7Y[8.N2GI@U.^
M+@KM5M>4V^7%8#QH7WPT\T7@%X>7YY6>TRV%/ZH/#D^'G934%%1Z8TOE*+L8
M7(U?7!_Q>EGP-T-+W_NLV)*9M9_YX6UZ,1@Q(,HI"2Q!X]\=W5">LR# ^-+(
M''0J>6/_<RO]C=@.6V;:TXW-_V[2L+@8G Y42IFN\_#1+G^AQIYCEI?8W,M?
MM8QKI].!2FH?;-%L!H+"E/&_OF_\T-MP.MJQ8=)LF CNJ$A0OM)!7YX[NU2.
M5T,:?Q!393? F9*#<AL<OC78%R[?EHDM2'W2]^3/#P,D\OO#I-E]'7=/=NP^
M4[_9,BR\>EVFE&[N/P22#LZDA7,]>5+@+55#-1WMJ\EH,GU"WK0S;RKRIM\T
M3[TR/LFMKQVI?U[-?' @Q+^VF1PE'FV7R$GRPE<ZH8L!LL"3NZ/!Y4\_C$]&
M+Y_ >]3A/7I*^C?#\=_O5F]!>>_)>U/.55@04DCGYJN>F=R$E;(9DY><HU0%
MN(?7!K^O3)GD==KN*5$64 "<#OP&[O,JT<ZM4 V6VJ5>_?S^]U_]LWU9?&.+
M2I>K1BT@\$M]ITVN9SFIRGK#*:ATF4+P7,L#W9F4RH14L(I\,$@T4B9#E<@R
MDQ@J@\KJP%$#2I%CHI5+D^=J1FI.)>-C,ZRJ ZS[BC7!*[HW7F!OL7.HKI'*
MJ4)=X*41,6I-V+1DH;VJG&6(J=(  I5W.J]UK"@Y2IIF['J.\N>#R&*7;=&(
M?RS:N-:<"#5*<L3UTZL:PES 1Z4#5AML004<JBO/\7I%"14S<FHZE@09/P0+
MC!7@WHL3\Y7:FYR.AR.4C3QG+1#QAE(X*U<<M5YHX#F;98"YP]=T7QG'KLR<
M+:!Z.H)F9^OY@A].ANI3#P?HPLV"/08[2IVO/ SAH*<4R*&(L6,68B$UL %N
MB3#ZA:E4LM#EG!CM')3%#EY<JN/1C\K>X4FKZ<&*-%Y3C"\4&BNQ?*?+&JU%
M38ZC@\1S&N[U*-+[:F]\<CH\[?N#_?<-+PG/Q &(6=D0+-TT>>EL8,19M*NR
M+O04/&:#> -OZD1<02JQ6. K6TKF;:-8M(&_!3OVQN/)<-J''!G$7_?!1Y1+
M9QIT3P-Z#$0@"A HW8:*$Z2TRL -26 :L8R9SN7+.%58U[+(!T23DVRH?K52
M(/!%+4!F!,J0['Y,A,=Q[9+?U[-_4]0L9,.R7.6F,$&W$=@;/Y]"L*T]VUBC
M43G41M *S%0?Z8[*F@.9DKIM)H7IZ617RDV^F7+3H[]6QI5P2Q6B$\;1_9.-
MM&I)]5 <TNWT=#CY_\JKA]'[:Z?5X\A^3V)])6?5<F% VOR!7ITQB7:)+VUX
MH&(MV#^1>3<$;\+S3E<$OB1^6_Z-1\.S/Y]_?R*_(&NI_?\@P;!ZBP?%"<R/
MQW8_WV8WH]P;'V_26BC3H_+Z>2,MI?8P>;CD].K/T40HSDT8 OZ0"1/3D<9P
M@Y/=9SB522WV[J%6C3O5# :X\Y7L*.6S2<3O68.71SG>.!D>'_T8K15("RV3
MXW8J/O#%V?CYNN*33A8"-9K:XT/L#J.3]=J.P,A+MALC:SC0R9?:\.@*7<VH
ML24N(-0CRBKCA>Q;F1[Y8RDNB1X?BL$__7 Z&3]_B5@L; Y[F$>INJKYS)(;
M^ #RO$D-=T1FPMYX<ZB)<5P8V-VF,P_M!D*:N;W1O:'YDU"7>?WM.9=]$]FS
M(UE%P?81]7;-M74ZPM_O<8)_AWRA5>3-\?!X@S=[9\_7)-[GNEV1'.GS%4H#
M' /;2J.;H/;X+IM/SM;B'F[F!:S]']9]5C?-X0A./=L4,9[NUO_=[7RRD4Y#
M.:TEZ!*I^'EIPJ(_CK0=YM'<DF!NB2X&@6.%Z?F[(Y)X&Z$5]H$&<\".#&\J
MD^E5JY@GW!3E+-8<&]M4VW:T@>24*C"73VLUNIR(;@YFS;[M?DEKUQXUF]1:
M+@29]5A+!3H^LSPU&;3R,=&#S7%G[*&0M5FKI:0T9\\W5[?7G0_D',=W29ZS
MH'?48D/BV53:3U]8,Y5$:6%I#WR@BB4!B.>@=_4_GG4+6Y<AS@V)G9<\T(CX
M&5R1&33H-]"\H4\5:.:M"PHTZX/<? :E#KA!''!^@B?D40C2_;Z.GH*F5B60
M9G.3RE$X,R6(9,"4;CJ0,/'"7+LY3DXMJ-BXI*,\[DX"QBPL'Z\R[(C3BY91
M+4:ZXPF8$'+1%.D;KQQRNM-X(V2I$5;,3*M-'W>6\/P Y0R-\PU\TI!-<CJW
ML(7M$LD[0J?$!) #L"B&H6$9+T,&4NEWGJ5W5*R./;MT+KEH8FP\6C<1*1:C
MS0HQ5*]J:@>Y?D,!%"[YWZ<49B$(?'\Q6SU0#H^W=R']"2 V>.Q*Y;H#;UK)
M#T>!;O3FS@%.@9P1.<6&$.]6=B-K$SVFLW\\R;2W>YN=H6N$,_ -Q:V=I)K^
MQ4N898XI'6N6*(M8'F3;&H[<%\1[K/O0# &<@C*Y((\-IZ,%G/%9A--.(>R5
M.@XBO=F4,XCO$&,C[5^OZ?L-[W41C-YE4([@%HB()PJ^5"O%J_<:Y2-629'9
MW69DDOGB^LS6+>9N)$N;.2E#A2KG0_5[J:Y@4*Z.M[D7'B(0,1:&/,Y+B.=:
M7*_[OD;4;6$2Y BH:RM)Z:LV>=7/;-QD]/+]N]>OKN3S^.6SYES-DCY1LBAM
M;N<K=5W#.UPI^?[U!H0Q&:8]X/[D=.E1T=4'9^=.%YW0YKD3"^,]@0+BE@1
MFB;'<>]!?GQ-"7JL@0J]6YG[[6C$_.))BK[4$(PY"^53$D>K+S7/$\V4VAPQ
MV'NS>@705>U\+54MYG-K!,>/D4A_H%1XOS=9'X$C1?8>W-PT\-:9N^X77LKR
MC*B4*NGD%I*+7%NZ)7SK(D>^.W#*52T4>)W'.7S4&\,[84Q$3K16QL]-E7PV
MW':7?=C[F:$@-!'^,049P0TI_N+0O>U^K[F*/U.LE\<?>WY##^(+SYPR;,71
MY7B@7/P!)3X$6\F/%C,;@BWDXX(T.,8+\'UF;6@?6$'W*];E?P!02P,$%
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M\M&% #ZOK*7-(B08_D3F?P%02P,$%     @ <(%B5U<-(?T; P  . <  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULI551;]LV$/XK!Q4H$L"S9-EQ
MLL0V8&<;F@%MC2;;'H8]T-39(D*1&GFJXW^_(R6K[N &6/<B\<B[[[[O2!YG
M>^N>?8E(\%)IX^=)253?IJF7)5;"#VV-AE>VUE6"V'2[U-<.11&#*IWF639-
M*Z%,LIC%N;5;S&Q#6AE<._!-50EW6*&V^WDR2HX3G]2NI#"1+F:UV.$CTF_U
MVK&5]BB%JM!X90TXW,Z3Y>AV-0G^T>%WA7M_,H:@9&/M<S >BGF2!4*H45)
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M3!9OWXRFV=TKO"<][\EKZ/]]G_X''#Q4M=(6GDITHL:&E/3P8.#71A_B/@R
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M-_CH[$::<O-PKJ33^;*Q T8ERI5 *5%@2V&/HWKUO/\?<KM^N$+0$^2QL\9
MPWPC8 UPQTA2B/7E2J'>+X!C!3N$1/GE_/WI9"1.2_ZQ!%KQAQ[G87L[0B%H
MY.OD^Z=>+"R\)7/]2CJULH9=ES[XJ9**H$O(DDP:B?>KMNC"V0NX[EGSF<T*
MF6]"L.E"]!+F<^C875F5*^OT'PI0/(^V\BV51P2!F&;(]UD(<&L-1]1E8:P.
M7G;"!]\]1<W# A?J!_O;#D),#^U]1?L&-27J"K&;/9X.Q[-Q<-G3E<1F&00
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MP45\$DR=0-1%6V YF@W/Q%D@&-QO(KI3)6AZ41 13#8/:P[+#Z6;HFQKXSY
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M:R[@NF/-STU1R7(;@DT7HI<PGT/'[LK:KXW5ORO ]S+:RK?4#A$$RN9COL]
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M3G*<V2H//TQUUMB:P@XI \&#TA59-K19U@V[44 A[S]>_Z2VS?.W 8KLY7Q
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MGU=**!)OTZWA0DFMD//.6O65PPOOIJ'":LI_?HW^\^NDW7_H+?$FJG7,?7Z
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M:%W6PJ<G0TI<RIF?<Q?=WN"2UIC68U"2ICUQC+IN'?7A4%&&>T.E1+WVH].
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M6K0R(; >A3ZF%/^@^RA1K5V/I4EX&V'J1J3]VK9QL[I[>3*O>\"/3*TYE:'
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MSE.RX/SW(NVV.)6W<L.X>9IZWL1Y^N#VLQ4?)$&XDVM57I%4B.+OEV&WU\F
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M!<'$KR@37I:XM5QEB6R0,P&Y(KJI*JJ>+X#+-O5";[-PRQ9+M M^EM1T 3/
MNSI79N;W+G-6@=!,"J*@3+WS\.PB#*S [?C%H-5;8V)#N9?RP4YNYJD76"+@
M4*"UH.;R!)? N74R'(]K4Z\_TPJWQQOW:Q>\">:>:KB4_#>;XS+U3CPRAY(V
M'&]E^QW6 8VM7R&Y=K^D[?9.S>:BT2BKM=@05$QT5[I:)V)+$([V"**U('+<
MW4&.\HHBS1(E6Z+L;N-F!RY4IS9P3-BJS%"9N\SH,)MUU2"R)#.V$*QD!15(
MSHM"-@*96)!<<E8PT.0+R95Y&A0^$RKFY-MCPVI3'R2?K@ IX_ISXJ-!LL9^
ML3[^HCL^VG<\U,<D#HY(%$3Q2[EO(NG#B?IP(N<WVN-WW2C!L%'@$$NVLF.]
MBVO0Q[X+9[JF!:2>>=@UJ"?PLH\?PDGP=8 R[BECYQ[OH=SD\8CDW&;[93K_
M_##;R0U"I?_N(H\/0#[JR4>#^;W34#:<<%;"+K1A<1B09Z!*#W",>X[QH-6E
MK.H&01'8I&T7SJ#'&S,UZ0DG!ZSQY #DTYY\^IX:#XOC5TM\TF.<##K-9(DM
M53L9!I5O3,]ISW5ZP,*>'H \#/[_V0?O*>TKZH':^EL=R';SGU0MF-"$0VFL
M@N.I>155UR"["<K:-:5[B:;%N>'2?%2 LAO,_5)*W$QLG^L_4[)_4$L#!!0
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M#)TO\DKI,*$C@M[1F_=-$_^T2J!5:>?9U#ZN=A5?YQDSFB%98Z=X3:O25]7
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M8^6>7GDBZ+;8M%I3(6A6'&X 1\!4 _E]3*EX/5$&]<[JXC]02P,$%     @
M<(%B5TCG@@8> @  KP0  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
MM931;ILP%(9?Q?*JJ96VF#@DZS) 2II5J[164=-N%],N'#@)5@VFM@G=V\\V
M!&52DKO=@(]]_M_?,<=$C50O.@<PZ*T0I8YQ;DPU)42G.11,#V0%I5W92%4P
M8T.U);I2P#(O*@2A03 A!>,E3B(_MU1))&LC> E+A71=%$S]F8.038R'>#_Q
MR+>Y<1,DB2JVA168YVJI;$1ZEXP74&HN2Z1@$^/9<#H/7;Y/^,&AT0=CY"I9
M2_GB@KLLQH$# @&I<0[,OG9P T(X(XOQVGGB?DLG/!SOW6]][;:6-=-P(\5/
MGID\QM<89;!AM3"/LOD&73UCYY=*H?T3-6UN&&*4UMK(HA-;@H*7[9N]=>=P
M(*#TA(!V NJYVXT\Y8(9ED1*-DBY;.OF!KY4K[9PO'0?96647>569Y)[4%M0
MZ"-Z8$HQ=T+H<@&&<:&OT 7B)7K*9:U9F>F(&+NADY&T,Y^WYO2$^0JJ 1J.
M/R :4(J>5PMT>7'UKPVQO#TT[:&I]PU/^-Y\?5@<HSFK<NT]U15+(<:V?S6H
M'>#D_;OA)/ARAFG4,XV\^^@$TTQK>X5FZ6O--?<-]^N[34%W!@K]^QCMZ#_0
MACUM>/8$GZ1A E6U2G/;TJA2/(5CC*W+Q+NX^[U+1I/@\W5$=H>;DX/^<U?Y
MGJDM+S42L+&Z8/!IC)%JKT<;&%GYEEQ+8QO<#W/[1P'E$NSZ1DJS#UR7]_^H
MY"]02P,$%     @ <(%B5VVYPNRZ!   Y!8  !D   !X;"]W;W)K<VAE971S
M+W-H965T-# N>&ULS9AM;^HV%,>_BI5=;:UTVSQ!@ Z0>F'3*K5==7N[O9CV
MPB0'8C6)<VT#[;??<9(& JE5I%QI?5$<Q^=O^Q<?^QR/MUP\RQA D9<TR>3$
MBI7*KVQ;AC&D5%[R'#)\L^0BI0H?Q<J6N0 :%49I8GN.$]@I99DU'1=U#V(Z
MYFN5L P>!)'K-*7B]0LD?#NQ7.NMXBM;Q4I7V--Q3E?P".HI?Q#X9-<J$4LA
MDXQG1,!R8EV[5W-WH V*%G\QV,J],M%367#^K!]NHHGEZ!%! J'2$A1_-C"#
M)-%*.([OE:A5]ZD-]\MOZK\7D\?)+*B$&4_^9I&*)];0(A$LZ3I17_GV#Z@F
MU-=Z(4]D\9]LJ[:.1<*U5#RMC'$$*<O*7_I2@=@S<'OO&'B5@?=1 [\R\#]J
MT*L,>@69<BH%ASE5=#H6?$N$;HUJNE# +*QQ^BS3W_U1"7S+T$Y-[T"L0)"S
M.2C*$GE.+LC3XYR<?3HGGXA-9$P%2,(R\I0Q)3]C)9:_Q7PM:1;)L:UP#%K)
M#JO^OI3]>>_T]PCY)7'[GXGG>%Z+^>P#YKY3F/LMYG.S^1Q"-'?;>K<17$W/
MJ^EYA9[_CMZUE.B:U^'W-9.L6,?_W&(3<J,@E?^VT2GU>NUZVLFO9$Y#F%CH
MQ1+$!JSISS^Y@?-K&ZLNQ>8=B34X^C5'WZ0^O5^G"UR%?$E"GJ:(L5IW6*%B
MT)4+M(AT(:?9*^%;_;1X)3/((H).$C['/(E 2'+&WJS/V_@;QW$J_U*L7XCI
M#78S';K^J-<;C>W-/MKC=H-A$#B!6[=K4.O5U'I&:K/?[N=M<S1:G3K'+L7F
M'8DU:/5K6OV.?;7?)<<NQ>8=B34X!C7'X'_BJ\&1V_B#@3<(ADWWFAG'>RK:
MCL0:: <UVH$1[1T&*RQ/6,E+TUQ2)LB&)FL@.4(O8&G2MTSB:5]_ 0V58 &/
M1US-^O,8CM@OY2"&>UR#2Z]_ -4XTE.A=B36@#JLH0Z-4+]Q19,V#*59L(?!
M\_M#YX"#4?Q4#AV)-3B,:@XC\VE!A7AEV:I:3O4B^D7B,I**I*!B'F%XMP&I
M,+)7.M+3/MO&;G3DFJZ#?P?LC ,ZE5U'8@UVKK,+DQTCO9LL%*"IT&3?*9&B
M1H0,E^LD>26:'41O#IGK8Z8]2':. 'JN'QSP,X_I5(!=J34)[B4:KI%@M64I
M03-)RZ1/K[MV/.[QUC_T#ND8^SN93D=J33J[1,(UQM?E+D7RM0ACS&))+E@(
MK62\8S*!,SH\$LV]G<SF1^0&[BXY<,W9P8S*F&"Z24)=  S@T/G0%=N73DNP
M[01':Z?+/&#>E5J3SRX-<,UYP#W&M?IV16_N(<V97DEG\!(FZZBLDG%K?%7)
M[J.Z<(/1X2YN[OUD5C\B!W!W28!KC(VG?V)4)4C"Z((EF 5 ^QKJ'X/QCI90
MIQ%]5VI-++N8WC4']45:)$ ?_Q>YX"%(270_%/>CPO4BV$#"<WT"MA)KB=4=
M?^0?,NLT5.]*K<EL%ZR[YFC]%K?H3+;OTH.CV-+O'T;89OF3870:8]M[-XKZ
M_O>.BA7+)$E@B?+.Y0"_M"BO5,L'Q?/BDG'!E>)I48R!8I:G&^#[)>?J[4'?
M6]87V]/_ %!+ P04    " !P@6)7W+P<''<%   E(@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6RU6FUOXC@0_BL6MSKM2ML2VR% CR)UV]L7:2M5
M9;OWX70?3# E:A)SMBG;^_7GA#3&<6)(%;ZT"<P\>69LSZ,9,MDR_B16E$KP
M*XE3<=E;2;F^Z/=%N*()$>=L35/US9+QA$AURQ_[8LTI6>1.2=Q'GA?T$Q*E
MO>DD_^R.3R=L(^,HI7<<B$V2$/[RB<9L>]F#O=</[J/'E<P^Z$\G:_)(9U0^
MK.^XNNN7*(LHH:F(6 HX75[VKN#%M8\RA]SB9T2W8N\:9*',&7O*;KXM+GM>
MQHC&-)09!%'_GNDUC>,,2?'XMP#ME<_,'/>O7]$_Y\&K8.9$T&L6_Q4MY.JR
M-^J!!5V232SOV?8K+0(:9'@ABT7^%VP+6Z\'PHV0+"F<%8,D2G?_R:\B$7L.
MT&]P0(4#.M8!%PXX#W3'+ _KAD@RG7"V!3RS5FC919Z;W%M%$Z79,LXD5]]&
MRD].KYY)%)-Y3,_4ECB;$74QH^&&1S*B IR!F=HWBTU, 5L"VQ;LV=[3D*5A
M%$<D7Y_W-U0J<_%!@3S,;L#[=Q_ .Q"EX,>*;01)%V+2ERJ C$8_+,A^VI%%
M#61G='T.L/<1( _A&O=KM_L-#94[S-V1Z=Y7:2MSA\K<H1P/-^+-Y5X&/E82
M)+($_?U=.8%ODB;BG[J =T_PZY^0G>$+L28AO>RI0RHH?Z:]Z>^_P<#[HR[\
MCL",9. R&=B%/KUF0M8%N/,*<J^LICQ/!] ;!9/^\SYSVRKPAX-1:650\DM*
MOI/2%\Z$  ^I*F]Q]!]=@"^JK-5NNQW.8._Q7H6@R\(@-RC)#=J1^Z[N:2V[
M@?7L,SBL\*NS:4A?4#(,G S_%#)2=5)1^TPB#GZ2>$/KZ 76H]4*!^,*0=M*
MK;#?D,1A27%X8-/Q->.*HZK<ZBR*\BS6\71"M3UJ'8$948_*J$<GKSNC+I/1
M$9B1C'&9C/&;ZL[8VF]H-$*CRJZTK7P?>PT'!WI:5+V.*D\!Y"H]3A.3X)[J
MPZZJ3X%DEI9J_:XU&C:PU/H*G8IU= 4J8"J+#5&5I&WF^V@,&VAJY8.'I"])
M* \C$H,U65->2]$)T?; =85F!JQU%?HG+T#0J=VM$](1FID0K>70+>9-10C:
ML@S'PVH1JK$:C@>X85MJ^89N_6Y1A&QQMHJ0R\0DJ,4;NM6[31$:'F;H,C$9
M:J&%3NDZO@"-CEIGV\JQSEH H5L!;UE*7U1/R)]4U[_<-'563I#6YZTC-+/O
MTOJ*O--W7DX);]UZ=81F)D3K.7+K>5,!0K8N0SP85I6QQLP?#1N$$>WUQV[]
M/KX"(5N:J^?;:6(2U,J-W,K=H@(52$Z&+A.3H99:Y.YACZU R&Y0:Q?:-G,L
MM-8_Y-:_JT>:AB]@SAJ*C]N]]5GK",T,5NLJ"DY??)S2W3HA':&9"=$ZC@YU
MX0W%QU9D.!Y5)Q<U5DVG1NLV<NMVB\)C:[)UK%TF)D&MV<BMV6T*C]VCGL$J
M1=NF@2+6&HO=/>RQE0?;[:E:96O =W03B[7H8;?H_5#9$QNNZDX4Q[6Y<P.T
M/69=H9GA:C7%IQ\WXT[GS5VAF0G9FSB_<>1LZS >CZT=>;1:8ZW6N*N),SX\
M<G::F 2U4./.IL[8[DHMABX3DZ%65]S-U!G;#6G=(A_=MF(M=]@M=[>;- JC
M-8F/&3J[L5H?N%.,G;&657SZP3/N=/+<%9J9$"WC^&W#9VSK\1 -JGNSQBA
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MH]@_0./'"DP$5_9)]DVNYY"D4EKD#1@5Y*RHW_2UJ4,'X \^  0-(/A70-@
M0FNT5F9MS:FF\42*/9$F&]G,P-;&HM$-*\PI+K7$588X'=_M*.-TQ>$*;\35
MDN)@"4DEF6:@R!69<:H42UE";=5%2HX1I(,XGX/&=76!V.?EG)R?79 SP@KR
ME(E*T6*M)JY&W69W-VDTWM<:@P\T+J&\)J%W20(O"'O@L]/P.20(]RT\> MW
ML5IMR8*V9('E"S_D6^F.Y<N^BORZ6RDM\8[^[K-;\P_Z^<UW.U8E36#JX(>I
M0.[ B3]_\B/O2Y_Y_T3VIA1A6XKP%'L\HRHC\%*Q'9HN=._9U@R193 ]91<'
MM[Z'Y[CKNNC)&D7139OU1MZ@E3<X*>\[E5N\CG@R1+7GU:>QIAEV=_=OH^B=
MQN.L<.2-@GZ-PU;C\*3&)Z$I[],T/*K(T/>BVW>:CK.BP6C@O=/D=AJ$:<Y8
MF TK%.&0(LZ['B&-K!M>'6A1VIZQ$AH[D!UF^(\ :1)P/15"'P+3AMJ_3OP7
M4$L#!!0    ( '"!8E=*9OT@V (  -L)   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;*V686_:,!"&_XJ555,KC28$$J"#2"VLVZ15JDK;?3;A(%:=
M.+,=*/OU.R=I!"6D$^(+V/&]YWO./MO#M9 O*@+0Y#7FB1I9D=;IE6VK,(*8
MJDN10H(C"R%CJK$KE[9*)=!Y+HJY[3J.;\>4)58PS+_=RV H,LU9 O>2J"R.
MJ=S< !?KD=6VWCX\L&6DS0<[&*9T"5/03^F]Q)Y=>9FS&!+%1$(D+$;6=?MJ
M/##VN<$S@[7::A-#,A/BQ71^SD>68P("#J$V'BC^K6 ,G!M'&,:?TJ=536F$
MV^TW[[<Y.[+,J(*QX+_97$<CJV^1.2QHQO6#6/^ DL<S_D+!5?Y+UJ6M8Y$P
M4UK$I1@CB%E2_-/7,@];@G;W@, M!>[_"CJEH).#%I'E6!.J:3"48DVDL49O
MII'G)E<C#4O,*DZUQ%&&.AU<KRCC=,:AA3NB-:78F$*82:89*-(B^^-D:WRV
M(6.1:(F+D5%.[J@V(QMR/@&-.G6!'IZF$W)^=D'."$O(8R0R19.Y&MH:HS<Q
MV&$9Z4T1J7L@TBFDEZ3C?"&NXW9JY.-F^01"E+=SN;LKMS%G5>+<*G%N[J]S
M*'&QD)K]A3EF0.DZG$+?K=>;ZKQ2*0UA9&'Y*9 KL(+/G]J^\[4.[D3.=E [
M%6JGR7OP"Y0B.J()$0F0#5!9AUOX\',?YNQ8!5[;Z?M#>[7-T3C3D1S=BJ/;
MR/$=CSD-\F.4PHVWA>*\PVB<Z$@,K\+P&C$.[3=O+^JZ!?#VELGO]KQ^9;43
MDE^%Y#<6PS>E&1ZI6 RWE$GR3'D&=2'ZIRR)$SG; >Y5P+T3E$2O;D7\P;L5
M:9SI2(Y^Q=$_34GT/RR)QHF.Q!A4&(-&C$>A\?J!:A<NS"Y<'=J%@[J3:F]9
M]JVP4+K.NT*QMZY>\^RYHW+)$D4X+%#G7/8P9;)X2A0=+=+\-IX)C7=[WHSP
M]072&.#X0@C]UC$7?/6>"_X!4$L#!!0    ( '"!8E>JVJXXS@,  $ 4   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+5878^;.A#]*Q:WNFJE[?*1
M0#;;)-)N:'4KM5+4[<=#U0<O3()5P-0VR?;?7QL(@<1+FY7W);&-YXS/L<<,
M,]M1]I,G  (]9&G.YU8B1'%MVSQ*(,/\DA:0RR=KRC(L9)=M;%XPP'%EE*6V
MYSB!G6&26XM9-;9BBQDM14IR6#'$RRS#[/<MI'0WMUQK/_");!*A!NS%K, ;
MN /QI5@QV;-;E)ADD'-"<\1@/;=NW.O0#91!->,K@1WOM)&B<D_I3]5Y'\\M
M1ZT(4HB$@L#R;PM+2%.%)-?QJP&U6I_*L-O>H[^KR$LR]YC#DJ;?2"R2N75E
MH1C6N$S%)[K[#QI"OL*+:,JK7[2KY_IR<E1R0;/&6*X@(WG]CQ\:(3H&$D=O
MX#4&WK'!^!&#46,P^EN#<6,PKI2IJ50ZA%C@Q8S1'6)JMD13C4K,REK2)[G:
M]SO!Y%,B[<1BQ>018N(WPGF,WOXJ22$W5:"7(0A,4OX*O49?[D+T\L4K] *1
M''U.:,GE7#ZSA72O0.RH<75;N_(><35%'VDN$H[>YC'$?7M;+KM=N[=?^ZTW
M"'@'Q24:.1?(<[R19CW+OS?W-.;AL'D(D31W=>8]-J-V)T85WN@/.W&!5BF6
M6]#?D.\?Y'3T7D#&?^BDK[''>FQU>5SS D<PM^3MP(%MP5K\^X\;.&]TNID$
M"PV!]30=MYJ.A]#[IQOV8EZ@#:-<>X)KN*""4U?F=A$$[LS>=M49='FN.J<.
M)^ZH==@C[;>D_4'2-U%49F6*!<3R!I2+B A6=ZR.;XWD=]R_'ON3(\*#[LXE
MK//H3O2,@Y9Q\*1MSD'H2 <G2_"<\1'G08?G<M8XG 9ZRI.6\F20<OB'C9V<
MN+R:'E&<G!P]=8]UIX2#:WAB[%ZU#*\&&;XK64Y$R:#:U35Y4&UMT [BG'OW
MF00+#8'U])NV^DV?\7TR-:FI2;#0$%A/4]<YI$N.V3=*@]>-1.<H$(==GJN/
MQJ'GZR\;MY,ENH.TES0K2@'L0%G+=1#DW%-C%"TTA=87T#L(Z#UC-#;@IH0U
MB1::0NL+>\B:W<$$\@D!.3J)#__DW3CL]&R)AEWVF1]R6W<XN?T \GLWH6F,
M2%8PN@5%7$_99,JZ-(H6FD+KBWC(E5W_.>/29&J\-(H6FD+K"WM(R=VGY>2/
MQV5P^BGD'8>ET;1<XW%Z')5VI[22 =M4)2J.(EKFHJY4M*-M&>RF*OX<C=^Z
MU\NZF'6 J6MK'S';D)RC%-82TKF<R(UC=;FJ[@A:5 6<>RH$S:IF C@&IB;(
MYVM*Q;ZC'+1%P\7_4$L#!!0    ( '"!8E<.>\(P)@,   H-   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;,U7;6^;,!#^*Q:3IE7:REM>NP2I33NM
M4BM%S;9^F/;!A4NP"C:S3=+]^]F&4,@(6B4^Y O8Q]WC>Q[NT#';,?XL8@")
M7M*$BKD52YE=V+8(8TBQ.&<94/5DS7B*I=KRC2TR#C@R06EB>XXSLE-,J!7,
MC&W)@QG+94(H+#D2>9IB_N<*$K:;6ZZU-SR032RUP0YF&=[ "N3W;,G5SJY0
M(I("%811Q&$]MR[=BX5K HS'#P([45LC3>6)L6>]N8WFEJ,S@@1"J2&PNFUA
M 4FBD50>OTM0JSI3!];7>_0OAKPB\X0%+%CR2"(9SZV)A2)8XSR1#VSW%4I"
M0XT7LD28*]J5OHZ%PEQ(EI;!*H.4T.*.7THA:@$*ISW *P.\PX#!D0"_#/ -
MT2(S0^L:2QS,.-LAKKT5FEX8;4RT8D.H?HTKR=53HN)D<$M#E@+Z<,>$.$-+
MX&@58ZX,UR Q293M$Q+:(O8W0M&WF.4"TTC,;*ERT$AV6)YW59SG'3EOBNX9
ME;% -S2"J!EOJ]PK MZ>P)77";B"[!SYSD?D.9[?DL_B_\.]CG3\2D_?X V.
MX4D6/B.6Z1IME:<S7#?MA<AP"'-+=:4 O@4K>/_.'3F?V[CU!-9@.JB8#@RZ
M?X3I)94D(DFNVQ"M(,PYD435Q\U+F.3JW:(U9RE:L#3+)38MR];H!G-*Z$;4
M*NWGG0)&MQ)2\:M-L$&?@O4$UA!L6 DV["R-AF#B53!H"!8V!8.]8)D23!2M
MJ3JPZ,6S-KV*)(8F"?T1WP:N[[DS>UO7H<UI.JV<&OQ&%;]1)[]'S#FFLK7J
M.R/?^A)[ FN0'%<DQR=1]>,^!>L)K"'8I!)L<@I5/_FWH ?Z@]ZH^E:G07O5
M3RM^TTY^#R D)Z%43(3Y]N>4M/= )\Y;7VE/8 W*KO,Z-#@GT05E&CUIUA=:
M4[3:I.6>0B>46=2K7,TV!YW0XC28'#2"79LJ4^ ;,VP+E6!.93&?5=9JH+\T
M8^R!_4H/^F9:?84I_A+N,=\0*E ":P7IG(]50KP8O(N-9)F979^85).P6<;J
M9P6X=E#/UXS)_48?4/W^!'\!4$L#!!0    ( '"!8E=S?@4XN0,  !@3   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;,U876^C.!3]*Q9;K6:DMF"2
MD*2;($U3C6:DSJAJY^-AM \.W"16#<[8)IG]]VL#A5!<VJI4ZDMBFWN/SSW8
MSHEG>RYNY09 H3\)2^7<V2BU/7-=&6T@(?*4;R'53U9<)$3IKEB[<BN Q'E2
MPES?\P(W(31UPED^=B7"&<\4HRE<"22S)"'BOW-@?#]WL',W<$W7&V4&W'"V
M)6NX ?5]>R5TSZU08II *BE/D8#5W/F SQ:^9Q+RB!\4]O*@C4PI2\YO3>=S
M/'<\PP@81,I $/VU@P4P9I TC]\EJ%/-:1(/VW?H'_/B=3%+(F'!V4\:J\W<
MF3@HAA7)F+KF^T]0%C0R>!%G,O]$^S+6<U"42<63,EDS2&A:?),_I1 '"7CX
M0()?)OA/31B4"8.\T()97M8%422<";Y'PD1K--/(M<FS=34T-:_Q1@G]E.H\
M%7XD5* ?A&6 O@"1F0#]CI1$[RY $<KD>W2"KB'*A*#I6K>_WUR@=T?OT1&B
M*?JVX9DD:2QGKM)<#*(;E?.>%_/Z#\Q[ ]M3-/".D>_Y TOZHCO] B*=CO-T
MOYGN:@4J&?Q*!C_'&SPJPS'Z("5H!71=Z)*2)65449!W\L1(+[Y:$1/UE:>B
M&C@GDDKTZU)/@#XK2.2_-G$*-D,[&[-US^261#!W]-Z4(';@A'__A0/O'YM4
M/8$UA!M4P@VZT,,%D1L$OS.Z(\PL'%NQ!4*0(YAC91?Z4^SIM[X[K,(2-0Z"
M2175H#>LZ T[Z7TAXE8OY"4#),TK*E[E"2([O;CS87T2(JFYVX@7V*-#2G@:
M!/>(MZ,&8V_LVXF/*N*C3N+%(CQ&*[,P=_G^C*F,&#=KT,9UU&(QPEXPO<>U
M'14,QT//SC6HN :=7"]A!PQA&ZO.Q.>N\Y[ &C6.JQK';^J &/<I7$]@#>$F
ME7"3%Q\0D_8^LQP0EJB'#XAI16_ZB@?$M$7)NT>Z*Z)!&'OU+[;7[]%0XCVF
MKRWL88'Q@</ 3S@>?"NSSLSG+O.^T)IUUA8"ORT/@7LU$7VA-<6K;01^N8\H
M(;JV6V=(DUIM(?!K>@C\-!-A">MP$;BV$;AG'X';%L'*MQW6Q;>V$O@I7L+V
MC^"\._/9Z_TUW 2N[01^6WX"]VHH^D)KBE=;"OQR3X';=J%U6'2%-*G5=@*_
MII_ CQN*SI#F?]_:4?@].XH2+^C@V1E2\'0/KBW,G9'6;DU3B1BL=(YW.M9%
MBN(:IN@HOLUO,I9<*9[DS0V0&(0)T,]7G*N[CKD<J2[#PO\!4$L#!!0    (
M '"!8E<2(7R)Z@(  &L(   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM
M;*V674_;,!2&_XJ5(002(U_-QZ"-!*VF3=HT1&&[F';AIJ>-A6-GMDOAW\]V
M0BBM*9NTF]9VSGG]O#ZQG>&:BSM9 2CT4%,F1UZE5'/F^[*LH,;RE#? ]),%
M%S56NBN6OFP$X+E-JJD?!4'JUY@PKQC:L2M1#/E*4<+@2B"YJFLL'B^!\O7(
M"[VG@6NRK)09\(MA@Y<P!77;7 G=\WN5.:F!2<(9$K 8>1?AV3@W\3;@.X&U
MW&@CXV3&^9WI?)Z/O,   852&06L_^YA#)0:(8WQN]/T^BE-XF;[2?VC]:Z]
MS+"$,:<_R%Q5(R_WT!P6>$75-5]_@LY/8O1*3J7]1>LV-DD\5*ZDXG67K EJ
MPMI__-"MPT9".'@E(>H2HK]-B+N$V!IMR:RM"5:X& J^1L)$:S73L&MCL[4;
MPDP5ITKHIT3GJ>*B+,4*YN@+P3-"B2(@T=$$%"94'J/WZ'8Z04<'Q^@ $89N
M*KZ2F,WET%=Z;J/@E]T\E^T\T2OS3*$Y17%P@J(@BAWIX_WI$RAU>FC3HY?I
MOG;<VXYZVY'5B__!]L^+F51"OU>_7/9:O8%;S^RU,]G@$D:>WDP2Q#UXQ>&[
M, W.76;_D]@+ZW%O/=ZG7DPQQ4+[/4%0-Y0_ J 9,%@0)9&NK=Z:%"N]- H_
M@+/0K7QJY<TA<5]$<9H._?M-AXZ@)'\.>D$^Z,D'>\G'>H"4F%K,ZT-<-^>3
M'I<^5](%W2HG&SP?PF2+>3<FRQ,W<M(C)WN1]7O&5TP1MD26UZPJ*CF3^I0Q
M@V]0)SM$41QL4>_&!&[FM&=.]S)_:T#@E@[T ;G)B [?Y5$8G>N320A@RL6<
M[O"$Z6"+V1&3OT*=]=39?FI5@7#Q9+MS#;8K[XC),C=/WO/D>WENN#)O:G?.
MO%'G?&>WQ'FT76A'4!;E6Y3^QE5@KN&O6"P)D[J4"YT6G&;:I&BOMK:C>&-O
MAQE7^JZQS4I_#8 P ?KY@G/UU#$73O]]4?P!4$L#!!0    ( '"!8E>'&@N(
M70(  !4&   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;*U5;6_3,!#^
M*Y:1T)"@>>LZ&&FDK1,"B9=I$_ !\<%-KHTUQP[VM=W^/6<GBSJ45B#QI?&=
M[WE\S]EWS7?&WKD: -E]H[2;\QJQ/8\B5];0"#<Q+6C:61G;""33KB/76A!5
M #4J2N-X%C5":E[DP7=MB]QL4$D-UY:Y3=,(^W )RNSF/.&/CANYKM$[HB)O
MQ1IN ;^VUY:L:&"I9 /:2:.9A=6<7R3GBZF/#P'?).S<WIIY)4MC[KSQH9KS
MV"<$"DKT#((^6UB 4IZ(TOC5<_+A2 _<7S^ROPO:2<M2.%@8]5U66,_Y:\XJ
M6(F-PANS>P^]GE//5QKEPB_;=;%G,6?EQJ%I>C!ET$C=?<5]7X<]0#(] $A[
M0/HG8'8 D/6 + CM,@NRK@2*(K=FQZR/)C:_"+4):%(CM;_%6[2T*PF'Q9<6
MK$"IU^PC4#4<>\4^"^M=6V G5X!"*O<BCY#.\HBH['DO.][T .\MM!.6Q2]9
M&J?9"'QQ''X%)<&3 $^?PB-2.,A,!YEIX,L.\/7B?EPL'5IZ.C_'%'44TW$*
MWT[GKA4ES#GUBP.[!5X\?Y;,XK=C^OX3V1.UV: V.\9>? ^/%RHFMG2[:Z!V
M\PWM;UGY0C $VS : <P,UZ^Z"IU(S1Y V/$[/WYLVB''JG$<F 0@F['&:*S=
MD0I,API,_ZT"E72EV6AD)!<.2"='"1I'E7?')=U[]:-Q6\23^,TL/<VC[;[2
MOPCL%$5[3>L'YB=AUU([RF9%R'AR=LJ9[8909Z!I0Q\O#=)4",N:YC98'T#[
M*V/PT?"C8?@G*'X#4$L#!!0    ( '"!8E<_B%>"_0(  "L+   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;*U6:V_:,!3]*U963:U4FB>0,HC4@J9-
MZE14UNVS"1=B-;$SVT#W[V<[:7@TI(+Q);&3>T[.N==V;G_-^(M( "1ZS5(J
M!E8B9=ZS;1$GD&%QPW*@ZLV<\0Q+->4+6^0<\,R LM3V'*=C9YA0*^J;9V,>
M]=E2IH3"F".QS#+,_]Y#RM8#R[7>'CR112+U SOJYW@!$Y#/^9BKF5VQS$@&
M5!!&$8?YP+IS>T/7T0 3\8O 6FR-D;8R9>Q%3[[/!I:C%4$*L=046-U6,(0T
MU4Q*QY^2U*J^J8';XS?VK\:\,C/% H8L_4UF,AE8H85F,,?+5#ZQ]3<H#;4U
M7\Q28:YH7<8Z%HJ70K*L!"L%&:'%';^6B=@">.$!@%<"O#V &QP ^"7 -T8+
M9<;6"$L<]3E;(ZZC%9L>F-P8M')#J"[C1'+UEBB<C!YSX%@2ND /H+(A4 O=
MXQ33&-#$+*,Q!P%48I/TRQ%(3%)QI<*>)R-T>7&%+A"AZ&?"E@+3F>C;4JG2
MW'9<*K@O%'@'%$P@OT&^<XT\Q_-KX,-F^ AB!7<-W-N%VRH754*\*B&>X?,/
M\)F%W&+SUK, ="<$2-&K,U6P!/4L>O/U1(YC&%BY3B!?@15]_N1VG"]U%L]$
MMF/8KPS[3>P;PTME&!O#=7X+DHXAT6?#*O*#L&^OMFV\CPG";A6SHRZHU 6-
MY=A;G^B!X"E)B2107Y;@G&4Y$]F.\79EO-U8EHWQU!A/-\:OU<' N=J4=0DH
M6-M;-7 [P5Z=:F)"I[Y.G4INYW2YE-$&Q9T:->Z>XO<QOM.N5]RM%'=/55RG
MLENS_MM[*M_'!.$!E6&E,CQV=UZK_U9Q0A<_>@U!1$)6)[N9_5$FP ]O^N&I
MZ!VKMY75V_]>\4=Y;_[<71SS)<P^J/NPD>3$,\!U-G]GYQS;ZJBT?/1)4]64
MT45+ L\^RD\SV[$)LK<Z&=U&_L!\0:A0[N>*WKGIJB. %YU9,9$L-\W-E$G5
M*IEAHKI9X#I O9\S)M\FNE^J^N/H'U!+ P04    " !P@6)7MYS99KX"  #N
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6RM5EUOFS 4_2L6JZ9.
M6@L!0EA&D-I$U2:U6M2TV[-#;A*KQF:V2=I_/]M0EB:$3M%>P->^Y_B<:_DC
MV7+Q)-< "CWGE,F1LU:J&+JNS-:08WG)"V!Z9,E%CI4.Q<J5A0"\L*"<NK[G
M16Z."7/2Q/9-19KP4E'"8"J0+/,<BY=KH'P[<GK.:\<]6:V5Z7#3I, KF(%Z
M+*9"1V[#LB Y,$DX0P*6(^>J-QS')M\F_"2PE3MM9)S,.7\RP??%R/&,(*"0
M*<. ]6\#8Z#4$&D9OVM.IYG2 '?;K^PWUKOV,L<2QIS^(@NU'CFQ@Q:PQ"55
M]WS[#6H_?<.7<2KM%VWK7,]!62D5SVNP5I 35OWQ<UV''4 O/ +P:X#_KX"@
M!@36:*7,VII@A=-$\"T2)ENSF8:MC45K-X2959PIH4>)QJGT1P$"*\)6Z!9T
M-22Z0#>E*@6@.\)(7N95/YKB%[UV2J+S"2A,J/RD,Q]G$W1^]@F=(<+0PYJ7
M$K.%3%REA1EZ-ZM%7%<B_",B9E!<HL#[C'S/#UK@XV[X!#(-[UFX_Q;NZG(T
M-?&;FOB6+SC"=T,89MFQ"K39J_C"=CZS$8>RP!F,'+W3)(@-..G'#[W(^]IF
M]C^1O;$>--:#+O;TR )<5ZC(HLS!L$G#.'$WN[([B4^4'3:RP_=DAVVR*U1_
M1W;OB[>GNY/Y1-W]1G?_/=W]-MW]0]UAL*>[D_E$W5&C.^K4_< 5IHC:?5%T
M[(OHP$<0]_9\=,YTHH]!XV/0Z>,6I!RBJYR7YF@38*=@]C@D3(&.5)NMP8&M
MBR#:L]4Y\8FVXL96W&EK6ME &TQ+0'Q9KQ0E>$XH401:%RL^V.-!V-]S=9@3
MQG]S*K'NSFUD7@)W6*P(DUK$4J.\RX$NG*ANURI0O+ 7U)PK?=W9YEH_2$"8
M!#V^Y%R]!N;.:YXXZ1]02P,$%     @ <(%B5U9!7VI[!0  /2H  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3$N>&ULS9I=<^(V%(;_BH9VVMV9W> O;$@)
M,PG^VDZSS6RZ[46G%P(+[%G;8B41-OWUE6S'X&!4F)Z+Y@)L6>]SI/@=2>AH
MNJ/L"T\)$>A;D9?\9I *L;D>#ODR)07F5W1#2OED15F!A;QEZR'?,(*32E3D
M0\LPW&&!LW(PFU9E#VPVI5N19R5Y8(AOBP*SYSN2T]W-P!R\%'S*UJE0!</9
M=(/7Y)&(SYL')N^&+27)"E+RC):(D=7-X-:\CDU/":H:OV=DQP^ND>K*@M(O
MZN9#<C,P5(M(3I9"(;#\>B)SDN>*)-OQM8$.VIA*>'C]0@^KSLO.+# G<YK_
MD24BO1F,!R@A*[S-Q2>ZBTG3H9'B+6G.JT^T:^H: [3<<D&+1BQ;4&1E_8V_
M-?^( X'D] NL1F"]%C@G!'8CL%\+W!,"IQ$XYT88-8+1N0*W$;CG"KQ&X)TK
M&#>"<?5VZ]=1O4L?"SR;,KI#3-66-'51&:)2RU>8E<J[CX+)IYG4B=FCH,LO
M*<T3POB/*/BZS<0S>O]R\8'S+2Z7A*,W/A$XR_E;^?#SHX_>?/]V.A2R 0HS
M7#;![NI@UHE@$W1/2Y%R%)0)27KTOEYOC36 H>QYVWWKI?MWEI;X2#97R#;>
M(<NP[)X&S<^76WW]^6_1 [W<)TLI-T]&#\^(;HY.RB.]_!ZS*V19)^6Q7O[S
MMKQ"AE/)3<V;M%LCVQ7//L&;YYAS1%>H<C3Z\Q?Y''T0I.!_]1FUACG],#5A
M7/,-7I*;@9P1.&%/9##[X3O3-7[J,PDDS(>$!9"P$!(60<)B(%C'>$YK/$='
MG_VZ%5S@,LG*->*5]T0JHZ@QM<]X6MBEQH.$^9"P !(60L*B&N96,+6R>YIY
M(Z/ZFPZ?#DT%%+5CJE%KJI'65!_EJG7#Z)*0A*,5HP7*FJE8#7%+6A1RW5>Y
MK<]CHZ,N6A/OJ(/SOFI'M7QM0R^U!20LA(1%D+ 8"-:QCMM:Q]5;9ULL"#NT
M28IE%%4@4J(*%U*1J(L-+I\1W:F[Q3.:DS*I/=6L!]&;[$7=N]BKVS$Z\,_8
MM">.,WGE,VU[+QVES@P:'-?SQJYKN&:W7@C9N @2%@/!.B;R6A-Y6A/-@X]^
MWRO7JBZ=O2!A/B0L@(2%D+ ($A8#P3H.&[<.&T.NU\>0QH.$^9"P !(60L(B
M2%@,!.L8;](:;_(_F1^U[;C4LY P'Q(60,+"R=&T;7N>Y;GC[K0=00:-@6 =
M.YK&?@?.T!KR]K=[=+MFA!2D%+V;:EK]I48"I?F@M "4%H+2(E!:#$7K>NY@
MU]>$G'T;&I0#(6D^*"T I86@M B4%D/1N@ZT]@ZT]*/>6@YY:RS4AL:*,+5[
MA@NZ+07"6Y%2EOTM9]V-G*BQ=FC4!KG8F) T'Y06@-)"4%H$2HL;VN&^5+-!
MM]^:ZIINGR,PM3O!L_G!QMD[](3S+7F'Z'X#M]=BH*D"4)H/2@M :2$H+0*E
MQ0WM<)GIV*[.8OML@*E/!SSBO-JCK5,!^ EG.5[(HA5EB,MGO18#30J TGQ0
M6@!*"T%I$2@M-H_S#*;G3L83QSYAL7UNP-0G!QX(6\KY$*\)2DE>_38M:?D>
MKU99GLD9E?=Z#'*#>PY*\T%I 2@M!*5%H+2XH4T./&9<V:?\M4\@F/H,0OV;
M0"6<Y!+L7_8XS.-]=M>Q)\ZK%( ^XL5^.2MH !HT!*5%H+08BM8US#Y98.JS
M!?\M6]G .WE(S_"\(P^!Y@O.C!J 1@U!:1$H+8:BU28:'IQ)*PA;5^<3N32#
M_(E7G\]J2]LSD+?5R;]7Y7?F];P^R;C'U <K[S%;9R5'.5E)I''ER0&!U6<5
MZQM!-]7)MP45@A;594IP0IBJ()^O*!4O-RI >V)T]@]02P,$%     @ <(%B
M5_@-SGU[ @   @<  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULQ57?
M;],P$/Y73D'BA\26-.U:&&VD=AMB$H-J%=L#XL%-KHFU.,[LR]+^]]A.&HK4
MY0&$>$GL\WW??7>VS]-:J@>=(1)L15[HF9<1E>>^K^,,!=.GLL3"K&RD$HS,
M5*6^+A6RQ(%$[H=!,/8%XX4739UMJ:*IK"CG!2X5Z$H(IG8+S&4]\P;>WG#+
MTXRLP8^F)4MQA?2M7"HS\SN6A LL-)<%*-S,O/G@?#&Q_L[ACF.M#\9@,UE+
M^6 GU\G,"ZP@S#$FR\#,[PDO,,\MD9'QV')Z74@+/!SOV3^ZW$TN:Z;Q0N;W
M/*%LYKWS(,$-JW*ZE?4G;/,YLWRQS+7[0MWZ!A[$E28I6K!1('C1_-FVK<,!
MP/ <!X0M('2ZFT!.Y24C%DV5K$%9;\-F!RY5AS;B>&$W947*K'*#HVA%,G[(
M9)Z@TJ_@ZK'BM(,3<&;X6MK*:6!% O=,*5:0AB]V8$L)KR^1&,_UFPX@&\#4
M)R/-!O#C5L:BD1$^(^,]W,B",@U718+)[WC?I-3E%>[S6H2]A"LL3V$8O(4P
M"(<]?,.N3D/'-WR.+V,*3^S^)W AA;D3FKEC-;=E2=&<4X+U#@[]EFSGS/.:
MJ02^?S:4<$TH](]C!6KBCX['MW?S7)<LQIEG+I]&]81>]/+%8!Q\Z,ENU&4W
MZF./[E 3+U(@5.*8MG[T"';(E.[1<=;I..MENF%;+JJC$GJ!?UB><2=K_)\W
M?_P/LIMTV4W^:O/[T8/@^=WW#_J20)6Z[JLAEE5!38OJK%V#GS=][9=[\SK<
M,)5RTXIRW!AH<#HQYT$U';>9D"Q=EUM+,CW3#3/S2*&R#F9](R7M)S9 ]^Q%
M/P%02P,$%     @ <(%B5T*-U:T/"   SD$  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3,N>&ULM9QKDYLV%(;_BL;MM,E,8J,+-DYW/;-9TC:=R60GVR2?
MB:VUF6!PA;R7?U^!660!%I)7Y$/6QM)[T(,0[^%@7SQD[&>^H92#QVV2YI>C
M#>>[=Y-)OMS0;92/LQU-Q2=W&=M&7+QEZTF^8S1:E9VVR01YWG2RC>)TM+@H
MM]VPQ46VYTF<TAL&\OUV&[&G]S3)'BY'</2\X4N\WO!BPV1QL8O6]);RK[L;
M)MY-:I55O*5I'F<I8/3N<G0%WX4^*CJ4+;[%]"$_>@V*H?S(LI_%FX^KRY%7
M[!%-Z)(7$I'X<T^O:9(42F(__JM$1W7,HN/QZV?U/\O!B\'\B')ZG27?XQ7?
M7(Z"$5C1NVB?\"_9P]^T&I!?Z"VS)"__!P]56V\$EON<9]NJL]B#;9P>_D:/
M%8BC#D*GNP.J.J!&!W2J ZXZ8-,.I.I 2C*'H90<PHA'BPN6/0!6M!9JQ8L2
M9ME;##].B^-^RYGX-!;]^.*69\N?FRQ949;_#C[\MX_Y$W@+RLW@\ZXX-CF(
MTA7X'C$6I3P'KT+*HSC)7XMF7V]#\.K7UQ<3+G:E$)PLJ[#O#V'1B;!3\"E+
M^28''](5777TO];WG_?U#_7](=((3 3#&B1Z!OD>:17_V:=C@+TW 'D(=PU(
MW_V6[K3=0WWWD"Y%=UAV1YK1X'I:X%(/ZZ;%\_%_ VXW$:-YUV$^R)!NF6+1
M>I?OHB6]'(E5*:?LGHX6O_T"I]X?78A<BH6.Q!1\I,9'=.J+&MSG/<^Y.'WB
M=/T&O*?K.$W%2Y#=@1O*XFP%7L4IR$NZG6?1(8Q?ABF6\/L%Q'.(?7&,[X_)
M&;8+M;M])A2_AN*;0?FK6$AH[]BU:K93RV\#"KQ@/FWP<113X3.M^4S-^'QX
MI&P9Y_V$IJU!O84(S6:SQK"N.QH&R/>\QNBU^W?FZ&?UZ&=FHQ>7\SL:&\P/
MK9[M_)AUH"3$GY,&(D=!%41!C2@PG2"[F/4#TJK9 @K:@!"9>KC!QU%,A<^\
MYC,_8]45%WCS]58;P!;9O&-11I[OPP:SKG;JXJW@@)[T=IX9D&\T+TZHPL?1
MQYVPW.(-S\"]V-Q'1!_"%DFEIHX53B%NGF>NPJKDCEPQM"+7!TFK9@T)MB$A
M-(>MD\U56!42DI"0C4G\7N98 M;5/64B9ZRO8^"&Q4O:R0TYY>92+72EIL*5
M!AQJ#6KG8C8^:2%769)$+ <[R@[SM'N:'D(&QQ/+&P>-:75MUBS4#^!<0-)B
M0T./?6PG#3DXLL$5KH,:Q$>\\)@TK:6KH"HN:;ZAH?M6W:4A,*=>O%)3@,%Q
M$#2!#6'&H73CT-".JX;4$)@C*UT!FW;-L&GKA!S"OT-IX*&A@S^VIX:XG'KY
M2DW!A>;CU@DYA)>'TLQ#0S??XU8-"3HU^Y6:>H:*2T#S=D+5[O250F4CC3PT
M=/)]QM40CE-;7ZFUX+0LK*.HZNU(:?Z1G?DWQZ47ML55J2ES!(Z1WZ#E*JA*
M2QI^!%_D9:^SE+-HR?=1 OZE;%M.R8]B6YSF\1)\BY)]I\-%3C,#IVJA*S45
MN4P?D-9!GU@ 6^2_T*)\55C>YC'HY.TTH^@9P10\T>)TPF![*";  *RBIZX;
MY6&/U*R2@EZ'@@I8IA#(,(70K*(O!^ZT M SHC9P<AKX$.D)DND),DQ/#O!?
MSMEISM*S\\^<X8$S0*<I#Y'5()G5(,.L1EE#KM9K1M<1IT8KM-/<IE*;'EWM
M9L&L=:>]HQD,9M.C=BH0F;4@PZQ%>\[; 7*:RZ!V+:(3T!"Y#)*Y##+,99[/
M7CMB3M.92DV=4JA-;(AT!LET!@5: _7\?("N6(R<)BE.U4)7:BH^F?$@?<8C
M\;VT9(PZR@D$X=FLD9]<FS8,];M^)AHL$QFL3V0D&L/"L5[/^J&$=LFB>>JY
M"J@"DKD+UA<K)"#CRK%>T1I1NV#10C1$KH%EKH'U]EHB,BXOZQ6M$:%^1$,4
M'/#1$S]Z;WT\BXS*RWH]:T"XH\#LM:YRKH*JD*2KQWIC?&*9MJHQZT-8<^MX
M](<@."/-5;R[H;+<JU"D"<=Z$RZAO*#.K(]A3:7C>9]N*D,4&;"TZUAOUUOH
M^B@Y]>*X[<5/4!K"C6/IQO',T%N>46/&3LVX4[70E9K*57IVK"]!U,_T&GE.
MLYO'N%T2(&CLSQKFTZQ9J!_ N8"D*\>FKMR^R*R7MIYW;;/>NC0.8=.)M.G$
MU*:?4V'6B]O2(OV>W55 E9;T[,34LY]37M:+6]/JM^^N JJTI'TGIO;=OK:L
ME[9FA=K%OR 88S(_^M>$-X2Q)]+8$S-C[Z;0K ]FC1.W<1;7@>8CDJ3]2))Z
MN5#9'#VG;^KG>YQ%;= RUK:V A[?4'"WYWM&;5@ZS01(QW-(G2R'N&5/9+9
M[+*%7O0V0)TF$95:<]*U> Z10A"90I#IN>;XW*(U<9IE.%4+7:FIM&4J0O2%
M@1,W %Y8W-,'M0:N'P*JBGM!740MJGN=K/5"N!(BM1#N*UX3F9L0L]QDV.JU
M?B>LP>N'9 %^B+2'R+2'F*8]CHK7^GC6F/5[;X%YB(S)EQF3;Y8QO:!XK8]@
M_24YKU5I;"8"VB8J!YD+^::YD+NBM3ZD-9C^#,E50)6AS)!\TPSIK(JU7MT:
M%^J?1TYSHLG1%^"WE*W+'Q+(P3+;I_SP7?AZ:_UC!5?E5_0GLOGAEPX^16PM
M8(&$WHFNWG@F#CH[_'C X0W/=N77Z7]DG&?;\N6&1BO*B@;B\[LLX\]OB@#U
M3S@L_@=02P,$%     @ <(%B5^C84*()!   T1(  !D   !X;"]W;W)K<VAE
M971S+W-H965T-30N>&ULQ5C;;N,V$/T50EVT"; ;W7R14]M XNRB"S1%$#>[
M#T4?&&ML$9%$+TG9,="/+TDINM@RLPX$Q ^V1,T<G3/B4,<<;RE[XA& 0,])
MG/*)%0FQOK1MOH@@P?R"KB&55Y:4)5C(4[:R^9H!#G52$MN>XPSL!)/4FH[U
MV!V;CFDF8I+"'4,\2Q+,=M<0T^W$<JV7@7NRBH0:L*?C-5[!',3#^H[),[M$
M"4D"*2<T10R6$^O*O9RY@4K0$=\(;'GM&"DICY0^J9.OX<1R%".(82$4!)8_
M&YA!'"LDR>-' 6J5]U2)]>,7]"]:O!3SB#G,:/R=A"*:6(&%0ECB+!;W=/L'
M%(+Z"F]!8ZZ_T;:(=2RTR+B@29$L&20DS7_Q<U&(6H+$:4_PB@1O/Z%W),$O
M$GPM-&>F9=U@@:=C1K>(J6B)I@YT;72V5$-2]1CG@LFK1.:)Z5S0Q5-$XQ 8
M_PU]_I$1L4.?T#UPP<A"0(AT!,)I>#CXD!+!T=D-"$QB?B[S'N8WZ.S#.?J
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M:I@ CH%* _%\30B_GT@'S3\8P2]02P,$%     @ <(%B5^9USATX P  4PP
M !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULQ5=K;]HP%/TK5UDUM=+:
M/* 4.D "VFF5U@G!NFF:]L$D%V(UL3/;0-FOG^V$0%5(MZI=OQ"_[O$Y]K%]
M:2^YN)4QHH*[-&&RX\1*9>>N*\,84R)/>(9,]TRY2(G253%S92:01#8H3=S
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M>LA060=:7TAIMA,;H'D:XS]02P,$%     @ <(%B5\=<JI,["0  SW,  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULM=UO;]I('@?PMS+B5J==J1NP
MS=]L$JF)YX^M;K?:;&]U.MT#!X;$5^-A;1/2T[WX&X.#&6RF(?WF21N(YS-
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M0B4@E$:A- :E<13-KHR->SI?+@'=B,[18N_+;-5VV],"]H;+8SC T#C T.T
M/XE2#^G312F5*LG'K%2)6BA9S1%?Y&B:Y6E^__A='*![1SO7!=0!0FD,2N,H
MFEU Q@&&)W> (=0!0FD42F-0&D?1[,HP#C!\R3K UJ"A%A!*HU :"W>=8MOM
M!*A.[02-!@S=&K"KQ77C.N<'=8%0&FMHF_G%+?$=PP2&Q@2&;A/8P>*Z29V3
M@PHZ*(TUM*UUZL%V<L<0;Z$1;Z%3W[QL";6;W3E+J%*#TEA#VSX*=P[#8[BR
MR+BRZ*";)?_"$NIH]TZ_* S"P=8*:G?_72."TAB4QE$T.TGCT**7W""Y.BQ+
MHI9Y?>ZKID7[:8Z[EZX'*)1&H336T*P;Z%KF252G=JS&9T4ON[E23)2^<)DD
M1:GJ&;0U4ZBP@M(HE,:BW9LB_;91%]6K':I149%;15U/JPO/ZJ1GE&>JR--]
M%QUN3N?DH#X*2F/1[EV3X6YL1_D+8!M_ NSOZ*,J(/N%MI8'5$M!:11*8U :
M1]'L.C):*CJYEHJ@6@I*HU :@](XBF97AM%2D5M+V7^[Y+DS\,%A9^!0U02E
M,2B-HVAV>,9(16XC=;+IP;&XR;W+G<<!J/6"TAB4QE$TNY2,'8O.3SY#0*T:
ME$:A- :E<13-K@QCWR*W?3OD4VPWHG.T4,D&I;&&MB5,P^W+AF,XMM@XMMCM
MV$XW+^Q?W>3>Y:XE J51*(U!:1Q%LTO)2+[8/_6\$$,%()1&H30&I7$4S:X,
MXPECMR<\9%YP(SI'"_6 4!IK:,ZU4AS5Y2JQ_L9W?53?_?))%/=)5I)43C3>
M>WNFK].*U=>IK)ZH?%Y__<==KE0^JQ].I1C+HMI _WZ2Y^KI2?6-(NLOM1G^
M"5!+ P04    " !P@6)7S5=:^T %   8*P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6S%FFMOVS84AO\*H0U#"V31Q;<XLPTDUJ4%&C1+T.[#L ^T
M?6P+E42/I.T$V(\?=;%D.3)CMZ=(/L22S/,<BGQ#GKS@8,OX-[$$D.0ICA(Q
M-)92KJY-4TR7$%-QR5:0J&_FC,=4JEN^,,6* YUE07%D.I;5-6,:)L9HD#V[
MYZ,!6\LH3.">$[&.8\J?;R%BVZ%A&[L'#^%B*=,'YFBPH@MX!/EE=<_5G5E2
M9F$,B0A90CC,A\:-?1W8_30@:_$UA*W8NR;IJTP8^Y;>?)P-#2OM$40PE2F"
MJH\-C"&*4I+JQ[\%U"ASIH'[USNZG[V\>ID)%3!FT5_A3"Z'QI5!9C"GZT@^
ML.T'*%ZHD_*F+!+9;[(MVEH&F:Z%9'$1K'H0ATG^29^*@=@+L-M' IPBP#D,
MZ!P):!4!K5,#VD5 ^]0N=8J SJD9ND5 ]]0,O2*@ETU6/KK9U+A4TM& LRWA
M:6M%2R^R^<VBU8R$22K%1\G5MZ&*DZ,'$$#Y=$G47$9TPCC-%9+,R*=PJB0'
MY&;! 93Z)'GG@J1A)-Z3W\F71Y>\^_7]P)2J%RG+G!89QWE&YTA&F]RQ1"X%
M\9(9S!KB77U\Z[5X7Q_?U\2;:O3*(71V0WCK:(&/L+HD=ON".);C-(V'/MR'
MR25QKK)PNVDX3LC>LK+P5D.X=WIX4^?]'\L>?'?VVE2T2C6W,E[K"&]/Q!LE
M7,YILLBEFPIZ__ZS7 (G<DD34@_Z^Y-BDH\28O%/PPO=YAUH-W<@W3BNQ8I.
M86BHG4$ WX Q^NT7NVO]T:0,3)B+"?,P83XF+$""U?35+O75UM'5:KF!9 UD
MSEE,IFH9X6HK;5*)%G.N2C!A;@[K9K"T3MF,K(&YV9_Z5UOXK[8(="UJ(]\I
M1[ZC'7GO:1JM1?H'NMN6TK_H^J95;53_D3_#:*T^BL9-4Z3-=^X48<)<3)B'
M"?,Q80$2K":G;BFG[EMO%%U,?6'"7$R8APGS,6$!$JRFKUZIKYYVN1H7>X.J
MYN6RJ..!7Y HI),P"N5SDV*TR',5TWNQ MM6_E-?JEW,K!XFS,>$!4BPFAJN
M2C5<X90-5R\FK=,T9V-MNG.7 TR8APGS,6$!$JPF@'XI@+Y6 )]768$B&9'
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MT-^TO].4+?*D&74#"U&/VK2_P?3TH_#ZW43G8B*E2YJ.ZZZ<34S3TPV=M?X
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !P@6)7N"TK6>P$  #M*   #P
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MJ*M^]\IE5\8FJG!/,O5%/A]FB &Q(EX;ZXI_;Y8G)H0!L1'&I;&:YX*S>S#
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M$Y>VD'/%L^/?>L<_#;_^"U!+ P04    " !P@6)7=TMQA08"  #Q)   &@
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !P@6)7.5E[*.T    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !P
M@6)7F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( '"!8E>KOYL@VP4  -0>   8
M  " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !P
M@6)7!H%^U,@%  #U%@  &               @($=#@  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ <(%B5UM=AQW0 @  _ <  !@
M         ("!&Q0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( '"!8E?L."(#^P4  +T<   8              " @2$7  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !P@6)7'<6[M;@#   ##
M&               @(%2'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ <(%B5[/^Q?\6#0  ,(H  !@              ("!0"$  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( '"!8E<R/Q)ZW@8
M %T<   8              " @8PN  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " !P@6)7K1[QS2P2  !,,@  &               @(&@
M-0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ <(%B5^C.
M^M<C$P  -3<  !@              ("! D@  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( '"!8E>R/YPK/00  !D)   9
M  " @5M;  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M<(%B5YBPW[@M!   #@L  !D              ("!SU\  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " !P@6)7@9H^\>T"  ">!@  &0
M            @($S9   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( '"!8E?O8O!PWP(  '0&   9              " @5=G  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ <(%B5T1OFF'I!
M6 P  !D              ("!;6H  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " !P@6)7*_$(WKD"  !"!@  &0              @(&-
M;P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( '"!8E?^
MIH/;\P0  #(,   9              " @7UR  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ <(%B5Q?@"E81"   FQ4  !D
M     ("!IW<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '"!8E=7#2']&P,  #@'   9              "
M@?24  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ <(%B
M5QMAMCAL#   %BT  !D              ("!1I@  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " !P@6)7X<)8TG0,  !*+0  &0
M        @('II   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( '"!8E<RC_-C\14  "E%   9              " @92Q  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ <(%B5V8W)$CY @  OP8
M !D              ("!O,<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " !P@6)7LU*VD)8#  !Y!P  &0              @('LR@
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( '"!8E=CAC+9
MA00  'P,   9              " @;G.  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ <(%B5U!AP,OB @  M08  !D
M ("!==,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !P
M@6)7@XS!"Z "  #*!0  &0              @(&.U@  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( '"!8E?K^7/U @,    '   9
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M970S-2YX;6Q02P$"% ,4    " !P@6)7':U"K@T#  !&#   &0
M    @('AZP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M '"!8E>99B-Y?@(  +((   9              " @27O  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ <(%B5[61$+VQ!   91T  !D
M             ("!VO$  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " !P@6)72.>"!AX"  "O!   &0              @('"]@  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( '"!8E=MN<+LN@0
M .06   9              " @1?Y  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ <(%B5]R\'!QW!0  )2(  !D              ("!
M"/X  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !P@6)7
M N+]QX0"  "!!@  &0              @(&V P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( '"!8E=*9OT@V (  -L)   9
M      " @7$& 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ <(%B5ZK:KCC. P  0!0  !D              ("!@ D! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !P@6)7#GO","8#   *#0
M&0              @(&%#0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( '"!8E=S?@4XN0,  !@3   9              " @>(0 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ <(%B5Q(A?(GJ
M @  :P@  !D              ("!TA0! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " !P@6)7AQH+B%T"   5!@  &0
M@('S%P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( '"!
M8E<_B%>"_0(  "L+   9              " @8<: 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ <(%B5[><V6:^ @  [@@  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( '"!8E=-#(24@0,  ,T0   9
M  " @9HU 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M<(%B5^9USATX P  4PP  !D              ("!4CD! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " !P@6)7<0D2$-@"   F!P  &0
M            @('!/ $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( '"!8E?'7*J3.PD  ,]S   9              " @= _ 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ <(%B5ZG $.HW P
M! X  !D              ("!0DD! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " !P@6)7-9"'T:H"  #_"   &0              @(&P
M3 $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( '"!8E?I
MO1"4[@@  .!F   9              " @9%/ 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ <(%B5\U76OM !0  &"L  !D
M     ("!ME@! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
M" !P@6)72"#]"%P#  "6%@  #0              @ $M7@$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( '"!8E>7BKL<P    !,"   +              "
M ;1A 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( '"!8E>X+2M9[ 0  .TH   /
M              "  9UB 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !P
M@6)7=TMQA08"  #Q)   &@              @ &V9P$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !P@6)7_R>G=>,!  !L)   $P
M            @ 'T:0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     1@!&
+ "$3   (; $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>306</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - The Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusiness</Role>
      <ShortName>The Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Merger</Role>
      <ShortName>Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Available-for-Sale-Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecurities</Role>
      <ShortName>Available-for-Sale-Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShare</Role>
      <ShortName>Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Australia Research and Development Tax Incentive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive</Role>
      <ShortName>Australia Research and Development Tax Incentive</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Technology Transfer Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TechnologyTransferAgreement</Role>
      <ShortName>Technology Transfer Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Research Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</Role>
      <ShortName>Research Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Merger (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/MergerTables</Role>
      <ShortName>Merger (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/Merger</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Available-for-Sale-Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale-Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AvailableforSaleSecurities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/PropertyandEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareTables</Role>
      <ShortName>Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/OperatingLeases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/StockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ShareBasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - The Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusinessDetails</Role>
      <ShortName>The Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/TheBusiness</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Merger - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/MergerNarrativeDetails</Role>
      <ShortName>Merger - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/MergerDetails</Role>
      <ShortName>Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/MergerTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails</Role>
      <ShortName>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareDetails</Role>
      <ShortName>Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShareTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails</Role>
      <ShortName>Operating Leases - Balance Sheet Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Operating Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails</Role>
      <ShortName>Stockholders' Equity - Equity Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Warrants Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeTaxes</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Australia Research and Development Tax Incentive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails</Role>
      <ShortName>Australia Research and Development Tax Incentive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Technology Transfer Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TechnologyTransferAgreementDetails</Role>
      <ShortName>Technology Transfer Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/TechnologyTransferAgreement</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/LicenseAgreements</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="lsta-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Research Collaboration and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails</Role>
      <ShortName>Research Collaboration and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="lsta-20230930.htm">lsta-20230930.htm</File>
    <File>lsta-20230930.xsd</File>
    <File>lsta-20230930_cal.xml</File>
    <File>lsta-20230930_def.xml</File>
    <File>lsta-20230930_lab.xml</File>
    <File>lsta-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lsta-20230930_g1.jpg</File>
    <File>lsta-20230930_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="639">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lsta-20230930.htm": {
   "nsprefix": "lsta",
   "nsuri": "http://www.caladrius.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "lsta-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "lsta-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lsta-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lsta-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lsta-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lsta-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 240,
   "keyCustom": 66,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 40,
   "memberCustom": 9,
   "hidden": {
    "total": 14,
    "http://fasb.org/us-gaap/2023": 8,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://www.caladrius.com/20230930": 1
   },
   "contextCount": 178,
   "entityCount": 1,
   "segmentCount": 52,
   "elementCount": 467,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 639,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "report": {
    "R1": {
     "role": "http://www.caladrius.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.caladrius.com/role/TheBusiness",
     "longName": "0000008 - Disclosure - The Business",
     "shortName": "The Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:BusinessTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:BusinessTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.caladrius.com/role/Merger",
     "longName": "0000010 - Disclosure - Merger",
     "shortName": "Merger",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecurities",
     "longName": "0000011 - Disclosure - Available-for-Sale-Securities",
     "shortName": "Available-for-Sale-Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.caladrius.com/role/PropertyandEquipment",
     "longName": "0000012 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.caladrius.com/role/IncomeLossPerShare",
     "longName": "0000013 - Disclosure - Income (Loss) Per Share",
     "shortName": "Income (Loss) Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.caladrius.com/role/FairValueMeasurements",
     "longName": "0000014 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.caladrius.com/role/AccruedLiabilities",
     "longName": "0000015 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.caladrius.com/role/OperatingLeases",
     "longName": "0000016 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.caladrius.com/role/StockholdersEquity",
     "longName": "0000017 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensation",
     "longName": "0000018 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.caladrius.com/role/IncomeTaxes",
     "longName": "0000019 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive",
     "longName": "0000020 - Disclosure - Australia Research and Development Tax Incentive",
     "shortName": "Australia Research and Development Tax Incentive",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.caladrius.com/role/Contingencies",
     "longName": "0000021 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.caladrius.com/role/TechnologyTransferAgreement",
     "longName": "0000022 - Disclosure - Technology Transfer Agreement",
     "shortName": "Technology Transfer Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:TechnologyTransferAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:TechnologyTransferAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.caladrius.com/role/LicenseAgreements",
     "longName": "0000023 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement",
     "longName": "0000024 - Disclosure - Research Collaboration and License Agreement",
     "shortName": "Research Collaboration and License Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://www.caladrius.com/role/MergerTables",
     "longName": "9954473 - Disclosure - Merger (Tables)",
     "shortName": "Merger (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables",
     "longName": "9954474 - Disclosure - Available-for-Sale-Securities (Tables)",
     "shortName": "Available-for-Sale-Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.caladrius.com/role/PropertyandEquipmentTables",
     "longName": "9954475 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.caladrius.com/role/IncomeLossPerShareTables",
     "longName": "9954476 - Disclosure - Income (Loss) Per Share (Tables)",
     "shortName": "Income (Loss) Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.caladrius.com/role/FairValueMeasurementsTables",
     "longName": "9954477 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables",
     "longName": "9954478 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.caladrius.com/role/OperatingLeasesTables",
     "longName": "9954479 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.caladrius.com/role/StockholdersEquityTables",
     "longName": "9954480 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationTables",
     "longName": "9954481 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.caladrius.com/role/TheBusinessDetails",
     "longName": "9954482 - Disclosure - The Business (Details)",
     "shortName": "The Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-79",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-79",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.caladrius.com/role/MergerNarrativeDetails",
     "longName": "9954485 - Disclosure - Merger - Narrative (Details)",
     "shortName": "Merger - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.caladrius.com/role/MergerDetails",
     "longName": "9954486 - Disclosure - Merger (Details)",
     "shortName": "Merger (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-75",
      "name": "lsta:AssetAcquisitionSharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails",
     "longName": "9954487 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
     "longName": "9954488 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "shortName": "Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "longName": "9954489 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "shortName": "Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.caladrius.com/role/PropertyandEquipmentDetails",
     "longName": "9954490 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.caladrius.com/role/IncomeLossPerShareDetails",
     "longName": "9954491 - Disclosure - Income (Loss) Per Share (Details)",
     "shortName": "Income (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.caladrius.com/role/FairValueMeasurementsDetails",
     "longName": "9954492 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-108",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-108",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
     "longName": "9954493 - Disclosure - Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails",
     "longName": "9954494 - Disclosure - Operating Leases - Narrative (Details)",
     "shortName": "Operating Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
     "longName": "9954495 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)",
     "shortName": "Operating Leases - Balance Sheet Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails",
     "longName": "9954496 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)",
     "shortName": "Operating Leases - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
     "longName": "9954497 - Disclosure - Stockholders' Equity - Equity Issuances (Details)",
     "shortName": "Stockholders' Equity - Equity Issuances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-114",
      "name": "lsta:OutstandingStockThreshold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "lsta:OutstandingStockThreshold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails",
     "longName": "9954498 - Disclosure - Stockholders' Equity - Stock Options and Warrants Narrative (Details)",
     "shortName": "Stockholders' Equity - Stock Options and Warrants Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails",
     "longName": "9954499 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)",
     "shortName": "Stockholders' Equity - Stock Options and Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
     "longName": "9954500 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "longName": "9954501 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
     "longName": "9954502 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "shortName": "Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
     "longName": "9954503 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "shortName": "Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.caladrius.com/role/IncomeTaxesDetails",
     "longName": "9954504 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
     "longName": "9954505 - Disclosure - Australia Research and Development Tax Incentive (Details)",
     "shortName": "Australia Research and Development Tax Incentive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "lsta:IncomeTaxIncentiveReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "lsta:IncomeTaxIncentiveReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.caladrius.com/role/TechnologyTransferAgreementDetails",
     "longName": "9954506 - Disclosure - Technology Transfer Agreement (Details)",
     "shortName": "Technology Transfer Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "lsta:InvestmentOwnedCanceledShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.caladrius.com/role/LicenseAgreementsDetails",
     "longName": "9954507 - Disclosure - License Agreements (Details)",
     "shortName": "License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-161",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
     "longName": "9954508 - Disclosure - Research Collaboration and License Agreement (Details)",
     "shortName": "Research Collaboration and License Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
       "span",
       "div",
       "us-gaap:CollaborativeArrangementAccountingPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-174",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20230930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived Assets",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_BondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BondsMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agency bonds",
        "label": "Bonds [Member]",
        "documentation": "Debt security, in which the authorized issuer owes the holder a debt and is obliged to repay the principal and interest (the coupon)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/Merger"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger",
        "label": "Asset Acquisition [Text Block]",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r476",
      "r487",
      "r681"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r766"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r145",
      "r651"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r132",
      "r135",
      "r485"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term for operating leases (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r680"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r317",
      "r324",
      "r355",
      "r356",
      "r357",
      "r441",
      "r465",
      "r502",
      "r522",
      "r523",
      "r580",
      "r599",
      "r603",
      "r604",
      "r632",
      "r646",
      "r647",
      "r660",
      "r664",
      "r675",
      "r683",
      "r686",
      "r733",
      "r739",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r324",
      "r465",
      "r502",
      "r522",
      "r523",
      "r580",
      "r599",
      "r603",
      "r604",
      "r632",
      "r646",
      "r647",
      "r660",
      "r664",
      "r675",
      "r683",
      "r739",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r317",
      "r324",
      "r355",
      "r356",
      "r357",
      "r441",
      "r465",
      "r502",
      "r522",
      "r523",
      "r580",
      "r599",
      "r603",
      "r604",
      "r632",
      "r646",
      "r647",
      "r660",
      "r664",
      "r675",
      "r683",
      "r686",
      "r733",
      "r739",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r324",
      "r465",
      "r502",
      "r522",
      "r523",
      "r580",
      "r599",
      "r603",
      "r604",
      "r632",
      "r646",
      "r647",
      "r660",
      "r664",
      "r675",
      "r683",
      "r739",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r284",
      "r290",
      "r433",
      "r652",
      "r654"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r160",
      "r162",
      "r167",
      "r473",
      "r493"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term",
        "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Share-based Compensation Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "lsta_WeightedAverageExercisePriceWarrantsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageExercisePriceWarrantsExercised",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Exercised (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Exercised",
        "documentation": "Weighted Average Exercise Price, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157"
     ]
    },
    "lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "RevenuePerformanceObligationPercentageOfSublicensingRevenues",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of sublicensing revenues",
        "label": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues",
        "documentation": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "lsta_WeightedAverageRemainingContractualTermwarrantoutstanding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageRemainingContractualTermwarrantoutstanding",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Weighted Average Remaining Contractual Term warrant outstanding",
        "documentation": "Weighted Average Remaining Contractual Term warrant outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SharesIssuedUnderLicenseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "SharesIssuedUnderLicenseAgreement",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued under license agreement (in shares)",
        "label": "Shares Issued Under License Agreement",
        "documentation": "Shares Issued Under License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Lisata Therapeutics, Inc. stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r85",
      "r86",
      "r102",
      "r534",
      "r550",
      "r572",
      "r573",
      "r681",
      "r694",
      "r717",
      "r730",
      "r753",
      "r772"
     ]
    },
    "lsta_InvestmentOwnedCanceledShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "InvestmentOwnedCanceledShares",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares canceled (in shares)",
        "label": "Investment Owned, Canceled, Shares",
        "documentation": "Investment Owned, Canceled, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option and Warrants Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r63"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-Sale-Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from option exercises",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18"
     ]
    },
    "lsta_CommonStockWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CommonStockWarrantsShares",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants, Outstanding, Beginning of Period (in shares)",
        "periodEndLabel": "Warrants, Outstanding, End of Period (in shares)",
        "label": "Common Stock Warrants, Shares",
        "documentation": "Common Stock Warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r655"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative translation adjustment arising during the period",
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r20",
      "r159",
      "r162",
      "r166",
      "r416",
      "r417",
      "r422",
      "r472",
      "r491",
      "r713",
      "r714"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit from income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r137",
      "r190",
      "r191",
      "r209",
      "r374",
      "r383",
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SharesHeldByThirdParty": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "SharesHeldByThirdParty",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares held by third party (in shares)",
        "label": "Shares Held by Third Party",
        "documentation": "Shares Held by Third Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r408",
      "r438",
      "r439",
      "r440",
      "r662",
      "r663",
      "r672",
      "r673",
      "r674"
     ]
    },
    "lsta_QiluMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "QiluMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qilu",
        "label": "Qilu [Member]",
        "documentation": "Qilu"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AggregateIntrinsicValueWarrantsvestedandexpectedtovest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AggregateIntrinsicValueWarrantsvestedandexpectedtovest",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "documentation": "Aggregate Intrinsic Value, Warrants vested and expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Weighted Average Contractual Term and Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AssetAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AssetAcquisitionSharePrice",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiplied by the fair value per share of Lisata common stock on September 15, 2022",
        "label": "Asset Acquisition, Share Price",
        "documentation": "Asset Acquisition, Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r154",
      "r175",
      "r255",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r389",
      "r393",
      "r413",
      "r681",
      "r737",
      "r738",
      "r757"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York",
        "label": "New York State Division of Taxation and Finance [Member]",
        "documentation": "Designated tax department of the government of the state of New York."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r316"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired license - intangible",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r470"
     ]
    },
    "lsta_InProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "InProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "label": "In-Process Research and Development",
        "documentation": "In-Process Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r412"
     ]
    },
    "lsta_ResearchAndDevelopmentTaxIncentiveTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "ResearchAndDevelopmentTaxIncentiveTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australia Research and Development Tax Incentive",
        "label": "Research and Development Tax Incentive [Text Block]",
        "documentation": "Research and Development Tax Incentive"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageRemainingContractualTermwarrantsvested": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageRemainingContractualTermwarrantsvested",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested, Weighted Average Remaining Contractual Term",
        "label": "weighted Average Remaining Contractual Term, warrants vested",
        "documentation": "weighted Average Remaining Contractual Term, warrants vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewJerseyDivisionOfTaxationMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Jersey",
        "label": "New Jersey Division of Taxation [Member]",
        "documentation": "Designated tax department of the government of the state of New Jersey."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxHolidayTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxHolidayTable",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Holiday [Table]",
        "label": "Income Tax Holiday [Table]",
        "documentation": "Income tax-exemptions and reductions which may be granted by a taxing authority for a specified period. Such \"tax holidays\" are typically granted to induce business investment in the tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "lsta_EPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "EPSAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted loss per share",
        "label": "EPS [Abstract]",
        "documentation": "EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Lisata Therapeutics, Inc. common stockholders",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r100",
      "r122",
      "r142",
      "r158",
      "r161",
      "r165",
      "r175",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r196",
      "r206",
      "r211",
      "r215",
      "r217",
      "r255",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r405",
      "r413",
      "r490",
      "r553",
      "r569",
      "r570",
      "r659",
      "r692",
      "r737"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options, Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "lsta_OptionsVestedweightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "OptionsVestedweightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested, Weighted Average Remaining Contractual Term",
        "label": "Options, Vested, weighted Average Remaining Contractual Term",
        "documentation": "Options, Vested, weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_RevenuePerformanceObligationPercentageOfNetSale": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "RevenuePerformanceObligationPercentageOfNetSale",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sale",
        "label": "Revenue, Performance Obligation, Percentage of Net Sale",
        "documentation": "Revenue, Performance Obligation, Percentage of Net Sale"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WarrantsExercised",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Warrants, Exercised (in shares)",
        "label": "Warrants Exercised",
        "documentation": "Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r263",
      "r477"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r195",
      "r197",
      "r198",
      "r199",
      "r203",
      "r404",
      "r405",
      "r474",
      "r494",
      "r657"
     ]
    },
    "us-gaap_IncomeTaxHolidayLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxHolidayLineItems",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Holiday [Line Items]",
        "label": "Income Tax Holiday [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r372",
      "r376",
      "r378",
      "r379",
      "r382",
      "r384",
      "r385",
      "r386",
      "r515"
     ]
    },
    "lsta_WeightedAverageExercisePriceWarrantsExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageExercisePriceWarrantsExpired",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Expired (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Expired",
        "documentation": "Weighted Average Exercise Price, Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_OperatingLossCarryforwardsPostAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "OperatingLossCarryforwardsPostAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, post acquisition",
        "label": "Operating Loss Carryforwards, Post Acquisition",
        "documentation": "Operating Loss Carryforwards, Post Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "lsta_AssetAcquisitionCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AssetAcquisitionCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Asset Acquisition, Cash and Cash Equivalents",
        "documentation": "Asset Acquisition, Cash and Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AssetAcquisitionOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AssetAcquisitionOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other liabilities",
        "label": "Asset Acquisition, Other Liabilities",
        "documentation": "Asset Acquisition, Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "In process research and development expenses",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r552",
      "r692",
      "r754",
      "r755",
      "r771"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized to be repurchased (in shares)",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_UniversityOfCaliforniaAtSanDiegoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "UniversityOfCaliforniaAtSanDiegoMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University of California at San Diego",
        "label": "University of California at San Diego [Member]",
        "documentation": "University of California at San Diego"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "lsta_TechnologyTransferAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "TechnologyTransferAgreementTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology Transfer Agreement",
        "label": "Technology Transfer Agreement [Text Block]",
        "documentation": "Technology Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee, year four",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less than one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "lsta_SaleOfStockAvailableForSalePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "SaleOfStockAvailableForSalePercentage",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage held by non-affiliates",
        "label": "Sale of Stock Available for Sale, Percentage",
        "documentation": "Sale of Stock Available for Sale, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "lsta_SaleOfStockAvailableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "SaleOfStockAvailableForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock available for sale",
        "label": "Sale of Stock Available for Sale",
        "documentation": "Sale of Stock Available for Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Greater than one year",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "ResearchCollaborationAndLicenseAgreementOptionToTerminate",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to terminate",
        "label": "Research Collaboration and License Agreement, Option to Terminate",
        "documentation": "Research Collaboration and License Agreement, Option to Terminate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r146",
      "r487"
     ]
    },
    "lsta_AssetAcquisitionNetWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AssetAcquisitionNetWorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net working capital (excluding cash)",
        "label": "Asset Acquisition, Net Working Capital",
        "documentation": "Asset Acquisition, Net Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_TechnologyTransferAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "TechnologyTransferAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Transfer Agreement [Abstract]",
        "documentation": "Technology Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Greater than one year",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "lsta_AssetAcquisitionConsiderationTransferredEquityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AssetAcquisitionConsiderationTransferredEquityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Asset Acquisition, Consideration Transferred, Equity Value",
        "documentation": "Asset Acquisition, Consideration Transferred, Equity Value"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet",
        "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CaladriusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CaladriusMember",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Caladrius",
        "label": "Caladrius [Member]",
        "documentation": "Caladrius"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/Contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r269",
      "r270",
      "r645",
      "r734"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageExercisePriceWarrantsOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants Outstanding, Beginning of Period (in dollars per share)",
        "periodEndLabel": "Warrants Outstanding, End of Period (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Outstanding",
        "documentation": "Weighted Average Exercise Price, Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "lsta_StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesRelatedToMerger",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with Merger (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues Related to Merger",
        "documentation": "Stock Issued During Period, Shares, New Issues Related to Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r412"
     ]
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r731",
      "r732"
     ]
    },
    "lsta_OperatingLossCarryforwardsBeforeWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "OperatingLossCarryforwardsBeforeWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, prior to write down",
        "label": "Operating Loss Carryforwards, Before Write Down",
        "documentation": "Operating Loss Carryforwards, Before Write Down"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails",
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AtTheMarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AtTheMarketOfferingAgreementMember",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Agreement",
        "label": "At The Market Offering Agreement [Member]",
        "documentation": "At The Market Offering Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AggregateIntrinsicValueWarrantsvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AggregateIntrinsicValueWarrantsvested",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested, Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Warrants vested",
        "documentation": "Aggregate Intrinsic Value, Warrants vested"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails",
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AggregateIntrinsicValueWarrantsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AggregateIntrinsicValueWarrantsOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Outstanding, Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Warrants Outstanding",
        "documentation": "Aggregate Intrinsic Value, Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration amounts, milestones",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities - available for sale",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "lsta_WeightedAverageExercisePriceWarrantsExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageExercisePriceWarrantsExercisable",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested, Weighted Average Exercise Price (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Exercisable",
        "documentation": "Weighted Average Exercise Price, Warrants Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r746"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r49"
     ]
    },
    "lsta_OperatingLeaseRightOfUseAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-Use Assets:",
        "label": "Operating Lease, Right-Of-Use Asset [Abstract]",
        "documentation": "Operating Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WarrantsGranted",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Granted (in shares)",
        "label": "Warrants Granted",
        "documentation": "Warrants Granted"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r112",
      "r482",
      "r506",
      "r508",
      "r514",
      "r533",
      "r681"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options, Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Amounts representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average estimated fair value of shares granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding, Beginning of Period (in shares)",
        "periodEndLabel": "Options, Outstanding, End of Period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating lease liabilities",
        "verboseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding. Beginning of Period (in dollars per share)",
        "periodEndLabel": "Options, Outstanding, End of Period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Domain]",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreements",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreements",
        "verboseLabel": "Research Collaboration and License Agreement",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128",
      "r139"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities \u2014 current",
        "verboseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestones, Royalties",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r286",
      "r300",
      "r401",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r492",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Axis]",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,140,187 and 7,866,799 shares at September 30, 2023 and December 31, 2022, respectively; and outstanding, 8,139,449 and 7,866,061 shares at September 30, 2023 and December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r480",
      "r681"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r371"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r532"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock outstanding (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "terseLabel": "Number of common shares of the combined company owned by Cend stockholders (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r82",
      "r532",
      "r550",
      "r772",
      "r773"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average estimated fair value (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/MergerTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r119",
      "r175",
      "r255",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r413",
      "r483",
      "r534"
     ]
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AustralianTaxationOfficeMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australian Taxation Office",
        "label": "Australian Taxation Office [Member]",
        "documentation": "Designated tax department of the government of Australia."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r648"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r556"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r434"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, non-controlling interests and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r120",
      "r484",
      "r681",
      "r717",
      "r730",
      "r753"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r286",
      "r300",
      "r401",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r492",
      "r661",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r438",
      "r439",
      "r440",
      "r662",
      "r663",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, increase resulting from acquisition",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Minimum Lease Payments",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities [Abstract]",
        "label": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r681"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset, useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CENDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CENDMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails",
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/MergerNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEND",
        "label": "CEND [Member]",
        "documentation": "CEND"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering amount authorized per agreement",
        "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r204",
      "r469",
      "r509",
      "r519",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r554",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r571",
      "r687"
     ]
    },
    "lsta_ImpiloMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "ImpiloMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impilo",
        "label": "Impilo [Member]",
        "documentation": "Impilo"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsSublicensingFees",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicensing fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization/accretion on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_IncomeTaxIncentiveReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "IncomeTaxIncentiveReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax incentive receivable",
        "label": "Income Tax Incentive Receivable",
        "documentation": "Income Tax Incentive Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "lsta_WarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WarrantsExpired",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Warrants, Expired (in shares)",
        "label": "Warrants Expired",
        "documentation": "Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r131"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WarrantsOtherDisclosuresAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Contractual Term and Intrinsic Value",
        "label": "Warrants Other Disclosures [Abstract]",
        "documentation": "Warrants Other Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WarrantsVested",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested (in shares)",
        "label": "Warrants, Vested",
        "documentation": "Warrants, Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "lsta_WarrantsCanceled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WarrantsCanceled",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants, Forfeited (in shares)",
        "label": "Warrants Canceled",
        "documentation": "Warrants Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process Research and Development Expense",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/MergerNarrativeDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Table]",
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries, employee benefits and related taxes",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/MergerNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liabilities:",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/MergerNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r158",
      "r161",
      "r170",
      "r175",
      "r182",
      "r190",
      "r191",
      "r206",
      "r211",
      "r215",
      "r217",
      "r255",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r388",
      "r391",
      "r392",
      "r405",
      "r413",
      "r475",
      "r489",
      "r517",
      "r553",
      "r569",
      "r570",
      "r659",
      "r678",
      "r679",
      "r693",
      "r715",
      "r737"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r140",
      "r163",
      "r164",
      "r165",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r204",
      "r256",
      "r257",
      "r303",
      "r364",
      "r365",
      "r366",
      "r380",
      "r381",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r432",
      "r503",
      "r504",
      "r505",
      "r518",
      "r571"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock, at cost; 738 shares at September 30, 2023 and December 31, 2022",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r60",
      "r61"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13",
      "r33",
      "r396",
      "r399",
      "r432",
      "r503",
      "r504",
      "r713",
      "r714",
      "r715",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIncomeTaxRefunds",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax refunds",
        "label": "Proceeds from Income Tax Refunds",
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r99"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lisata transaction costs",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/MergerNarrativeDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Line Items]",
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental fair value of Cend's fully vested stock options",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r98"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails",
      "http://www.caladrius.com/role/MergerNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total purchase price",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r98",
      "r172"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue excluding taxes",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r210",
      "r213",
      "r214",
      "r218",
      "r219",
      "r220",
      "r314",
      "r315",
      "r469"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r80"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r329",
      "r360",
      "r361",
      "r363",
      "r676"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated Fair Value",
        "totalLabel": "Total estimated fair value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r263",
      "r471",
      "r722"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r88",
      "r153",
      "r481",
      "r507",
      "r508"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r469",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r649",
      "r665",
      "r682",
      "r702",
      "r735",
      "r736",
      "r740",
      "r767"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r147",
      "r486"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r469",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r649",
      "r665",
      "r682",
      "r702",
      "r735",
      "r736",
      "r740",
      "r767"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInAndAdvancesToAffiliatesLineItems",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in and Advances to Affiliates [Line Items]",
        "label": "Investments in and Advances to Affiliates [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current, balance sheet line item",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r288"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment owned (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521",
      "r584",
      "r610",
      "r635",
      "r686"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, balance sheet line item",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r73",
      "r140",
      "r141",
      "r164",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r256",
      "r257",
      "r303",
      "r364",
      "r365",
      "r366",
      "r380",
      "r381",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r416",
      "r418",
      "r422",
      "r432",
      "r504",
      "r505",
      "r516",
      "r534",
      "r550",
      "r572",
      "r573",
      "r643",
      "r693",
      "r717",
      "r730",
      "r753",
      "r772"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, noncurrent, balance sheet line item",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r434"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r127",
      "r129",
      "r133",
      "r134"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r685",
      "r686",
      "r688",
      "r689",
      "r690",
      "r691",
      "r718",
      "r719",
      "r752",
      "r769",
      "r772"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r333",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury bills",
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r132",
      "r135",
      "r136"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r117"
     ]
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from collaborative arrangement",
        "terseLabel": "Revenue from contract",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r751"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r674",
      "r768"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LossOnSaleOfNOL": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "LossOnSaleOfNOL",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on sale of NOL",
        "label": "Loss On Sale of NOL",
        "documentation": "Loss On Sale of NOL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal debt securities",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r768"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r75"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r174",
      "r287",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r303",
      "r402",
      "r574",
      "r576",
      "r644"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r149",
      "r175",
      "r206",
      "r212",
      "r216",
      "r255",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r389",
      "r393",
      "r413",
      "r478",
      "r544",
      "r681",
      "r694",
      "r737",
      "r738",
      "r757"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r211",
      "r215",
      "r217",
      "r659"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value, outstanding",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r532"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r434"
     ]
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total Compensation Cost Related to Nonvested Awards",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r62"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from option exercises (in shares)",
        "negatedTerseLabel": "Options, Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r112",
      "r339"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- Controlling Interest in Subsidiary",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r303",
      "r718",
      "r719",
      "r720",
      "r772"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, year one",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental fair value of Cend's fully vested stock options assumed",
        "label": "Liabilities Assumed",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r711"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Lisata Therapeutics, Inc. Stockholders' Equity",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, year two",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, year three",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, year four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate for operating leases (percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r680"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, remainder of fiscal year",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r173"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r199"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with merger",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r193",
      "r195",
      "r197",
      "r198",
      "r199",
      "r203",
      "r404",
      "r405",
      "r474",
      "r494",
      "r657"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r199"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r144",
      "r175",
      "r255",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r390",
      "r393",
      "r394",
      "r413",
      "r681",
      "r737",
      "r757",
      "r758"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r685",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r110",
      "r111",
      "r112",
      "r150",
      "r151",
      "r152",
      "r205",
      "r288",
      "r289",
      "r290",
      "r292",
      "r295",
      "r300",
      "r302",
      "r510",
      "r511",
      "r512",
      "r513",
      "r664",
      "r701",
      "r716"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r205",
      "r288",
      "r289",
      "r290",
      "r292",
      "r295",
      "r300",
      "r302",
      "r510",
      "r511",
      "r512",
      "r513",
      "r664",
      "r701",
      "r716"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r466",
      "r467",
      "r468",
      "r470",
      "r656"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r284",
      "r290",
      "r433",
      "r653",
      "r654"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before benefit from income taxes and noncontrolling interests",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r89",
      "r121",
      "r206",
      "r211",
      "r215",
      "r217",
      "r475",
      "r488",
      "r659"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership after transaction",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r323",
      "r408",
      "r439",
      "r662",
      "r663",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r175",
      "r255",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r390",
      "r393",
      "r394",
      "r413",
      "r530",
      "r658",
      "r694",
      "r737",
      "r757",
      "r758"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r323",
      "r408",
      "r438",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Classified by Contractual Maturity Date",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r408",
      "r440",
      "r662",
      "r663",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r575"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (Loss) Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r200",
      "r201",
      "r202"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "lsta_MassachusettsInstituteOfTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "MassachusettsInstituteOfTechnologyMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Massachusetts Institute of Technology",
        "label": "Massachusetts Institute of Technology [Member]",
        "documentation": "Massachusetts Institute of Technology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available for sale securities - net unrealized gain",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r157",
      "r251"
     ]
    },
    "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee, year seven",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less - net income attributable to noncontrolling interests",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r116"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r518",
      "r718",
      "r719",
      "r720",
      "r752",
      "r772"
     ]
    },
    "lsta_BusinessTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "BusinessTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/TheBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Business",
        "label": "The Business [Text Block]",
        "documentation": "The Business [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_FairValueMarketOfTaxNOLs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "FairValueMarketOfTaxNOLs",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value market of tax NOLs",
        "label": "Fair Value Market of Tax NOLs",
        "documentation": "Fair Value Market of Tax NOLs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentTables",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 14)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r76",
      "r479",
      "r531"
     ]
    },
    "lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accrued liabilities and other liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "NetCarryforwardOperatingLossCarryforwardAnnualLimitation",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL annual limitation",
        "label": "Net Carryforward Operating Loss Carryforward Annual Limitation",
        "documentation": "Net Carryforward Operating Loss Carryforward Annual Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AssetAcquisitionAcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AssetAcquisitionAcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development",
        "label": "Asset Acquisition, Acquired In-Process Research And Development",
        "documentation": "Asset Acquisition, Acquired In-Process Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ProceedsFromSaleOfNOLS": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "ProceedsFromSaleOfNOLS",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of NOLs",
        "label": "Proceeds From Sale of NOLS",
        "documentation": "Proceeds From Sale of NOLS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuances of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r112",
      "r518",
      "r571",
      "r642",
      "r693"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "lsta_OutstandingStockThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "OutstandingStockThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock threshold",
        "label": "Outstanding Stock Threshold",
        "documentation": "Outstanding Stock Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "lsta_WarrantsWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Exercise Price",
        "label": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of shares issued",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r112"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "lsta_SanfordBurnhamPrebysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "SanfordBurnhamPrebysMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanford Burnham Prebys",
        "label": "Sanford Burnham Prebys [Member]",
        "documentation": "Sanford Burnham Prebys"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, fair value disclosure",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from option exercises",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r29",
      "r112"
     ]
    },
    "lsta_CollaborativeArrangementRightsAndObligationsChangeOfControlFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsChangeOfControlFee",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change of control fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Change of Control Fee",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Change of Control Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r204",
      "r469",
      "r509",
      "r519",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r554",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r571",
      "r687"
     ]
    },
    "lsta_Sharesvestedandexpectedtovest": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "Sharesvestedandexpectedtovest",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested and expected to vest (in shares)",
        "label": "shares, vested and expected to vest",
        "documentation": "shares, vested and expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from issuances of common stock (in shares)",
        "terseLabel": "Stock issued (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r112",
      "r510",
      "r571",
      "r642"
     ]
    },
    "lsta_ExclusiveLicenseAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "ExclusiveLicenseAndCollaborationAgreementMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exclusive License and Collaboration Agreement",
        "label": "Exclusive License and Collaboration Agreement [Member]",
        "documentation": "Exclusive License and Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AccruedGrantFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AccruedGrantFunding",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting &amp; tax consulting liabilities",
        "label": "Accrued Grant Funding",
        "documentation": "Accrued Grant Funding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Remeasurement",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r112"
     ]
    },
    "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee, after first sale",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value of Lisata's cost method investment in Cend",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r748",
      "r749",
      "r750"
     ]
    },
    "lsta_StockIssuedDuringPeriodValueNewIssuesRelatedToMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "StockIssuedDuringPeriodValueNewIssuesRelatedToMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with Merger",
        "label": "Stock Issued During Period, Value, New Issues Related to Merger",
        "documentation": "Stock Issued During Period, Value, New Issues Related to Merger"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ClinicalAndRDRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "ClinicalAndRDRelatedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical and R&amp;D related liabilities",
        "label": "Clinical and R&amp;D Related Liabilities",
        "documentation": "Clinical and R&amp;D Related Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r411"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement, Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r29",
      "r140",
      "r163",
      "r164",
      "r165",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r204",
      "r256",
      "r257",
      "r303",
      "r364",
      "r365",
      "r366",
      "r380",
      "r381",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r432",
      "r503",
      "r504",
      "r505",
      "r518",
      "r571"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r327"
     ]
    },
    "lsta_WeightedAverageExercisePriceWarrantsCanceled": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageExercisePriceWarrantsCanceled",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Forfeited (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Canceled",
        "documentation": "Weighted Average Exercise Price, Warrants Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "lsta_PaymentsForAssetAcquisitionCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "PaymentsForAssetAcquisitionCostsNet",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Asset acquisition costs, net of cash acquired related to merger with Cend",
        "label": "Payments for Asset Acquisition Costs, Net",
        "documentation": "Payments for Asset Acquisition Costs, Net"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee, years two and three",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties, net of sales",
        "label": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r112"
     ]
    },
    "lsta_WeightedAverageExercisePriceWarrantsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "WeightedAverageExercisePriceWarrantsGranted",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Granted (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Granted",
        "documentation": "Weighted Average Exercise Price, Warrants Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r256",
      "r257",
      "r364",
      "r365",
      "r366",
      "r380",
      "r381",
      "r395",
      "r397",
      "r398",
      "r400",
      "r403",
      "r503",
      "r505",
      "r518",
      "r772"
     ]
    },
    "lsta_AssetAcquisitionIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20230930",
     "localname": "AssetAcquisitionIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "Asset Acquisition, Intangibles",
        "documentation": "Asset Acquisition, Intangibles"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r681",
      "r770"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "SubTopic": "50",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-4"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "SubTopic": "40",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0000320017-23-000063-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000320017-23-000063-xbrl.zip
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MY<:,AJ9[^Q@&M=6=/$RH!Z]PGK]3$$=/J,8>AC]]VO%]&O0"(" $TL/PF^4
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MVYK *4R:H#1%7"W+-N=^___Y4U-5],^^%%";3D:N0R6'6;)E--;L$,E# @>
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M1PIN!NZ$>UC&K!5QU@R0>!O4ZW<.GP$0@8@O:SD2.: XLE/D7<RYT<W::CP
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ME6OY;_9P,&@5H$@B5]?]>S)?GUU:RK(:VGZJ)2^U^ #H7"""SXA+=RDA\&X
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MC)_=//R]>UM16H!2@-T8@\_Q%?',YYA_?A69]Q9>[<,+\/HP]C9]EI5@C2=
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ME($1@*@>A%'Q472!NI#A 6__ S8[FVT7Z0T,#'@4C ]X'WR"9UI-OP":C%-
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MV!)4^@'/C7SI#FP%4^K1"=C,X#E)FEQ.4;&PU=$N*&CNX9.TD,E&\@4F\X7
M2X8"2KX1K<JJEM>!TURSGA/@U#P$Q)G"1A!5+D1U[$2#$PC=S(-@LDPU/\,\
MTLS'YSIFS]DXF'H.C;JR(NA(=T([25O!A(()CSXTIIY'"R].N5 PFF T;J;'
MU//HWR4833!:L1GM\&-DZGDT[SH6H^72O*L(6?QB#6XK(XIR,?(0C*B'94$3
MCXZHXULOE 4SKD6WHPM9(]=N1_P3?.>%6#9+"0 -*/D$<P.H$7I68-'IG*W0
M\2CL]-_4E)Z)Y6QDA8^24-/6@W-G>>0X)HL)EYM%V1*U#_TY@^]?71O!\Q>
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MS:WWFQ\WQO.9=%U--FE^W!LO"BPP0S22S@]AX ?$0:!D3C*IE=JULJPU]VV
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M&;V[XYC]N1I-9_I@G=P^'9\%O0FI(+ DL%1$+!UFT,?Q9'=+R.Y"T9N0"D7
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MZXH)</BO:;VTO\ ?T]461*%!49[GK=,4>9M24U&I]2B5B&&X8WCW.YQ!<MP
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M2 4:TO=.0>(T L>[( 4WGKGKTH2\8ZBMC-URO) NN7T+5NW"I\*DW5GPVGY
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M<^&:5JG=TLJ*OLXUHG[H;*ALFSP^-)759$9E3:Z:*ER8E<RN L$9!84;C1>
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M:<2X2;RF@_&FKS.;2! ^&Q+<$F,Z-@EF2TFK8V%ZN:GQ5&%[ 9[$S29)+Y%
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M$N!^Z$_Y,K#0O(<76(M%Z+@QJN()+6=N32PZ'[YXP0,#J,:'RY@:P']-KA
MO_67'N(D#5<B,,*B I.7AH<MXF;TV,0U5Z]3V"Q>%2"FV;8Q0?F"FYP;<-O&
MPO"QL06B+MXL7!-F:%PK*F8F\@F3+\#\47?#G3ENP(2/;0M)%E]M,(^JHZE2
MVO*C2^08WA=_Q @00:&%Y72B-(9-Y_"6(,61\F#V_<OM]03[9['DLW!@ER4H
MDBZ9;CO>.QINQB,<G\8)&C,> +,)@+0\X;M;2:RC;)252%58+&T>$/H"Y)T'
MES:J8!-X@#QIPI>P28$&KM0Q#<^\=F<  (\G3[HBE@6WA(5" <IQ@E#Z_@ ?
M^,\E2 :%*#'FPO+BO/1N.IG!'I%5!_3NF!$"@AO"04DL%S]/7MH6AO$)F(!I
MDA$JL%'M#>&<8-C((A\\8^$S<4>H 6".=0AP=A_<T&=W[[N]_X=-N6TS!8*
M3^<.?@\\ ,@=W::"0UH!GMWG7!"72YCNH&PB^@?<"3U/F.G1]E#( +9@U,T-
M ]M8%1OFIR2QL]*)>_[<6@+PC(6\!>08ODBYL6UQ=VQBN6LB&%%Y[2,EUY(7
M"1@'.^6(S 9P0M]?0ZR8^!@*\@?74Q0J1!LC^4_;22Y+W=2 D\5$-/?<\&%.
MMRNWX?$'2W ;0!]<T39"9SH'+ 14>G#A1Q8AL5PWHR-PM9(O!:UI@J#R@9V@
M7$,6%P)+!Y(@)<1F#K:42I$<*=G#M\ R <%PVRD4MY8<+TCR+NZ_86>!8B35
M!I&A^?Q;4-[O:PR0O=%Z[3["0FI8) +#R;]D.XYO-'E)F_RJ&W3_^B3FRWX
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MT80:%)/7UDILAC496(\R)Y5S@ALQ4# F"YOP57-06%Q/UB5M6W3MHM1V5]P
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M@IH<<Q(L)_(#R6HSX5^)H@=2Q.&?J6"$BM(0,$X@5I-2MZ@@U(XN=4KRT[0
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MQV3*X88\P[6$-[\@7["=H0CB#2!:_R5"G$8>95@E":.[&4.*"=Q/(H\T7+[
MNO>@,#_RW^EB2V/0( H//O_F_PG\YJ,;>J4W/7S!37\G;<S$2?0?+=S:/XFQ
MECS!Z(7!?H\LL/2NQR^]ZR>WY)Y!\[JZ&6H9%EG%!VML%L-V-%@CXK< "39#
MTTD*UA?I_MSTD3XH<;?7).[68BM'[R,]W*./-,Z5<T+^T7,7=S*4\0^PD>Z
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M (1P")\%\/74-GS?F@%6$IW#WO#3S?NSX+G08W>N0R1 !WQGV(8SY>S'G//
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M__:K<9-W=\<@C8/3!9+4JWB9/KK6KTHF$R18YYT,8G/SW>H.?H5\,#3LWXT
M#;C5>R/@]\A4LKD&V-&K.->@OID%6R+[&)Y?@HB!1RQW>\+!9$7 EF!C"PFW
M_:/X)Q:T/V(,O+-_7/YE@O8[;W@/?\)6[]3X-./46X+V^9#2M6K2&\IH9?4&
M8U2XP[!R9X>\AYV.?E$@C#/./F+&&061FJ0) ,QG[F/"&[S8=3A;<<-KTB::
MX.U1:XRE^@E_?><+ W5&[^OLHX6&_#\!_PXO4QSWCM,OZ%P\>0VI-J1:":FB
M+-TK'V/</XXSOLG'J!K5?O,XJ$W>9A6AB:)73FZN#?MX0"*[?W+OYP#)A_E'
MZY$?-.-N7-V,NR:5XX*1L(#O;\:]Z@;=G4;R1ZW9>I/QT02"Z\F,JNY9,ZY/
M\]C3M!8;<F_(O?[MY\;CLTOOJC[K8]](]I;?X15L#\KW!E=;Z^X'N67K1\?Z
M3,Q@2T[$%S?@K,](G=7>LG+Q^6^>NX1K7WVS#2>X=4S,@%IBN/Z]Y4]MUP^]
M;#R^W^D(.H.+YN9M(#_#Q=-1>K4X,QR312MG\69[[H%8ONC;[DBCS(22-UF7
M-($4F+@"$T(8- R,$LEZ_SB58->0?QH*^7&QER_E[XQ5.7[YK(#^Z$C!^Z:4
MORH/R(F6M>]5XW]Q4&J*__.@\C'T0"D%V4DL?09*(_R[:0'0!,BV&BS#\6:+
MI5!?HU9[NWM ^YWJ9C W<>F&[$Z<[,;]P\@N2UY@CQP^FJZ))Q\71>[<Q3+$
M@#*/C=,FF%Q (Z-.U332O;KICPYVD37!WQHCS7A0-=+TZH8TEVKD?.:&S^>N
M;3)KL?3<1[[(ZW.V$RWDG/X<:6%8-2WTKVX.[UZQH5O$"VGH#<[$.#.J&F<&
M5S?CJL)2M6&?&]BYII-WN=:L-#\"T&(/>(F'J*2'V;*G33I;8K_E*6=X=3,8
M9,?8[Z=YU,9;4J$N>\G8MJ7#1'EL&X%LUP[NS?E<V':I2G!BV G<_](#%*#(
M](6IP96.>8U!^CX!4?BWS?$?0#TR$8\^+Z2L/*(:7]WT^A6,>FV4Y5IBUK8A
M)\?#+*T#F%7%$.':,.,S5:D=GO'Q[B@\F]339P!0O9G1<Y@?7W@N?]&N;O1.
MKUIU\ 2RQK=8)PWI-J1;'UNN@'0Q%#RNJEWURY-N029X8>;WGDFH.^2&9Y-\
MY2?R\#7.^<768!A]-IP59>$,W_K,XWYH!SBY:VJ'YII!R?C/)7=\3GW"EDO/
M_4DM9.P5^TL9U-8VHW92+2Y9]-#7NE<WA8$YE:U,ZEBI'6\)FARTXQY09E'\
M)-HQK$GIUPY<(EO WN8^XP[>3Y0B*GZA\D3IC)@+V<(K7?(I-J.T5^VUYG^[
MT\Q!F'U@G<1X>YU$_GB_>M9)#/:LD_A@>'#_#_XW[OV8&WE%$5H_6Q2A];-%
M$9^<J;O@[!4.PWW-8#U&"^Y5%4'KG^S@Q8\'$%80\T_DEZ'GP<_ MF,V@!6G
M,\*3\(Q'TX:9X]((1A>/"'>6G,O%GN A%@8632AF5%C!&7"**3H*Y+1%T\+F
ML"8MSD#V,Q^OC!DTG7%%HR!!%;"NZ3D@]G9)[/HQG7,SM/G7V2TLHU:)Z\\^
M_!02X:/G+D3.$FWMZVP'M!SDH.4@BY:W04FH<[FGM=*4)5 9O(V&8JJ#)+M8
M9DI7-J%]%K&1_PD_1A%)#(@DGK>$93QNC_K=7XHK6'XI*LL8#-J#T;CPZTY;
M*_QNT[):K]T?#/9:=O-W_:Y^C,T.M>Y.RTK/UAZE$[4SU?+5_^A09]!D,Z\4
MY )N[AP[5NY:_M2T^LP"+K<DZJR#HC](R7*7*)</2@B\F(0"TB?]3/+7EF*@
M Y7%VP6 /"AM- ^O;K165S\X$>;$RH8:O-T9;[7.EE*!ET'<$2%N9<F/SY53
M<]85./\P/,_8-VW\#$LHB@AJB]_V90AJC 35*_2@-A4\9X-^>@W13^\(]*LJ
M*/X,+%OYFV"S?#/&/M>3EV".?.=^X%E3=. *]R^B>U.HM(7DMV5I5D/R6:JF
M1)>FJ.GL\6M;KN:Q\$N_NNF-:H1>Z72*3%!X0[#X9:)V:Y J&4_NZ^<53Q[N
M&4^.FE;'??;\;/!.[V:#=WHW&[R+QPBQW[F!B\E:W#UBRF+]G+=N[+!7[T@S
M#>)#&#T2C-P9FUF.X4PMPV:&[_- !(QMRYA8MHA3!G,CH,#NA&-8<R' *O)7
M/(YC^_ /^-[DL!;^FX+!&!:=&\X#9TN .!?+/+FA;<)"\,,I!WYFLL!E/K?A
MY8YX/W,]MC0L^B( @]B?<8\9T88PQHW/DL?!7HE')*.=\.")<X?!??P)"RT-
MY#76$HUJ%<V&K3CXD:T>@CWAYXL85YAI #:_XC^M0.S\=9O=)V/LF)[T[]#R
MQ.:G8I;C*@G5Q&KT9IS/D.E<.(77/+@>0'C7KH7UQJS/_)';3(/S@BSRUQ'B
MWZ&+:$( ]=FKT#%,W#\W7].%4F*0O!.?\HPL/ ^*"H66\%D&*Q&B @41HO@#
M0)"YQ#^%,'!)!D@IWR^Z[/89P5\O@+_\U,5,$#$T)'TC4:;=DQ7,X4;4;4;$
M[TY@7X^42Z#2P'(OIL6X12\Q@4*F 9 H7J:C_CHG6'<+8!TZ"6#)1S;"K,W.
M BH?MTD2A-,TFGW+)H:/+5T%9P:N",8ILPFRP"P);@+]@./Z<%SXT11X.0F&
MM!1+$'2*5T?YI+@?WR>"EWPX7G J$DFEN AMPU/OWO0>)0/\]2'4FW(9+W),
M][ 9TUV+K50WIKM87=Y#,7XAM/Q7:#X0'2./6A@K9@ DID(_0&*/$AZ#C,)<
MQ-Q$GB4\N;2-J6 24IBNK3&WN&=XT_E*<#N_G;%&]K">;FE7TN8QOSK?T5,
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M,"H?,U7OJO[M;%N@B&$;GIC%OEC:[HIS-N$.GUER'"K-FP:V'A@_>:;/]#9
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MT=W;[A_GTOU];KUW_%OO%]]Z9C[58=7<D>#Z70Y6*ZAM&@W.I;;I8TB#XQ:
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M:TJ?7,_TN1/#MG=U$W!'E)%FBDM5P,+RF.M90$G 7TS)D^GT<IYD!$;)?!3
MA6\*V,XCQS&?.&73V :3\<O#I']U,W-#[QJ!DH&)& Y:,BH]G7,S)-=,[F&2
M9'*+(;7" M1!9Y!1B^"S;+CZ/C5U3I92A@M@B#08500&Q9M(G*1O+A5'5+-
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M:>N7OPT;)ET.-&RM2WFC@5U^*(%N&-MEGB) /S;)3+@/,7,CS7=,1J+N<5Q
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M2[X/95)XZ*SN3?G&5H_DJV36*>Z#5Q05\XP[C;Z<"2#FQL&G,GEM3,[!QF:
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MHR2BH<VP/9ZL97Y=["^<= :O_!>W7Q"HU"K6:>I89J[&:T5J::-:UB.[)PZ
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MEB5#*5+C71"XF#AF)I_I3I/]M.5ITD7&C0NYD[C)211C1@-4 )IWG E)YDZ
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M(;S5\^ZH!3W,%=;'L,D74_\&H['FB2Q3Z5+X2@5/@.L-2#/A/9YQL#$<=YA
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M CDK8&PB-R0;4DQ>"[""918]YX:WMD!K9;[32)Z=3J?T6@VBSYEA"D#>%;E
M6I!#; ,"2PEE2+K$+IV-<Q0]-8]WDO8MM-UFKINQ=Y$VN02F6MQS/(PG+<G1
M!4ST+JID'#B!!1)YP]I[(X*UC66_'DU/;=I.'&@T]UUHL@M.9D\\-#F 1$.:
MV='(@B<KBE;EE B$9^R>W_^M4KJ34_(1WH:SZE9>C$T*+41.!H1.U95,"2)]
M!34!$'/2.K+2/G.[ DE/]=LV'%B1H-UUZEMF]J>GF%>,T%OR%6.TP(I&4)Y<
MABBL EM8]IG7>%^V9\)J,#U5=(W(T$  [?@PF^%\-K#68DPF@0REK@D$>K:4
M"B):8TWFG%S'UL)?/+D-_J^O5%91:D7.+GHR1-YS\$DX0"68-,Q9$D\GP^BA
M$MM"LC>XNO7D-N/GB^&8AOEJ^ GSR_$\C#\,28,N<;U!>A.5C_1:"!I.+#43
M4NB="0Z2R$QJSX77K5WSVQ'U27,U8$##Z6_KK9]C^.8LQB)<"=9!1@R5G>2#
MVB @&96<5E$9UWJ=8"60/N4<&A!@]\EN)O>WT\E'G,[/WH[">+X_SC5O\K'F
MO2H3H_,I!FW!B\)J82^'P .O>5$ID<F0C6XL_MOP]&F]L $+FDU]8[_EPC19
MQP0*84 S3F.SD4/,:" EIJ)F%"S&YK[K>KN_15H]S(YK\I;^J5/[*8P6Z=SY
MLS"=G@W''Y9+<9$GP70,8!./H#!J\$;6S%Z(,MM(^K>U=[,1L/YY/=OPXD9>
MO;E,VE6JANF?N%@=>H^DDI=)&(-"NJ(0@A;T&E)4 M$:!=Y1')E9X=ZVUH"K
M</3/ 6I!AIUGO*$5Q(]AF ^^?,3Q#(F@ERST5T\]YB!])BK&1,"$)3Z*H,%Q
M60H:^HW YL;PN[#ZYQFU8$9K>5PCRM^?7I^M5_2YR6:;]T?T\_7!FZ/WAR\.
MWQZ\VS]Z2;^]BN/NNV[6W+7Y]IM-T#?:AT..;W5_PGRQ_%[K*<^E/5#HE,BF
M  _,D@:@N)BX(L E(;7V6"QKO>2]%LRNBN7E^!/.%NO(R]M6UXY&$'@LI.%\
MW2Y'43[I.BU :"=\U#F2M]=X?"M@],F_:,.%ZTIDU[EO&UNO'Z-T,J*W K0W
MGA192! <1F#HN&5.6Y5;\^%V1'WR-KJA1D.)M(S$RW!>B\H'-@I.-C("V3%!
M+ T(KE8M9)$S2ZD6"+?6@-^>OKO*NRB.?T'27);.G-(4'R[G>C*>_8)E,CTO
MHC\*7W!V\&4^#42LX3A,SUX2'V9KRK,"\[%X$\'D6 5C*=+F/(,VO%C-I(VA
M=3ZJP^'T205OR;Z;.K<?PF_V5GX%>JX;?L$QEEK$[V@J3.$05'"@8MU,*2E@
M*9+K[$7QPK?>\[H&RAVU=;<%U$UIM-NL-Z, ^0W?:#VP286D/#GKRNIEV!&,
M,F!1RZ0=6M5\W\05  W-C,R2E9(*S6&L:1:+%&776KE0DXY*:F5:#V6=F7E@
M_W-K":_(Z6XSNXW5U6WZ][8RZ .Z?'XVL$&8D(V#DEE=B& "*-)V(#4FIY/P
M076CVW;#W2M%V(Y2]R[2=G'/A7=]KL5G ^>U=3'1<WTHH%C=)5DB30OGC//H
M%5F,UJ'.=1#;CJIF:$@8](8GG,W>X0QIBFHR^SE^PM%DL7(SH/@@61,-Q%(%
MS8VE>$1%R-5SL8I'D:[EBV\F?C9Y4)^TYVYBOJ![\^EMUYD %V_2K^2#3,.(
M$.WGD^%X.)O747_Z&C3:'".+*4$IU3U-,E,\:@UPF0)&)W5RK</XS9#U*9QO
MPY4.)=-P;_8J!I]#.OAROC=I/_WK=#BM=2#GQ'\VH4C'DE8./%B@_V10+G.H
MS >KHF+<&H.Q=?R_ ]P^+4&TY==]R;"]Q;WD>^B@<H@2:P4DQ6%&&PAYL1A3
M-[]@H+"Y>;']31CM?0G&I=+<2LA.)7)I*+[T% ,"#PE3CN1QW;<O\5TSW*W+
MN:OP;R1)=YKR>PQIMD\IJ6BT#$E X=+0@(2#&((#4026Y)/6IG6A_KWE$]MH
M#PH-4HDL 8N%HE@*6L$KS2J?8L2"RHK6.8+O:H^'=7?[PL>UK^N6TFN7+UN[
MKN*T8<)QBCVM9V03"_U/" [6879<F>)BZVJ:1['(U5=*M9'DPQ1?/#M\_?;=
MP6\';]Z__,?!J\/W36LP;MZ\TU*,[XRE447&BA977]M;992,H2YU2PXG>9,+
MX6,A*ME4:UQS$+*#-@3KX+1<:K5U''4O+",V*QXD.,,I0+2E2)NDC*IU^6<_
M<^"MI']+1OPN<]VV^.*[W=N<9#QY"8C!DY+4%*PEKX!B-"=+IL^J=6W?8^NO
MUQ4_FLOG?IGCF!1*DTNEK*DA$9<46ZD"3"7,7DH?7/,H],[,:3OV%^2)##^,
MEW68Z>QH&L:SD!:T'.?%IW.2YO\]7=9??9TM;A(O$15X1%T;$=36=X;B28_6
M"H9!\^;11"<CZ9/F;L[3N[RB]T2&SE_JW\=3#*/AOS'_-AG5K-ZO83BN SP<
M?RM.WY\.9_2KY_1Q_.$M3H>3_&TTR5@5M0,N?9W@PB#(@L"CX>ASDDJW=B2Z
M&DN?S,Z#D?M>"?% (=+^^]]>O#K\HVUH]/6FW89$J[&W*D['>=VB1+[KIR'=
M[9>SWV<UO_\UQ;)/&N[3>9N6S*RNQYB0IR-!L6@@)";!,HY16!WU]17?%O5
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MFE8A8[%D_!H3Y;N@>F5F.N%*6[FT:17XC+X=TF37_=[/;P(;*!MEM+R 3CJ
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M,.@ HQ-!)2:$:1U>;906?"0NVR[L:2&2#>WB^??U1Z1G_?RW_P-02P,$%
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MB6AYX=*KYG72#STAL <.K"/E'A,"N32Y*,R@DT+:$',";XL!RZ6PSG*5._:
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MEEAD#$:[UH<L=P)Z9$QH)_P=G0N_#L/)HKWC;XLTF^4Q]A9'PW<^K\7I<'?
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M-+OK;;/ZI>DM&'\R=Z]:;W@HL/:TSJ+.CXYI:Z"/\+?A"4YGXQ%^"-\7"OF
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MM##%[])O.0?V!+FW=_W>Y.K&K86O'%#])Y[DY]\_?QE.\@?RH+X/?!12H5?
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M8T,OHNXAA[#FP+PO5RSG93:4LSI;8B53M;U4C0\/* 7PG*)CU516G<IEK^%
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MPN]GIMMFY.B4Z;:.D@X@(:D+W)^9;ELI><O,I$TT= #$TA&-"03;^E+[Y,0
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MRD<5FP(MFV@ C[H52:$JVU?Q3^CC&]MJ ]=.VYWV>"BTYCD6O0A?L?&%FM$
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MXTXWEF?&]KY]6<5DY:I UN_![TMVTQFN]1*_I/Y@870QT3]):,O2RXSTH3#
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M4!%&F_2[SXH/0K_A(-NZ-( JX$&?2<MIP:TT@/$/G&IK3I?FJFVH/\8-=VA
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M[C'\)+A-#CDL>"PG"DN@RH+I"YO'EU>?DK1]KE.=S$R&'.&J!NS0&==*:W7
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M=*V\]MI24)QP\\1WQ8&PO?EL.ZMMYOX1>[DM-F@B1! IAI $/4C+"$L2-#8
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MUID5^ 6?(P9B"%:[K=CH+.<D$H@R(7XL4G^7&U3R7)3'S<K\O ='TZ/+!%'
MO:CWK>/!730EFPAKHP&8'%Y=.!$V/Y:DZXV''U'\ E?,]2OQVA(U=<9/[79
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MQGX.(%1+.KY,=98$L]E5RW[+/Y3NJ3<\NU@>*'^[>"^P&&#H0-!53$0 Z+J
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M$N0I^O\] O!3Z)HK&KY3N4\:DG@ 6])4@Z8X::7*^:,5XMT=',D_(,7SPF"
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M1%I%EK!/Z=^*F1:_T>*1>;[923]\%OW[YI[_^"GL/;JZ3%#L1.!F[NFV?UM
M669//J?ZU5B;[W_RDW%Y;D2P_R.:+<&Y@F,Q\68WW_[[DIAL*\?"@!MZ],VB
MR&;,G;%7H\*@>9FZ8N@@GF"$_6P->Y+FQ&90V2=@449:>M[WX[G&0$WI]K)=
MP1M]V5UBKOUB$<XSX)=X00W32<B0_61[1<:B<"R>?)2(?F-+ZEG45!Q0YC)I
M_W[TG1_%ST6N?:SUV+U]F-91]Z_O[VU87Z 7:LH@U?LT[">OEI"P;S1<"$R0
MH(,%'PZK_+[3W-IB(?(;.<Y?2NY8_MN:$RV3]-'P2YK^?7C;"?_RB6"WS>Q<
M;M+'M*RFW(FYKH52_0QK>,H^UX<%YGL5)*]$Q]3Q[?-3SO^$^H[G\C14A?>L
M5*K.##L/;Z D>VVIOM_6-WGM'B2?O)['Z;@FSX.I:,;^OFEBV)EX>AYUAB2:
MG37BJ"E/<@M#*N\M9X)>_BC[4HHOQ$G47P^3*3]S\$[GMY8A2JXE9+B">!5:
MS%],&JGC3X)<[:4]\4KS+;2*NUEUN(XOJJ/J2%Y+(\)MK#Z_$4'0E[L$T5^$
MY*_6CODTJ 64>J=:*SI9O'\^Q@A/R.UV-(V;NVP9G]-_F:,Y(GWZ<</E>S#E
M9[ A+<*C)/8N#<FDHPD#.IV;%Y03SRT]SUVN:HN9JJAHX_O^A#TB-K)]SU32
M>TYD- $"2*O60T/&-;^2=*(S+0#8C4X7M_#B;#,$[ [Y]*A5G4?GU0C+X3#R
ME<%#'2<>\10="_<-M*9GHXZ;(0\!T*SFR0HT)U*?S,"[$<J4F"!NR[LU+A^O
M=YQN5J^>N1!_(,1#QUR?6Z'=/1:TLZ>6"3I DYN<$'36/-V]L1U7;]&0FQ'#
M2//T=?>4[1PYH6>J^&VP6DK\7IG$;X5/3#1%:&=) [5APJOZI+QW].B/8_"[
M3C<MV:=C]JYK;IM?#1WAS9>R(>@8@;"O<!!4-YR7!B%'$[W\D093>$[P80/B
ME*-(T;!U?MYY/]DZ_^X-'W/A&Z_YO,^=N=U,K2?[3ZX.-Q%GZS$AXX?($@,A
MR',$RZ-68O4VJ]=QA;VR15[4O6^P$MT7^Z<?+N1UK;S@YO2(_,8V7W7S[YMA
M<48 #]424?J3>B4FJSQ\P?7"ID&5ZIKY;MD.XP)]17JI"2?3<Q10]=:76H;,
MTSA&CMO9+XI8,BX.T)F@.:<T\HG<[PG2J>5M_V&/2&4'Q1M08'5= H2E)$'&
M(&-T(FM\ >I$51@B4X*&K=ZIXL?&0F??V^_)>/Z =]<:$U2''WS'."QB25A>
MI4FBW5B"T:#>HA$_S00]V$8[49_SK3V9%4FR?E(Q,S97_+V4QC/CL%RT 3LV
MN. ^C @T'7AWC0P.Y&)$>KA=\><QIV?MC;IB>DKLK!#4 ]>8&G>: R*%ZH!^
M":&QDSM8OI4*/SD@WKE<?%ZXGXO]D>UOX]?$):Y\;^7.O/0YW?;CJ$U5].1
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M&K!':%<[*WV(^ .+X\=+2HKPAJ>>#MU#3%KEOR@U><)W4?_XFJ$9O1*IFXV
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M'SJ)?)A__NY5%#:DSB VXX)4QDH>SO%CN>;6]:D&.Z,0(YY*ZZ9Y=#CZ/O3
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MI_#\-00S.1?7ITR0$ "K+K?.S+CZW7A6H&O9G%NBM?Y I&#$T:]L2W):E%/
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M%&,<:C0<K]=J6$"0,N: )5^LZO64/99^/2CI<NJ7UDMG'[(_!3&I:R5H3(_
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MGG(&5G"#R#PVW53S-;X 8FUX9-\YS^^R[!>Z._)*BK_9G7S$YP3A0"C 7^'
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M&Q^_4J++X<&N^+&$X09@(#'%<(X_KU!^/WFM"7)8R;< =KW9QCAF'7OVU6Y
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M,=>.1]7BHYR_<36;,W?>X7ZJ\,S C-H.8GE,OL*4SQ$L;GIBZ'8E;\AV+F[
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M4YKV\]'E/X!/?UZHO$$6)J"?8DI!931 P>,@]';(*+5W'O=R<F[-N=;71>G
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MY@VZ5[QM4IWWK+;[,%+;R2>>W#!(N)^=6!5QLWC'L<74JO-MN7_5V'BU3_X
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M9J4#"SS&H23C[0[2I1E+E$Z_$II_MWB)__RHH[>WD.U<:62*AG/I3'EU/&^
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MT9+0EU?&.WE;M0T:PAN^=IW95R-68;M%7=0/A'1E^LG<<BE?'DF]U NFQ'H
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MQ!I_Z^C;[X\J]Q:TD ^1_53A"J('FDL[2/.PU0+A\]OT,;C1EL:!'*P3_]G
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M<'!5_Q:KR-5Y<'51]&MI)<-QW>-AKY@N/S[.<>4RD D.;*K"/$<Y"RI=0L)
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M%54 (41M?E,R Q2#E>JNEAL/$#(+KBMO%U<]C F0!W&5_9AT_Z']2,<#1V2
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M_#CN&4+7"WYQS@I9H+YBJB;UH;#;>EHTP@JRXV!+@46 .9'R (YX)?E9&O>
M=->]7HE;'E;[#13RC&#5V?N.^1W72G-;"]LP BS'M34-H4*(2Q36XGP ?2U2
M]<GC+'_)\.PO#1HK/Q8MC_N,3PH_,#Y$+3[5+AT1Y?RY7*IJQK]6C"P*%LNW
M5HJ&]V2H[52ZJ*DN%!:\,]*L&AFT+HC?/A\A@\V#[/N["6A9O]X L,FS*J?Z
M8W<8H,X^0Y*>]6ME,WV?Y'^DN_4_._C^1M?,BCF/7\J9N_HD^=OP?T+G+.J;
M! 5'"US&K:7.CZ&!DYP-Z - QAAGB,<ZYJF5Y_,E!JADZ1NE8",UL\->3HE'
M,S-^$7)BCP&W6 PK2&5;Y8.+:II8MV))%5"](_1#LNQSY$,;2F6"PU>QJ" #
M7=8*S#,<&U6"K%AG/GJ,K!-/"R?.^TDFRT%*VA^6ID9J$.2JA..@)P,ARBKX
MH392TE,&R($9H]'ER$LU#AGP8"B0KQ#F[N.4/DMYZC)9]..KV(_%%Q#X&&[G
MY@#00"I?U"=#; ;8FB B0!GGH3HW-Z]L %^/W-^]KBU[T@ZM7HMV_1JK8"OV
MR_/&P)$OD+NNX")H7;1UW9.!9TO50E, RK(?_QS[8;=;JV%JSE'=%'C*(S*T
M-5-Q1\6I&59$J(>(PB,M^]=1A[X.;/]\T)3/+F*UT<IA9"?6K) >="\&<132
M+^?$HO&6,PIBAWE^%+((INRT* &;36DR71.X[H.?.[54-AB@Q9*XT>E6O\7%
M#UG)//JPI+:5H#=RB>ILS2@/?/1 )631GH06@&LHG/:PJ.M7I:"/ 0X9#S@6
M7 =+>MWKML^B1TR0F7"G#5O :0P#1M4[$+%'U$)+^X.$7(Y$YHP,6N%Y3DTV
MQ@TUR=;)W!QCBUICRV']A)1#-N/8:M7@>:N-:2KDL(W^4C\G/HPV?B-U0F@L
MNO%YBMWK&W=?"C^-CV'&\D2H(+(/(K)&4]H(IQB\IIQ=6U0BUF+?#\Y:"3H_
M\:I3]OIY?%#J<?FJZC/ANT^_S3?YB++3<G NG$.ND.>5TPV:-K;- 6Q7RS]V
M*VNKXO7.N]S;>K^#2.K)ZG<0&+KS!6JN@2W"XNPQSP03T>/1LM/U.@YAT85W
MJ@:(])YJL'LB/X'[GLDK\D_2N;>;[>8#$#MTL.B)VNK**K('H;S%G9=6^C[?
MW]T]1[Z"%5RJR],F4G=MS_>\QLUV$!R_:$9)(=&#2<O,6%CP9#6!PP<M.JJ2
M'2Y65ER,4UVQZWDB<26N\&J;S'XC-@FI4+GI4!J6KCT#.435':]"A[/GHMD1
M!M #*,?V]!^23U(_GE.J:9"4;9WP<SU\4FN_1V8H.&-4%F ?4Q1T2V/M6_?D
MU%?9#)):K=;JA,I7/_&_R]8F;)K3NL\LL/ #R';_(PM8$:JN"G]@;O1X2MWP
MFK:%#0/T+'%E8.<:V:\RYNST$K<';'//07H[""'/1!9[!A&7:.D,T/V L[4<
MJ/J!?@4/B> K*72I7%J"5NSM/!S&5PMZ9&K(]XM 6%(<*[]Z/WB?#XX#V8?Y
MA&K 1T'N4@HS^,,\)7KE5<0J0W!)M1N7[J"4N:1?UEJM'-C/^C.0 YD"EQC#
M!-&%X6U-H[+DI6A:*A;^R7E))1^WF\R<B7[<4#22<+;F\X6WTVE]T12)#4?
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M#-MD18]<_[<VFT5NR^=$)>@M#9?#/DU7I^!4*J4&-[01HIISO3\U/ LV&:!
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MGIK!##4I$;B%-PWTI],,4& ;-6S]">$K?2J 71^QS@!Q@H"#S/!AFF[&C"*
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MX0AFB\55-(R>.I?QTE$-MO!'\ZEWRW438((,GW>U3Y@L Q'[&*!TIHV6V62
MJ'9H ,[V!;H-AJR@40Q0LUS^CO09!NBMWQ^!HC@=:[T+4-*=_P&  OGDQ;G-
MAJ&S**YPYO?3#3>59JSDIK%_R4#F/]C"GP&;X+EUW.Z#YHO8FO\M^;_B_Q=;
M%=NN\9Q >>F$_"-BRM"_?8?,B** P[BO.O])$:<0?N2!!@SWA[4JZ+%9PI#Y
MMF,&:X%S&B+6S_=JD7/F]_N9B])+;W*7./S8_A\<*%,8-%T0\"+%)#B\!S"F
M])Y/Q;C@ZT&*.I?*;E\<)B&:6TW[I_>-;;+F(RX!QD1HI%5 =':$<C%2>2>A
M^M/GH"DWZQ2C,*,3:?Q&$O<?)MR-K<.>^G]04%LBH8@!>K:&#T\&AWO/9I?W
M+!0.F^.*JI-)]'F+W@2M*K?(_.'7F7&_/#V<=MLP$%^E95?#3W*JYSR,N%W:
M/4[AR&JX/:MV<<>D][3"9''5IS=[JTC))RUN!^D*U"T=V>_WA$X@[+$,A(DD
MZ@0;]$* )NE=;9U\R  =G(9LL.TJC!<R>&MG>.Z/^M';+O"'#>(J4E3!1=CZ
M  U299@N#GW;.-?3NO'!?!)Y_EB[S%Z#N&V-1-_#H"WCQ8W"X3K,?@0WF0E"
M*I-"O*&<PPWIKG%0A0SW1WCO@>4SC?B'DM^7E=3'2J(:HXX$5=MOW*&]8X"(
M;HA; #K+Z '>01N_$1.%C:5'/;TCQM*9< OFF:^QCLU:4G1?%)1*@Z>[6-]S
MDPA1:'DK,!>0_Z6>Y&*7NV/E;X.M^+'N]2:>/W9<)R,B.KM- #5F=HVJZ#3U
MFK2MN&!-]KK8RS&)>S:9!EO(+5%!7^U77#X14W]5;]B0IZ=2$NY8GQ=8H=YT
MKF%#!M"X&R!%))?VIS_8UIO1++7Q-:MEO_/MX_#;-&*]F"V/C! JC+6F.6+^
MDQ;W]#<&Z XFR,(*F757+;34[X//65!M67Q3<H.^[T3.+:T^-3A*_@)[E>8%
MD%W-].7NQ1(3!;SII\AOQ<4A\F/HA^ZQ[T+,XHS408],7?MX%E[\]V5:II,X
M'K?4;Q_)^##G14LQZ2G(K*I,L8<D\;A:#KL&F?)P!QY<PTH7T8IJ.5TQA\:
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M,7F3?N@MTPK(,$ AAF.P[6-49K@?E ,!(N9E"C$%%@P0!KWL9+@1HT9'&3-
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MP-B!X 8=WC#;GLR7%ZW\?*[)3Z?Q6I[YK(^>O.;5]8IE459N8OD9KJRT);*
M>C/;UF4;_-RS6F[L.>*Z%Q;N>3VVA';M6HRMS+5+>HU5&1+R<4=T;>5>=:'&
MWM(5*87I;DY$</"9^4<,4#T7.'KYRNBI'?7RD 3TBXR%^_<>W9 =XVBJ.+1'
M><]&$R]9NFD9D%D8> ()&OYB*XJK$'R?DCE_/GHQIM3=<T/ 4_I,2_8EIX\5
MYE()F^?RSMR0NE28A1K+N.XZRDWVWF9K,,L#JBP$B_JHVEXD:_]]G2'/@C0$
M_7.[[(>^?PL:5O<X]R!S5QJBHBB2,)160\:/ZX>%L09GPGOJ=43#K#\.:$EC
MZT@FJK_X75/=:_Z4YU)(H$Q7;(=7=VT[X)]GXY:VA]R1%:"(\?=[;WT;JM!9
M-0%/>#4&8C72VA,!FI%Y5SV\$45!8L<@P;8G!KSE<!_GRG!.*QY:)?$>\\]C
M:RWVF]Y\]4ASP$ TJD@E_:+0MTSLU,+C.Q^+6^QR[YXJR;IV67;'UK1U9Q9K
MW^V,;<<!;KA(V)HJ:E)U]^]),P:(PY?B1@_%4]\/H2AY.Y[KBF?H\( 5!F@"
MVH<C\4W#5C>2Z/LA] LTR7<X9E1&+*3+HSH'&:"7PU"ZBFW\C@:]"W.4ZD=)
M:ACBJR*!RUTL8,ZK!?0F3]'%LI5*ZK?C=T-O:HGVX9\3A1\+1LUW/"BY[M&^
M9D&_CA8BUKH_K>]KZLTW:7YS._4-UCF_RC_21A/CWF5[EP0=,OY2RT?ISQ@;
M#E\?T6L<\JE6LTA&AA$#KM]T@V?M:U[J+^N6#:UKAMK;P$*08B[(,Y_A]^5]
MJGRMX4OA?=Y"B]J/=1X'#AQM9H\2;CZR/OY @)<B/2EMI,_;!D!)GJ'5#TF<
M/,[))[,V1J -:B[V^;H3QN#!]_>.R7KX'-JZ=N3JQ\UVD ^/V<UUD8L<TM#*
MVLKXUM*R\/>)5[A+>8ZUL,0'<EX&%>D_M&4#FHB>X>>13W/@'E,,T(T>E6&^
MWOLJ^[H]C_5?TG/7?.\<9+ U*QQ5>.'K-8W"3RW72OK$7>XOI5>%6]^%2QYA
M.3+(AI58?<NN;*%(8H#":P7)HD7$:#F;WMH&%,EZ>6'D)%C<4J?GX<?:[^]>
M8&3CD\0>]I>>I$AEX<+E2U3_O_;>,ZJI[VT3CH*"4B*]$Z5*ERXU-IH( 0LM
M0%2D"Q$4"34*TIN @((0I8HTZ;V7B(CT%DI((D@GH1XEA.$W,^\\\S[/K'?>
M_[/6?!H_[ _G7CG7+M?>]WWOO5>N$TZ=FX%7?[N9[M-I\^KV"1;O<QT)R1W*
MX:*O&3E/%/[;N6)OOJ&(WZ/[B=FI3@XO0#^3KW@40?0"92@Y>^'C+>?=>2S\
M3=9PON%$[]?=GCWJ=>8]OQE__OID_\(A=ML>3<!$"HN0@_.$:,G%=K@?K]CI
MPQ(/W\&8=2++!C\]\90N.74[3X\/6HGLWSEX!\PI='UG8;Z3<S,F4V7]>SI"
MI>3S^O/2X!1S^R RC)B+X&KB$<Y=^N)FL?X3<97W@L45Y?JG5%D-X??QHYNA
M$/X=2#R4-9M2&L.RD9FKTSU6;W=/-/K&I5L4P_[RJ6L+O*&-^<KQ*>2Z6)U;
M<M9FGTLN-BKOQ@K+QT/!S!;"EJ_&1FBM'*W9=0E,@=Z %^F= HF,[P(SH5[N
M "S]Q&7_L>K>FDB?I"OQSR_2*&VET!Y\C>1Q#G**JC'1Y Q):-(AFB@;F"].
M VCKRH:Z5'WF7GKW7Z#A+P;282^UX$(L3S,C*H=L[4,I&>VZYP%7#\I),*?K
M.>":%;?OV*_1\W 7I6LI2?<751T=RL,W>-G&B^#48."!WT<WFQD(&U5<-R[_
MYFN$F^)J:@G25510VOA\LINB-JB+XXK0.M?\G/)A70L32N$>.249V+\Z-M)E
MF?]#JU_2NB)K[NNIA\[UZ,M^3Q;.;O+]KNM^C L>1S E=ZHU+-:26,"=:K6^
MZFKC0RO\"Z_ZU5]/)@Z5E$I<^W ?DR'-BSR+^@"^GUT7#BR09Q4^EB,C=;GA
M4TE\(C6:8[7O1+XW?G2T^RVB=[X0@O)6MFV).+ (O$QAP'K "7)9S6XTZ9'U
M<8LCT*V:2P/RO\#NW.+R(]CR&.P7+CJ)%SK!T=N7CT N92?@J_YS:26H-#UR
M_WA:\)_GLW"[D=<SAHE1O-GBG0T/3&_>+*^C$U<,":(S&']V!#JWG(I+30GR
M*%R>D%J\ZNNLU,=9=+C@(W9I__0+>7,]3M _Q>)Y"5%._:K9Q/X7W,;"O>E%
MZ-71,1@_*H;&AF:=15QDN71"Q&+)E@R5;PU#U88'2GX.O#$J[_FH'O>Q4G5F
MZJ'5#LA7=P8$/4O%1Z$^MUC&Y*4X/M.ID<YNL&.?L-S7_=QK5[FD1*WA3;_=
M173N-=7QK\15X05<;*J( G:F9R2TZ1_>K?W"P$>5\6Q2Z$:?00:J%^CL-N/P
M[>=F+[*]\1&NZ_VZN]@(?J6K@+&IQ)@TO^[S<ON8DQAOG;,<NAH:']3M]:@)
M_M98.=X$0[C'/V(98TI)2]VL'#-:S8^=YDL9M/*-:;_[*V3NH*QO2X<]>@L#
MIHW8TX^K0OAQ^)5$P 9ZUCVG,\TWZT)=R(^Y@)JX1_=>?L=<NE#'X,X.[K,^
M G&WN@^$X1F:N/)1.;<INI@BU_24+2L;M,,*=Z7V]T<W$D>>?>83F2NY0+]V
M)TEF]\XBS.DXI-@>YNER $Y!\G)WB 9AQ9B[M?$;?=_'YKO(AM>P2IF36Y.O
MZ0Y')D<1[/_HPD1 SM+P[L4 MK.P#'>CXCCH0A4B55:UEJ^#[DK/VE[+.?^3
MQY'>]P/8-+MI'(J#$Q2FPS'J79NG<2L?GTIDJD<6MPRQ3=<5G7^S==JHQX#O
MAT9I;3M-FSS190(Y@'>TB P'FN3]CN.9K@J8+)V?4TS!"W!]_?IUP!\TF]T2
M %P_\ F4 KJ+ J]6?AD3'_2@<EQ*,!]MND:VL>[E2R%RZ"FD7TWP/Y$V&?R,
ME+[+#8R1]Z!@A'L_:8"Y-,Q!NM.W,//A#!S^%7LVR;C537'M#/T@@[,>*B&N
M]3$F3)?A"/1*?A'!N?RG)HJ8:6HBC>_B-_WHJI;AJN(BU-^/?<_%>9)!(-Z0
MV(CF^\>AD'_=.>;0^1^/XF"6RN8EE%]9 K>Y26&_\B1),RFWB)DD"+D)6E\J
M4\#LO0'\"E9M4O+SB"4,1B./U]:1X;5!9<N%KMJ^?%O1)[P=S;PZC?AEG'\Z
M+3:V,@&5URDM,<ABU%/KD=U#$9*NZ<>\6?'^IK=B0A47I)]<%10>/5'T/T2?
M[,LI['AC(",;L*XY A78](J6TW@&-K!$=E.=\282L2R^R8^,L;7.;HRX-^CY
M/L.IL>;.0E:^Q".<MQ:[M\'@1/@JYIRJ20"6KEOI+7'4PF51+T'K7,_IP1,Z
MNHC1B>'YBB@+^V&3RU7KGD<@,GAP*Y@[2TF^:8'OSAN$#&S]<6EQS>IB0J-+
MV7MM#HH#$=R-9I?(+#!RSL$I##SU\7 3Z$U8O7#?:H>N?N]T,YPDV1TD.J_0
MT8S$\E/YPVC)V5>2; WN1XE_?]'0HQ;QZ+9WVU9G,PHH%B,GF7T:.Y#/*OCF
M9&UG6^J6XB?O7)+<W/RLIN"I'FKBU1'(C05L X0YSF/.H=R[$&#J]4^NFY]=
MRU&I6@A)L]JK#7>8]R8X;EASAC]R8C[Q0]%F\\ T4,R#"3ZV1A,'#.Y6#7FT
MC 4^._0?=CCK>;:Q7(+G:8K>S!79-A_5+M2O G-[=?(1:*\),"%MAC7 $HY3
M'M4A;8V/*^"?ZY331:[N<E4'OD%9R+D4HQI"C:<D/?^N BN09D@)CW$O=M$L
M2:W-M9,_"#C4),B??^>M?_N&N-4CMO;U*_QW_Y]KD45TE65W-R!*+KA#T>Q)
MGC,0,[.9KB=:"[5AYQNG:7161Z"JOD##02KD"'0&VNEAG=,Z?"^O:2AK7&/X
M#VON)T=9(8W+M]69XPU/MFJVJ >/V2L"OPG]DOH43GZ/YA;,DXD+54 65./;
M^FU"9OA=GA[%_?[ />=T P:^VY5WW U&_ABLV8+;4E#QS<Q/WTM&Q!Z!_ 1:
M'J76N/49/4Y'&LQJ!=<LX:I+6W,F5U*5SA27W8]?/,.@'S>JA.EBLY39PA/0
MZS$4!QAY(#Q8$- ?,*EKB&1BDDH?RV](?IH9LZW;QGDN9V%>WJAL\#B]["VF
M:@"6\CDDCX=(=G?^H#<-X04^](KYQ$@[4ABGR+I9H^7E'TI>Z2MMBY>P"K/=
M2]5!"I/DRV6ABK92,L25CI%DLVB/_FYH5)&U7*UO8X6-EJ^*9205>E@@ 202
MA!2ZTY$=K?PV ,R\4O.5YMQ'G^SK)Z?7Y,5\--/>AM(U>&4]43(PR0\>@H#E
MJU@X[HQ2'Q".0*PU90]5F=QU8'9?MF^)UVRR<&X*1@LLX 4:G%_T-#_=[AR^
M6*K5 ^%K.D&FR$*Z[37(^/ [9K%]3KB>,J2+O)F#'.0M"?736WG4 AH6K(MR
M[D'S5.,C_&_/SJRDZR>[EAA]^A!5["FW 1U[FVO-I(B%/F,6/O,!;)3=Y-Z-
MK\9V@L]0KY#Q(1%1CU5;V59M<EQ-''/PN!FC_*^??@P\SW)!O?8XGYG[BXX+
MCD74I+4CZ0!)..4B$$? G.O.[7!,A@WZ],ED]$Z_U^,,?C(K^N!+/5_[S@>P
M9W93Q_1>%F B^6H'PC9+-2#G)^:M/N$KSANM[C.\T?A$[,JM#.O$^(FSIN/T
M_#LQ3 <>MWOF]KX19?JT(L>M/.5FM+USF(MD6!G/AS"N7N$8^N]A..67L-QA
M3K  "G+; VI)>8YAV7G<)]XD[X1Z*\CUY,6Z+O9T4\S>"C#[*5"'7)I)"#J]
MO*[J\5AKQK9C,DG L>V"X8)Q<MQ<]"S9?;NB14&=R/"R9->?S=3X^=X.5&<
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M0UCWN6*;G\$"=55;"E-F^A55OFK;C N,BHMZY0U)1HO-_WS/\2$4D$1T-G/
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MS%OQ3]^;WY4:A*6J-WK0M%:F:WK%&]6Z'EY""7*2WQIM?PMHB>C(TCQ,:;F
M2C_V.%ZMKXBM(]4)L3:(J)SH@$:+>))1M*IUOJ.K)O,YAP=->W?,J?J':2V2
M*Q9'((BE/KGI]G&"HS%(-?DPF;=;#,6QP=^HBRO-Z_^Z3[S]#OMK?YWKP'J+
MH4U8]Q 3++&*9M>5!^+!9U#?/"#$<(P[?;I%YF? ^TQ)TF66IM2T+;N\WCC4
M7)G3U@-X8A-(&C6RITH9648+E3S#,\69KEJ0Y5\2!ECF;-TL*OJ?BE<9IBG^
M+EGP6%3I:_)BP#'2?3@\>SQKU3X<[_("T.2T+IQ:T;R,5N8=<^!=GKN][82%
MZ?"RN0'[K07J=P^Z'\+66I%.'9DS!Z89Y%IB1*>6 B[C#CGB%2D93K'/3Q/F
M")'ILTHE!7V^-K(M';FGX2MR+7?],H,HU/YX(;[%5ZE3.0:(T%<T7@!F"L#\
M/@$;NU4:V@JEKK[;RS7F>3F:,^%174]X[M5;(N>:RK9C(4TP2TK$GB> S:,-
MC=/$ ;]Y.1'$:;3#TO.T.YW(W/X #_&BUYL%G2@B9WV\TKU'B=?"+M_VMUSR
M.0[B.D3D% S+GU6/)L)B</19$"#(E^2W&^1^AZ)?G2/[Q:KOD5S+B,*4]7D.
ME;!+Y1*^*6T.VT*0J8D]+PHMCW $8@RT&U5)X 6P77^B81X/B'8<%B,>/CI:
M-\/!%5-=>_SI JXYZ:JRWQ$H]D<AWOU_/NJ!@LT K3T%H _<U:_0DZ4&P 3W
M&WQ2,_>8!D"K_J:)/GD#@C_Z9=5B\W]8W^62CV47Z7KCD(QX2ONJRT;Y%4KE
M(:*:?'.F7&IY6D2:FD=(\1.PVM;TL6]KJ537%;GTA2^^*GY?>TS=9Y?^QU_^
MP>_1+HC(+52T+_EY&!VB^/;IYB3>[Z^^@ME*3RSY)^+C>YK.DF -54WN1NOY
MX>M64B&&W^H<!CVT%UNOSM=&CZE=9[_Q[L?DZ,4!@CV46!;6BL,+J\@]NM[0
M81@\X>V%S3@]6/]G(R8></NSUJB<IR^,3>J5V S"4SEVM4,CR9,W88R%WOJ*
M;\H"ZHUD]N [OT6_T\Z@ME8)GLT2*653)@_R5E@__JQ_T3-H%"O#?D4K@&VZ
MK#0(O#<(^!'!,9B*(U \58H@!SU (,;D1(RUKFH_^5TL&?<5+RH-3C%:B+BY
M5RAJE",E(ALYP_7@-?JL%<EJR)Q3Y&+;/5Z0_UFR5]TGXDK /5;+";N!J/YM
M:;\\9'%/FAB^NV1D;<_"N1O"K<M-M09^DY!G5LA4M6IR3>:\ MC-&59-R1L+
MFY]0E2F"598T=GJH?*LA>5HUQDV_P IZX\_2Z*FN8[IJ*&,;"BS<QT/AUDC@
MF: /MG,KE4O<>U_L3,YU-Y?4O-N6^USW.W! L?QP[CA;OVN9A3+XA0^E\0?Z
MDC&=F!![H5K .2#/:#X#WB@'MQR!17CN9GXO65#+4%T;UN.4?QYEG-T;"RH^
M[3[[CR9<N*X28$P6L>/!:JJDL]:JU7]"Q)SQ7"^UN9R?X>^XWNJ3G-QQBN\'
ME[_E4-6_2;F_IHU (,4M)P&VLKOB^"A5YNEE?K^??0I\S^DRHU[#"J5;N].I
M&13Y,** FAT"/HPLYKB=:B1:7U_I(IJYQ;?G>.V])Q_3B$BK)^[;;.GX\H?(
MF<]KUM$LA" ZGVX49+V=7$HB1K1KM%9ZV*Q:#\L3FZOC%=.>P-)$P!ZE<!I(
M9J$RMJ%4GKUD@%PBBFRU_[6I*T")9XB@<%;L1U26J7R^Y[UK?E.M(AH)KVT,
M*OE-(".[LF0 .>(L$U$H+:),7N6K]0!&->,P:_'DK:?2-RU!\TH;#"&ZV:UW
M2IN,'"E%\_9EGX";L'7>ZG[N%9G+?=+JZ>0&Q@S)L^T_1I)?7/TE.'X$ZD2<
M@E,U /3QJF6V(60/KV77R)_6QMX3P*_TU[?RSU57U)9;PEU$:BT?KHE<^?AV
M5U((1H=Q6_NV]><MXU;]K(Z'!R99%QE?UWBF.V7,BE O?<=3VLURL<#7\>*T
M?JWIH4W-^&_?>?1:H^\\8@IM.+Q)I(@)Z\9T)+MN+W, +7^([?)94R3%&(=G
MX_<=ZW"-=^=C'507T S01WAAEX:"3FMMV/ST\XCK@#F:T)=098LSE=O5\!0L
MOG)&0#SGN<"$3/CY6C%+?)5E0_#=8$_4<2WK9^:/0.$MX,&!ES\=7.=EXEB)
M,%8(6.C>!HYHE^J;ED:[SQUL+-5=YY#TM/^_'AVL#5$4"-#8:H$!7I>$#],#
M\W+JU^(WU\?W3\D3G>=>Z,E 7G/];MG\6-;PZ0.X+P,_94#2QY#QQ]6$/"L+
MU93;:)V7NWXO?;4+E_^Q8"!W)>I26M\L6\9 HKA\X[CAA "HG9Z(9@_N:X7H
M2MCK-R2\VC6&2A*.]ST1WW'-$Q'K<A9[=RW@QH8J,YPUK+D7WM3S\4GU0@MV
MS!C:=2^3G;'(<[KO_R [9HWURF/:,.0$0Y4:<J<[C_K':RH\ZK[>ID7WV\I/
MLK5JR!9U!RD>B  \71#F5B=,1!87Q>3=2-/5W&57=S^WD=RY.^'(-']EJ3;L
MK)AEV?^DIG.>-JZKV@A *94=--FZH74?/.M*NG:#SF[*]YM$PU=Y>6:&OWF+
M8^*Q](*Q$^]-YJ$A$#!?L&2< XT=P6H7]T?R%5S8K\'>7F/+:/(5\P;O[QY?
MK\:UUE@\8U5"G#UC/7FCU$;P2SINY1+3]/<39TDZ*#&V&?;+JPAZH'*/#2CX
MN%(!7]8,*HB2W;KE^[PV\7K*@$"JTVU6+98V_XDVI\G']_BW"DT3JF/&->UZ
M[)[!2VNFD9A%OCDPWW4.Z=%/ 2Y&VP;&=<;.V;,Z:SO-C>X+"*X6.50HB2<*
M;SU1ZLLE;%?]WOJ<#79*U+YS=%>R)$B+I# UT 7EA3[<?*7+%'/#XZ$$13R\
M\#/NL$1NZAFV+MT(_E13,#)?4 J_I"1=U@Z=Y+')L*D<T[W0BW3(;UL5=1G?
MBG)Z'YJ9I$G]7-_S/%7LD==XRV:\2KA*O"ICY,G/\2]80VH)U%8NTY);3O(K
MMRTF@M=;ZY8)@65\^M6W@E55I62.MS8FM=..#ELM2$!RLT<KH4:O9%H]JD0;
M7.3:8-D)_!SU>%,:W_"RKJ[N0?.5!]Q=G=2?)S^<*[3/H CL60(Y9>B.N0-P
MN/81:'TSFA\66;4)O+4IPQ1T)JAY.@H\/P+Y?,%6I!^>SFZ9/^2E+E%@:T@*
MZR(DVIZN<:C)F AC04UTC[CC'X_X]+-V&J=*.5F;;^3756+,XJVBYR.3]"X+
MH)Q* [H0%;X]<I9MS[,8R6F=RSLLK!/7QHOM^WK2P\,*.^^/2%WJSL5/]]3F
M]'MWQ[7I=3XH1Q0<.]=%6B(YASB>DAOH.^(#"?%?V/W5E<"ZW*";HHV+3Q/!
M]9_.JBFM9:V-%8UZA%3D??0:XV-ZZH$K]$M9-Y*5]EU8@QSKSZD>K%-'R4]#
M%ZRJ[:=F^ZU[Y+PT&;ZY=?*CX;L4VZ*M8$0&9@1WD6Y[>AZSED !=URB7B(;
M1.XD< SD 9)=6+B=/8OSM5"]N:2OJUZ,QNJCCJY<>U6WW_0ZO .=-7A X=C3
MH:#7V4C@>&$QBGU>(>J:G>ELH!;!G4E_Y%?T2L?4C<$!9>VGVE<W*!*BJ$<G
M_+"\!T[1(.K,\4;-&1/7D)I! =/8CT"O-"UCJX] D7NZ$.NRZB W-F3NC'6V
MGM=>#LLPK$K%Z=&!3+F&F:'&21V&O4M RD<J V"4W3T_Z4"Q3R":>!]8H\I*
M;H0P17HZ1'W/=VBZ[')Z<*W-P?<Z(O?8 RRD=4 F"TC@#CP]D&$T2M4B>IAK
MNQ)6=33WL)T-V B256"=#9^<@GA+N/,-OID*&YXVJ.\3WB&*+Y6C@*A66PPC
M%YG*.)/MK>!=B2L\-F_NJ-AL[CVH-L0\Q(J69='G=9W-LR*#^Q %;XXKPW;!
M)F.(V&YTN#T'>2>+GW*JI6@^\X+'6EJ7YEX8:XKN1$1_9:TQ$TS798'-T6;%
M<.]U7H6QY0BT<K,3P]MY8!EX'8@JHBJF$5HC?#"LRSB?*F7\)$R\NTMR/_;V
MN.O)^0=7=>YQDDV'=GW^VZ7\?ZK8LC932&WV/$#)!ZKJF+81TID4]/QT_<A.
M:ORU$?W&WW.<V<D++727Y*KF^3<_T;T 9LD&G0A($^L<+T5S%NN9IHBWQB^/
MO%60E<\1PWK1O]42LWW/SO@SA%&U4W+-EZ#SM(N_IIZTCK0'/A8AEBH /T]M
M$_&*DKS8=]OLC.OW7[+-0-)M^2X3P@V+\-666 _+>=]0JK:V<J[-:K BQ:+1
MG=#,/D[3-[[7@'DNCD%^=[B2^[I.,M[ O',54L70A0AMY:U*  %4P+U+$<BY
M/NHCQ&0S^&PZXX30PGL3E9K]<T;:TZ_SU;Y62)%.^?6#GJ4[KWE]P/K,OYG0
M]B!!>5VRF)H2S :?R7EOC95X2,8^9%#@JGK:O\#*T9]"9M!8;+88: M^'EKF
MTB(ZH0KF=VUH?R<1:A,^9*'E9^D.OU@;<MX!9_A['RHIZTZ$TM'P6>H3-$B@
M&D76_CR )"EPH#!WPGLV"6D1LO*BX_,&B6/O'AT$3JM)^X7EO;1T7;DLF4OQ
M72\AVHD2%7IFV7]ACT!,U#/(>:-Q'4D812W32W7C"TMK^K7U49&'[2\0LUV_
M%@6=0TZLV,#6E G&.I*=NH*C@0](8#840Z?EZJ=E>Y:QTO7<$6(B7[I8XOBL
M<_K%OL#R/IF+N!/T7I94DP-6J@(E 5MB2>RI= Y"E[JEWVTPF<L0^RHK'F_\
MU'/+@U&,G=?(I./6_5]\BPT#+]'<5!CE>H<NSVC353+)AIS24YAK\&G&UM;X
ML<>%E'CM%^$/O'EC+\\RFK$R.35AK@+K%#3)(H]B:0ZX\[Q20;*@)._6#ZX]
MI'"%C2WTU <\SOUQ*]'V1@V%W4SJC(RS6+S:((/>TP/.I8:TEZ7: H540R"J
M$+!:5G))3;^%JV)K=WR\<NZ4U?K(P",S+IM?/Z9CX_T*4#E[XN2:YF*KE3_(
MF"8[@HX-OB,14(.OLR\.FCPM. ^241D?]O/TZNM<2*=LOH22S4L"2.IQJF*5
M@&OAJKU@#;F*?WH:Y7?>?5KKQ;K0MS[QL5$I$09]MLB) '\?K-X\&KBX'T(U
M)B2< ^*G=A4X<- H#VT-PKJ,Z6!WW,)Z_S?NZ'..33ZO8X6&O[Q@*6#T5CKQ
MC\Q*R".JPM":7,F%B2;;H6ELP8U\X[[;AA69!3&7:P13O05&'7BU)VJH%@!#
M=N!="D]XTRT?#^>.%GDRR?CP'1$,'A#T-3>0IR]7ZA-,-!;PX+,6?3#!VULF
MD[&W,^A!_>>R9P]V$O4AT$HS>SEF/L5=K>[^8- 'NS-=--@4M=1X\ZNV1YM$
M4VTWA&PVP+<,8=,5=]E'LU1C&)=H'.0U__<#12YDV[FI'_+<&N*H(U#5!^,B
MBQ^3.(8^=@&MJQ_ \);#$&VV0G<.5#JIBR:?3.1L^*Y)0N'74SMO<W3RQ:LP
MRM&^BS!V/V=4#%V3:N$X?!G(00AR-QT7HUC&^O3;#'2WDM-5-XH"W,72U&F(
MU!L9<J.\7W^YA6DL72&63]/.ZI'[] "U.>V)$NVK]U/3MU!.VR9)'9S-\$[&
ME-QS,1'FK-]K;L0^N:0NW)S0"9FFNPF$$<OHE_9I3!3(*Q'*>*9N(<']\#Y.
MQ>:-XL7$B7,_UCFSX+(O;;USMQ-#0"ULAU'!0H DT;EK0' Y[K-$-6G5.$;G
MJKU+K%JAQJSZU(M(3OE)AZ;6\\^)]5^/0/.9T+/H&AKW2AK[:EH:!"P[CC6U
MWG@P[<=ON*7O6=/!Q.GK=#M,9]L:P05UZP_H0%?1&LDXF"!5$T 2#J&=-7^Z
M^&OC9'/?;10D72LYB:F=5KA:=U^Q39N_'U ^"'9#GZO*Y-%+(_04$:&1EJF6
M_N7EY/EXW'"0$M\M\Q5&I'A<HJ2G:&RJY\_YPO-"T%?'+<+HLI"#/Y(/2P+=
M2:X[B)-NR,]+]I#TE2ZK=F7#1QX$.6XC/S%/7_D3Y]4EFD/GT>U"X'F>T(TF
M#<)!\[6M'M+MAC%ADYN&<^:RF\VCG#<$KBXIOO>1:+K3AB:;EYV@6L$7R9*A
MVCXDA;4^0_E=PZH2S<D9J]^Y";+3O=Z5IDMW-[B7+_+.9TDOEAR!3ITE<\=\
M O(\M65(7A\!R[L1-R>H>H?)Y\I'Q%+V1&_R/U";V67B4/KI:69(3[?"+[,0
M@  N&KP2&WX&X[!#7>_61'>N!__Y=6NHR=J+ZTMM2UV8;1B;WYRW;+ZDU=3@
MR39GE]XS#L?U<)/I@UG(1Z!8;3T"C!^EW$X['[YB)V,[7BQW2]UIEF_N4NJ^
MTK?B=H$'J#&XH"HHZ(Y>(%9]_??\N@+A>Y;V.)6+%,?0 <N3*'(LLG7=FU";
M^+91*'A&O/I[$>?:C[KXIVP_?_%>WJ#QT(:^H+:)XK]>[)8QN@>?HCS3O*%)
MU0RNV!MF*N*#]&V+HL1?>UK^MA:@9]?< ^WQRVQ/H><_"*L@3Z*FNSR(F^%L
MJ-!K%*'QA ?DY:KIU'$?%V*=50X;5ZM"RY6NDW+OKMZ&\6$;4)B]V0JR1(AJ
M D>@)!"7L^SJ>_J=VD>O_.FKCQ4<]43$MC=$4D8"_!ZB96]8!5&?7H'<'$*P
M4_\1K(EP:Y%E<VD1 7P^VP$35A3=O.PE3?O0/4-27?0(BT+Z\)P:-HQQ6Y#
M^V5K_T'-H1SY.LDIF=+7R1]?6."Z_T=N+_FSK4MZ:>)GQN[^N#5F;BM,G^_U
MT7/?NLZU409!_N)<6UBJM@.A]O"$]KTCT(M4/#71X-\;[!#W2J@%DT>@PM]'
MH,.3QL?,**_XRRPD "AL)_+/2531$>B$7.MOD?]H^#Q.,SL"W=D^ OVA3R/0
MG$=W+/L@9$I".'Z'GF)).PE';^G]A^?CVC[2"GX=@7;.*'12!PJ7RE*A!!*$
MI77I#+&,2E]S!/H9_1\,ND7PW]</80-'H"5V1,1OS)TAA"RZLT=7 #W(T8T
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MM.52(T7H>PMS0*^LWJM+@$%;JLU)Z0WF+>WHX1\;TU=D%HM1=#^_]GNC_[7
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M*6]MZ<-T=WL/TR(2.F]JVO3/K8Q79Y78S K_V9C"C,W71!\^TRQQ[]K_@^^
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M-<J.EEEFG?]/2[C]WU7HCJ;^"U!+ P04    " !P@6)7ZBU(W:?]  !9G0$
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M"' P?V<#6)B. LP"3"P"3/1.  ( 3&Q,?WN ?W^8F!D^'F+GX.3B9OR@YC#
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M?+(FG-22.167I&V&?!? (>LY5OKXT+F< BD^(Z;T\=)E.L")-*&8H7IK6[C
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M-O2AW/!&*0\9JJ(_>A_^\D%"$V_M;B,=V6(9SE?-_W&WL!N]+S]WAD&.>>D
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M^Z(Z'QJ0]!J7DA,J[:YAFA2>-^)>Y_("]R+_2LL[ARLCYTOU#GD 5N?-]Q0
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M@*F$10VC]6"CTV%-1G+Z:>GU3(G/W0]62)381L%DWBTSC.IOWZTQ?01[I^A
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MBY?<CQB,K'A5KIYB.B)"*L BL>DX6:0ZQ3 >Y66VY^<#4SH0TZ"<YX X1SM
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MWZZ?5FMR%!K_^GE%GM<E73KZ/D2BK]9#!O-J9+D%RP[RMX3P?5OO,EQ0GY#
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M>EQK;D==87C^ UH7[=@WFN3/B6-@]531[,#:"S83QX-TH(7O-AUPV??)6CS
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M@%\H6%Z;>)I 76_GS>HT-2\E\5CW\,124%NY! U3L'3CA(KAHSN!7S^WM)@
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MFPIP4E^D9MV]5"1+F-1"?/Y4]E(F9*;I:W-J:&X7NU-'TN_G 9.5M,+"KI]
M=<@-MN4MWB^)YPU^Y2G4^NJFK^-(\6(G91W^"71%L>[_@%=$"?S"Q/R%B?EK
MS7ZMV?^F-5.AV8^G"/56CH\+?.:4Y:V'Z2X<EVP.<2A(D-2T"IW5?ZFT+FBW
M)GE@Z,#XY%-5WW!UK@:N9-&K^@$&',"38TU_/W:0&]M^05S'QN!V?>N6B638
MMT?WQ?IR)>T^4Z+ QHM7_L4*T\=&_CC<4_@G\,4M2<7#+/HFK_Z5PS>V?\#B
MW"F#$HN(T&P[(W&2L/7V,='D]__V4QNW"YW ;=@V96TS"_]T+_,340/N*APJ
MFI-_Z5\X0OO?HX,=?S_*>/_O)QR-E+6;7U-B:<.K/Z-E<"#Q@7;(\3+*'J%\
M'2R#8NEZR$ YA==GO3^JYY6J4?T 2_K+R\?(6LY4,N"^1-G":60 M^02"OS
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M+L"LB<K]DH6= &ASLRJVL[*B5R)')-;6?$WI^M=' )5@(M  /&;1MW#8NX;
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M5&+9T@D"M0.Z&:9-'E:S]OC["$%^R[<ZRYX/-0Z0%I;MI4*0!6EUJ "D4^&
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M7]$:7Y/MC;I(05Y%!"%^1O2AL ^;SKLHO_C%J/0Z0CYI>],1#\98NE<&%$[
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MV'96Q+H!]B&QFE+FQB=]C^>MSGJXHT^DH73RS=(;QGY?VD P>DIG*S.9G:1
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MN<L=X'-K*7PU\7"AR-Z"7A&&^ZS3_<N'[O%J6P8_1[Z<U; FC<]1.I5?(L4
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M(T)*%R(ZJ,6YBWG^7]9Z^__7.$6=^+\ 4$L#!!0    ( '"!8E=WL7X8,-D
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MN]9EW<CC[H$NV\/ +<E]UC[0V]7:/#032F19)I7>391Q'G(%"RDDC-,LB9G
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M;^<+^>&ISM3%/)8TC3$L%(DA9CB&5$@*J4IB$C-B2DK:%J<X''QJ]-+(!XR
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M63:-#F<*81X9ZL@0->T+$F(ZDBN82IJK6- HD=CI!,E=ALG9")U3AJX2CJ=
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MR]YF-GKF/:MPS$:W%_W7645N)K=A+L WK>9,[OX,WNN_3$"C?^,NO]63VV
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ME!8RMJH(9C?<V&BHDM:C#NAY/.WLFW H]<Q7];%1(RGXW&YW'+RUI!TH(<N
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M(F/]4QJQ.(M8EA=N#8$L!AW;PK6O,:J_L)W48"NV39,:_PFP,Y]#P]KSVA0
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M@N H4WD2I_9=? Z>/;9O>Q_=7\MW96A_ Z"%>\L?EIZ_Z=>(^*/@$<_OCL;
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M%,37AFH$,:<93 NI%&(HIL*JF<:%<<:VM-2B@JVLH!86--+:<=<E:+L7B("
M];P*>&)ES2N62)RP5U>2_^UA\?SO^@FUJ:I_V%NHEYX["'58*K?E!]O+_?:M
M-\^TG)D(WX^+I:DRO#_)-0>[38:I_M?.+MZEXD8TI3BA#!)!3)<O4_L>\]B$
M_/.\D)'$4>:RJ_669'1$LEJ7CZ;3+=AO\-PVP/Z38K<]'@3JWAWU!W$'$[!3
M"JK%$AJU)J"]PQXL<_IJ= -MP_WE&'23?C5<K[?PUS_0\^2@R>.^7]SP?VW*
MI;QKCH>>974JO9H*@2@W[1!5+#%$$2NT914S8V-QF:I$_\(M\N'2B&.CQG?:
M?GTQ!L.SP=UD_M1UC_]M!?ABM0:/<OU]81J-&@.WRHTNY^"=G#MF0E^>"<O3
MA9#X]GW(T,AJJD4TTH*]N'5<1,!.K=;0A#IRN#C>L"</MNH?'4!8W^B;:;5N
M0F'JQWV1ZP\_^6PCC-VX6(@?Y6PVS2,B&<42ICS2[%,D*:1%U:J59T3E)"?$
MJ5VBS:!CHZ*]S(!60E=MBEQSF2S MJ.:T!#VS#8M]&X:]$PRV2\[F<%6Z/,G
MPAXY0_88!4O^L1ARX"P>>Q".TW$<[O5M9O_C_S5?[\O[)JZTRCROG*#;[M T
M$4@J#+4A9 +4<Z6-(&$.1V.>X4)1P7,7\KDXXMB81PL,:HE=^]-?@M:.:H("
MUC//[+$"6VF;&AIU4%OX8U)K=()UGK\TWL -YRW5/^XS;WNC=PKYTA3.>B_K
M_WZ:'W>C^+J8S?2FSQ0&G.92\ISK;5:2*F/9J R2&%/]3YK()"N*/'/*@W$<
M?VRDLQ4?_+)5X%>SMVKK\&^@U@+\:?0 C2*.L>BNTV1K'?4&?N^&4G#<?7*M
M?= +ES_M-/K0.=$^T)S(<_9Z3%_5--H]D>X7APG4]5G"E!?<--0B$"=I"A&C
M C)M?$&4)6DFE<HP+QSY\6JAQD::GTW**ZS:US;5,.BK9E-#U<2PF%!K)AUT
MFOJG5ZLJ%^WJ:\<MPT90[<(>]<'*6EB(-++Z%?8@NA>J<'BV>SC&^R98J#ZC
MNJN*?W[4OUM-5<XBD44)S!71N^4L%9#@+(&1RO2?DDSAV"I[J7.4L?'N5M#M
MF5TM*JADM0_$. ]J-U4&@ZKO$U ?E)Q","ZBX!6 <?ZI@X5?7%2L'7QQ^6(_
M,\Y8%U(V##-_."@+_=(J"OU%_ES?_Y"S9_F[IISOJRE%1$:F.DTL$FH\:!$D
M+(J@(G&4)Q0K(JW"@J\59&RTH=\RY&9X>4^!G;$U!+ ]DTRMP@3LE+A0G[X*
MK[B=GP]X<;:=K@4QD+WD+<:@-M*U8+VVBZY^GG=+CG(MJ]3^5V<6?ZRDVLP^
METI.HUCFC.<Q)"3#$,D\@S3%&2QPFB>22(H2UV8<%P<=&^6]/L6<@$TE*YAI
M89V[<%S&W([W0B/9,\?5XC:5)%Z?;$Y +3/XW(6H3WL-:XC"-=:X/.30+36L
M03C13,/^7L_86+VM$^5L8X(S]D%D]8FI%/5&\?%I4Z=XW*H/=&E"]E?:0JR;
M%;V<?D!5CR4F>8Q3Q6#.F=[7I9F F*$,XHC%"F%3Q<O)_=:CK&/CO+:D!Y6G
M/$KG]#G%=EPYDHGKF6(]Y\P]]K9_-$-%Y_8HZ;#QN_U#?A3A.\"0GCT2+G6R
M.]?([O:I\C+>;M8KO9B9@)Q7*6$??IIF["MYMRRYG").5<P3#K'*8HA($4$6
MIP*FF8P$RPLD<#*MFPA]6]/EVFX1&4AZ%UYZK4-_%-7HH+>Z>RW^!GZ3#^6\
M2J=<J*V'S90[$8O9C"Y7IE%37?K$L?+)4"]*HHV, JD,1BB.(,(9@YBB",8*
M<X4C_;<B;EZ4#W/Q%W]-MAH,^Y),@![W+_IZV-DH(YSPGNT5F_ZVG>UMC<?L
MU*MR5*Y@BP"H( C8\F38.0O5/F4@J8=MQ3+L5!RU=1EX>#_+2<OVN)BW&KU/
M<Q9A2G())2\R$Y>B=\<24<@Q3Y3("I'SU*WQX-$8+HPS3,_ 6L0Z/LQMR3@&
MT([<KP*E9QINH]%#K.]9U0.QV?'S!^6=L^J]9HCS%WJZ[YL6=8O-?+U\:=[&
M B$J&$(PYA1!I-("XEA&,"H8HYPQ5DBW*F@G!AF;JVK;*_*>_@0WF_7WA4DZ
M=G3+G\+2T@U_)4)]N]U/@=-'X;,.&$*YUD\-,:PKO4/)(]=YU[7>==^YE***
MGMHU\_DJU68N5M,X2H62>0(I*4S:LPDUC6($\T1*DF.4X<3)U]TUV-@8X-.N
MBQI8UA(ZUW8_#ZP=#82"JV<ZV(I91W'NVY&!KQ=P\ZGF?A&0<&7<SP\U=/WV
MBTJ?*-Q^^9ZW<93^O:J#]6E>^URF*!.4BBR"22X81"GA$!<JA5DADRS3TT(H
M<NH_&U2\L9'2SC51B7E- >? TSB,.\I_<OY"7J=:29-K5*NYBX#7J[^2Y7JS
M[&B&-+BWZ?24C,2I]$JXOY3OZ#2PH5U$9T9Q#X1_I[< -TM)WRV$G!+.490D
M$JJ,1A#EB$,:%1'D4H@LS9301J1M['O[P6.C8R,;,,(!(YU]@/L!6-W4>0T$
M??MX[+1W"EP_I:I7K/K!@P8+3S\E?CLB_>3??8N W@BAIW-UMUBMZ>S_*Y^J
MMXD7+%-2Z ].9@@BDE!(,V$24(H(1Q%)L\BJU47W,&/[$)NREHVH$U +"[2T
MCE]F![*7O],P>/7\U?I"Y5$"M N)*RJ GGSLP 5 NU0[KO_9>;7;Y[]:KJ=-
MY:G;Y3>Y?"YYW2>.T;B@^NN&F#,)D8R;$),4,9*H7! 46^66G!M@;)]\(V/5
MWZD1TRF0\"R0W=]Y"'CZ]\>X(F/]<5]2O\OPU_>VC'[]K_W'??:Q@WS6EY3:
M?M 7K_/SJ+R.<MLWI$Z8DK*(%(RR!$-DHHY)@2G,",XX2ED41TX5E\Z.-+:/
M^S [7(M;[YS=7!SG<;7S5@1!J^_5O)%QCU'@3M_68 3:\I\?9]#=^T5U7V_$
M+]]P3<F0J@&PV;M_-A.E-^[O%Z;/P#3C44PB)?2BCPJ]Z*<<$IH0F.$4)0SG
MHE!.":6=HXV-).X7QG"MO)^052XUWG:]R9_F9T?.Z(;;CC>"@=@S=S0DNQ,4
M;"4%?]:RAJUD=!F3H 4RSHWU!I4O+JA]NJ3%I9O\Z.3KXH7.UKO(#B$IC0H.
M"Q0+B.*X@%0F N89D5DB8Q$I)_OBX.ECHXM&.#<^.,3+[OOW1J'G[[V1JX=
MC9,:!_J:#Y\]Z-=[4JW77^OIBZZM)&.R\>N2)UFJ<I[0#.8)SB R5><9T5^K
M*%):T+S(4^591V8WQMB^U-?U4:K2!%?5D-G#>=F+%P"DGC]D#WRNJ!YSA$"
MVC'[9[Y1Y9@CI<[7C3F^=.# B;H*X:?Y:KVLQ%K=KK_+Y?UW.F\.\6Z$*,T/
M=/9>2SQ;K,P1\:ZS3)YGN$A0!"DNF%[DDQ@2O>Q#F@J9<Q[+@CN%;[Z1'F,C
MJ6U#RX'"+JY\">PLE[_ U/9,K0$".9J:L"TP0(4&6&LX]F$>>T1 "Y)>^AJ]
M\;2^=3#(E5K\-:)&PDQ5L/"20.)XKK1')7SUEKINEG"W6%8:=-2$W!81G4J&
M8IXS"EE,C>6M4D@SI?1F.4H)BW.&93)=&R>4Y<(91"RG=7 G7.]>N(.RV++2
MSG%E##-IJ2R(P@6!26Y*[*4LA7J:"DB)R#F1>D99[I%?/_C4#9<^OT^49U3_
MH2.5M<]Y(RG2,Y=FD*M<SUL<<4ABR:%*\S3)68&2.').=W^C6>L_F_U#E=3Y
MIA-F:5$./@5]'[A52DS 3@W0Z#%\;>JPV(:RTL((-:S1%13((QLJ[-/=3**J
M1_D?\_)9#ZY'OE7OZ*Q4B^6\I#?K;W3^OI0/B\:[K:@L\H*F4-LW#")!!20J
MHE"*.$>I)!P1JR:7#F..;5._E]H$W._E!G0-M.2@$MV.;EV0[^;2GO#LF2BM
MH+Q\%N&-J6B<>-6.96AL#P8?Z^MJO>!X@%2O)N;&:HF(2!I5RX3+HP99 SQT
MVQ*\SZT>[/WNPY?WVPY\(LTHXRF,<V%:OS"]KXD1ABG)"\DT0_/"*MSCU7/'
MQL)&,@=": %D0:1^:O=,ED8H'RYLJ>[ =WX0#,1IG9/O1EG'>G;24NORX:CG
M6,8#>CGQ9_=X\=_+>?FX>6Q>E*P0.),8PXR8 K8YR2$E<:$YA60J9FF1,2LS
M[^C)8Z.11CC[</!#G+JYY"KM>V:31JZ @1YGM;TBWOOP>8,%>I]4HQWA??H"
M/T_TJ[);7S;FF;>J\IFWRW/MSNF2C+$HR3$DL4F'ETKI/5BB8)H2F2@9Y4GL
M5''#58"Q?<.[JGNTJ;K'Z\)2=<X[6.PU<'.".4^,G;NK3[A[)HVC^H:U\&9C
M48M_6 [QO2G"JZ_NX[S2%\5 +BSGX0=U5OF"\]HMY?T<[SI#3W*Y?KG3+]WZ
M9EX=$#X9<_*+7$\UK:4TQ0)R1&*(E#9)<);%,!91AFBL!(HRQSI#9P<;&\-M
M9:W2M>16T(GI7>E<<.@\PJ(JR"@%C$F>0)1&.22"I+# (HYQRE)N6J[8GV4&
M0WB $\IA$+9;($+AUO-BL!5S BI!*^0^[)'[TH&<3U&GBY"$*^IT?JBABSI=
M5/I$4:?+]WA&3/#O4FQFLN'_HXB/Z@QC&[G!U^5SN7ZYKXXK=CEU/,,\2C2'
M1RB2YO0@ACC5A),(FF2$4$&Q4U.GZT4:&]-O-:I,JJHP:BU^]75MPPG!5A?'
M0]WK)]#R0'?0:>F9YDY&\>V#F[9%F2:[20%_5KJ 7E(LPT$;ZBSW>H&&/<<-
M!N#1&6ZX)_L1=!4^9T9<RN]ZT/)9[AL?:_J_5??TYY23(D<QR6 6%P0B2I@V
MHW,,J8@5XBI.HU2X&'DV@X[-V*O#T195P"UOBPYF6FHW4K4"W8XV0T/9,S'6
M <L'\H*#G/QV6_9P#.B"4B".LQIR4!9S >$U3SG=ZQM<V^2EFO/.U?>/L\6/
M?9J!S&(L<KVY+!#7&WF:IY"DG$+*$4-8L43%3AOYKL%&9][M\JBKL_C5=U")
M:^,A<P?:TE@+!%_?9I@_<AY!<Y<A"18*US'4P %NEY4^#ENSN,>S/:=I]KE_
MEUE&L(@B#"-3:AR1C$-*(KUSE SQ B')8^S44?/@\6.CB9MOWS[<?W-L=GD(
MF-W'[P]#SY][+5@O7_=IG4,U?CQ\^+"]&D\J=M1>\?15'D%'7?V"MJZ*#S^?
MRJ444QX+KK]2! N948@*X_G)\AAR&26\R!,F,F(=E>0P\-B^[*UX$] (>%5#
M.>=IZ&:%/L$=^F3RL//:9.\[:V3O"6"'"*N>@!XH!"L<X&[Q6AZH=09TN3QO
MN(@O#RT/0L)\[K_"3KOA_]J4JRI7\]U";RGU[=7K=Z\'6BFYU,-LLQKJ3(5/
MJ]5&2S<7Y@?C YMFF1)IQB(HHKR " D%*=+_5"PJ9)PB2BAU-O"NEVMLZX?>
MJB\KBYO.@*+E$CS3V:8Z+7@GY^+?5D!M9K,7\*QUT=]FE7$)%K7/T<.<##"O
M#G;HL+,UA $+6BI-P(%2H*55JQY K1BH-:L.?;:Z!3: PX$=TG(.(-7P)G<X
M*$_:Z@$?[QF64Y]ZK;[*F=[NB_O%/?WY7^7ZN\E7*^</'Q?+TP<>4Y3'E+!"
M0BDXAXA1!ED1%9 KE.=<""Y2.IW+A^JI#I$[GO)8L0.IV>%(JAY/(^A/\&,O
M/GAJU .:).::0ZH- = OPGI6.\#JS'E 30T%UX9COE-I1^.]SLQ 42VU"I.J
M.5E+]LGI<B[[@^" P2Y7HA@J$,97C&&#9*X$ZRB YMKG^7'LYY*R<J9)OE6/
M*9&49%%!(!4J@XA*"8G".10D1RG)122X4^'>$V.,S;QMB>A&;*?PL^.L*U'I
MF8Y:TO7B#.W0/A"-G!IA4(;H4/'UQ]]UJ6=,QE-EK<T?/DO-&%_-KOQ6_;&2
ME677.C[Y6,[IG)=T=K>H3;T//]?F<%9;;Y_+U7J:2T49T:94%B'3+CUED"H2
MPPSSA#$J%1&1"Q<$DFML_%$I A<*;E82T,K3/=E60-&&E-3FE!Y9@E+KYQCG
M$6@B[4CI#::G9R+;:00JE29@-U5:+5#I-0$'A[P[W<!6.?#G7CWP8;YY;'9"
M ?DP,/"A E "235LC$I8*(_"6 (_WCME195K$SHSC8N492)/(45I E$A3,YL
M;DJCZ#UOFO,$1TZEX/:/'EO\G GK<H^4:T$5J0(7*HN@BH5>S5!&(8TYA5$A
ME+9S%4\2Z9C+XP/5  O2U5!9;KR] .B9\HWNKP("1U 1ZQBJ<(DCVP</G2;R
M2J$322&OK_!C.SVC)LY'/^^Y%%+\]J+Y5GR:-Q0[?VC"FK7Y/)4)2C F"209
MEQ#A)#:UI1/(\UBAM& BHYD+&]H//4:VY"9@[:F1W=0&_F5CW$CE_%>@MAH
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MFFABH/;^"(>!QT8+>Z.O$7 8DV\[#8$L/@]P1V/P-;+W!'!@<\\#Z-%9>Y<
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MP%/NZ\ OOM(M4/H5'3H?'7H?%:_1X84U E$)P4UT_%6I8(CTMZ51Z3_;96W
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MU;I:90^RQD[--\;, TGZ)HKIP.F[TT7OY&S]B=S8_\(\$8[SR&/M?<(LU"I
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M-Q%XBL2*XPX"[>7ULV*%9DXUW\SNIV3</'0S_#00<P=@N:=[[SDC0CC:A&.
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M8CV_$7,I4PISC7$L P^"7".- 2)2X.MM5CDK=*7YV,3]J1O7D7CBO,% 2NO
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MU?V79<X]A,2SBS8Q2+K..$##P4?,H#U/S <O3&G="W OPO8#WH]VC-!>)UT
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MT*V+_N$3/CM;3>>X6OV"ZS"='>28W_.41E._OT->5Z,H2Y&FEOQ!]%Z!2KQ
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M#JFG;D\_]^M)?U^'KR,.2X]_Z5,VY-^;^>&[]*=D:WL[!UAJC)(CIV!4>,#
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MG$ T0D,0RH/R3($3(M4/OIY&.;-?CWUZP37TT%=7R-GU[M$;/3?2ZJ*AB/N
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M^R&0T,5\^KT%L)C1(SY6MC_\L?CP:;DX^_CI96UV=E<(R0O-L$APDM=6GD:
MTZE 5((EQDM26HRU'/9GH]=0KILE,1 BNEP6WSV@IN7-G34:I!81E+89:+4C
M&&Z8TKKP;(>^/=JDN&"$D/&I =U4EQT6&^R2[,LP76X2?I=2Q62XMA'!*95
M!6<H1B\>,D>4/AB35/,I4(<2VZLY?E+O^S@5_NB>]R7W$^LP)X$%7'0(JG8,
M]\YJL(&E6%3) ;MRN"\I_S'\["-AUM+'/DSG/Q+2=[E15YQ'9,%'2T%%SJPV
MC8O@N%0@++KLD[$E/UUGBL=2WZO=[@+Q;77?/>JO'1M)[V(108&,SM)N2;Y<
M%$D#AGKWC+9+IH<N #NJ=F9T/_DI$7N@WKH];WF[7'S&Y?I;F&_Z7F]:F1UQ
M=/+0X]J<@NQ-<*,#C8OWO9V%^?KDVDNO C+!A21<@63H0<F<(&1%?J]UB4F3
MI&T^0/:[1+6[VK+S5>=W,C*S7A0&.1H!2A5R14P6$'B4+!?+I6U],KPO;>,Z
MF&UQL_LZ2T/]=+!I[N3FV;=Z0VW3=86$DR-W"3"J0-ZORA UDQ \0VY,$;KY
M[,,]R.KEODI+/-R>\]%8.3WCK3)T?O&1,Y8P<0VL2%J=D6GPNEZ9K9=M,":T
MO'7,L0=9G5JW0Z&P+]0.U$L'4'MYMIQ/R65%8N?E]&O][+(S@"I%1%F :U:[
M3)!/&6OY#BW1F&BU9MZ\5<-N:CH%UJ&*O]T;KHT6.L#3\\7IYS-ZW*6$SMF0
MSD=Z'[%!?@6QD6C9V1J;!(<B,&^9;QU.[B!EW'S'T$AJ(?\.8/0:PPH_+6;Y
MU>GGY>(+;FH)SUGA7*N0?*Y]]^MU%!$A%NEKQP@N6)W0$%EC*#U SKC)B*'A
MU$H/'4!JIZA>7UYT$M+:;)*IW; C+1+#P2=5LWH\9H8NJ-CZ/N_WJ>KELNX8
M+OQAJND9;)OKF!-5DHTQ:#"V=BUA2'(*W(")6B6G=(S9/!70-A1UZEX=J/]]
MX?5X970 K6MW>W]!(B)=-&?_/,.-PN;YO&1B\_V=S$^"4$(9R\!E5B>K!H3
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M7O_PZ_=;#9D%8N0J0B[*U5'D&:),!J1"YD)QPHC]*FEOOK,O>1\CGOGIO.I
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MC:[-F%C&UL-ZAZ!CY SS\;"ZKRO'EG$'.+^:P'C+I-JFVP-J*Z(U@(R,;[+
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M[(%H@J"%#AE]P/NS3'=!]K"%QPGC#B_^^3/)HI/0[!X47@4*C=<Y<)W .9M
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MHS[^OE9J?.*4U1XQ@Q'D+9&;3!K,T^6+0IKDG"I%=S.#Z(']GVE;KI%/T*E
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MG&$$STL&SKGGC$NA?8LX>X=]QPX2V<Z^8X?P;VS!W^V;592U(2:07J9:>A_
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MX71 H6.(>XZA.'H++ZB[T E ?0[Y#5^WM?U!_2.&)?Z?__'_ 5!+ P04
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M8UIY4V?F.#3>FW+07KC(H3.Z]JLNO_-R3_,97S5Z%UYQ^C]02P,$%     @
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M.3,P+GAS9%!+ 0(4 Q0    ( '"!8E<;; CR)AD  &KL   5
M  "  <\N 0!L<W1A+3(P,C,P.3,P7V-A;"YX;6Q02P$"% ,4    " !P@6)7
M?8*DF!E!  #=UP( %0              @ $H2 $ ;'-T82TR,#(S,#DS,%]D
M968N>&UL4$L! A0#%     @ <(%B5ZX:*/G B0$ @T@" !0
M ( !=(D! &QS=&$M,C R,S Y,S!?9S$N:G!G4$L! A0#%     @ <(%B5^HM
M2-VG_0  69T! !0              ( !9A,# &QS=&$M,C R,S Y,S!?9S(N
M:G!G4$L! A0#%     @ <(%B5W>Q?A@PV0  430) !4              ( !
M/Q$$ &QS=&$M,C R,S Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( '"!8E<U _!*
M@X(  "#J!0 5              "  :+J! !L<W1A+3(P,C,P.3,P7W!R92YX
M;6Q02P$"% ,4    " !P@6)7R4MLLOX&  #I)   %P              @ %8
M;04 ;'-T82UE>#,Q,5\R,#(S,#DS,"YH=&U02P$"% ,4    " !P@6)7Y:G]
MWUD%  !X&@  %@              @ &+= 4 ;'-T82UE>#,R7S(P,C,P.3,P
:+FAT;5!+!08     "@ * )<"   8>@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
